

# **Special Assessment of Outpatient Treatments for COVID-19**

**Final Evidence Report and Meeting Summary** 

May 10, 2022

**Prepared for** 



AUTHORS: Kai Yeung, PharmD, PhD

**Assistant Investigator** 

Kaiser Permanente Washington Health Research Institute

Melanie D. Whittington, PhD, MS

**Director of Health Economics** 

Institute for Clinical and Economic Review

Molly Beinfeld, MPH

Senior Research Lead, Evidence Synthesis Institute for Clinical and Economic Review

Rasheed Mohammed, PharmD, MPH

Health Technology Assessment Fellow Institute for Clinical and Economic Review

Abigail Wright, PhD, MSc

Senior Research Lead, Evidence Synthesis Institute for Clinical and Economic Review

**Emily Nhan** 

Research Assistant

Institute for Clinical and Economic Review

Noemi Fluetsch, MSc, MPH

Research Assistant, Health Economics and Outcomes Research Institute for Clinical and Economic Review

Marina Richardson, MSc

**Health Economist** 

Institute for Clinical and Economic Review

Steven D. Pearson, MD, MSc

President

Institute for Clinical and Economic Review

DATE OF

**PUBLICATION:** May 10, 2022

**How to cite this document:** Yeung K, Whittington MD, Beinfeld M, Mohammed R, Wright A, Nhan E, Fluetsch N, Richardson M, Pearson SD. Special Assessment of Outpatient Treatments for COVID-19; Final Evidence Report and Meeting Summary. Institute for Clinical and Economic Review, May 10, 2022. <a href="https://icer.org/assessment/covid-19-2022/">https://icer.org/assessment/covid-19-2022/</a>.

Kai Yeung served as the lead author for the report. Molly Beinfeld led the systematic review and authorship of the comparative clinical effectiveness section of this report in collaboration with Rasheed Mohammed, Abigail Wright, and Emily Nhan. Melanie Whittington developed the cost-effectiveness model and authored the corresponding sections of the report with assistance from Noemi Fluetsch and Marina Richardson. Steven D. Pearson provided methodologic guidance on the clinical and economic evaluations. We would also like to thank Laura Cianciolo and Monica Frederick for their contributions to this report.

#### **About ICER**

The Institute for Clinical and Economic Review (ICER) is an independent non-profit research organization that evaluates medical evidence and convenes public deliberative bodies to help stakeholders interpret and apply evidence to improve patient outcomes and control costs. Through all its work, ICER seeks to help create a future in which collaborative efforts to move evidence into action provide the foundation for a more effective, efficient, and just health care system. More information about ICER is available at <a href="https://icer.org/">https://icer.org/</a>.

The funding for this report comes from government grants and non-profit foundations, with the largest single funder being the Arnold Ventures. No funding for this work comes from health insurers, pharmacy benefit managers, or life science companies. ICER receives approximately 29% of its overall revenue from these health industry organizations to run a separate Policy Summit program, with funding approximately equally split between insurers/PBMs and life science companies. Life science companies relevant to this review who participate in this program include GlaxoSmithKline, Merck, Pfizer, and Regeneron. For a complete list of funders and for more information on ICER's support, please visit <a href="https://icer.org/who-we-are/independent-funding/">https://icer.org/who-we-are/independent-funding/</a>.

For drug topics, in addition to receiving recommendations <u>from the public</u>, ICER scans publicly available information and also benefits from a collaboration with <u>IPD Analytics</u>, an independent organization that performs analyses of the emerging drug pipeline for a diverse group of industry stakeholders, including payers, pharmaceutical manufacturers, providers, and wholesalers. IPD provides a tailored report on the drug pipeline on a courtesy basis to ICER but does not prioritize topics for specific ICER assessments.

#### **About Midwest CEPAC**

The Midwest Comparative Effectiveness Public Advisory Council (Midwest CEPAC) – a core program of ICER – provides a public venue in which the evidence on the effectiveness and value of health care services can be discussed with the input of all stakeholders. Midwest CEPAC seeks to help patients, clinicians, insurers, and policymakers interpret and use evidence to improve the quality and value of health care.

The Midwest CEPAC is an independent committee of medical evidence experts from across the Midwest, with a mix of practicing clinicians, methodologists, and leaders in patient engagement and advocacy. All Council members meet strict conflict of interest guidelines and are convened to discuss the evidence summarized in ICER reports and vote on the comparative clinical effectiveness and value of medical interventions. More information about Midwest CEPAC is available at <a href="https://icer.org/who-we-are/people/independent-appraisal-committees/midwest-comparative-effectiveness-public-advisory-council-m-cepac/">https://icer.org/who-we-are/people/independent-appraisal-committees/midwest-comparative-effectiveness-public-advisory-council-m-cepac/</a>.

The findings contained within this report are current as of the date of publication. Readers should be aware that new evidence may emerge following the publication of this report that could potentially influence the results. ICER may revisit its analyses in a formal update to this report in the future.

The economic models used in ICER reports are intended to compare the clinical outcomes, expected costs, and cost effectiveness of different care pathways for broad groups of patients. Model results therefore represent average findings across patients and should not be presumed to represent the clinical or cost outcomes for any specific patient. In addition, data inputs to ICER models often come from clinical trials; patients in these trials may differ in real-world practice settings.

In the development of this report, ICER's researchers consulted with several clinical experts, patients, manufacturers, and other stakeholders. The following experts provided input that helped guide the ICER team as we shaped our scope and report. It is possible that expert reviewers may not have had the opportunity to review all portions of this report. None of these individuals is responsible for the final contents of this report, nor should it be assumed that they support any part of it. The report should be viewed as attributable solely to the ICER team and its affiliated researchers.

For a complete list of stakeholders from whom we requested input, please visit: https://icer.org/wp-content/uploads/2021/08/ICER COVID-19-Stakeholder-List 082621.pdf.

#### **Expert Reviewers**

Andrew D. Badley, MD
Professor of Infectious Diseases
Professor and Chair, Department of Molecular Medicine
Chair, SARS-CoV-2 COVID-19 Task Force
Mayo Clinic

Dr. Badley is supported by grants from the National Institute of Allergy and Infectious Diseases, Amfar, and Mayo Clinic. Dr. Badley is a paid consultant for Abbvie, Gilead, Freedom Tunnel, Pinetree Therapeutics, Primmune, Immunome, MarPam, Rion, Symbiosis, and Flambeau Diagnostics, is a paid member of the Data and Safety Monitoring Board for Corvus Pharmaceuticals, Equilium, CSL Behring, and Excision Biotherapeutics, has received fees for speaking from Reach MD, Peer Voice, and Medscape, owns equity for scientific advisory work in Zentalis Rion, and Nference, and is Founder and President of Splissen therapeutics.

Rajesh Gandhi, MD
Professor of Medicine, Harvard Medical School
Director, HIV Clinical Services and Education
Massachusetts General Hospital
Co-Director and Principal Investigator, Harvard University Center for AIDS Research

Dr. Gandhi previously served on a scientific advisory board for a Merck HIV medication.

Shivanjali Shankaran, MD
Assistant Professor
Director, General Inpatient Infectious Diseases
Associate Director, Adult Antimicrobial Stewardship Program Division of Infectious Diseases
Rush University Medical Center

Dr. Shankaran served as the principal investigator for "A Phase III Randomized Study to Evaluate the Safety and Antiviral Activity of Remdesivir in Participants With Moderate COVID-19 Compared to Standard of Care Treatment" and "Study to Evaluate the Safety and Antiviral Activity of Remdesivir in Participants With Severe Coronavirus Disease (COVID-19)."

# **Table of Contents**

Executive Summary	ES1
Background	ES1
Report Aim	ES1
Mechanisms of Action and FDA Regulatory Status	ES2
Comparative Clinical Effectiveness	ES2
Cost Effectiveness	ES4
1. Background	1
Report Aim	2
2. Patient Caregiver Perspectives	4
3. Comparative Clinical Effectiveness	6
3.1. Methods Overview	6
Scope of Review	6
Evidence Base	6
3.2. Results	10
Clinical Benefits and Harms	10
Subgroup Analyses and Heterogeneity	13
Uncertainty and Controversies	13
3.3. Summary and Comment	18
Midwest CEPAC Votes	21
4. Long-Term Cost Effectiveness	22
4.1. Methods Overview	22
4.2. Key Model Assumptions and Inputs	25
4.3. Results	28
Base-Case Results	28
Sensitivity Analyses	28
Threshold Analyses	30
Scenario Analyses	30
Model Validation	33
Uncertainty and Controversies	33

4.4 Summary and Comment	35
5. Contextual Considerations and Potential Other Benefits	36
Midwest CEPAC Votes	38
6. Health-Benefit Price Benchmarks	39
Midwest CEPAC Votes	40
7. Potential Budget Impact	41
8. Policy Recommendations	42
Federal Government	42
Guideline Developers	44
Manufacturers	45
Payers and Manufacturers	45
Researchers	46
References	48
Supplemental Materials	
A. Background: Supplemental Information	A1
A1. Definitions	A1
Intervention Definitions	A1
Outcome Measure Definitions	A1
A2. Potential Cost-Saving Measures in COVID-19	A2
B. Patient Perspectives: Supplemental Information	B1
B1. Methods	B1
C. Clinical Guidelines	C1
IDSA Guidelines as of April 20, 2022	C1
National Institutes of Health COVID-19 Treatment Guidelines as of April 20, 2022	C2
D. Comparative Clinical Effectiveness: Supplemental Information	D1
D1. Detailed Methods	D1
PICOTS	D1
Data Sources and Searches	D5
Study Selection	D8

Data Extraction and Quality Assessment	D9
Assessment of Level of Certainty in Evidence	D10
Assessment of Bias	D10
Data Synthesis and Statistical Analyses	D10
D2. Additional Clinical Evidence	D10
Evidence Base	D10
D3. Evidence Tables	D26
D4. Ongoing Studies	D129
D5. Previous Systematic Reviews and Technology Assessments	D135
E. Long-Term Cost-Effectiveness: Supplemental Information	E1
E1. Detailed Methods	E1
Target Population	E2
Treatment Strategies	E3
E2. Model Inputs and Assumptions	E4
Model Inputs	E5
E3. Results	E16
Description of evLY Gained Calculations	E16
Base-Case Results	E17
E4. Sensitivity Analyses	E17
E5. Scenario Analyses	E23
E6. Model Validation	E24
Prior Economic Models	E24
F. Public Comments	F1
G. Conflict of Interest Disclosures	G1

## List of Acronyms and Abbreviations Used in this Report

AHRQ Agency for Healthcare Research and Quality

BMI Body mass index

CDC Centers for Disease Control and Prevention

CI Confidence interval

EUA Emergency Use Authorization

evLY Equal-value life year

FDA Food and Drug Administration
HIV Human immunodeficiency virus

HR Hazard ratio

ICER Institute for Clinical and Economic Review

ICU Intensive care unit

IDSA Infectious Diseases Society of America

IV Intravenous
kg Kilogram
mg Milligram
mL Milliliter
N Total number
n Number

NIH National Institutes of Health PCR Polymerase chain reaction

PICOTS Population, Intervention, Comparators, Outcomes, Timing, Settings

QALY Quality-adjusted life year RCT Randomized controlled trial

RNA Ribonucleic acid RR Risk ratio

SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2

SpO2 Oxygen saturation

SSRI Selective serotonin reuptake inhibitor

US United States

WAC Wholesale acquisition cost WHO World Health Organization

# **Executive Summary**

# **Background**

COVID-19 is an infectious respiratory disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As of April 2022, there have been over 80 million confirmed COVID-19 cases and 980,000 COVID-19 deaths in the United States (US). The severity of the disease is classified into four levels. Most symptomatic COVID-19 patients have mild or moderate disease and do not require hospitalization. Patients who develop severe or critical disease require hospitalization with respiratory support. Many factors can increase the risk for developing severe or critical COVID-19. Some of the most common risk factors are older age, obesity, cardiovascular disease, and chronic obstructive pulmonary disease.

This Evidence Report is considered an Institute for Clinical and Economic Review (ICER) Special Assessment because the epidemiological landscape and evidence base for potential treatments for COVID-19 are both rapidly evolving and will continue to change throughout and beyond the course of this review. This constantly shifting landscape is a dominant contextual reality. However, due to the unprecedented immediacy and scale of COVID-19, and the near-term policy decisions that will be made across multiple treatment options, ICER believes that an independent review of existing evidence on comparative clinical effectiveness and value of these treatment options will be helpful to all stakeholders.

# **Report Aim**

In this Evidence Report, ICER is presenting a full evaluation of clinical and economic outcomes of three treatments for mild-to-moderate COVID-19 among outpatients at high risk of progression to severe disease: molnupiravir, Paxlovid™, and fluvoxamine. The scope of the review had additionally included two monoclonal antibody treatments, REGEN-COV and sotrovimab. However, neither treatment currently has emergency use authorization (EUA) from the Food and Drug Administration (FDA) for use in any US region due to substantially reduced activity against the Omicron variant and Omicron BA.2 subvariant, respectively.<sup>2,3</sup> Around the time of posting of the draft Evidence Report, the FDA granted EUAs for remdesivir and bebtelovimab for our population of interest. Further, peginterferon lambda is seeking EUA based upon recent positive trial results.<sup>4</sup> While these treatments emerged too late for us to consider in the Evidence Report, we note that the interactive economic model will be available on ICER Analytics. Decisionmakers can input clinical and economic data on other emerging treatments to generate cost-effectiveness results and suggested health-benefit price benchmarks.

# **Mechanisms of Action and FDA Regulatory Status**

Molnupiravir is an oral ribonucleoside analog that causes viral genome replication errors. Nirmatrelvir/ritonavir (Paxlovid) is a combination oral drug that inhibits SARS-CoV-2-3CL protease, an enzyme necessary to produce other functional SARS-CoV-2 proteins. Fluvoxamine is an oral selective serotonin reuptake inhibitor (SSRI) with FDA approval for the treatment of obsessive-compulsive disorder. One hypothesized mechanism of action for fluvoxamine in the treatment of COVID-19 is through modulation of the body's inflammatory response. Molnupiravir and Paxlovid currently have EUAs from the FDA. Fluvoxamine is available on the US market while university-based researchers are pursuing an EUA specifically for the treatment of COVID-19.

# **Comparative Clinical Effectiveness**

Studies of all three therapies were conducted in overlapping timeframes but with potentially important differences in location (US vs. overseas), and in the spectrum and relative prevalence of SARS-CoV-2 variants within the population. None of the clinical trials were performed at a time when the Omicron variant was present. Within this context, trial results demonstrated that, if given within a limited number of days following initial symptoms of COVID-19, all three drugs of interest were superior to placebo in reducing hospitalization related to the acute infection. Molnupiravir and Paxlovid significantly reduced the relative risk of hospitalization or death from any cause compared to placebo by 30% and 88%, respectively. Fluvoxamine reduced the relative risk of COVID-19-associated acute care (i.e., retention in a COVID-19 emergency setting or transfer to tertiary hospital due to COVID-19) by 32% over placebo. A per-protocol analysis of fluvoxamine limited to individuals who did not stop treatment (i.e., had greater than 80% adherence) suggested substantially greater efficacy (66% relative risk reduction) in reducing acute care use.

Molnupiravir and Paxlovid were well tolerated and had low discontinuation rates in their Phase III clinical trials. However, each drug has some notable risks. With molnupiravir there were important safety considerations given laboratory evidence suggesting it may be mutagenic, teratogenic, and toxic to growing bone and cartilage. Based on a short five-day course of therapy, the FDA considers molnupiravir to have low risk for mutagenicity, but the EUA label limits usage to individuals 18 years and older who are not pregnant or breastfeeding and who are without alternative COVID-19 treatment options. The FDA also recommends that men of reproductive potential who are sexually active with individuals of childbearing potential should abstain from sex or use a reliable method of contraception for the duration of treatment and for at least three months after the last dose of molnupiravir. Molnupiravir is only authorized for individuals for whom alternative COVID-19 treatment options approved or authorized by the FDA are not accessible or clinically appropriate.

Paxlovid is a combination therapy containing ritonavir. Ritonavir has many known drug-drug interactions that pose a safety risk. These include interactions with certain anticoagulants,

antiplatelets, antiarrhythmics, anticonvulsants, and immunosuppressants.<sup>6</sup> These interactions may be more common among certain patients who are at particularly high risk for severe COVID-19 disease (e.g., immunosuppressed patients).<sup>7</sup> Paxlovid is not recommend for patients with severe renal or hepatic impairment.

As an SSRI, fluvoxamine also carries an FDA drug class warning for increased risk of suicidal thinking for children, adolescents, and young adults taking antidepressants for major depressive disorder and other psychiatric disorders. The risk of adverse events in the fluvoxamine arm was similar to the risk in the placebo arm of the Phase III TOGETHER trial as well as to the risks in intervention arms in the Phase III trials for the other drugs of interest. However, there was a sizeable percentage of individuals who stopped treatment due to tolerability in both the fluvoxamine and placebo arms of the TOGETHER trial (11.3% and 8.4%, respectively).

Table ES1. Number and Percentage of Hospitalizations or Deaths in Key Phase III Trials<sup>6,8-13</sup>

Intervention (Trial)	_	r Death from Any n/N (%)	Death, n/N (%) Intervention Placebo	
	Intervention	Placebo		
Molnupiravir (MOVe-OUT)	48/709 (6.8)	68/699 (9.7)	1/709 (0.1)	9/699 (1.3)
Paxlovid (EPIC-HR)	8/1,039 (0.8)	66/1,046 (6.3)	0/1,039 (0)	12/1,046 (1.1)
Fluvoxamine (TOGETHER)	79/741 (11)*	119/756 (16)*	17/741 (2.3)	25/756 (3.3)

n: number, N: total number

While further evidence on all three treatments of interest continues to be gathered and analyzed, the COVID-19 landscape has been evolving so rapidly that currently available data cannot be expected to have evaluated the safety and effectiveness of these drugs in the real-world US population as of the date of this report. Important uncertainties that must be considered include: 1) the rapid evolution of SARS-CoV-2 leading to variants with treatment resistance and with different morbidity and mortality impacts; 2) the enrollment of predominantly unvaccinated patients who were generally healthier and lower risk than those in the general population; and 3) the uncertain generalizability of data related to hospitalization rates and other health care resource utilization from studies conducted prior to the advent of the Omicron variant and based predominately or exclusively in countries outside of the US. Such issues are compounded by the early phase of evidence generation in which only one Phase III trial has been conducted for each drug in the population of interest at this time.

Substantial differences in patient populations across the Phase III trials preclude us from making direct comparisons or formal quantitative indirect comparisons of safety and effectiveness across the drugs of interest. For example, the molnupiravir trial enrolled substantially larger proportions of individuals with obesity compared to the fluvoxamine and Paxlovid trials. Further, as noted, large variability in the countries of recruitment and the timing of trial enrollment periods reduce study comparability. The Phase III trials also defined outcomes differently. In particular, data from

<sup>\*</sup>Observed in a COVID-19 emergency setting (for more than six hours) or hospitalized.

the fluvoxamine TOGETHER trial appears to be the least comparable to others since this trial used a distinct composite primary outcome of retention in a COVID-19 emergency setting for more than six hours or transfer to a hospital. Keeping this context of substantial uncertainty in mind, ICER Evidence Ratings shown in Table ES2 should be viewed with corresponding caution, particularly when making inferences between the comparative effectiveness of the different agents.

**Table ES2. Evidence Ratings** 

Treatment	Comparator	Evidence Rating
Molnupiravir*	Usual care	C+
Paxlovid	Usual care	B+
Fluvoxamine	Usual care	C+

<sup>\*</sup>Note: Population excludes individuals who are pregnant or who have childbearing potential.

#### **Cost Effectiveness**

To estimate the cost effectiveness of each outpatient treatment, we used estimates of relative treatment effectiveness from each intervention's pivotal trial and applied those estimates to a common "usual care" comparator synthesized by pooling across the usual care arms of each pivotal trial. This approach was considered optimal given how disparate the results were in the usual care arms across the pivotal trials, reflective of the differences in the background patient population, timing of study in relation to COVID-19 variants, and differences in health care practices across the different countries in which the trials were conducted. Base-case results were calculated from the health care sector perspective over a lifetime time horizon. We acknowledge the societal perspective may have particular relevance when the government is paying for the treatments outside of usual health care cost budgets. Therefore, we present results from a modified societal perspective as a scenario analysis. All treatments had base-case estimates lower than \$100,000 per quality-adjusted life year (QALY) gained and equal-value life year (evLY) gained from both perspectives at their current price set by government negotiation or the generic marketplace. Results were particularly sensitive to assumptions regarding the relative effectiveness of the intervention and the background rate of hospitalization within the common usual care comparator arm. Table ES3 reports the health-benefit price benchmarks for each treatment from the base-case health care sector perspective and the scenario modified societal perspective. The current treatment course price listed is based on government negotiation or the generic marketplace; the pricing and value considerations for these treatments will shortly transition to the private market.

Table ES3. Health-Benefit Price Benchmarks for Outpatient Treatments for COVID-19

Perspective: Health Care Sector				
Treatment*	Treatment Course Price	Treatment Course Price at \$50,000/QALY	Treatment Course Price at \$100,000/QALY	Treatment Course Price at \$150,000/QALY
Molnupiravir	\$707	\$560	\$1,200	\$1,900
Paxlovid	\$529	\$1,660	\$3,600	\$5,600
Fluvoxamine	\$12	\$600	\$1,300	\$2,000
Treatment*	Treatment Course Price	Treatment Course Price at \$50,000/evLYG	Treatment Course Price at \$100,000/evLYG	Treatment Course Price at \$150,000/evLYG
Molnupiravir	\$707	\$590	\$1,300	\$2,000
Paxlovid	\$529	\$1,750	\$3,800	\$5,800
Fluvoxamine	\$12	\$630	\$1,400	\$2,100
		Perspective: Modified So	ocietal	
Treatment*	Treatment Course Price	Treatment Course Price at \$50,000/QALY	Treatment Course Price at \$100,000/QALY	Treatment Course Price at \$150,000/QALY
Molnupiravir	\$707	\$830	\$2,200	\$3,600
Paxlovid	\$529	\$2,400	\$6,500	\$10,600
Fluvoxamine	\$12	\$880	\$2,400	\$3,800
Treatment*	Treatment Course Price	Treatment Course Price at \$50,000/evLYG	Treatment Course Price at \$100,000/evLYG	Treatment Course Price at \$150,000/evLYG
Molnupiravir	\$707	\$890	\$2,300	\$3,800
Paxlovid	\$529	\$2,600	\$6,900	\$11,100
Fluvoxamine	\$12	\$950	\$2,500	\$4,000

evLYG: equal value of life years gained, QALY: quality-adjusted life year

These treatments also have important potential benefits that may not be fully captured or evaluated in the economic model, including the potential for preventing further spread of SARS-CoV-2. We modeled quantitatively the potential impact on improving hospital intensive care unit (ICU) capacity but, in addition, effective outpatient treatments may help address the disparate burden of the pandemic in disadvantaged communities and help provide psychological reassurance, allowing for broader opening of schools and workplaces. There are also important relative disadvantages of each drug when considered against other options. These disadvantages are described in Section 5.

In conclusion, assessment of the evidence on outpatient treatments for COVID-19 must be viewed as highly sensitive to the evolving landscape of COVID-19 variants and vaccination status in the US. The available data come from single pivotal trials, all conducted in settings not reflective of the health care patterns and the background risk of progression to severe disease occurring in the current Omicron wave of infections in the US. With these limitations in mind, current evidence does suggest that the drugs of interest reduce hospitalizations among patients with mild-to-

<sup>\*</sup>We advise against comparing between interventions given the systematic differences in the trial populations and design.

moderate COVID-19 who are at high risk of progression to severe disease. Numbers of deaths in the pivotal trials are too small to draw firm conclusions. There are no short-term data suggesting serious concerns for side effects of these drugs when limited to the populations for which they are indicated. And at their current negotiated price (molnupiravir and Paxlovid) or their generic market price (fluvoxamine), these drugs appear—at this time—to have prices reasonably aligned with patient benefits. To the degree that hospitalization from mild-moderate COVID-19 is reduced with the Omicron (or future) variant, and to the degree these treatments are used in lower-risk populations, including patients with full vaccination, their cost effectiveness would be reduced.

Appraisal committee votes on questions of comparative effectiveness and value, along with key policy recommendations regarding pricing, access, and future research are included in the main report. Several key themes are highlighted below.

- Federal policymakers should view the advance market commitment strategy followed with outpatient COVID-19 treatments as a success that should be built upon. This approach substantially reduced manufacturer risk and resulted in multiple drugs becoming available in a relatively short time at prices that were aligned with clinical benefit. The framework for drug price negotiation between the government and drug makers during a pandemic should be made more transparent so that the public is aware of the parameters that the federal government considers in pricing negotiations.
- The FDA needs to establish a clear and effective pathway for supporting evaluation of repurposed drugs. This may include proactive outreach to study investigators to invite applications and providing technical assistance during application development as well as consider internal FDA application initiation and development in cases where there is not a clear external sponsor.
- The federal government should work with states and other policymakers to adopt policy changes needed to improve the effectiveness of its "test-to-treat" program. Test-to-treat sites are greatly needed to more immediately link diagnosis with treatment. Further, test-to-treat sites, which offer the convenience of co-located services, may differentially benefit individuals with low incomes since these individuals may have lower means to make multiple visits to access testing and treatment. Given the need for rapid and broad distribution of treatment during pandemic, the federal government should consider working with states and professional stakeholders to broaden the functional scope of practitioners who can prescribe COVID-19 treatments. It may be possible to use telemedicine or other means to accomplish this goal, but allowing pharmacists to prescribe under certain circumstances should also be considered.

- When COVID-19 drug pricing and payment moves from federal contracts into private markets, manufacturers and payers should work together to explore innovative approaches for coverage and pricing that minimize the use of restrictive coverage access as a means of cost control. Manufacturers should price treatments so they are affordable to private insurance systems and patients. Given the need to treat COVID-19 rapidly upon symptom onset, payers should ensure that any prior authorization process leads to immediate coverage for an available and appropriate treatment and does not risk having patients not fill their prescriptions.
- Future research is needed to understand the epidemiology of long COVID and the impact of
  different prevention and treatment strategies on this condition as well as to define and
  measure the effects of treatments on a more inclusive set of patient-centered and societal
  outcomes.

# 1. Background

COVID-19 is an infectious respiratory disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As of March 2022, there have been over 80 million confirmed COVID-19 cases and 966,000 COVID-19 deaths in the United States (US).<sup>1</sup> The direct medical costs of health care utilization from COVID-19, while substantial (>\$100 billion<sup>14</sup> over the expected course of the pandemic), are overshadowed by the costs of reduced economic output due to the pandemic (>\$7 trillion).<sup>15</sup> Further, COVID-19 has uneven clinical and economic impacts as older individuals, those living with comorbidities, and Black and Hispanic populations are at higher risk of infection, hospitalization, and mortality,<sup>16</sup> while younger individuals, women, and Hispanic populations are at higher risk of job loss as a result of the pandemic.<sup>17</sup>

COVID-19 is typically diagnosed using nucleic acid and antigen tests taken from the nose or throat. 18,19 The severity of disease is changing as the proportion of individuals who are vaccinated increases and the prevalence of different SARS-CoV-2 variants changes. Symptoms of COVID-19 typically appear two to 14 days after infection and include fever, dry cough, fatigue, joint/muscle pains, nasal congestion, loss of smell/taste, sore throat, headache, diarrhea, nausea/vomiting, shortness of breath, cyanosis, persistent chest pain, loss of appetite, or confusion. Prior to the Omicron variant becoming the predominant strain, roughly 30% of unvaccinated individuals infected with COVID-19 were asymptomatic. Among those who were symptomatic, 80% developed mild-to-moderate disease while the other 20% progressed to require oxygen and/or mechanical ventilation. 21,22

The severity of symptomatic infections can be classified into four levels, <sup>23,24</sup> as illustrated below.

- 1. Mild disease: Individuals have symptoms but do not have shortness of breath or abnormal chest imaging.
- Moderate disease: Individuals show evidence of lower respiratory tract disease but have oxygen saturation (SpO2) ≥94%.
- 3. Severe disease: Individuals have pneumonia and one of the following: SpO2 <94%, ratio of partial pressure of arterial oxygen to fraction of inspired oxygen <300, require more than 30 breaths per minute, or have >50% lung infiltrates.
- 4. Critical disease: Individuals have respiratory failure, septic shock, and/or multiple organ dysfunction.

The rise of more infectious variants and the failure to reach population vaccination goals highlight the need for outpatient treatment options for mild-moderate disease. Oral options will be particularly helpful in improving access to treatment across diverse communities in the US. Multiple outpatient treatments for COVID-19 are in varying stages of development, and evaluation of the rapidly evolving evidence of the comparative clinical effectiveness and potential cost

effectiveness at different pricing levels for highly anticipated emerging outpatient treatments will be important to guide policy decision-making.

# **Report Aim**

Due to the unprecedented immediacy and scale of COVID-19, ICER recognizes the need for a timely review to inform policy even though definitive evidence on all treatments and outcomes of interest is not available at the time of review. The treatments for this report were chosen based on the timing of expected availability of clinical evidence, expected Food and Drug Administration (FDA) approval, and clinical expert input on which treatments would be likely to have the greatest relevance for patients and clinicians. Using these criteria, we selected to evaluate the health and economic outcomes of molnupiravir, nirmatrelvir/ritonavir (Paxlovid™), and fluvoxamine for the treatment of mild-to-moderate COVID-19 among patients at high risk of progression to severe disease.

Our scoping document<sup>25</sup> had included two additional drugs, casirivimab/imdevimab (REGEN-COV) and sotrovimab. However, these two treatments are not authorized by the FDA for use in any US region due to their markedly lower activity against the Omicron variant and Omicron BA.2 subvariant, respectively. Therefore, this report will focus on the other drugs of interest.<sup>24</sup> A discussion of the clinical evidence on REGEN-COV and sotrovimab is available in Section D2 of the Supplement.

# **Description of Interventions**

Molnupiravir is a ribonucleoside analog that inhibits SARS-CoV-2 viral replication by being incorporated into viral ribonucleic acid (RNA), resulting in an accumulation of errors in the viral genome. Molnupiravir is administered orally at a dose of 800 mg every 12 hours for five days. Nirmatrelvir/ritonavir (Paxlovid) is a combination treatment. Nirmatrelvir is a protease inhibitor that blocks the activity of the SARS-CoV-2-3CL protease, an enzyme necessary to produce other functional SARS-CoV-2 proteins. Ritonavir is used in this combination to slow the metabolism of nirmatrelvir, thereby increasing nirmatrelvir concentrations in the body. Paxlovid is administered orally at a dose of 300 mg of nirmatrelvir and 100 mg of ritonavir every 12 hours for five days. Fluvoxamine is a selective serotonin reuptake inhibitor (SSRI) and a  $\sigma$ -1 receptor agonist. While fluvoxamine's exact mechanism of action for the treatment of COVID-19 is unknown, one theory is that by binding to the  $\sigma$ -1 receptor, fluvoxamine modulates cytokine production and dampens the body's excessive inflammatory response to COVID-19. Fluvoxamine is administered orally at a dose of 100 mg twice daily for 10 days.

Molnupiravir and Paxlovid are available under EUA from the FDA. Fluvoxamine is already available as a generic medication with FDA approval for the treatment of obsessive compulsive disorder, but an EUA is being pursued by a university-based group for its use in COVID-19.<sup>28</sup>

**Table 1.1. Interventions of Interest** 

Intervention	Mechanism of Action	Route of Delivery	Dosage and Administration	EUA Population
Molnupiravir	Promotes RNA replication error	Oral	800 mg every 12 hours for 5 days	Individuals ≥18 years old, with mild-to-moderate COVID-19 who are at high risk for progression to severe COVID-19; not recommended for pregnant individuals; only for individuals without alternative COVID-19 treatment options
Paxlovid	Protease inhibitor	Oral	300 mg of nirmatrelvir and 100 mg of ritonavir, every 12 hours for 5 days	Individuals ≥12 years old, weighing ≥40 kg with mild-to-moderate COVID-19 who are at high risk for progression to severe COVID-19
Fluvoxamine	Unknown, potentially σ-1 receptor agonist	Oral	100 mg twice daily for 10 days	EUA is being reviewed; but in the pivotal trial, <sup>9</sup> individuals were ≥18 years old, with mild-to-moderate COVID-19, at high risk for progression to severe COVID-19

EUA: Emergency Use Authorization, IV: intravenous, kg: kilogram, mg: milligram, RNA: ribonucleic acid

#### **Other Potential Treatments**

#### **Note Regarding Emerging COVID-19 Treatments**

Reflecting the rapidly developing evidence base for COVID-19 treatments, around the time of posting of the draft Evidence Report, the FDA granted EUAs for remdesivir and bebtelovimab for our population of interest. And on March 17, 2022, trial results were reported via press release of peginterferon lambda suggesting clinically significant results in reducing hospitalization or emergency room visits among a vaccinated population with mild-moderate COVID-19. The manufacturer of peginterferon lambda announced imminent plans to submit the data to the FDA for consideration of an EUA.

While these treatments emerged too late for us to consider in the Evidence Report, we note that the interactive economic model is available on <u>ICER Analytics</u>. Decisionmakers can input clinical and economic data on these and any other available treatments to generate drug-specific cost-effectiveness results and suggested health-benefit price benchmarks.

# 2. Patient Caregiver Perspectives

We spoke with three patients, a physician-scientist who maintains a COVID-19 patient registry to track longitudinal quality-of-life trends, and the Chief Executive Officer of Solve ME, a non-profit organization whose goal is to promote research on chronic fatigue and long-term COVID-19. We supplemented our understanding with a published systematic review that documented the diversity of symptoms associated with COVID-19.<sup>29</sup>

Patients mentioned the importance of comorbid respiratory conditions (e.g., chronic obstructive pulmonary disease, asthma, and being an ex-smoker) that exacerbated their experience of COVID-19 symptoms. For instance, one patient described her difficulty in being transported to the hospital with their existing supplemental oxygen support that she uses for her chronic obstructive pulmonary disease. A patient with asthma mentioned that COVID-19 greatly exacerbated her shortness of breath causing her to feel like she was "unable to breathe" and "about to faint" while carrying out activities of daily living.

Caregivers were heavily involved with supporting activities of daily living after patients were discharged from the hospital. Caregivers supported activities such as preparing meals, bathing, and providing care for other household members who were previously cared for by the patient with COVID-19. A complicating factor for caregivers of COVID-19 patients was that they themselves may have been infected at the same time as the patient, which would greatly limit their own capacity to provide care. If the caregiver were not infected, they would need to exercise particular caution to reduce the risk of infection. Adding to this, households with members not eligible to be vaccinated or with members who were at higher risk from COVID-19 faced greater care impact and disruptions to daily life due to greater need for isolation.

Patients endorsed averting death as being the most important outcome. Patients also endorsed the restoration of their ability to carry out activities of daily living as being very important. A systematic review of quality of life and symptoms associated with COVID-19 documented a large number of symptoms, with fever, muscle pain, cough, shortness of breath, and diarrhea being the most common.<sup>29</sup> Additionally, the study noted that symptoms may persist for months after infection, with respiratory symptoms, fatigue, and reduced mental health being some of the most common longer-term symptoms.

In terms of their experience with treatment, a patient reported appreciating the near immediate restoration of their ability to taste and to smell. At the time that the interviews were conducted, only monoclonal antibodies were available. However, patients expressed a preference for oral agents, and intramuscular and subcutaneous injections over IV infusions. Patients ultimately expressed willingness to use whichever treatment was most effective, regardless of mode of administration.

Patients with employer-sponsored health insurance (in contrast to patients dually eligible for Medicare and Medicaid) mentioned the substantial financial burden of COVID-19 hospitalization. Whereas COVID-19 testing and vaccines are covered without out-of-pocket costs, there is no federal requirement that plans fully cover the costs of COVID-19 treatment. Earlier in the pandemic, many individual health plans waived cost-sharing for treatment either voluntarily or due to state requirement.<sup>30</sup> However, the majority of the voluntary cost-sharing waivers have now expired. Research supports the potentially large financial burden of COVID-19 hospitalizations. Even early in the pandemic, when cost-sharing waivers were likely more common, out-of-pocket costs for hospitalizations for COVID-19 for privately insured and Medicare beneficiaries were \$788 and \$277.<sup>31</sup> Among those who did not have hospital facility cost-sharing waived in that study, out-of-pocket costs for hospitalizations for COVID-19 for privately insured and Medicare beneficiaries were \$3,840 and \$1,536, respectively.

Stakeholders also discussed the need for easy access to rapid diagnostic tests so that patients could be treated early. Currently, treatment is constrained in part by lack of availability of rapid testing, leading to a potential undercounting of COVID-19 cases. Inequities in diagnostic access could amplify inequities in treatment. Further, with constrained diagnostic capacity, patients need to rely on self-assessment of symptoms. Indeed, several patients indicated that difficulty breathing was a key reason for initially seeking treatment.

# 3. Comparative Clinical Effectiveness

#### 3.1. Methods Overview

Details on our systematic literature review methodology may be found in <u>Section D1 of the Supplement</u>.

## **Scope of Review**

In January 2022, the FDA revised the EUA for REGEN-COV to exclude its use all US geographic regions due to the emergence of the Omicron variant, which is not susceptible to REGEN-COV. Similarly in April 2022, with the emergence of the Omicron variant sub-lineage BA.2, the FDA similarly revised the EUA for sotrovimab. The BA.2 Omicron subvariant is currently the dominant variant in all US regions.<sup>32</sup> This review focuses on assessing the evidence of the clinical effectiveness of molnupiravir, Paxlovid, and fluvoxamine for non-hospitalized patients with mild-to-moderate COVID-19. The full scope of the review is in Section D1 of the Supplement. A discussion of the clinical effectiveness of REGEN-COV is available in Section D2 of the Supplement and a discussion of sotrovimab is available in Section D2 of the Supplement.

#### **Evidence Base**

Key information about the pivotal trials for each agent, including information on study size, duration, patient characteristics, and outcome measures is shown in Table 3.1.

#### Molnupiravir

We identified a Phase IIa and a Phase II/III randomized, double-blind, placebo-controlled trial of molnupiravir as well as a Phase III, open-label RCT in India of a generic formulation of molnupiravir supported by a generic drug licensee. The Phase IIa study evaluated the effect of molnupiravir on viral load, safety, and tolerability.<sup>33</sup> The pivotal trial for molnupiravir, MOVe-OUT, included a Phase II portion and a Phase III portion. The Phase II portion served as a dose-finding study and was followed by the Phase III portion of the study, which evaluated the 800 mg dose of molnupiravir (the authorized dose in the EUA).<sup>34</sup> In this review, we focus on the Phase III portion of the trial and refer to this Phase III portion as "MOVe-OUT." We obtained results from this Phase III portion from an interim data analysis and a final data analysis from an FDA Advisory Committee Meeting and from a peer-reviewed publication.<sup>10-12,35</sup> Information on the Phase IIa trial is included in Section D2 and Tables D5, D10, D15, and D22 of the Supplement.

In addition to the MOVe-OUT trial, we identified a Phase III, open-label RCT conducted in India evaluating the safety and efficacy of a generic formulation of molnupiravir for COVID-19. Data for

this study was acquired from a conference presentation.<sup>36</sup> The inclusion criteria were not fully defined in the conference presentation but appear to be different from our population of interest. This study included individuals who had mild (as opposed to mild-to-moderate) COVID-19 symptoms and who were not required to have a risk factor for progression to severe COVID-19. In addition, individuals in this trial had substantially lower levels of comorbidities and were younger than participants in the MOVe-OUT trial. Due to these differences, we describe the results of this trial in Section D2 of the Supplement.

#### MOVe-OUT

MOVe-OUT was a randomized, double-blind, placebo-controlled Phase III trial of molnupiravir. Patient enrollment took place globally with 46% of the participants from Latin America, 33% from Europe, 12% from Africa, and 3% from Asia. Patients were included in this trial if they were unvaccinated, at high risk for progression to severe COVID-19, and had a laboratory-confirmed diagnosis of COVID-19 as well as symptom onset within five days of randomization. Obesity was the most common qualifying risk factor for progression of disease (74%). 12

A total of 1,433 patients were enrolled, short of the 1,500-enrollment goal, after a decision was made to stop recruiting patients based on positive interim results. Participants were randomized to 800 mg of molnupiravir or placebo twice daily for five days. The median age of participants in the full-population analysis of the MOVe-OUT trial at baseline was 43 years, and 51% were female. Most of the participants in the trial were White (57%), 5% were Black, and 50% of the participants identified as Hispanic or Latino. The primary outcome assessed in MOVe-OUT was the percentage of patients who were hospitalized and/or died from the time of randomization through day 29 and incidence of adverse events. The secondary outcome for the study is a patient-reported outcome of improvement or progression of COVID-19 signs and symptoms through day 29, which was reported by measuring the severity of disease at different timepoints using the World Health Organization (WHO) 11-point scale. Description of the study is a patient timepoints using the World Health Organization (WHO) 11-point scale.

#### **Paxlovid**

Evidence to inform our review of Paxlovid in non-hospitalized patients came from one Phase II/III randomized clinical trial, EPIC-HR (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients).<sup>13</sup> An additional Phase II/III trial, EPIC-SR (Evaluation of Protease Inhibition for COVID-19 in Standard-Risk Patients) is described in <u>Section D2</u> and Tables <u>D5</u>, <u>D12</u>, and <u>D19</u> of the Supplement.

The EPIC-HR trial was a multi-center Phase III trial that randomized 2,246 patients to 400 mg oral tablets of Paxlovid or placebo twice daily for five days (Table 3.1).<sup>13</sup> Non-hospitalized adults were eligible to participate if they had a positive SARS-CoV-2 test with symptom onset no more than five days prior to randomization and had at least one risk factor for high risk of progression to severe

disease. Patients were excluded if they had been admitted to a hospital or had received any treatments for COVID-19 prior to randomization, had received a vaccination for SARS-CoV-2, had a known human immunodeficiency virus (HIV) infection with a viral load greater than 400 copies/mL or taking certain medications for HIV treatment, or were pregnant, breastfeeding, or could become pregnant. The mean age of the participants in the EPIC-HR trial at baseline was 46 years, and 49% were female. The majority (72%) of participants were White and a small minority (5%) were Black. The most common risk factor for severe COVID-19 was obesity (33%) (Table 3.1).<sup>13</sup> The primary outcome of EPIC-HR was COVID-19-related hospitalization or death for any cause through day 28. Secondary outcomes included adverse events, COVID-19 symptom severity and time to resolution, pharmacokinetics, viral load, and hospital and intensive care unit (ICU) length of stay.

#### *Fluvoxamine*

Our review of fluvoxamine was informed primarily by one randomized placebo-controlled Phase III trial conducted at 11 sites in Brazil (TOGETHER). Two additional small US-based trials of fluvoxamine, STOP-COVID and STOP-COVID 2 and one open-label cohort study, were also identified and are reviewed in <u>Section D2</u> and Tables <u>D5</u>, <u>D8</u>, <u>D13</u>, <u>D17</u>, <u>D20</u>, <u>D23</u>, <u>D28</u>, <u>D34</u>, and <u>D40</u> of the Supplement.

The TOGETHER trial was an adaptive platform-based trial focused on evaluating repurposed drugs (i.e., drugs already marketed for other indications) with anti-inflammatory properties for mild COVID-19 symptoms.<sup>37</sup> In the TOGETHER trial, 1,497 patients were randomized to receive 100 mg fluvoxamine or placebo twice daily for 10 days (Table 3.1).<sup>9</sup> Patients 18 years and older were eligible to participate if they presented to a participating outpatient care site with symptoms consistent with COVID-19 that began within seven days, had a positive rapid antigen test for SARS-CoV-2, and had at least one risk factor for high risk of progression to severe disease. Patients were excluded if they had been hospitalized previously for COVID-19, had been vaccinated for SARS-CoV-2, had any other concomitant infections, were currently using SSRIs, or had uncontrolled psychiatric disorders or suicidal ideation consistent with the FDA black box warning for fluvoxamine.<sup>38</sup>

The mean age of the participants in the TOGETHER trial at baseline was 50 years, and 58% were female. The vast majority (96%) of participants were mixed race. The most common risk factor for severe COVID-19 was age ≥50 years (44%) (Table 3.1). The primary outcome of the trial was a composite endpoint of COVID-19-related admission to an emergency setting (defined as observation for more than six hours) or referral to tertiary hospital due to COVID-19 progression within 28 days. Retention in a hospital-like setting was described as an adequate proxy for conventional hospitalization given that the wave of COVID-19 infection in Brazil during the study period (June 2020 to August 2021) exceeded conventional hospital capacity. At that time, Brazil implemented hospital-like services in emergency settings that provided care including oxygen support and mechanical ventilation. Secondary endpoints of the TOGETHER trial included viral clearance, time to symptom resolution, hospital length of stay, and adverse events.

Table 3.1. Overview of Key RCTs in Non-Hospitalized Adults with Mild-to-Moderate COVID-19 at High Risk for Severe Disease<sup>6,9,10,12,13,37,39-41</sup>

Intervention/Trial	Inclusion/Exclusion Criteria	Outcomes	Baseline Characteristics	Trial Status
Molnupiravir MOVe-OUT Phase III N=1,433 Enrollment: 5/6/21-10/2/21	Inclusion: -Symptom onset within 5 days Exclusion: -Unwillingness to use contraception at least 4 days after treatment -Prior COVID-19 vaccination -Pregnancy, breastfeeding, or could become pregnant -HBV or HCV infection with complications	Primary: -Incidence of hospitalization or death from any cause through day 29 -Incidence of adverse events Secondary: -WHO 11-point clinical progression scale	-Age (median): 43 -Gender (female): 51% -Race/ethnicity: 57% White, 7% American Indian, Alaska Native 7%, 5% Black, 3% Asian, 50% Hispanic -6% US enrollment -Risk factors: BMI ≥30 74%; age >60 years 17%; diabetes 16%	Complete  Main source: Bernal NEJM 2021
Paxlovid EPIC-HR Phase II/III N=2,246 Enrollment: 7/16/21-12/9/21	Inclusion: -Symptom onset within 5 days Exclusion: -Prior COVID-19 infection or vaccination -Pregnancy, breastfeeding, or could become pregnant -HIV infection	Primary: -COVID-19-related hospitalization or death from any cause through day 28 Secondary: -Adverse events -Symptom severity and time to resolution -Viral load -Hospital or intensive care LOS	-Age (median): 46 -Gender (female): 49% -Race/ethnicity: 72% White, 5% Black, 14% Asian, 45% Hispanic -41% US enrollment -Risk factors: BMI ≥30 33%; age >60 years 12%; diabetes 12%	Complete  Main source: Hammond NEJM 2022
Fluvoxamine TOGETHER Phase III Adaptive Trial N=1,497 Enrollment: 1/20/21-9/9/21	Inclusion: -Symptom onset within 7 days Exclusion: -Prior COVID-19 vaccination or hospitalization -Current use of SSRIs; uncontrolled psychiatric disorders or suicidal ideation	Primary: -COVID-19-related admission to an emergency setting or referral to tertiary hospital within 28 days Secondary: -Viral clearance -Time to symptom resolution -Hospital LOS -Adverse events	-Age (median): 50 -Gender (female): 58% -Race/ethnicity: 96% mixed, 1% White, 1% Black, 3% unknown -0% US enrollment -Risk factors: BMI ≥30 31%; age ≥50 years 44%; type 2 diabetes 13%	Ongoing (interim data)*  Main source: Reis Lancet 2021

BMI: body mass index, ED: emergency department, EUA: Emergency Use Authorization, HBV/HCV: hepatitis B/C virus, HIV: human immunodeficiency virus, LOS: length of stay, N: total number, SSRI: selective serotonin reuptake inhibitor, WHO: World Health Organization

<sup>\*</sup>Our data represents the results from the entire population, after the trial's data safety monitoring committee recommended that recruitment be stopped after the study met prespecified superiority criterion for the primary endpoint trial. However, the study investigators informed us that they are continuing the study to evaluate secondary outcomes.

#### 3.2. Results

#### **Clinical Benefits and Harms**

Table 3.2 summarizes key clinical benefits from the Phase III trials of the drugs of interest.

Table 3.2. Key Trial Results<sup>6,9-13</sup>

Intervention (Trial)	Hospitalization or Death from Any Cause, n/N (%)		Mortality, n/N (%)		Change in Vii Baseline, log: (95%	10 Copies/mL
	Intervention	Placebo	Intervention	Placebo	Intervention	Placebo
Molnupiravir (MOVe-OUT)	48/709 (6.8)	68/699 (9.7)	1/709 (0.1)	9/699 (1.3)	Difference from placebo: -0.33 (-0.5, -0.16)†	
Paxlovid (EPIC-HR)	8/1,039 (0.8)	66/1,046 (6.3)	0/1,039 (0)	12/1,046 (1.1)	Difference from placebo: -0.70 (-0.86, -0.53)†	
Fluvoxamine (TOGETHER)	79/741 (11)*	119/756 (16)*	17/741 (2.3)	25/756 (3.3)	NR	NR

CI: confidence interval, mL: milliliter, n: number, N: total number, NR: not reported

#### Molnupiravir

In the full-population analysis of the MOVe-OUT trial (N=1,433), 48/709 (6.8%) of participants in the molnupiravir group and 68/699 (9.7%) of participants in the placebo group had been hospitalized or were dead by day 29 following randomization, a 30% (no 95% CI reported) relative risk reduction in favor of molnupiravir (Table 3.2).<sup>12</sup> One death occurred in the treatment arm and nine deaths occurred in the placebo arm; the patient who died in the treatment arm had metastatic cancer and died due to multiorgan failure from COVID-19. No formal statistical testing was performed for this relatively rare outcome of death, other than as part of the composite outcome with hospitalization described above.

At the time of the interim analysis (N=775), the primary outcome was more favorable; 28/385 (7.3%) of participants in the molnupiravir group and 53/377 (14.1%) of participants in the placebo group were hospitalized or dead by day 29 following randomization, a relative risk reduction of 48%. This represents a decrease in the reported efficacy for the primary endpoint from the interim analysis to the full population analysis of 18 percentage points in relative risk reduction. Similarly, the absolute risk difference dropped from 6.8% (95% CI: -11.3 to -2.4) in the interim analysis to 3% (95% CI: -5.9 to -0.1) in the full population analysis (Table 3.1). <sup>12</sup>

Diarrhea, nausea, and dizziness were the most common adverse reactions in the MOVe-OUT trial. The incidence of adverse events was higher in the placebo group due to the higher incidence of COVID-19 complications. A total of 216 patients (30.4%) in the molnupiravir arm had one or more

<sup>\*</sup>Observed in a COVID-19 emergency setting (for more than six hours) or hospitalized.

<sup>†</sup>Reported on day five.

adverse events compared to 231 patients (33%) in the placebo arm. Participants in the treatment arm were also less likely to discontinue their treatment regimen due to an adverse event, an outcome that occurred in 10 patients (1.4%) in the treatment arm and in 20 patients (2.9%) in the placebo arm (Table 3.3). $^{12}$ 

Molnupiravir is also suspected to cause embryo-fetal toxicity and bone and cartilage toxicity based on data from animal models.<sup>42</sup> It is not recommended for use during pregnancy and is not authorized for use for patients under 18 years of age.<sup>5</sup> While molnupiravir's mechanism of action (causing viral mutagenesis) raised concerns with mutagenicity in initial in-vitro assays,<sup>42</sup> subsequent in-vivo animals assays and the short course of therapy has caused the FDA to classify molnupiravir as "low risk" for genotoxicity.<sup>43</sup>

#### **Paxlovid**

The primary endpoint of the EPIC-HR trial was hospitalization or death calculated in the modified intention-to-treat analysis population, which was defined as the participants randomized within three days of symptom onset who did not receive previous monoclonal antibody treatment. To align with our reporting of the molnupiravir Phase III trial, we present the outcome of hospitalization or death among participants randomized within five days of symptom onset (n=2,085). In this population, the proportion of patients with a COVID-19-related hospitalization or death through day 28 was 8/1,039 (0.8%) in the Paxlovid group and 66/1,046 (6.3%) in the placebo group, an 88% relative risk reduction (no CI provided) and an absolute reduction of 5.62% (95% CI: -7.21, -4.03, Kaplan-Meier estimated) (Table 3.2).

In the EPIC-HR trial, adverse events were more common in the placebo group. Adverse events that occurred more frequently in the Paxlovid group than the placebo group included distorted sense of smell (6%), diarrhea (3%), hypertension (1%), and muscle pain (1%). Discontinuation due to adverse events occurred in 2% of participants in the Paxlovid group and 4% in the placebo group.<sup>13</sup>

#### **Fluvoxamine**

In the TOGETHER trial, 79/741 (11%) of participants in the fluvoxamine group (intention-to-treat analysis) were observed in a COVID-19 emergency setting (for more than six hours) or transferred to a hospital compared to 119/756 (16%) of participants in the placebo group (relative risk reduction 32%, 95% CI: 12% to 48%) (Table 3.2).<sup>9</sup> The observed difference in the primary endpoint between fluvoxamine and placebo was driven largely by the proportion of patients observed in an emergency setting (1% in the fluvoxamine vs. 5% in the placebo group, p=0.0001), while rates of hospitalization (all cause or COVID-19-related) did not differ between groups. There were also no statistically significant differences in viral clearance, time to hospitalization, hospital length of stay, death, or mechanical ventilation between the two groups.

Adherence to both fluvoxamine and placebo treatment regimens (defined as adhering more than 80% of the time) was relatively low in the TOGETHER trial. See the Uncertainty and Controversies Specific to Fluvoxamine section for further discussion of potential reasons for non-adherence in this trial. Among patients taking fluvoxamine, 548/741 (74%) were adherent, compared to 619/758 (82%) for patients taking placebo.<sup>9</sup> In the per-protocol population, the relative risk reduction of the primary endpoint was more favorable (relative risk reduction 66%, 95% CI: 46% to 79%) than in the intention-to-treat population. Furthermore, in the per-protocol analysis, there was one death (<1%) in the fluvoxamine group and 12 deaths (2%) in the placebo group (p=0.022). The exclusion of the relatively large number of non-adherent individuals can introduce bias in the per-protocol analysis. Therefore, we suggest that the intention-to-treat analysis be given greater consideration than the per-protocol analysis for informing clinical and policy decision-making.

In a recent systematic review with meta-analysis, the researchers judged that the primary composite outcome in the TOGETHER trial (observation in a COVID-19 emergency setting for more than six hours or hospitalization) was not comparable to the hospitalization outcome in the STOP-COVID 1 or STOP-COVID 2 trials and, instead, researchers pooled data on emergency room visits or hospitalizations lasting >24 hours across the three trials.<sup>44</sup> In this pooled estimate, 88/1,093 (8.1%) in the fluvoxamine group had an emergency department visit or hospitalization lasting >24 hours compared to 121/1,103 (11%) in the control group (RR: 0.75; 95% CI: 0.58 to 0.97).

As noted earlier, in the TOGETHER trial, 84 (26%) participants in the fluvoxamine group and 64 (18%) participants in the placebo group discontinued due to treatment intolerability. However, the risk for having any adverse event or a serious adverse event in the fluvoxamine arm is similar to the risk in the placebo arm of the TOGETHER trial as well as to the intervention arms in the Phase III trials for the other drugs of interest (Table 3.3).

Table 3.3. Key Adverse Events<sup>6,9,10,12,13</sup>

Intervention	Any Adverse Event, n/N (%)		/N (%) Serious Adverse Events, n/N (%)		Discontinuation Due to Adverse Event, n/N (%)	
(Trial)	Intervention	Placebo	Intervention	Placebo	Intervention	Placebo
Molnupiravir (MOVe-OUT)	216/710 (30)	231/701 (33)	49/710 (7)	67/701 (10)	10/710 (1)	20/701 (3)
Paxlovid (EPIC-HR)	255/1,109 (23)*	266/1,115 (24)*	18/1,109 (2)	74/1,115 (7)	23/1,109 (2)	47/1,115 (4)
Fluvoxamine (TOGETHER)	169/741 (23)†	188/756 (25)†	59/741 (8)	70/756 (9)	84/741 (26)	64/756 (18)‡

n: number, N: total number

<sup>\*</sup>Treatment-emergent adverse event.

<sup>†</sup>Summed treatment-emergent adverse events of various severities.

<sup>‡</sup>Discontinuation due to side effects.

## **Subgroup Analyses and Heterogeneity**

In the pivotal trials of the agents in this review, treatment effects across most subgroups were generally indistinguishable from the average treatment effect. In patients with diabetes in the MOVe-OUT trial (full analysis set) of molnupiravir, patients treated with molnupiravir had slightly greater risk of being hospitalized or dying compared to the placebo arm (15.9% vs. 14.5%).<sup>10</sup> In the EPIC-HR trial of Paxlovid, lower risk patients (such as those 65 years of age or younger or with SARS-CoV-2 seropositive status) had lower absolute risk reduction relative to placebo compared with higher risk patients.<sup>13</sup>

We sought subpopulation data from manufacturers on the effectiveness of the interventions in subgroups of interest such as race, vaccination status, variant of concern, time since randomization, serum antibody status, and individual risk factors for progression to severe disease. Data was either not available or insufficient to assess differential effectiveness in these populations. In particular, we highlight the low representation of Black patients in the Phase III trials for molnupiravir and Paxlovid. This is problematic because Black populations are at higher risk of infection, hospitalization, and mortality due to COVID-19.<sup>16</sup>

## **Uncertainty and Controversies**

While the clinical trials of all three agents demonstrate statistically significant benefits of treatment, there remains substantial uncertainty regarding the comparative effectiveness of each drug in the current US landscape. Some of this uncertainty comes from the preliminary nature of the evidence base, which rests upon a single Phase III RCT for each drug, without an additional confirmatory trial. Further, in attempts to compare these drugs to each other, we note that there are some differences in the composite outcome measures used, and differences in the spectrum of risk factors for progression to severe COVID-19 among different trial populations.

But perhaps the most notable source of uncertainty is the difficulty in interpreting the generalizability of results of studies conducted in ex-US settings during periods with different prevalent COVID-19 variants. This is not to criticize the design of the clinical trials of these drugs, nor should anyone expect studies done during a fast-moving pandemic to be able to provide high certainty in all areas. Clinical and policy decisions will need to be made given the best evidence available, yet it will be equally important for decisionmakers to be aware of the limitations of the evidence and the key remaining questions that future studies should address. We expand on these issues below.

#### Early Status of the Evidence Base

The evidence base for all three drugs remains at an early stage of maturity. Each drug's evidence is based on a single Phase III RCT among the population of interest. This lack of data makes it difficult to fully evaluate these drugs. Illustrating the evolution of our understanding of treatment efficacy, in the molnupiravir Phase III trial, the interim analysis reported a relative risk reduction of 48% in all-cause hospitalization or death while the full analysis reported a relative risk reduction of 30% (Table 3.2). However, as we note in Section 3.1 and in Section D2 of the Supplement, there is an additional open-label Phase III RCT conducted in India evaluating a generic formulation of molnupiravir for the treatment of COVID-19 not in the population of interest and with different outcome measures. The results of that study support the efficacy of molnupiravir over standard of care.

#### Lack of Comparability Across Trials for the Drugs of Interest

Substantial differences in patient populations across the Phase III trials preclude us from making direct comparisons across these trials. Molnupiravir trials enrolled substantially larger proportions of individuals with obesity compared to the fluvoxamine and Paxlovid trials. Clinical experts have advised that the current broad definition of "high-risk" outpatients contains groups that are at much higher risk, such as older individuals, than others, such as individuals with hypertension only. Further, as will be emphasized below, the large variability in the countries of recruitment and the timing of trial enrollment reduces study comparability.

Another factor in the uncertainty across trials is that they defined outcomes differently. The trials of molnupiravir and Paxlovid have very similar composite outcomes, but experienced clinical trial experts know that even identical composite outcomes in different trials are prone to differences in clinical record-keeping and other factors that can create unknown biases. In this review, the most obvious difference lies in the composite outcome measure for fluvoxamine compared to the other agents. The fluvoxamine TOGETHER trial appears to be the least comparable in this regard. The primary outcome in the fluvoxamine TOGETHER trial was retention in a COVID-19 emergency setting for more than six hours or transferred to a hospital. In contrast, the primary outcome for the Phase III trials for molnupiravir and Paxlovid was hospitalization or death. The authors of the TOGETHER trial, which was performed in Brazil, point out that the way they defined their composite outcome was driven by the limits on hospital capacity in that country during peak COVID-19 waves.9 These limits meant that very ill patients were required to be held for long periods of time in emergency department settings rather than be admitted to hospital. This broader definition was described therefore as an adequate proxy for conventional hospitalization, but the comparability of these outcomes remains unclear. Further, while molnupiravir and Paxlovid reduced hospitalizations or death, fluvoxamine did not have a statistically significant effect on hospitalizations alone or death alone as secondary outcomes.

#### **Generalizability of Results**

The SARS-CoV-2 virus is rapidly evolving, with different variants appearing and gaining dominance in different parts of the world at different points in time. None of the Phase III trials reported inclusion of patients infected with the Omicron variant. Only the Phase III trial for molnupiravir (MOVe-OUT) reported inclusion of patients infected with the Delta variant. This rapid evolution reduces the certainty with which we can apply results from trials conducted even as recently as one year ago to the current population of patients who will become infected with COVID-19 in the US now and in the future. As a result of these shifts, the relative effectiveness of treatments may vary. As an extreme example, as noted earlier, while REGEN-COV demonstrated high efficacy in its Phase III RCT and was the dominant outpatient treatment used for many months,<sup>45</sup> when the Omicron variant emerged, laboratory data indicated that REGEN-COV had limited activity against it, and its EUA was revised to limit its use. 32,46 Similarly, when Omicron variant sub-lineage BA.2 emerged, laboratory data indicated that sotrovimab had limited activity against it, and its EUA was also revised. The clinical consequences of COVID-19 infection appear to be changing as well, with the Omicron variant leading to less severe disease compared to prior variants.<sup>47</sup> All else being equal, less severe disease will reduce the clinical and economic value of treatment, whereas if a more lethal variant were to emerge and become dominant, the relative effectiveness of outpatient treatments might lead to significantly greater absolute benefit across the population.

In addition to rapid evolution of SARS-CoV-2 affecting the generalizability of prior study findings, the population being treated in the studies we reviewed also differs from the full population of patients likely to be treated today. First, key trials for the drugs of interest either explicitly excluded individuals vaccinated against SARS-CoV-2 or were conducted at a time when few to no individuals were vaccinated. Compared to trial results among unvaccinated groups with comorbid risk factors, clinical experts have advised that it is likely that vaccinated groups with comorbid risk factors would have lower risks of serious infection progressing to a requirement for hospitalization, thereby reducing to some extent the relative and absolute benefit of treatment.

Second, individuals enrolled in the Phase III trials may be healthier than treated individuals in the real world. We identified 10 real-world studies of populations treated with the drugs of interest or REGEN-COV.<sup>48-59</sup> See Section D2 and Tables D23-D27, D29-D33, and D35-D40 of the Supplement for more details regarding these studies. When comparing the characteristics of the trial populations to the real-world study populations, we find that the trial populations were younger than those reported in real-world study populations, with median ages ranging between 43 and 53 in the Phase III trials (Table 3.1), and 51 and 65 in the real-world studies we identified. Similarly, the trial populations were less likely to have chronic obstructive pulmonary disease, diabetes, chronic kidney disease, or liver disease than the treated populations in the real-world studies. These factors may be associated with the highest risks for severe COVID-19 disease.<sup>60-63</sup> Perhaps reflecting the lower-risk population in the clinical trials, the rates of hospitalization for the untreated COVID-19

population (i.e., placebo arm) in the Phase III trials—with the exception of fluvoxamine—were lower than in most of the control arms in these real-world studies (Table 3.2).

Lastly, study participants in the molnupiravir and fluvoxamine trials were primarily or exclusively outside of the US. This reduces the generalizability of results to the US population since countries may vary in prevalent SARS-CoV-2 variants, health care practices and infrastructure, and risk factors for developing COVID-19. Recent information from the Centers for Disease Control and Prevention (CDC) suggests that in the current Omicron wave, the risk for hospitalization among known-infected individuals has been dropping well below the rates seen in the usual care arms of each of these agents.<sup>47</sup> Even among the trials of the agents themselves, there exist important differences in the background rate of hospitalization and death in the usual care arms. For example, the primary outcome rates for the usual care arm in the TOGETHER trial of fluvoxamine were substantially higher (16%) than in the Phase III trials for molnupiravir and Paxlovid (6.3 to 9.7%).

#### **Uncertainty and Controversies Specific to Molnupiravir**

The dramatic change in efficacy between the interim and final data from the Phase III trial is very unusual and raises substantial questions about how to interpret the results. Without a clear explanation for the potential cause of this shift, we have focused on the final data findings as the best estimate of the effectiveness of molnupiravir, but the uncertainty around that estimate is high. Also adding to the uncertainty about the risk-benefit balance with molnupiravir are concerns that use of this drug could lead to new, viable viral variants. A briefing document prepared by FDA staff for the Antimicrobial Drugs Advisory Committee Meeting to judge molnupiravir's efficacy and safety contained additional data on the potential for molnupiravir to cause mutations that result in reduced viral susceptibility to host antibodies or other COVID-19 antiviral or antibody treatments.<sup>64</sup> In the Phase III MOVe-OUT trial, among the 12% of patients with full genome sequence data, there was a statistically significant increase in the viral mutation rate after the five day course of therapy, as compared to placebo. The briefing document also reported on findings from the Phase I and II studies suggesting that molnupiravir could cause mutations in the SARS-CoV-2 spike protein, a key determinant of host antibody and targeted monoclonal activity. However, there is no clear evidence that emergence of spike protein amino acid changes in MOVe-OUT was associated with a rebound in viral RNA shedding, or prolonged detection of infectious virus beyond treatment day three. Clinicians and policymakers will need to balance the concrete needs of an individual patient for treatment against the theoretical concerns that such treatment has for entire populations. Further, since the EUA of molnupiravir, there have been reports of three cases of hypersensitivity reactions, including anaphylaxis.<sup>65</sup>

#### Uncertainty and Controversies Specific to Paxlovid

A key source of uncertainty with Paxlovid is the early status of the evidence base. At the time of this Evidence Report, the efficacy and safety of Paxlovid is principally supported by one study, the Phase III EPIC-HR trial.<sup>13</sup> This limits our ability to fully evaluate the quality of the study, understand the generalizability of the results, and assess potential subgroup effects. Another potential, albeit theoretical, concern is that viral resistance to Paxlovid, a protease inhibitor, is possible as HIV has developed resistance to certain protease inhibitors.<sup>66</sup>

#### **Uncertainty and Controversies Specific to Fluvoxamine**


Aside from the issues that reduce comparability, it is possible that fluvoxamine may not help contain the population-level spread of COVID-19 as much as other treatment options. In contrast to the other drugs of interest, fluvoxamine treatment did not reduce patient viral load, so it is possible that treated patients could spread the disease for a longer time. This hypothesis was not tested in any of the trials.

An additional source of uncertainty specific to fluvoxamine is the large number of study participants who did not adhere to treatment in both the fluvoxamine (26%) and usual care (18%) arms. As noted earlier, there was a much higher relative risk reduction in the primary outcome in the perprotocol analysis (66%) as compared to the intention-to-treat analysis (32%). While the reasons for this lack of adherence are unknown, it is possible that the longer duration of treatment (10 days compared to five days for Paxlovid and molnupiravir) combined with many individuals' symptoms resolving before day 10,<sup>67</sup> contributes to lower reported adherence. Fluvoxamine is generally well-tolerated and similar numbers of participants stopped fluvoxamine (n=84) and placebo (n=64) owing to issues of tolerability. None of the Phase III trials for the other drugs of interest reported on adherence, so clinicians and policymakers will need to weigh the degree to which the perprotocol results for fluvoxamine should be considered in decision-making.

# 3.3. Summary and Comment

An explanation of the ICER Evidence Rating Matrix (Figure 3.1) is provided <a href="here">here</a>.

**Figure 3.1. ICER Evidence Rating Matrix** 



#### Comparative Net Health Benefit

- A = "Superior" High certainty of a substantial (moderate-large) net health benefit
- **B = "Incremental"** High certainty of a small net health benefit
- **C = "Comparable"** High certainty of a comparable net health benefit
- **D= "Negative"-** High certainty of an inferior net health benefit

**B+= "Incremental or Better"** – Moderate certainty of a small or substantial net health benefit, with high certainty of at least a small net health benefit

**C+ = "Comparable or Incremental" -** Moderate certainty of a comparable or small net health benefit, with high certainty of at least a comparable net health benefit

**C- = "Comparable or Inferior"** – Moderate certainty that the net health benefit is either comparable or inferior with high certainty of at best a comparable net health benefit

C++ = "Comparable or Better" - Moderate certainty of a comparable, small, or substantial net health benefit, with high certainty of at least a comparable net health benefit

**P/I = "Promising but Inconclusive"** - Moderate certainty of a small or substantial net health benefit, small (but nonzero) likelihood of a negative net health benefit

**I = "Insufficient" –** Any situation in which the level of certainty in the evidence is low

#### Molnupiravir

Molnupiravir significantly reduced the risk of hospitalization or death from any cause (relative risk reduction of 30%; no 95% CI reported). Determining the clinical relevance of this relatively small absolute benefit is further complicated by the likelihood of lower baseline risks for progression to serious illness with the Omicron variant, and by lower hospitalization rates in general in the US compared to overseas health systems. Theoretical concerns about an increased risk of evolution of new viral variants and potential side effects due to the mechanism of action also cloud the precision with which the overall net health benefit can be determined. We believe that when molnupiravir use is restricted to the FDA label (e.g., individuals 18 years and older, who are not pregnant or breastfeeding, and who are without alternative COVID-19 treatment options and limited to a course of therapy of five days), much of this risk can be mitigated, but it does not seem unreasonable to assume that these risks may, on a population basis, negate the relatively small clinical benefits. For these reasons, we have assigned an ICER Evidence Rating for the overall net health benefits of molnupiravir of "Comparable or Incremental" (C+).

#### **Paxlovid**

Paxlovid significantly reduced the risk of hospitalization or death from any cause (relative risk reduction of 88%; no 95% CI reported). The treatment was generally well-tolerated and had low discontinuation rates. There are a large number of known drug interactions with ritonavir that present a safety risk (due to its mechanism of action of inhibiting the cytochrome P450, family III, subfamily A [CYP3A] enzyme).<sup>6</sup> Further, it is not recommend for patients with severe renal or hepatic impairment. There was only one Phase III RCT to support Paxlovid's efficacy and safety. For these reasons, we believe the evidence is adequate to demonstrate at least incremental net health benefit compared to usual care, but the true magnitude of that benefit cannot be determined given the current status of the evidence and the rapidly evolving COVID-19 landscape. We have assigned an ICER Evidence Rating for the comparative clinical effectiveness of Paxlovid of "Incremental or Better" (B+).

#### **Fluvoxamine**

Fluvoxamine significantly reduced the risk of COVID-19-related emergency observation (more than six hours) or tertiary hospital stay (RR of 32%; 95% CI, 12% to 48%) in the TOGETHER trial.<sup>9</sup>
However, there is uncertainty regarding fluvoxamine's efficacy in the US given the relatively wide confidence intervals, differences in health care management and outcomes in Brazil versus the US, the lack of effect on hospitalizations alone, and the potential implications of a smaller US-based trial that was stopped early due to slowing recruitment and lack of efficacy.<sup>68</sup> Further, the relatively long duration of treatment (10 days in the largest trial) may lead to lower real-world adherence and effectiveness. There was a lower percentage of serious adverse events in the intervention arm compared to the placebo arm but there was a sizeable percentage of individuals who stopped

treatment due to tolerability in both arms (11.3% and 8.4%, respectively). As an SSRI, fluvoxamine also carries an FDA drug class warning for increased risk of suicidal thinking for children, adolescents, and young adults taking antidepressants for major depressive disorder and other psychiatric disorders. <sup>46</sup> For these reasons, we do not feel we can have high certainty in the overall net health benefits of fluvoxamine and have assigned an ICER Evidence Rating of "Comparable or Incremental" (C+).

**Table 3.4. Evidence Ratings** 

Treatment	Comparator	Evidence Rating
Molnupiravir*	Usual care	C+
Paxlovid	Usual care	B+
Fluvoxamine	Usual care	C+

<sup>\*</sup>Population excludes individuals who are pregnant or who have childbearing potential.

#### Midwest CEPAC Votes

**Table 3.5. Votes on Comparative Clinical Effectiveness** 

Question	Yes	No
Given the currently available evidence, is the evidence adequate to demonstrate that the net	2	
health benefit of molnupiravir is superior to that provided by symptomatic care alone?	2	11
Given the currently available evidence, is the evidence adequate to demonstrate that the net	e, is the evidence adequate to demonstrate that the net	
health benefit of Paxlovid is superior to that provided by symptomatic care alone?	13	
Given the currently available evidence, is the evidence adequate to demonstrate that the net	net 7	
health benefit of fluvoxamine is superior to that provided by symptomatic care alone?	′	6

A majority of the panel voted that the evidence is inadequate to demonstrate that molnupiravir is superior to symptomatic care alone. Panelists cited the uncertainty around potential harms as well as the dramatic change in efficacy between the interim and final data from the Phase III trial.

The panel voted unanimously that the evidence is adequate to determine that Paxlovid is superior to symptomatic care alone. Panel members emphasized the strength of the evidence, and in particular, the relative risk reduction of 88% demonstrated in the Phase III trial. Further, Paxlovid was well-tolerated and had low discontinuation rates.

The panel was split on whether the evidence was sufficient to demonstrate that fluvoxamine is superior to symptomatic care alone. Panelists who voted "Yes" cited the treatment's ability to reduce the risk of emergency observation and hospital stay, while those who voted "No" expressed uncertainty around adherence, wide confidence intervals, differences in health care management and outcomes in Brazil versus the US, and the lack of clarity around the exact mechanism of action.

# 4. Long-Term Cost Effectiveness

### 4.1. Methods Overview

The primary aim of this analysis was to estimate the cost effectiveness of REGEN-COV, sotrovimab, molnupiravir, Paxlovid, and fluvoxamine for the treatment of COVID-19. At the time of posting of this Final Evidence Report and Meeting Summary, REGEN-COV and sotrovimab were judged by US authorities to not be effective against the dominant Omicron COVID-19 variant and are no longer authorized within the US. Therefore, economic analyses for REGEN-COV and sotrovimab are not included in this report, but we have included those findings based on pre-Omicron data in <a href="Supplement E">Supplement E</a>. We continue to use evidence from the usual care arm of the REGEN-COV and sotrovimab pivotal trials to inform the comparator arm of our economic model due to the large percentage of US patients within each of these trials.

We developed a decision analytic model for this evaluation, informed by ICER's inpatient model for COVID-19,<sup>69</sup> key clinical trials, and other prior relevant economic models.<sup>70-72</sup> Additional components were added to the model structure to account for the outpatient setting of these interventions of interest. The base-case analysis utilized a lifetime time horizon, with future costs and outcomes discounted at 3% per year, and a health care sector perspective. Productivity changes and the potential for other indirect costs and effects were considered using a modified societal perspective as a scenario analysis.

The model focused on an intention-to-treat analysis, with a hypothetical cohort of patients with mild-to-moderate COVID-19 being treated in an outpatient setting entering the model. The target population mirrored that in the pivotal trials and consisted of individuals with mild-to-moderate COVID-19 who also had clinical characteristics denoting a high risk of progression to severe disease or hospitalization. The outcomes in the usual care arm of the model were derived as a weighted average (based on US sample size) across the control arms of the pivotal trials. Given that these trials occurred prior to the emergence of the Omicron variant, it is likely these probabilities of hospitalization, respiratory support, and death may be high in comparison to the current landscape in the US. This approach would overvalue the cost effectiveness of these outpatient interventions. Another difference between the data in the trials and the likely real-world cost effectiveness of treatment is related to the vaccination status of patients in the pivotal trials. The key clinical trials enrolled primarily unvaccinated individuals with COVID-19. For our base case, we chose to model a population including both unvaccinated and vaccinated individuals to reflect what we believe will be the true real-world population of patients treated in the US once these treatments are widely available.

The model was developed in Microsoft Excel, Version 2111. A cohort of patients transitioned between health states during cycles of one month over a lifetime time horizon, modeling patients

from treatment initiation until death. The model consisted of an acute phase decision tree followed by a lifetime Markov model. The acute phase decision tree represented the COVID-19 infected period and tracked the highest setting of care received (e.g., outpatient management; emergency department visit; or inpatient hospitalization, with stratifications for level of respiratory support received). The acute phase decision tree had a duration of one month in alignment with the typical follow-up period from the pivotal trials. The lifetime Markov model consisted of health states for alive and dead. Individuals in the alive health state who did not experience any long-term sequelae of COVID-19 had costs and consequences characteristic of the general population throughout the Markov model. Individuals who experienced long-term sequelae of COVID-19 had additional utility decrements, costs, and mortality as suggested by the evidence. Patients remained in the model until they died. All patients transitioned to death due to all-cause or COVID-19-specific mortality. The model structure is presented below in Figure 4.1.




Figure 4.1. Model Structure

Cost effectiveness was estimated using incremental cost-effectiveness ratios, with incremental analyses comparing each intervention to usual care. Health outcomes and costs were dependent on the highest setting of care received, respiratory support received if hospitalized, time spent in each health state, clinical events, adverse events, and direct medical costs. Model outcomes included costs, life years, quality-adjusted life years (QALYs), equal-value life years (evLYs), and inpatient hospitalizations.

<sup>\*</sup>Model included stratifications based on level of respiratory support received.

<sup>†</sup>The alive health state tracked long-term sequelae and its associated costs and consequences, as data suggested.

The evidence for the comparator was based on a pooling of the usual care arms from each pivotal trial. Pooling was based on a weighted average across the trials, where the weight assigned was based on the US sample size (i.e., trial overall sample size multiplied by the percent of trial participants from the US). If a model input from the usual care arm of an individual trial was not available, that trial was excluded from the pooling of comparator evidence for that input. If the input was missing from more than 50% of the weighted comparator, literature was used to estimate the model input for those trials that did not report the input. More detail on how missing data were accounted for in the pooling of comparator evidence is explained within the Model Inputs section of Supplement E.

In response to public comments and new evidence since the posting of previous versions of this Evidence Report, we have made the following key changes: 1) incorporated new evidence around the percent of infections occurring among those vaccinated; 2) updated the approach for how excess deaths averted are calculated in the modified societal perspective; and 3) added a scenario analysis without future unrelated health care costs.

### 4.2. Key Model Assumptions and Inputs

Our model includes several key assumptions stated in Table 4.1. Additional assumptions may be found in <u>Supplement E.</u>

**Table 4.1. Key Model Assumptions** 

Assumption	Rationale
The comparator arm was consistent across all interventions studied. The evidence for the comparator was based on a pooling of the usual care arms from each pivotal trial. Pooling was based on a weighted average across the trials, where the weight assigned was based on the US sample size (i.e., trial overall sample size multiplied by the percent of trial participants from the US).	Pooling across the usual care arms from each pivotal trial provided a more generalizable finding to the outcomes experienced by patients receiving usual care by accounting for different time periods within the pandemic, patient populations, and variants.
The relative treatment effects reported in each trial were applied to the outcomes from the pooled usual care evidence. The relative effectiveness seen in the trial population was generalizable to the comparator arm in the model that was constructed based on pooling evidence across the usual care arms in the pivotal trials. If a trial did not report a specific treatment effect, or the reported treatment effect was not statistically significant, a treatment effect of 1.0 was assumed.	The systematic differences in the trial populations should not affect the relative effectiveness of any of the drugs relative to usual care. We did not compare the cost effectiveness between the interventions given the systematic differences in the trial populations and design.
The baseline characteristics of the cohort modeled was consistent across all intervention arms and the comparator arm. The baseline characteristics of the cohort modeled was based on a pooling of the baseline characteristics from each pivotal trial. Pooling was based on a weighted average across the trials, where the weight assigned was based on the US sample size (i.e., trial overall sample size multiplied by the percent of trial participants from the US).	The US population eligible for each treatment is expected to be similar based on clinical expert consultation. Pooling across each pivotal trial was likely to provide a more generalizable finding to the population of individuals with mild-to-moderate COVID-19 and a high risk of progression to severe disease or hospitalization.
Adjustments were made to the risk of hospitalization and death observed in the usual care arms in the pivotal trials to account for the effectiveness of the vaccine in reducing hospitalization and death for the percent of infected patients that were vaccinated.	The trials were either conducted prior to an available vaccine or predominately included unvaccinated individuals. Given that a vaccine is now available, more than 70% of US adults have received at least one dose <sup>73</sup> and the vaccine is effective at reducing hospitalization and death even for breakthrough cases, <sup>74</sup> the evidence from the trials was weighted by the effectiveness of the vaccine for those individuals who were infected but also vaccinated. Clinical experts advised that these treatments, once widely available, are unlikely to be reserved solely for unvaccinated patients, and, in fact, would likely be widely prescribed for patients who are not at high risk of progression, leading to lower absolute risks of hospitalization and death than those seen in the clinical trials.

Assumption	Rationale		
Patients were hospitalized prior to dying from COVID-19. Any deaths averted between the intervention and the comparator arm resulted from reductions in the severity of the hospitalization associated with the treatment.	Deaths in patients who only received outpatient management or an emergency department visit are not common. Further, evidence suggested an increased probability of death with higher levels of respiratory support required during the hospitalization. Therefore, we modeled deaths averted indirectly based on hospitalizations averted and higher levels of respiratory support within a hospitalization averted. Trial estimates of the mortality in the intervention arm were not used given the small numbers and clinical rationale that the deaths averted should result from a treatment's effect on averting hospitalizations or reducing the severity of hospitalizations.		
The model accounted for the long-term sequelae of COVID-19 for those who were discharged alive following a hospitalization that required mechanical ventilation. These long-term sequelae consisted of an additional disutility, cost, and mortality risk.	Recommendations in the US report the occurrence and features characteristic of the long-term sequelae possible after a COVID-19 infection. <sup>72</sup> Continued patient engagement is needed to further inform the long-term sequelae of COVID-19.		

Key model inputs are described in Table 4.2. The population characteristics used in the model equated to a baseline age of 49 years, and 52% of the population was female. Recent data (from January 2022) suggest that approximately 29% of COVID-19 cases occurring today are among individuals who are fully vaccinated with at least the primary series, and thus our model included a population that was weighted 29% vaccinated versus 71% unvaccinated.<sup>73</sup> Using this current mix of vaccinated/unvaccinated, the model finds that among patients receiving usual care without an active treatment, 1.5% require an emergency department visit, 3.6% are hospitalized, and the remaining are managed with an outpatient visit alone.

In the model, each intervention could reduce the probability of receiving an emergency department visit or being hospitalized, with the relative risk associated with each intervention reported in Table 4.2. For the three interventions included within this review, the pivotal trials did not suggest a treatment effect of the intervention on reducing emergency department visits, potentially because the effect was not statistically significant, the effect was not reported, or emergency department visits were assumed to be included as an outpatient visit.

An intervention could also reduce the severity of the respiratory support received, with the relative risk associated with each treatment also reported in Table 4.2. For the three interventions included within this review, the evidence did not suggest a treatment effect of the intervention on reducing the respiratory support required, either because the effect was not reported or the effect was not statistically significant. If evidence becomes available that suggests the three treatments (molnupiravir, Paxlovid, fluvoxamine) reduce the respiratory support required among those hospitalized, the cost effectiveness of these treatments would become more favorable. Among those hospitalized in the comparator arm of the model, the respiratory support received equated to

26% requiring no oxygen support, 35% requiring low-flow oxygen, 29% requiring high-flow oxygen or non-invasive ventilation, and 10% requiring mechanical ventilation.

The probability of death among the comparator arm of the model, after pooling across trials and adjusting for the vaccinated population, equated to 0.44%. A treatment could only reduce mortality by way of preventing a hospitalization and/or reducing the severity of the hospitalization. Using recommendations from recent COVID-19 research, our model included post-acute costs and consequences for patients who were discharged alive after being mechanically ventilated. Our model included an increased probability of death for five years (hazard ratio of 1.33), a decrease in quality of life for five years (-0.13 in the first year and -0.04 in years two to five), and an increase in health care costs for one year (\$7,859 in the first year) for patients discharged from the hospital alive after being mechanically ventilated.<sup>72</sup>

**Table 4.2. Key Model Inputs** 

Parameter	Molnupiravir	Paxlovid	Fluvoxamine
Relative Risk of an ED Visit	1.0	1.0	1.0
Relative Risk of a Hospitalization	0.70	0.12	0.68*
Relative Risk of Respiratory Support Required	1.0	1.0	1.0
Cost of a Treatment Course	\$707	\$529	\$12
Primary Source	Jayk Bernal et al., 2021 <sup>12</sup>	FDA EUA label <sup>6</sup>	TOGETHER <sup>9</sup>

ED: emergency department, EUA: Emergency Use Authorization, FDA: Food and Drug Administration \*Using the outcome of retention in a COVID-19 emergency setting or transfer to a tertiary hospital, which was suggested by clinical experts as a reasonable proxy for hospitalization in the US.

Detail on all inputs used in the model, along with their respective reference, can be found in Supplement E.

### 4.3. Results

### **Base-Case Results**

The total discounted costs, hospitalizations, QALYs, life years, and evLYs over the lifetime time horizon are detailed in Table 4.3. Each outpatient intervention resulted in additional costs, but also resulted in fewer inpatient hospitalizations, resulting in more QALYs, life years, and evLYs.

Table 4.3. Results for the Base Case, Health Care Sector Perspective

Treatment*	Treatment Cost	Total Cost	Inpatient Hospitalizations	QALYs	Life Years	evLYs
Molnupiravir	\$707	\$298,500	2.49%	15.9380	19.4739	15.9386
Paxlovid	\$529	\$298,500	0.43%	15.9637	19.5046	15.9654
Fluvoxamine	\$12	\$297,800	2.42%	15.9389	19.4750	15.9395
Usual Care		\$297,700	3.56%	15.9247	19.4580	15.9247

evLY: equal-value life year, QALY: quality-adjusted life year

Table 4.4 presents the incremental cost-effectiveness ratios from the base-case analysis, which includes estimates for the incremental cost per QALY gained, incremental cost per life year gained, incremental cost per evLY gained, and incremental cost per inpatient hospitalization averted. If evidence becomes available that suggests molnupiravir, Paxlovid, and fluvoxamine reduce the respiratory support required among those hospitalized, the cost effectiveness of these treatments would become more favorable.

Table 4.4. Incremental Cost-Effectiveness Ratios for the Base Case, Health Care Sector Perspective

Treatment*	Comparator	Cost per QALY Gained	Cost per Life Year Gained	Cost per evLY Gained	Cost per Inpatient Hospitalization Averted
Molnupiravir	Usual care	\$61,000	\$51,000	\$58,000	\$76,000
Paxlovid	Usual care	\$21,000	\$18,000	\$20,000	\$26,000
Fluvoxamine	Usual care	\$8,000	\$7,000	\$8,000	\$10,000

evLY: equal-value life year, QALY: quality-adjusted life year

### **Sensitivity Analyses**

To demonstrate the effects of uncertainty on both costs and health outcomes, we varied input parameters using available measures of parameter uncertainty (i.e., standard errors where available or reasonable ranges) to evaluate changes in findings. <u>Supplement Figures E1-E3</u> present the results from the one-way sensitivity analysis for each intervention as compared to usual care.

<sup>\*</sup>We advise against comparing the cost effectiveness between interventions given the systematic differences in the trial populations and design.

<sup>\*</sup>We advise against comparing the cost effectiveness between interventions given the systematic differences in the trial populations and design.

Notably, the most influential inputs on the cost effectiveness included the relative risk of hospitalization for each intervention and the probability of hospitalization among usual care. <u>Supplement Tables E15-E17</u> present the inputs and results for each input that appeared in the tornado diagrams.

One-way sensitivity analyses were conducted to vary one input at a time across a plausible range. The results for molnupiravir ranged from further improvement in cost effectiveness to incremental cost-effectiveness ratios that far exceeded common thresholds when the relative risk of hospitalization was near 1.0. Cost-effectiveness estimates for Paxlovid all remained below \$100,000 per QALY/evLY gained and ranged as low as to be nearly cost-saving. Paxlovid would become cost-saving at a probability of hospitalization greater than 7% for usual care. Cost-effectiveness estimates in sensitivity analyses for fluvoxamine all remained well below common cost-effectiveness thresholds and included results that the drug would be cost-saving at a probability of hospitalization greater than 5% for usual care.

A probabilistic sensitivity analysis was conducted to vary all inputs with noted uncertainty simultaneously. Tables 4.5 and 4.6 present the percent of the 1,000 iterations that were beneath thresholds of \$50,000, \$100,000, \$150,000, and \$200,000 per QALY gained and evLY gained. The majority of the iterations were beneath thresholds of \$100,000 per QALY gained or per evLY gained. Additional results from the probabilistic sensitivity analyses can be found in <a href="Supplement Tables E18-E19">Supplement Tables E18-E19</a> and <a href="Supplement Figures E4-E6">Supplement Figures E4-E6</a>.

Table 4.5. Probabilistic Sensitivity Analysis Incremental Cost per QALY Gained Results

Treatment*	Cost Effective at \$50,000 per QALY Gained	Cost Effective at \$100,000 per QALY Gained	Cost Effective at \$150,000 per QALY Gained	Cost Effective at \$200,000 per QALY Gained
Molnupiravir	31%	69%	84%	89%
Paxlovid	97%	100%	100%	100%
Fluvoxamine	100%	100%	100%	100%

QALY: quality-adjusted life year

Table 4.6. Probabilistic Sensitivity Analysis Incremental Cost per evLY Gained Results

Treatment*	Cost Effective at \$50,000 per evLY Gained	Cost Effective at \$100,000 per evLY Gained	Cost Effective at \$150,000 per evLY Gained	Cost Effective at \$200,000 per evLY Gained
Molnupiravir	33%	71%	85%	90%
Paxlovid	98%	100%	100%	100%
Fluvoxamine	100%	100%	100%	100%

evLY: equal-value life year

<sup>\*</sup>We advise against comparing the cost effectiveness between interventions given the systematic differences in the trial populations and design.

<sup>\*</sup>We advise against comparing the cost effectiveness between interventions given the systematic differences in the trial populations and design.

### **Threshold Analyses**

Threshold analyses were conducted to identify at what treatment course price each intervention would meet certain cost-effectiveness thresholds. Tables 4.7 and 4.8 present the findings from these threshold analyses using outcomes of both the QALY and evLY, respectively.

Table 4.7. QALY-Based Threshold Analysis Results, Health Care Sector Perspective

Treatment*	Current Treatment Course Price	Treatment Course Price to Achieve \$50,000 per QALY	Treatment Course Price to Achieve \$100,000 per QALY	Treatment Course Price to Achieve \$150,000 per QALY	Treatment Course Price to Achieve \$200,000 per QALY
Molnupiravir	\$707	\$560	\$1,200	\$1,900	\$2,600
Paxlovid	\$529	\$1,660	\$3,600	\$5,600	\$7,500
Fluvoxamine	\$12	\$600	\$1,300	\$2,000	\$2,700

QALY: quality-adjusted life year

Table 4.8. evLY-Based Threshold Analysis Results, Health Care Sector Perspective

Treatment*	Treatment Course Price	Treatment Course Price to Achieve \$50,000 per evLY	Treatment Course Price to Achieve \$100,000 per evLY	Treatment Course Price to Achieve \$150,000 per evLY	Treatment Course Price to Achieve \$200,000 per evLY
Molnupiravir	\$707	\$590	\$1,300	\$2,000	\$2,700
Paxlovid	\$529	\$1,750	\$3,800	\$5,800	\$7,800
Fluvoxamine	\$12	\$630	\$1,400	\$2,100	\$2,900

evLY: equal-value life year

### **Scenario Analyses**

We conducted numerous scenario analyses to assess the robustness of the results across different economic perspectives and different assumptions about critical features of the evolving epidemiology of COVID-19 and corresponding health care utilization.

### Scenario Analysis 1: Modified Societal Perspective

In the modified societal perspective, we included societal costs and outcomes associated with productivity gains/losses and ICU capacity. Supplement E provides information on the methods and inputs used to generate estimates from the modified societal perspective. Table 4.9 reports the model outcomes from the modified societal perspective. Tables 4.10 and 4.11 report the threshold prices from the modified societal perspective using outcomes of both the QALY and evLY,

<sup>\*</sup>We advise against comparing the cost effectiveness between interventions given the systematic differences in the trial populations and design.

<sup>\*</sup>We advise against comparing the cost effectiveness between interventions given the systematic differences in the trial populations and design.

respectively. The threshold prices were higher in the societal perspective as compared to the health care sector perspective for treatments. Although we do not present the societal perspective as a co-base-case, we acknowledge it may have particular relevance when the government is paying for the treatments outside of usual health care cost budgets. The pricing and value considerations for these treatments will transition shortly to the private market.

**Table 4.9. Model Outcomes, Modified Societal Perspective** 

Treatment*	Treatment Cost	Total Cost‡	ICU Admissions	QALYs <sup>†</sup>	Life Years†	evLYs <sup>†</sup>
Molnupiravir	\$707	\$301,400	0.97%	15.9524	19.4916	15.9537
Paxlovid	\$529	\$302,300	0.17%	16.0059	19.5566	16.0097
Fluvoxamine	\$12	\$300,800	0.95%	15.9543	19.4939	15.9556
Usual Care		\$300,200	1.39%	15.9247	19.4580	15.9247

evLY: equal-value life year, ICU: intensive care unit, QALY: quality-adjusted life year

Table 4.10. QALY-Based Threshold Analysis Results, Societal Perspective

Treatment*	Treatment Course Price	Treatment Course Price to Achieve \$50,000 per QALY	Treatment Course Price to Achieve \$100,000 per QALY	Treatment Course Price to Achieve \$150,000 per QALY	Treatment Course Price to Achieve \$200,000 per QALY
Molnupiravir	\$707	\$830	\$2,200	\$3,600	\$5,000
Paxlovid	\$529	\$2,400	\$6,500	\$10,600	\$14,600
Fluvoxamine	\$12	\$880	\$2,400	\$3,800	\$5,300

QALY: quality-adjusted life year

Table 4.11. evLY-Based Threshold Analysis Results, Societal Perspective

Treatment*	Treatment Course Price	Treatment Course Price to Achieve \$50,000 per evLY	Treatment Course Price to Achieve \$100,000 per evLY	Treatment Course Price to Achieve \$150,000 per evLY	Treatment Course Price to Achieve \$200,000 per evLY
Molnupiravir	\$707	\$890	\$2,300	\$3,800	\$5,200
Paxlovid	\$529	\$2,600	\$6,900	\$11,100	\$15,400
Fluvoxamine	\$12	\$950	\$2,500	\$4,000	\$5,600

evLY: equal-value life year

<sup>\*</sup>We advise against comparing the cost effectiveness between interventions given the systematic differences in the trial populations and design.

<sup>†</sup>Includes costs/outcomes for the treated patient and any excess death averted as a societal benefit.

<sup>\*</sup>We advise against comparing the cost effectiveness between interventions given the systematic differences in the trial populations and design.

<sup>\*</sup>We advise against comparing the cost effectiveness between interventions given the systematic differences in the trial populations and design.

### Scenario Analysis 2: Unvaccinated Population Only

In this scenario analysis, we restricted the population to unvaccinated individuals and therefore did not make any adjustments to the usual care arms from the pivotal trials used in the pooled comparator arm of our model. Table 4.12 reports the incremental cost-effectiveness ratios for this subpopulation. Cost-effectiveness estimates for this subpopulation were slightly more favorable than the base-case estimates that included vaccinated individuals.

Table 4.12. Incremental Cost-Effectiveness Ratios for Unvaccinated Only Subpopulation

Treatment*	Comparator	Cost per QALY Gained	Cost per Life Year Gained	Cost per evLY Gained	Cost per Inpatient Hospitalization Averted
Molnupiravir	Usual care	\$48,000	\$41,000	\$46,000	\$51,000
Paxlovid	Usual care	\$15,000	\$12,000	\$14,000	\$15,000
Fluvoxamine	Usual care	\$4,000	\$3,000	\$3,800	\$4,000

evLY: equal-value life year, QALY: quality-adjusted life year

### Scenario Analysis 3: Lower Probability of Hospitalization

In this scenario analysis, we reduced the probability of hospitalization among usual care by half of what was used in the base case. Recent research has suggested that the Omicron variant of COVID-19 may be associated with a reduced risk of severe clinical endpoints (e.g., hospitalization) by approximately half.<sup>47</sup> Thus, in this scenario analysis, we assumed a probability of hospitalization among usual care of approximately 2%. Table 4.13 reports the incremental cost-effectiveness ratios for this subpopulation. Not surprisingly, cost-effectiveness estimates for this scenario were less favorable than our base-case estimates that assumed a higher probability of hospitalization, but all incremental results remained lower than \$100,000 per additional QALY/evLY.

Table 4.13. Incremental Cost-Effectiveness Ratios for Lower Risk Subpopulation

Treatment*	Comparator	Cost per QALY Gained	Cost per Life Year Gained	Cost per evLY Gained	Cost per Inpatient Hospitalization Averted
Molnupiravir	Usual care	\$74,000	\$61,000	\$71,000	\$181,000
Paxlovid	Usual care	\$34,000	\$27,000	\$32,000	\$82,000
Fluvoxamine	Usual care	\$21,000	\$17,000	\$20,000	\$50,000

evLY: equal-value life year, QALY: quality-adjusted life year

<sup>\*</sup>We advise against comparing the cost effectiveness between interventions given the systematic differences in the trial populations and design.

<sup>\*</sup>We advise against comparing the cost effectiveness between interventions given the systematic differences in the trial populations and design.

### Scenario Analysis 4: Exclusion of Future Unrelated Health Care Costs

In this scenario analysis, we excluded future unrelated health care costs despite best practices recommending their inclusion.<sup>77</sup> Table 4.14 reports the incremental cost-effectiveness ratios for this scenario. Not surprisingly, cost-effectiveness estimates for this scenario are more favorable than our base-case estimates because this scenario includes the future life years gained but excludes the future costs associated with those life years gained.

Table 4.14. Incremental Cost-Effectiveness Ratios Excluding Future Unrelated Health Care Costs

Treatment*	Comparator	Cost per QALY Gained	Cost per Life Year Gained	Cost per evLY Gained	Cost per Inpatient Hospitalization Averted
Molnupiravir	Usual care	\$30,000	\$25,000	\$29,000	\$37,000
Paxlovid	Usual care	Cost-saving	Cost-saving	Cost-saving	Cost-saving
Fluvoxamine	Usual care	Cost-saving	Cost-saving	Cost-saving	Cost-saving

evLY: equal-value life year, QALY: quality-adjusted life year

### **Model Validation**

We used several approaches to validate the model. First, we provided the preliminary model structure, methods, and assumptions to manufacturers. Based on feedback from these groups, we refined data inputs used in the model. Second, we varied model input parameters to evaluate face validity of changes in results. We performed model verification for model calculations using internal reviewers. As part of ICER's efforts in acknowledging model transparency, we also shared the model with relevant manufacturers for external verification around the time of publishing the draft Evidence Report. Finally, we compared results to other cost-effectiveness models in this therapy area. The outputs from the model were validated against the trial/study data of the interventions.

### **Uncertainty and Controversies**

The COVID-19 pandemic continues to evolve as new variants emerge, vaccination uptake slowly increases, and the role of booster vaccinations becomes a major issue. Linked to these factors, the rate of new infections changes across seasons of the year and region of the country. The management of more serious disease also evolves, resulting in ever-changing approaches to the "usual care" of patients in emergency room and hospital settings. And all these evolving factors also affect overall hospital capacity in different regions of the country as well as broader considerations of policies such as management of infections in school and business settings.

<sup>\*</sup>We advise against comparing the cost effectiveness between interventions given the systematic differences in the trial populations and design.

As these factors evolve, the impact and the cost effectiveness of new therapies for outpatient treatment change. To capture this uncertainty and variability, we have conducted numerous sensitivity and scenario analyses. Key analyses are described above and further details on these analyses and others can be found in Supplement E.

Our base-case analysis used a common pooled comparator for each intervention. If we had chosen to compare each intervention to its own usual care arm in its pivotal trial, we would have provided very context-specific results. Pooling across the usual care arms of these pivotal trials allowed us to be more generalizable to the eligible population and representative of various secular trends observed. Given the wide differences in usual care outcomes across the trials, we believe the pooled comparator approach we used will be less likely to provide results that could be misinterpreted.

Another reason for our selection of a pooled comparator approach was driven by input from clinical experts. Experts advised us that, with the exception of the pregnancy limitations on molnupiravir and drug-drug interaction concerns with Paxlovid, clinicians will view these drugs as possible choices for the same population of patients. We therefore pooled the demographic characteristics (e.g., age and sex) across the pivotal trials to unify the population characteristics in the economic model. Given that we pooled the demographic characteristics, it was imperative that we also pool the outcomes (hospitalization, death) given the documented relationship between age and these outcomes. Our current approach to estimate the hospitalization risk, a key driver of model findings, was based on what was observed in the pooling of the pivotal trials. However, we understand the pandemic rapidly evolves and the hospitalization risk may change based on which variant(s) exist and which are dominant.

Our justification for a pooled approach notwithstanding, any pooling of data introduces its own degree of uncertainty due to systematic differences among the trials (e.g., definition of hospitalization, symptom days to start treatment, etc.) that could influence the relative effectiveness estimate for each intervention. All stakeholders should be aware that due to all of the factors that make this report a Special Assessment, we advise heightened caution in making inferences of intervention versus intervention cost effectiveness and suggest that stakeholders make use of <a href="ICER Analytics">ICER Analytics</a> to update analyses with new data on relative clinical effectiveness and health care utilization as they become available.

Our model captures the long-term sequelae of COVID-19 through an increased mortality, increased cost, and decreased quality of life for individuals that are discharged alive after being mechanically ventilated. This approach follows recently published recommendations, but we understand that uncertainty and variability in these long-term sequelae exist, and the evidence is continuing to evolve, especially as it relates to the prevalence, duration, associated consequences, and the influence of an outpatient COVID-19 treatment on these sequelae. Ongoing engagement with patients will be important to further inform the long-term sequelae associated with COVID-19.

Our modified societal perspective has important limitations and assumptions to consider when interpreting the estimates. In the modified societal perspective, we included productivity gains/losses for the patient treated during the time of the COVID-19 infection and the indirect costs and benefits to society associated with alleviating ICU capacity. We heard from stakeholders that these outpatient COVID-19 treatments could play an important role in reducing ICU capacity, and reducing health system overload is undoubtedly a good outcome for society. Capturing these system-level capacity constraints is challenging, but we attempted to do so. In our approach, we extrapolated evidence around system-level capacity outcomes to an indirect societal benefit at the per-treated patient level to quantify this in the model. We had to make numerous methodological assumptions. First, we calculated the excess deaths by calculating the slope from the non-COVID-19 ICU occupancy to the total ICU occupancy (COVID-19 and non-COVID-19 ICU stays). Second, we assumed that the excess deaths averted at the national-occupancy level could be divided evenly among each ICU admission to estimate a per-treated patient effect. Our model did not include the potential productivity benefits associated with preventing premature mortality nor did it include the potential societal costs that may result if fewer people receive vaccinations with the availability of these treatments. Because the incremental cost-effectiveness ratios did not cross the \$100,000 or \$150,000 threshold between the two perspectives, the modified societal perspective was not presented as a co-base-case.

### 4.4 Summary and Comment

Our analyses suggest that each outpatient intervention produces improved clinical outcomes. At their current prices, each intervention is estimated to meet standard cost-effectiveness levels in the US health care system, even under a scenario with a lower hospitalization risk that may reflect the current Omicron wave. The cost-effectiveness findings are primarily driven by a treatment's ability to reduce hospitalization and the baseline probability of hospitalization.

# 5. Contextual Considerations and PotentialOther Benefits

Our reviews seek to provide information on potential other benefits offered by the intervention(s) to the individual patient, caregivers, the delivery system, other patients, or the public that were not captured in clinical trials and may not be fully captured within the cost-effectiveness model. These elements are listed in the table below and on the following page, with related information gathered from patients and other stakeholders.

**Table 5.1. Contextual Considerations** 

Contextual Consideration	Relevant Information
Acuity of need for treatment of individual patients based on short-term risk of death or progression to permanent disability	The acuity of need for treatment is low given the relatively low rates of hospitalization and death from COVID-19 in the population of interest.
Magnitude of the lifetime impact on individual patients of the condition being treated	The magnitude of lifetime impact is expected to be low. While a certain proportion of patients experience long-term symptoms, the large majority of patients no longer experience symptoms by 12 weeks. <sup>67,78</sup>

**Table 5.2. Potential Other Benefits or Disadvantages** 

Potential Other Benefit or Disadvantage	Relevant Information
Patients' ability to achieve major life	COVID-19 has a low impact on patients' ability to achieve life goals.
goals related to education, work, or	While the acute phase of infection limits activities of daily living, this
family life	phase is short.
Caregivers' quality of life and/or ability	COVID-19 has low impact on caregivers' quality of life and ability to
to achieve major life goals related to	achieve life goals, given the limited duration of acute illness.
education, work, or family life	achieve me goals, given the inflited duration of acute liness.
Patients' ability to manage and sustain	All treatments are short term and not expected to impose a
treatment given the complexity of	substantial burden for administration. Some patients may prefer oral
regimen	treatments over injectable treatments.
Society's goal of reducing health inequities	COVID-19 has had a higher prevalence and greater severity within communities of color in the US. Non-White COVID-19 patients and patients living in rural areas appear to be less likely to receive neutralizing antibody treatment for COVID-19. <sup>79-81</sup> If the oral drugs of interest (molnupiravir, Paxlovid, and fluvoxamine) are fairly distributed, these drugs would have some role in addressing the ongoing disparities in care and outcomes in disadvantaged communities since neutralizing antibody treatments require administration by a health care professional typically in an infusion facility or hospital.
Preventing spread of COVID-19	By reducing viral loads, molnupiravir, and Paxlovid could theoretically reduce the likelihood of treated individuals spreading SARS-CoV-2. However, this may be counteracted by symptom improvements among treated individuals that result in more social interactions than in untreated individuals.
Improving hospital capacity	Surges in hospitalizations for COVID-19 strain available capacity of local health systems to appropriately care for COVID-19 patients as well as patients with other conditions who require hospitalization. 82,83 The drugs of interest have a potential other benefit of alleviating hospital capacity by reducing hospitalization rates among the treated. We have sought to capture this quantitatively in the societal perspective analysis, but further consideration may be warranted.
Providing support for policies to manage	Effective outpatient treatments for mild-moderate COVID-19 may help
the pandemic with fewer restriction on	provide psychological reassurance allowing for broader opening of
schools and businesses	schools and workplaces.
Drug-Spe	ecific Potential Benefits/Disadvantages
Molnupiravir	Molnupiravir cannot be used in people who are attempting to conceive or who are pregnant.
Paxlovid	Paxlovid is a combination therapy containing ritonavir. Ritonavir has a large number of known drug-drug interactions that pose a safety risk. These include interactions with certain anticoagulants, antiplatelets, antiarrhythmics, anticonvulsants, and immunosuppressants. <sup>6</sup> These interactions are especially important among patients who are at particularly high risk for severe COVID-19 disease (e.g., immunosuppressed patients). <sup>7</sup>
Fluvoxamine	Fluvoxamine affects a different phase in COVID-19 pathophysiology and therefore it may be possible to combine its use with other agents.

### **Midwest CEPAC Votes**

Table 5.3. Votes on Contextual Considerations and Potential Other Benefits

Contextual Consideration	Very Low Priority	Low Priority	Average Priority	High Priority	Very High Priority
Acuity of need for treatment of individual patients based on short-term risk of death or progression to permanent disability	0	2	2	7	2
Magnitude of the lifetime impact on individual patients of the condition being treated	0	3	4	6	0

A majority of the panel voted that treatments for COVID-19 should be given high priority relative to other diseases. Although rates of COVID-19 have decreased, many panelists felt that effective treatments would offer additional protection for vulnerable populations, including individuals with comorbidities and those of older age. Further, though theoretical, effective treatments for COVID-19 may help address long COVID.

#### **Potential Other Benefits and Disadvantages**

Effective outpatient treatments for mild-moderate COVID-19 may help reduce population spread of COVID-19. Effective outpatient treatments for mild-moderate COVID-19 may reduce the number of hospitalized patients

Effective outpatient treatments for mild-moderate COVID-19 may reduce the number of hospitalized patients enough to increase capacity to treat non-COVID-19-related conditions.

Effective outpatient treatments for mild-moderate COVID-19 will help address the disparate burden of the pandemic in disadvantaged communities.

Effective outpatient treatments for mild-moderate COVID-19 may help provide psychological reassurance allowing for broader opening of schools and workplaces.

Molnupiravir cannot be used in people who are attempting to conceive or who are pregnant.

Paxlovid has many drug-drug interactions that may limit the number of patients who can use it.

Fluvoxamine affects a different phase in COVID-19 pathophysiology and therefore it may be possible to combine its use with other agents.

The above table includes potential benefits or disadvantages specific to the review of outpatient treatments for COVID-19. No vote was taken on these elements.

### 6. Health-Benefit Price Benchmarks

The health-benefit price benchmark is defined as the price range that would achieve incremental cost-effectiveness ratios between \$100,000 and \$150,000 per QALY gained or per evLY gained. health-benefit price benchmarks for the cost of a treatment course for each outpatient treatment are presented in Table 6.1.

Table 6.1. Health-Benefit Price Benchmarks for Outpatient Treatments for COVID-19

Treatment*	Treatment Course Price	Treatment Course Price at \$100,000/QALY Threshold	Treatment Course Price at \$150,000/QALY Threshold	Discount to Reach Threshold Prices
Molnupiravir	\$707	\$1,200	\$1,900	No discount needed
Paxlovid	\$529	\$3,600	\$5,600	No discount needed
Fluvoxamine	\$12	\$1,300	\$2,000	No discount needed
Treatment*	Treatment Course Price	Treatment Course Price at \$100,000/evLY Gained Threshold	Treatment Course Price at \$150,000/evLY Gained Threshold	Discount to Reach Threshold Prices
Molnupiravir	\$707	\$1,300	\$2,000	No discount needed
Paxlovid	\$529	\$3,800	\$5,800	No discount needed
Fluvoxamine	\$12	\$1,400	\$2,100	No discount needed

evLY: equal value of life years, QALY: quality-adjusted life year

<sup>\*</sup>We advise against comparing the cost effectiveness between interventions given the systematic differences in the trial populations and design.

### **Midwest CEPAC Votes**

Table 6.2. Votes on Long-Term Value for Money at Current Prices

Question	Low	Intermediate	High
Given the available evidence on comparative effectiveness, incremental cost effectiveness, and potential other benefits or disadvantages, what is the long-term value for money of treatment at current pricing with molnupiravir versus usual symptomatic care?	8	5	0
Given the available evidence on comparative effectiveness, incremental cost effectiveness, and potential other benefits or disadvantages, what is the long-term value for money of treatment at current pricing with Paxlovid versus usual symptomatic care?	0	5	8
Given the available evidence on comparative effectiveness, incremental cost effectiveness, and potential other benefits or disadvantages, what is the long-term value for money of treatment at current pricing with fluvoxamine versus usual symptomatic care?	1	7	5

A majority of the panel voted that molnupiravir represents a "low" value for money at current pricing. Although molnupiravir's incremental cost-effectiveness ratio is below traditional thresholds, panelists reiterated the substantial uncertainty around the data (as described in Section 3). On Paxlovid, eight out of 13 panelists voted "high," in line with the treatment's favorable incremental cost-effectiveness ratio (\$21,000 per QALY gained) and the strength and magnitude of the clinical evidence. Lastly, and similar to the vote on clinical evidence, the panel was somewhat split on fluvoxamine, with seven panelists voting "intermediate" and five voting "high." Although fluvoxamine had the lowest cost per QALY gained at \$8,000, there still exists considerable uncertainty around the evidence.

# 7. Potential Budget Impact

A potential budget impact analysis was not conducted for this Special Assessment. Due to the narrow margins of cost and survival benefit, a potential budget impact analysis was not considered policy relevant.

### 8. Policy Recommendations

Following its deliberation on the evidence, the Midwest CEPAC engaged in a moderated discussion with a policy roundtable about how best to apply the evidence on the use of outpatient treatments for COVID-19. The policy roundtable members included one patient advocate, two clinical experts, two payer representatives, and three representatives from the drug companies. The discussion reflected multiple perspectives and opinions, and therefore, none of the statements below should be taken as a consensus view held by all participants.

#### **Federal Government**

Federal policymakers should view the advance market commitment strategy followed with outpatient COVID-19 treatments as a success that should be built upon.

The federal government's advance market commitment mechanism was effective in reducing the financial uncertainty that could deter manufacturers from bringing a drug to market. These financial risks are due to uncertainty regarding the expected market size and duration because of difficulty in predicting to FDA indication, uptake by providers, and evolving variants with different treatment susceptibility and virulence. The federal government's advance market commitment approach substantially reduced manufacturer risk and resulted in multiple drugs becoming available in a relatively short time at prices that were aligned with clinical benefit.

The framework for drug price negotiation between the government and drug makers during a pandemic should be made more transparent so that the public is aware of the parameters that the federal government considers in pricing negotiations.

There is a lack of clarity regarding the parameters that the federal government uses to negotiate drug prices and the justification for the amount of treatment purchased for different therapies. Such frameworks for pricing and volume should be determined prior to the pandemic.

The federal government should continue to include pricing protection clauses in future pricing negotiations in order to be good stewards of tax-funded budgets.

The contract terms between the federal government and Pfizer for Paxlovid were made public through a FOIA request.<sup>84</sup> The contract terms included a buyback clause in which Pfizer would buy back the US government's Paxlovid supply if its EUA were withdrawn. The contract also contained a most-favored nation clause, which guarantees that if one of six other high-income countries gets a lower price, the US would automatically get the same lower price. Such provisions provide assurance that tax-funded budgets are being used to purchase treatments that are aligned with clinical benefit.

# The FDA needs to establish a clear and effective pathway for supporting evaluation of repurposed drugs.

Since manufacturers do not have a direct financial incentive to pursue FDA authorization to repurpose off-patent drugs for the treatment of COVID-19, the FDA needs to establish a proactive pathway to identify potential drugs where the data suggests that a review is warranted. For instance, this may include proactive outreach to study investigators to invite applications and providing technical assistance during application development as well as internal application initiation and development by the FDA.

The federal government needs to work with stakeholders to develop more robust data infrastructure and standardized treatment allocation approaches to achieve more efficient and equitable distribution of treatment supplies during a pandemic.

A recent study of Medicare beneficiaries reported that from November 2020 to August 2021 only 7.2% of outpatients with a new COVID-19 diagnosis received monoclonal antibody treatment.<sup>80</sup> A large proportion of these patients are likely eligible for treatment since older age and many chronic conditions common among the elderly are risk factors for severe COVID-19. The study also found that some of the highest risk patients were the least likely to receive treatment and that there was also substantial variation in the percent of patients treated across states with Rhode Island (21%) and Washington state (1%) having the highest and lowest percentages, respectively.

Greater investment in data infrastructure is needed to prioritize the communities where treatments are most needed. Often, these are communities in which there are many people of color or other communities in which access to care is inadequate. The federal government also needs to develop a standardized approach to allocating treatments to states and for states to collaborate with private distributors systems in a manner that ensures equitable and efficient distribution. Without appropriate data infrastructure and standardized approaches to distribution of supplies from the federal government to states and private entities, the distribution of new treatments for COVID-19 will continue to be ad hoc and likely to exacerbate inequities.

The federal government should work with states and other policymakers to adopt policy changes needed to improve the effectiveness of its "test-to-treat" program.

As of April 2022, there is a paucity of sites nationwide that provide point-of-care testing and treatment in a single visit.<sup>85</sup> While limited in number, CVS Health's "MinuteClinics" are an emerging example of how such a test and treat strategy can be implemented. These clinics have co-located services for testing, prescribing, and pharmacy supply where patients may access all three services in a single visit. Test-to-treat sites like these are greatly needed to more immediately link diagnosis with treatment.

One barrier to implementing test-to-treat is the FDA's restrictions on who may prescribe COVID-19 outpatient treatments. Given the need for rapid and broad distribution of treatment during a pandemic, the federal government should consider working with states and professional stakeholders to broaden the functional scope of practitioners who can prescribe COVID-19 treatments. It may be possible to use telemedicine or other means to accomplish this goal, but allowing pharmacists to prescribe under certain circumstances should also be considered. Beyond prescribing, strategies should also be developed to increase the options for testing and for delivering medications to patients, including mobile units, kiosks, and even drones. This kind of infrastructure should be considered a long-term strategic priority for the federal government as it assesses preparedness for future pandemics.

### The federal government needs to ensure that test-to-treat sites are equitably located.

COVID-19 has had a higher prevalence and greater severity within communities of color in the US. Non-White COVID-19 patients and patients living in rural areas appear to be less likely to receive neutralizing antibody treatment for COVID-19.<sup>79-81</sup> Further, test-to-treat sites, which offer the convenience of co-located services, may differentially benefit individuals with low incomes since these individuals may have lower means to make multiple visits to access testing and treatment. Therefore, the location of test-to-treat sites should address such access disparities.

### **Guideline Developers**

Guideline developers (including clinical societies<sup>88</sup> and the National Institutes of Health<sup>89</sup>) should adopt certain best practices in guideline development. These include:

- Involving patients from diverse communities in guideline development to make sure that patient preferences are reflected in guidelines.
- Defining the target audience of their guideline, whether it is individual primary care providers or specialists, health system leaders, payers, or policymakers.
- Tailoring guidelines to the target audience such that the guidelines can serve as useful decision aids rather than just data summaries.
- To the extent possible, different guideline development groups should coordinate and communicate so that recommendations are consistent across groups.

### Manufacturers

Manufacturers should anticipate from the earliest possible stage how they will share COVID-19 treatment intellectual property with low-income countries and, if possible, provide technical assistance with scaling of the manufacturing process.

Given the large global health burden of COVID-19, and the inability to contain spread of SARS-CoV2 across borders, it is imperative that we manage the pandemic from a global perspective.

Manufacturers should consider development of additional treatment options for immunocompromised patients.

There are seven million immunocompromised adults in the US. These individuals have among the highest risks for severe COVID-19. Further, immunocompromised patients may remain infectious for a longer period of time than non-immunocompromised patients. Yet for immunocompromised patients, vaccines have lower efficacy in preventing severe COVID-19. Further, some patients on immunosuppressants may not be able to use Paxlovid due to drug interactions. Molnupiravir may have relatively lower efficacy and has not specifically been tested in this population. Therefore, manufacturers should consider developing treatment options to address this unmet need.

### **Payers and Manufacturers**

When COVID-19 drug pricing and payment moves from federal contracts into private markets, manufacturers and payers should work together to explore innovative approaches for coverage and pricing that minimize the use of restrictive coverage access as a means of cost control.

### Recommendations for Manufacturers

- Manufacturers should price treatments so they are affordable to private insurance systems and patients. Aligning the price with the relative benefit to patients, as measured in cost-effectiveness analysis, is a good starting point, but other factors should be weighed as well. The scale and immediacy of the need for treatments can create an affordability challenge even with value-based pricing. Similarly, lower pricing or some form of installment payment over a longer time period may be warranted when there has been federal investment in the early science or later development of a drug.
- For uninsured and underinsured patients, manufacturers should collaborate with governmental policymakers to ensure that patients have access to treatments independent of their ability to pay out of pocket.
- Manufacturers should consider collaborating with private payers on innovative reimbursement approaches. For example, these approaches may include subscription-based models in which manufacturers provide as much supply of drugs as needed for a flat

recurring fee.<sup>92</sup> Alternately, manufacturers and payers should consider volume-based purchasing models similar to current federal contracts where a pre-specified volume of drugs are supplied at an agreed upon price.

### **Recommendations for Payers**

- Given the need to treat COVID-19 rapidly upon symptom onset, payers should ensure that any prior authorization process leads to immediate coverage for an available and appropriate treatment and does not risk having patients not fill their prescriptions.
- The treatments available currently through EUA are so different in their effectiveness and their risk and side effect profiles that any form of step therapy would not be clinically appropriate. In the future, if there are multiple therapeutically equivalent oral outpatient treatment options for COVID-19, payers may consider formulary negotiation approaches that include the possibility of step therapy as long as those coverage policies follow criteria established to protect patients.

#### Researchers

Future research is needed to understand the epidemiology of long COVID and the impact of different prevention and treatment strategies on this condition.

Current estimates of the number of Americans with long COVID are imprecise, but may be as high as eight to 23 million.<sup>93</sup> Common symptoms include fatigue, shortness of breath, and cognitive dysfunction typically one to three months after initial infection.<sup>94,95</sup> Given the potentially large population and non-specific symptoms, more research is needed to understand the incidence, prevalence, risk factors, and symptoms of long COVID as well as ways to prevent and treat this condition. Among the treatments of interest in our review, we identified only one study that evaluated the impact of treatment on long COVID,<sup>96</sup> although we identified other treatments in earlier stages of development focusing specifically on treatment of individuals with long COVID.<sup>97-100</sup> We recommend that the clinical research community work with patients in the design and conduct studies of long COVID and that the federal government fund these studies.

Future research is needed to define and measure the effects of treatments on a more inclusive set of patient-centered and societal outcomes.

The key trials in our review primarily measured efficacy in clinical terms including viral load, hospitalization, and death. In these trials, there was a lack of inclusion of patient-reported outcomes and a lack of uniformity in those outcomes when they were reported. The key trial for Paxlovid did not measure patient-reported outcomes. <sup>101</sup> The key fluvoxamine trial <sup>102</sup> measured the patient-reported outcomes measurement information (PROMIS) Global Health Scale while the key molnupiravir trial <sup>12</sup> measured specific patient-reported COVID-19 symptoms. Researchers should work to define patient-important outcomes and clinical trialists should apply them uniformly across

trials. For instance, patient-important outcomes in COVID-19 could include time to recovery and restoration of activities of daily living. Further, the impacts of improving ICU capacity, caregiver burden, and broader impacts on the opening of education and businesses are important societal outcomes that require better measurement.

### References

- 1. Center for Systems Science and Engineering at Johns Hopkins University. COVID-19 Dashboard. Published 2021. Accessed Jan 13, 2022.
- 2. Coronavirus (COVID-19) Update: FDA Limits Use of Certain Monoclonal Antibodies to Treat COVID-19 Due to the Omicron Variant [press release]. fda.gov: Department of Health and Human Services, 1/24/22 2022.
- 3. U.S. Food and Drug Administration. FDA updates Sotrovimab emergency use authorization. Published 2022. Updated 04/05/2022. Accessed May 3, 2022.
- 4. Eiger Biopharmaceuticals, Inc., Eiger's Single-dose Peginterferon Lambda for COVID-19 Reduced Risk of Hospitalization or ER Visits by 50% in a Predominantly Vaccinated Population in Phase 3 TOGETHER Study. Published 2022. Accessed May 3, 2022.
- 5. Fact sheet for healthcare providers: Emergency Use Authorization for Molnupiravir [press release]. 2021.
- 6. Fact sheet for healthcare providers: emergency use authorization for Paxlovid [press release]. 2021.
- 7. AST Statement on Oral Antiviral Therapy for COVID-19 for Organ Transplant Recipients [press release]. myast.org: AST2021.
- 8. Gupta A, Gonzalez-Rojas Y, Juarez E, et al. Effect of Sotrovimab on Hospitalization or Death Among High-risk Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial. *Jama*. 2022.
- 9. Reis G, dos Santos Moreira-Silva EA, Silva DCM, et al. Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. *The Lancet Global Health*. 2021;10(1):e42-e51.
- 10. Merck. Molnupiravir. Paper presented at: U.S. Food & Drug Administration Antimicrobial Drugs Advisory Committee; November 30, 2021, 2021.
- 11. Food and Drug Administration. Addendum to FDA Briefing Document Antimicrobial Drugs Advisory Committee Meeting. November 30, 2021, 2021.
- 12. Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients. *N Engl J Med.* 2021.
- 13. Hammond J, Leister-Tebbe H, Gardner A, et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. *New England Journal of Medicine*. 2022.
- 14. Bartsch SM, Ferguson MC, McKinnell JA, et al. The Potential Health Care Costs And Resource Use Associated With COVID-19 In The United States. *Health Aff (Millwood)*. 2020;39(6):927-935.
- 15. Cutler DM, Summers LH. The COVID-19 Pandemic and the \$16 Trillion Virus. *Jama*. 2020;324(15):1495-1496.
- 16. Mackey K, Ayers CK, Kondo KK, et al. Racial and Ethnic Disparities in COVID-19-Related Infections, Hospitalizations, and Deaths: A Systematic Review. *Ann Intern Med.* 2021;174(3):362-373.
- 17. Montenovo L, Jiang X, Rojas FL, et al. Determinants of disparities in Covid-19 job losses. *National Bureau of Economic Research Working Paper Series*. 2020;No. 27132.
- 18. Hanson KE, Caliendo AM, Arias CA, et al. IDSA Guidelines on the Diagnosis of COVID-19: Molecular Diagnostic Testing. 2020. Accessed January 4, 2022.
- 19. Hanson KE, Altayar O, Caliendo AM, et al. IDSA Guidelines on the Diagnosis of COVID-19: Antigen Testing. 2021;2022. Accessed January 4, 2022.

- 20. Oran DP, Topol EJ. The Proportion of SARS-CoV-2 Infections That Are Asymptomatic: A Systematic Review. *Ann Intern Med.* 2021;174(5):655-662.
- 21. World Health Organization. *Coronavirus disease 2019 (COVID-19): situation report, 46.* Geneva: World Health Organization;2020.
- 22. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. *Jama*. 2020;323(13):1239-1242.
- 23. Gandhi RT, Lynch JB, Del Rio C. Mild or Moderate Covid-19. *N Engl J Med.* 2020;383(18):1757-1766.
- 24. COVID-19 Treatment Guidelines Panel. The COVID-19 Treatment Guidelines Panel's Statement on Therapies for High-Risk, Nonhospitalized Patients With Mild to Moderate COVID-19. National Institutes of Health. Published 2021. Updated December 30, 2021. Accessed January 13, 2022.
- 25. Institute for Clinical and Economic Review. *Draft Scope Treatments for COVID-19.* Aug 26 2021.
- 26. Ishima T, Fujita Y, Hashimoto K. Interaction of new antidepressants with sigma-1 receptor chaperones and their potentiation of neurite outgrowth in PC12 cells. *Eur J Pharmacol*. 2014;727:167-173.
- 27. Rosen DA, Seki SM, Fernandez-Castaneda A, et al. Modulation of the sigma-1 receptor-IRE1 pathway is beneficial in preclinical models of inflammation and sepsis. *Sci Transl Med.* 2019;11(478).
- 28. Putka S. Doctor Submits Fluvoxamine EUA Application to FDA. 2021. Accessed January 13, 2021.
- 29. Amdal CD, Pe M, Falk RS, et al. Health-related quality of life issues, including symptoms, in patients with active COVID-19 or post COVID-19; a systematic literature review. *Qual Life Res.* 2021;30(12):3367-3381.
- 30. Ortaliza J, Rae M, Amin K, McGough M, Cox C. Most private insurers are no longer waiving cost-sharing for COVID-19 treatment. *Peterson-KFF Health System Tracker*. 2021. Accessed January 4, 2022.
- 31. Chua KP, Conti RM, Becker NV. Assessment of Out-of-Pocket Spending for COVID-19 Hospitalizations in the US in 2020. *JAMA Netw Open.* 2021;4(10):e2129894.
- 32. Centers for Disease Control and Prevention. COVID Data Tracker Variant Proportions. CDC. Published 2021. Accessed January 11, 2022.
- 33. Fischer WA, Eron JJ, Holman W, et al. A Phase 2a clinical trial of Molnupiravir in patients with COVID-19 shows accelerated SARS-CoV-2 RNA clearance and elimination of infectious virus. *Science Translational Medicine*. 2021;0(0):eabl7430.
- 34. Merck and Ridgeback Biotherapeutics Provide Update on Progress of Clinical Development Program for Molnupiravir, an Investigational Oral Therapeutic for the Treatment of Mild-to-Moderate COVID-19 [press release]. April 15, 2021 2021.
- 35. Merck. Antimicrobial Drugs Advisory Committee Meeting Briefing Document. November 30, 2021, 2021.
- 36. Kumarasamy N, Saha B, Jindal A, et al. Phase III Trial of Molnupiravir in Adults with Mild SARS-CoV-2 Infection in India. Paper presented at: Conference on Retroviruses and Opportunistic Infections (CROI)2022.
- 37. ClinicalTrials.gov. Repurposed Approved and Under Development Therapies for Patients With Early-Onset COVID-19 and Mild Symptoms. U.S. National Library of Medicine. Published 2021. Accessed.
- 38. Food and Drug Administration. Fluvoxamine Maleate Tablets for oral administration. 2018.
- 39. ClinicalTrials.gov. Intramuscular VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19. U.S. National Library of Medicine. Published 2021. Accessed Aug 10, 2021.

- 40. ClinicalTrials.gov. Efficacy and Safety of Molnupiravir (MK-4482) in Non-Hospitalized Adult Participants With COVID-19 (MK-4482-002). U.S. National Library of Medicine. Published 2021. Updated November 4, 2021. Accessed.
- 41. clinicaltrials.gov. A Study of PF-07321332/Ritonavir in Nonhospitalized High Risk Adult Participants With COVID-19. U.S. National Library of Medicine. Published 2021. Accessed.
- 42. Zhou S, Hill CS, Sarkar S, et al. β-d-N4-hydroxycytidine Inhibits SARS-CoV-2 Through Lethal Mutagenesis But Is Also Mutagenic To Mammalian Cells. *J Infect Dis.* 2021;224(3):415-419.
- 43. Food and Drug Administration. Fact sheet for health care providers emergency use authorization (EUA) of Sotrovimab. Published 2021. Updated Sept 23. Accessed Sept 30, 2021.
- 44. Lee TC, Vigod S, Bortolussi-Courval É, et al. Fluvoxamine for Outpatient COVID-19 to Prevent Hospitalization: A Systematic Review and Meta-Analysis. *medRxiv*. 2021:2021.2012.2017.21268008.
- Weinreich DM, Sivapalasingam S, Norton T, et al. REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19. *N Engl J Med.* 2021;385(23):e81.
- 46. Food and Drug Administration. Fluvoxamine Maleate Tablets. Published 2021. Updated September 2012. Accessed January 1, 2021.
- 47. Lewnard JA, Hong VX, Patel MM, Kahn R, Lipsitch M, Tartof SY. Clinical outcomes among patients infected with Omicron (B.1.1.529) SARS-CoV-2 variant in southern California. *medRxiv*. 2022:2022.2001.2011.22269045.
- 48. Webb BJ, Buckel W, Vento T, et al. Real-world Effectiveness and Tolerability of Monoclonal Antibody Therapy for Ambulatory Patients With Early COVID-19. *Open Forum Infectious Diseases*. 2021;8(7).
- 49. Razonable RR, Pawlowski C, O'Horo JC, et al. Casirivimab-Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate coronavirus disease-19. *EClinicalMedicine*. 2021.
- 50. Chilimuri S, Mantri N, Gurjar H, et al. Implementation and outcomes of monoclonal antibody infusion for COVID-19 in an inner-city safety net hospital: A South-Bronx experience. *Journal of the National Medical Association*. 2021.
- 51. Piccicacco N, Zeitler K, Montero J, et al. Effectiveness of Severe Acute Respiratory Syndrome Coronavirus 2 Monoclonal Antibody Infusions in High-Risk Outpatients. *Open Forum Infectious Diseases*. 2021;8.
- 52. Piccicacco N, Zeitler K, Montero J, et al. Piccicacco Data Collection: REGN-COV Only. In:2021.
- 53. Piccicacco N, Zeitler K, Montero J, et al. Piccicacco REGN-COV Data Only: Piccicacco OFID 2021.
- 54. McCreary EK, Bariola JR, Wadas RJ, et al. Association of subcutaneous or intravenous route of administration of casirivimab and imdevimab monoclonal antibodies with clinical outcomes in COVID-19. *medRxiv*. 2021:2021.2011.2030.21266756.
- Polk C, Jacobs A, Sampson M, et al. 550 -Bamlanivimab and Casirivimab/Imdevimab treatment outcomes: Results from large healthcare system's structured implementation experience. Paper presented at: IDWeek 20212021.
- 56. Huang DT, McCreary EK, Bariola JR, et al. Effectiveness of casirivimab and imdevimab, and sotrovimab during Delta variant surge: a prospective cohort study and comparative effectiveness randomized trial. *medRxiv*. 2021:2021.2012.2023.21268244.
- 57. Bierle DM, Ganesh R, Razonable RR. Breakthrough COVID-19 and casirivimab-imdevimab treatment during a SARS-CoV-2 B1.617.2 (Delta) surge. *Journal of Clinical Virology*. 2021;145:105026.

- 58. Kakinoki Y, Yamada K, Tanino Y, et al. Impact of Antibody Cocktail Therapy Combined with Casirivimab and Imdevimab on Clinical Outcome for patients with COVID-19 in A Real-Life Setting: A Single Institute Analysis. *International Journal of Infectious Diseases*. 2022;117:189-194
- 59. Wei W, Murdock D, Jalbert JJ, et al. Real-world Effectiveness of Casirivimab and Imdevimab in Patients With COVID-19 in the Ambulatory Setting: An Analysis of Two Large US National Claims Databases. *medRxiv*. 2022:2022.2002.2028.22270796.
- 60. Bennett TD, Moffitt RA, Hajagos JG, et al. Clinical Characterization and Prediction of Clinical Severity of SARS-CoV-2 Infection Among US Adults Using Data From the US National COVID Cohort Collaborative. *JAMA Netw Open.* 2021;4(7):e2116901.
- 61. Kompaniyets L, Pennington AF, Goodman AB, et al. Underlying Medical Conditions and Severe Illness Among 540,667 Adults Hospitalized With COVID-19, March 2020-March 2021 [Table 2]. *Prev Chronic Dis.* 2021;18:E66.
- 62. Kim L, Garg S, O'Halloran A, et al. Risk Factors for Intensive Care Unit Admission and In-hospital Mortality Among Hospitalized Adults Identified through the US Coronavirus Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID-NET). Clin Infect Dis. 2021;72(9):e206-e214.
- 63. Lippi G, Henry BM. Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-19). *Respir Med.* 2020;167:105941.
- 64. U.S. Food and Drug Administration. FDA Briefing Document: Antimicrobial Drugs Advisory Committee Meeting. In: Research CfDEa, ed. fda.gov: U.S. Food and Drug Administration; 2021.
- 65. FDA. Emergency Use Authorization (EUA) for Molnupiravir 200 mg Capsules: Center for Drug Evaluation and Research Review Memorandum. In: FDA, ed. fda.gov2022.
- 66. Wensing AMJ, van Maarseveen NM, Nijhuis M. Fifteen years of HIV Protease Inhibitors: raising the barrier to resistance. *Antiviral Research*. 2010;85(1):59-74.
- 67. Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID. *Nat Med.* 2021;27(4):626-631.
- 68. Reiersen AM, Mattar C, Ignacio RAB, et al. STOP COVID 2: A phase 3 randomized controlled trial of fluvoxamine vs placebo for treatment of symptomatic outpatients with COVID-19. In:2021.
- 69. Campbell JD WM, Rind DM, Pearson SD. Alternative Pricing Models for Remdesivir and Other Potential Treatments for COVID-19; Updated Report. Published 2020. Updated November 10, 2021. Accessed Aug 12, 2021.
- 70. Jiang Y, Cai D, Chen D, Jiang S, Si L, Wu J. Economic evaluation of remdesivir for the treatment of severe COVID-19 patients in China under different scenarios. *Br J Clin Pharmacol.* 2021.
- 71. Jo Y, Jamieson L, Edoka I, et al. Cost-effectiveness of Remdesivir and Dexamethasone for COVID-19 Treatment in South Africa. *Open Forum Infectious Diseases*. 2021;8(3).
- 72. Sheinson D, Dang J, Shah A, Meng Y, Elsea D, Kowal S. A Cost-Effectiveness Framework for COVID-19 Treatments for Hospitalized Patients in the United States. *Adv Ther.* 2021;38(4):1811-1831.
- 73. Centers for Disease Control and Prevention. COVID Data Tracker. Published 2021. Accessed.
- 74. Bahl A, Johnson S, Maine G, et al. Vaccination reduces need for emergency care in breakthrough COVID-19 infections: A multicenter cohort study. *Lancet Reg Health Am.* 2021:100065.
- 75. Hernandez-Romieu A, Leung, S, Mbanya, A, Jackson, BR, Cope, JR, Bushman, D, Dixon, M, Brown, J, McLeod, T, Saydah, S, Datta, D, Koplan, K, Lobelo, F. Morbidity and Mortality Weekly Report: Health Care Utilization and Clinical Characteristics of Nonhospitalized Adults in an Integrated Health Care System 28–180 Days After COVID-19 Diagnosis. Georgia, May 2020–March 2021. In: Prevention UDoHaHSCfDCa, ed. Vol 70. MMWR2021:644-650.

- 76. Ohsfeldt RL, Choong CK, Mc Collam PL, Abedtash H, Kelton KA, Burge R. Inpatient Hospital Costs for COVID-19 Patients in the United States. *Adv Ther.* 2021;38(11):5557-5595.
- 77. Sanders GD, Neumann PJ, Basu A, et al. Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine. *Jama*. 2016;316(10):1093-1103.
- 78. Michelen M, Manoharan L, Elkheir N, et al. Characterising long COVID: a living systematic review. *BMJ Glob Health*. 2021;6(9):e005427.
- 79. Wiltz JL, Feehan AK, Molinari NM, et al. Racial and Ethnic Disparities in Receipt of Medications for Treatment of COVID-19 United States, March 2020–August 2021. *Morb Mortal Wkly Rep.* 2022;71(3).
- 80. Behr CL, Joynt Maddox KE, Meara E, Epstein AM, Orav EJ, Barnett ML. Anti–SARS-CoV-2 Monoclonal Antibody Distribution to High-risk Medicare Beneficiaries, 2020-2021. *Jama*. 2022;327(10):980-983.
- 81. Wood DA, Aleem A, Davis D. Providing Access To Monoclonal Antibody Treatment Of Coronavirus (COVID-19) Patients In Rural And Underserved Areas. In: *StatPearls*. Copyright © 2022, StatPearls Publishing LLC.; 2022.
- 82. Bravata DM, Perkins AJ, Myers LJ, et al. Association of Intensive Care Unit Patient Load and Demand With Mortality Rates in US Department of Veterans Affairs Hospitals During the COVID-19 Pandemic. *JAMA Netw Open.* 2021;4(1):e2034266.
- 83. Janke AT, Mei H, Rothenberg C, Becher RD, Lin Z, Venkatesh AK. Analysis of Hospital Resource Availability and COVID-19 Mortality Across the United States. *J Hosp Med.* 2021;16(4):211-214.
- 84. Lupkin S. Feds' contract with Pfizer for Paxlovid has some surprises. NPR2022.
- 85. COVID-19 Test to Treat Locator. 2022. Accessed 4/15/22.
- 86. Administration FaD. FACT SHEET FOR HEALTHCARE PROVIDERS: EMERGENCY USE AUTHORIZATION FOR LAGEVRIO™ (molnupiravir) CAPSULES. In: Services DoHaH, ed. fda.gov2022.
- 87. Administration FaD. FACT SHEET FOR HEALTHCARE PROVIDERS: EMERGENCY USE AUTHORIZATION FOR PAXLOVID. In: Services DoHaH, ed. fda.gov: Department of Health and Human Services; 2022.
- 88. IDSA. *IDSA Guideline on the Treatment and Management of COVID-19: Neutralizing Antibodies for Treatment.* idsociety.org: IDSA;2022.
- 89. National Institutes of Health. Therapeutic Management of Nonhospitalized Adults With COVID-19. In: Services USDoHH, ed. .
- 90. Health NIo. Prioritization of Anti-SARS-CoV-2 Therapies for the Treatment and Prevention of COVID-19 When There Are Logistical or Supply Constraints. In: Services DoHaH, ed. covid19treatmentguidelines.nih.gov2022.
- 91. AST. AST Statement on Oral Antiviral Therapy for COVID-19 for Organ Transplant Recipients. 2022.
- 92. Trusheim MR, Cassidy WM, Bach PB. Alternative State-Level Financing for Hepatitis C Treatment—The "Netflix Model". *Jama*. 2018;320(19):1977-1978.
- 93. Long COVID. Government Accountability Office; 2022. Accessed 4/15/22.
- 94. Prevention CfDCa. Post-COVID Conditions. In: Services DoHaH, ed. cdc.gov2022.
- 95. World Health Organization Clinical Services and Systems CD, Technical Advisory Group on SARS-CoV-2 Virus Evolution,. *A clinical case definition of post COVID-19 condition by a Delphi consensus*, *6 October 2021*. who.int: World Health Organization;2021.
- 96. Clinicaltrials.gov. COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19). Published 2020. Accessed April 14, 2022.

- 97. ClinicalTrials.gov. Efficacy, Safety, Tolerability of AXA1125 in Fatigue After COVID-19 Infection. Published 2022. Updated 3/3/22. Accessed 4/15/22, 2022.
- 98. ClinicalTrials.gov. Post-Acute Sequelae of Coronavirus-19 (COVID-19) With Dyspnea on Exertion And Associated TaChycardia TrEatment Study (PEACE). Published 2021. Updated 3/28/22. Accessed 4/15/22, 2022.
- 99. ClinicalTrials.gov. (CBDRA60) to Prevent or Reduce Symptoms of COVID-19 and Prevention of Post-Acute Sequelae of SARS-CoV-2 Infection PASC. Published 2021. Updated 2/22/22. Accessed 4/15/22, 2022.
- 100. ClinicalTrials.gov. Short and Medium-term Effects of Pulmonary Rehabilitation in Mild to Critical Post-acute COVID-19 (STEPCO). Published 2020. Updated 12/23/21. Accessed 4/15/22, 2022.
- 101. Hammond J, Leister-Tebbe H, Gardner A, et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. *New England Journal of Medicine*. 2022;386(15):1397-1408.
- 102. Gilmar Reis P, et al, . Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial. *The Lancet Global Health*. 2022;10(1):E42-E51.
- 103. WHO Working Group on the Clinical Characterisation and Management of COVID-19 infection. A minimal common outcome measure set for COVID-19 clinical research. *Lancet Infect Dis.* 2020;20(8):e192-e197.
- 104. Samrah SM, Al-Mistarehi A-HW, Kewan T, et al. Viral Clearance Course of COVID-19 Outbreaks. *Journal of Multidisciplinary Healthcare.* 2021;14:555 - 565.
- 105. Sands BE, Peyrin-Biroulet L, Loftus EV, Jr., et al. Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. *N Engl J Med.* 2019;381(13):1215-1226.
- 106. Bhimraj A, Morgan RL, Shumaker AH, et al. IDSA Guidelines on the Treatment and Management of Patients with COVID-19. Infectious Diseases Society of America. Published 2020. Updated January 18, 2022. Accessed January 19, 2022.
- 107. Centers for Disease Control and Prevention. Variant of Concern (VOC). Published 2021. Updated December 1, 2021. Accessed January 19, 2022.
- 108. COVID-19 Treatment Guidelines Panel. Clinical Management Summary. National Institutes of Health. COVID-19 Treatment Guidelines Web site. Published 2021. Updated July 8, 2021. Accessed Jan 14, 2022. Published 2021. Updated Sept 24, 2021. Accessed Sept 30, 2021.
- 110. Food and Drug Administration. Fact sheet for health care providers emergency use authorization (EUA) of Regen-Covtm (casirivimab and imdevimab). Published 2021. Updated Sept 17. Accessed Sept 30, 2021.
- 111. Centers for Disease Control and Prevention. Underlying Medical Conditions Associated with Higher Risk for Severe COVID-19: Information for Healthcare Professionals. Published 2022. Updated February 15, 2022. Accessed April 5, 2022.
- 112. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Published 2021. Updated Aug 4, 2021. Accessed Jan 14, 2022.
- 113. Cook DJ, Mulrow CD, Haynes RB. Systematic reviews: synthesis of best evidence for clinical decisions. *Ann Intern Med.* 1997;126(5):376-380.
- 114. Higgins J, Thomas, J, Chandler, J, Cumpston, M, Li, T, Page, MJ, Welch, VA. Cochrane Handbook for Systematic Reviews of Interventions version 6.1 (updated September 2020). Published 2020. Accessed.
- 115. Moher D, Liberati A, Tetzlaff J, Altman DG, The PG. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. *PLOS Medicine*. 2009;6(7):e1000097.

- 116. Ollendorf DA, Pearson SD. An integrated evidence rating to frame comparative effectiveness assessments for decision makers. *Medical care*. 2010;48(6 Suppl):S145-152.
- 117. Ollendorf D, Pearson, SD. ICER Evidence Rating Matrix: A User's Guide. . Published 2020. Updated January 31, 2020. Accessed.
- 118. Mlcochova P, Kemp SA, Dhar MS, et al. SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion. *Nature*. 2021;599(7883):114-119.
- 119. Centers for Disease Control and Prevention. Delta Variant: What We Know About the Science. Published 2021. Accessed.
- 120. Osugi Y, Iwata H, Imai Y, Kobayashi D, Hirashima R. Clinical Prognosis of Patients With Mild COVID-19 Treated With Casirivimab/Imdevimab in Japan. *Cureus*. 2022;14(2):e21882-e21882.
- 121. Gupta AK GRY, Juarez E, Crespo Casal M, Moya J, Rodrigues Falci D, Sarkis EH, Solis J, Zheng H, Scott N, Cathcart AL, Hebner C, Sager J, Mogalian E, Austin D, Peppercorn A, Alexander EL, Yeh WW, Free A, Brinson C, Aldinger M, Shapiro AE. 502 Early COVID-19 Treatment With SARS-CoV-2 Neutralizing Antibody ID Week 2021; 2021.
- 122. Primary endpoint met in COMET-TAIL Phase 3 trial evaluating intramuscular administration of sotrovimab for early treatment of COVID-19 [press release]. November 12, 2021 2021.
- 123. GSK. Use of Intramuscular Sotrovimab in High-Risk Non-Hospitalized COVID-19 Patients. 2022.
- 124. GSK and Vir submit Emergency Use Authorization application to FDA for intramuscular administration of sotrovimab for the early treatment of COVID-19 [press release]. January 13, 2022 2022.
- 125. Aggarwal NR, Beaty LE, Bennett TD, et al. Real World Evidence of the Neutralizing Monoclonal Antibody Sotrovimab for Preventing Hospitalization and Mortality in COVID-19 Outpatients. *medRxiv*. 2022:2022.2004.2003.22273360.
- 126. Zaqout A, Almaslamani MA, Chemaitelly H, et al. Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild to moderate SARS-CoV-2 in Qatar. *medRxiv*. 2022:2022.2004.2021.22274060.
- 127. Pfizer Announces Additional Phase 2/3 Study Results Confirming Robust Efficacy of Novel COVID-19 Oral Antiviral Treatment Candidate in Reducing Risk of Hospitalization or Death [press release]. December 14, 2021 2021.
- 128. Lenze EJ, Mattar C, Zorumski CF, et al. Fluvoxamine vs Placebo and Clinical Deterioration in Outpatients With Symptomatic COVID-19: A Randomized Clinical Trial. *Jama*. 2020;324(22):2292-2300.
- 129. Seftel D, Boulware DR. Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19. *Open Forum Infectious Diseases*. 2021;8(2).
- 130. Regeneron. COVID Data Submission Regeneron. 2021.
- 131. Weinreich DM, Sivapalasingam S, Norton T, et al. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19. *New England Journal of Medicine*. 2020;384(3):238-251.
- 132. GSK and Vir Biotechnology Announce Continuing Progress of the COMET Clinical Development Program for Sotrovimab [press release]. June 21, 2021 2021.
- 133. Mascolini M. Sotrovimab mAb Limits Progression to Severe COVID Regardless of Serostatus. Paper presented at: Conference on Retroviruses and Opportunistic Infections (CROI)2022.
- 134. GSK. FACT SHEET FOR HEALTHCARE PROVIDERS EMERGENCY USE AUTHORIZATION (EUA) OF SOTROVIMAB. 2022.
- 135. Lenze EJ. Fluvoxamine for Early Treatment of COVID-19: The STOP COVID Clinical Trials. August 20, 2021, 2021.

# **Supplemental Materials**

## A. Background: Supplemental Information

### A1. Definitions

### **Intervention Definitions**

<u>Casirivimab/imdevimab (REGEN-COV)</u> is a cocktail of two recombinant human monoclonal antibodies administered as a onetime IV infusion or subcutaneous injection of 600 mg of each antibody. It works by binding to the receptor-binding domain of the SARS-CoV-2 spike protein, inhibiting either attachment or fusion to human cells. At the time of this report, REGEN-COV not authorized in any US region.

<u>Sotrovimab</u> is a recombinant human monoclonal antibody administered as a onetime 500 mg IV infusion. It works by binding to the receptor-binding domain of the SARS-CoV-2 spike protein, inhibiting either attachment or fusion to human cells. At the time of this report, sotrovimab is not authorized in any US region.

### **Outcome Measure Definitions**

<u>COVID-19 progression</u>: Progression of signs and symptoms of COVID-19 (i.e., cough, body ache, and fever) that gives insight into the course of disease and resources required during the illness.<sup>103</sup>

<u>WHO 11-Point Clinical Progression Scale</u>: An ordinal scale used to represent clinical progression of COVID-19 from mild, moderate, and severe stages, with a score of 0 being assigned to people who are uninfected and have no detectable viral RNA and a score of 10 being assigned to people who die.<sup>103</sup>

<u>Viral clearance</u>: Period when a patient is determined to have a negative nasopharyngeal or PCR test (two negative tests may be required to be confirmed as being negative). <sup>104</sup>

<u>InFLUenza Patient-Reported Outcome (FLU-PRO)</u>: A standardized measure of symptom severity for influenza patient-reported outcomes that requires a patient to record symptoms twice daily for 14 days to assess the presence, severity, and duration of symptoms across six body systems.<sup>105</sup>

<u>SARS-CoV-2 antigen test</u>: A diagnostic test that can generate results in approximately 15 minutes at the point-of-care. These tests tend to have high diagnostic specificity but lower sensitivity than molecular diagnostic tests.

<u>Molecular diagnostic tests</u>: A category of laboratory-based nucleic acid amplification tests that include reverse-transcription PCR tests. Molecular diagnostic tests are considered the gold standard for diagnostic COVID-19 testing and are also used for quantifying COVID-19 viral load.

Oxygen saturation: Defined as the percentage of hemoglobin in the blood that is bound to oxygen as oxyhemoglobin relative to total hemoglobin in the blood. This is typically measured using a rapid, noninvasive pulse oximeter. Hospitalization with oxygen saturation below 94% is considered severe disease.<sup>106</sup>

<u>Variant of concern</u>: Defined by the CDC as a variant "for which there is evidence of an increase in transmissibility, more severe disease, significant reduction in neutralization by antibodies generated during previous infection or vaccination, reduced effectiveness of treatments or vaccines, or diagnostic detection failures."<sup>107</sup>

<u>COVID-19 viral load</u>: Measures SARS-CoV-2 concentration after nucleic acid amplification. Viral load is typically used as secondary or surrogate measures for more clinically relevant measures such as hospitalization or death.

### A2. Potential Cost-Saving Measures in COVID-19

ICER includes in its reports information on wasteful or lower-value services in the same clinical area that could be reduced or eliminated to create headroom in health care budgets for higher-value innovative services (for more information, see <a href="ICER's Value Assessment Framework">ICER's Value Assessment Framework</a>). These services are ones that would not be directly affected by therapies for COVID-19 (e.g., hospitalizations), as these services will be captured in the economic model. Rather, we sought services used in the current management of COVID-19 beyond the potential offsets that arise from a new intervention. During stakeholder engagement and public comment periods, ICER encouraged all stakeholders to suggest services (including treatments and mechanisms of care) currently used for patients with COVID-19 that could be reduced, eliminated, or made more efficient. No suggestions were received.

# B. Patient Perspectives: Supplemental Information

# **B1.** Methods

We spoke with three COVID-19 patients, a physician-scientist who maintains a COVID-19 patient registry to track longitudinal quality of life trends, and the Chief Executive Officer of Solve ME, a non-profit organization whose goal is to promote research on chronic fatigue and long-term COVID-19. We supplemented our understanding with a published systematic review that documented the diversity of symptoms associated with COVID-19.<sup>29</sup> The three patients were identified through Savvy Cooperative, patient-owned public benefit cooperative focused on connecting health care researchers to patients.

We spoke to these stakeholders individually for 30 to 45 minutes. The conversations were informed by a semi-structured interview guide, which focused the conversation on several themes:

- 1. What is it like to live with this condition? What is the experience of caregivers?
- 2. What is the diversity of experience with the condition; what are the differences of those who have a mild versus a serious case? How does racial and socioeconomic status factor in the diversity of the patient journey?
- 3. What outcomes matter most to patients? Are there some clinical outcome measures in the clinical trials that are more relevant to what patients care about most? What outcomes are missing entirely from the "evidence" base?
- 4. What are the most important "potential other benefits" and "contextual considerations" that payers and other policymakers should be aware of in judgments of value?
- 5. What is the experience with insurance access and affordability for treatments for this condition?

After each of these conversations, patient comments were transcribed, collated, organized, and summarized. We drew upon themes that emerged from our conversations and summaries for the Patient and Caregiver Perspectives section of the report.

# C. Clinical Guidelines

Treatment guidelines for COVID-19 are rapidly changing, in part reflecting the changing treatment evidence and prevalence of different variants. We highly recommend that readers refer to current guidelines from the Infectious Diseases Society of America (IDSA). We briefly summarize this guideline—current as of March 2022—below.

# IDSA Guidelines as of April 20, 2022

For non-hospitalized outpatients with mild-to-moderate disease who are at high risk of progression to severe disease (defined in Table C1), the IDSA recommends treatment with Paxlovid or remdesivir. For this same population, the IDSA recommends molnupiravir for patients who have no other treatment options, citing concerns with low certainty regarding efficacy, the small effect size, potential viral mutagenesis as well as safety among persons of reproductive age. The IDSA currently recommends fluvoxamine only in the context of a clinical trial, citing the need for more precise estimates of efficacy and the need for greater generalizability of the results, as a key fluvoxamine trial was performed with patients having extended stays in mobile hospitals as part of the primary endpoint. Similarly, the IDSA recommends bebtelovimab only in the context of a clinical trial, citing the need for more precise estimates of efficacy.

Table C1. Factors or Conditions that Place Individuals at High Risk for Progression to Severe COVID-19 Disease<sup>43,109-111</sup>

Age ≥65 years
Cancer
Cerebrovascular disease
Chronic kidney disease
Chronic lung diseases
Chronic liver diseases
Cystic fibrosis
Dementia
Diabetes mellitus, types 1 and 2
Certain disabilities, including limitations with self-care or activities of daily living
Heart conditions
Human immunodeficiency virus
Mood disorders, including depression
Primary Immunodeficiencies
Pregnancy and recent pregnancy
Physical inactivity
Schizophrenia spectrum disorders
Smoking, current and former
Solid organ or hematopoietic cell transplantation
Tuberculosis
Use of corticosteroids or other immunosuppressive medications

# National Institutes of Health COVID-19 Treatment Guidelines as of April 20, 2022

For non-hospitalized outpatients with mild-to-moderate disease who are at high risk of progression to severe disease (Table C1), the National Institutes of Health recommends the following treatments in order of preference: Paxlovid (recommendation rating AlIa: strong recommendation based on other randomized trials or subgroup analyses of randomized trials) and remdesivir (recommendation rating BlIa: moderate recommendation based on other randomized trials or subgroup analyses of randomized trials). Molnupiravir (recommendation rating ClIa: optional recommendation based on other randomized trials or subgroup analyses of randomized trials) and bebtelovimab (ClII: expert opinion) are recommended only when none of the above options can be used. The National Institutes of Health panel's judgment is that there is insufficient evidence to recommend either for or against the use of fluvoxamine for this population.

# D. Comparative Clinical Effectiveness: Supplemental Information

# **D1. Detailed Methods**

### **PICOTS**

## **Population**

The population of focus for the review is adults and adolescents ages 12 and older with mild-to-moderate COVID-19 (confirmed with a positive SARS-CoV-2 PCR or antigen test) and a high risk of progression to severe disease.

#### Interventions

The list of interventions evaluated includes:

- Molnupiravir
- Paxlovid (PF-07321332/ritonavir)
- Fluvoxamine

#### **Comparators**

We compared each treatment to outpatient "usual care" involving only symptomatic treatments, as found in the clinical trials of each product. Data permitting, we also included real-world evidence as appropriate. Differences in patient populations and the natural history of care and outcomes for patients with COVID-19 have been evolving rapidly, making formal quantitative indirect comparisons challenging.

### **Outcomes**

The outcomes of interest are described in the list below.

- Patient-important outcomes
  - Time to symptom resolution
  - Return to work or usual activities
  - Symptom severity
  - Progression to severe or critical illness

- Degree of respiratory support
  - Conventional oxygen therapy
  - High-flow nasal cannula
  - Non-invasive positive pressure ventilation
  - Mechanical ventilation
- Medically attended visit
- Hospitalization
  - Length of stay
  - Readmission
- o ICU admission
- Long COVID
- o **Death**
- Adverse events including:
  - Side effects
  - Anaphylaxis
- Other outcomes
  - Viral load
  - o SARS-CoV-2 clearance
  - Oxygen saturation
  - Antiviral resistance
  - Inflammatory markers
  - Adverse events including:
    - Treatment-emergent adverse events and serious adverse events

# **Timing**

Evidence on intervention effectiveness and harms were derived from studies of any duration.

# Settings

The primary focus was on care settings in the US, but relevant clinical outcomes data from international settings were included. We paid particular attention to the geography and timing of the studies in considering differences among patient populations, viral variants, and outcomes.

Table D1. PRISMA 2009 Checklist

		Checklist Items					
		TITLE					
Title	1	Identify the report as a systematic review, meta-analysis, or both.					
ABSTRACT							
Structured Summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of					
ou dotal cu oullillary	-	key findings; systematic review registration number.					
		INTRODUCTION					
Rationale	3	Describe the rationale for the review in the context of what is already known.					
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).					
		METHODS					
Protocol and	_	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide					
Registration	5	registration information including registration number.					
Eligibility Criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language,					
Eligibility Criteria	0	publication status) used as criteria for eligibility, giving rationale.					
Information Sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional					
		studies) in the search and date last searched.					
Search 8		Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.					
Study Selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included					
-		in the meta-analysis).					
Data Collection	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for					
Process	10	obtaining and confirming data from investigators.					
Data Items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.					
Risk of Bias in	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at					
Individual Studies	12	the study or outcome level), and how this information is to be used in any data synthesis.					
Summary Measures	13	State the principal summary measures (e.g., risk ratio, difference in means).					
Synthesis of Results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., 12) for each meta-analysis.					
Risk of Bias across		Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting					
Studies	15	within studies).					
Additional Analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.					

		Checklist Items	
		RESULTS	
Study Selection  Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusion stage, ideally with a flow diagram.			
Study Characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	
Risk of Bias within Studies  Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).			
Results of Individual Studies  For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intergroup (b) effect estimates and confidence intervals, ideally with a forest plot.			
Synthesis of Results	ynthesis of Results 21 Present results of each meta-analysis done, including confidence intervals and measures of consistency.		
Risk of Bias across Studies  Present results of any assessment of risk of bias across studies (see Item 15).		Present results of any assessment of risk of bias across studies (see Item 15).	
Additional Analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	
		DISCUSSION	
Summary of Evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	
		FUNDING	
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	

From: Moher D, Liberati A, Tetzlaff J, Altman DG. The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(6): e1000097. doi:10.1371/journal.pmed1000097.

# **Data Sources and Searches**

Procedures for the systematic literature review assessing the evidence on outpatient treatments for mild-to-moderate COVID-19 followed established best research methods. 113,114 We conducted the review in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. 115 The PRISMA guidelines include a checklist of 27 items, which are described further in Table D1.

We searched MEDLINE, EMBASE, Cochrane Database of Systematic Reviews, and Cochrane Central Register of Controlled Trials for relevant studies. Each search was limited to English-language studies of human subjects and excluded articles indexed as guidelines, letters, editorials, narrative reviews, case reports, or news items. We included abstracts from conference proceedings identified from the systematic literature search. All search strategies were generated utilizing the Population, Intervention, Comparator, and Study Design elements described above. The proposed search strategies included a combination of indexing terms (MeSH terms in MEDLINE and EMTREE terms in EMBASE) as well as free-text terms.

To supplement the database searches, we performed manual checks of the reference lists of included trials and systematic reviews and invited key stakeholders to share references germane to the scope of this project. We also supplemented our review of published studies with data from conference proceedings, regulatory documents, information submitted by manufacturers, and other grey literature when the evidence met ICER standards (for more information, see <a href="https://icer.org/policy-on-inclusion-of-grey-literature-in-evidence-reviews/">https://icer.org/policy-on-inclusion-of-grey-literature-in-evidence-reviews/</a>).

# **Table D2. Search Strategy of Medline 1996 to Present with Daily Update and Cochrane Central Register of Controlled Trials**

1	exp COVID-19/ or exp SARS-COV-2/
	(COVID* or coronovir* or coronavir* or SARS* or 2019-nCoV or "2019 nCoV" or 2019nCoV or nCov 2019 or
2	"Severe Acute Respiratory Syndrome Coronavirus 2" or HCoV* or ((corona* or corono*) adj1 (virus* or
	viral* or virinae*))).ti,ab
3	1 or 2
4	exp "Antibodies, monoclonal"/
5	((antibod* or mAb or nAb*) adj2 (therap* or treatment)).ti,ab or ("monoclonal antibody").ti,ab
6	4 or 5
	("casirivimab and imdevimab" or casirivimab-imdevimab or "casirivimab plus imdevimab" or (casirivimab
7	ADJ3 imdevimab) or casirivimab or imdevimab or (regn10933 adj3 regn10987) or regn10933 or regn10987
/	or regn-10933 or regn-10987 or regen10933 or regen10987 or regen-10933 or regen-10987 or regen-
	COV* or "regen COV2" or regn-COV* or "regn COV2" or ronapreve).ti,ab
8	(sotrovimab or "vir 7831" or vir-7831 or "gsk 4182136" or gsk-4182136 or xevudy).ti,ab
9	(molnupiravir or "mk 4482" or mk-4482 or "eidd 2801" or eidd-2801 or lagevrio).ti,ab
	(paxlovid or pf-07321332 or "pf 07321332" or nirmatrelvir or ((pf-07321332 or nirmatrelvir) adj3 (ritonavir
10	or "a 84538" or "a-84538" or "abt 538" or abt538 or "abt-538" or norvir or RTV))).ti,ab
11	exp Fluvoxamine/
12	("ratio fluvoxamine" or "fluvoxamine maleate" or luvox or floxyfral or fevarin or dumirox or faverin or
12	desiflu or du-23000 or "du 23000" or "luvox cr").ti,ab
13	11 or 12
14	6 or 7 or 8 or 9 or 10 or 13
15	3 and 14
	(addresses or autobiography or bibliography or biography or comment or congresses or consensus
10	development conference or duplicate publication or editorial or guideline or in vitro or interview or lecture
16	or legal cases or legislation or letter or news or newspaper article or patient education handout or
	periodical index or personal narratives or portraits or practice guideline or review or video audio media).pt
17	15 not 16
18	animals.mp. not (humans and animals).sh.
19	17 not 18
20	Limit 19 to English language
21	remove duplicates from 20
4.0	sh last undeted on February 11, 2022

<sup>\*</sup>Search last updated on February 11, 2022.

<sup>†</sup>Search strategy updated to incorporate new search terms on February 11, 2022.

# Table D3. Search Strategy of EMBASE SEARCH

#1	'coronavirus disease 2019'/exp OR 'coronavirus disease 2019'
	(COVID* OR coronavir* OR coronovir* OR SARS* OR HCoV* OR 'nCov 2019' OR '2019-nCoV infection' OR
#2	'2019 nCoV' OR 2019nCoV OR 'severe acute respiratory syndrome 2' OR ((corona* or corono*) NEAR/1
	(virus* or viral* or virinae*))):ti,ab
#3	#1 OR #2
#4	'monoclonal antibody therapy'/exp OR 'monoclonal antibody therapy'
#5	('monoclonal antibody' OR ((antibod* or mAb* or nAb*) NEAR/2 (therap* or treatment*))):ti,ab
#6	#4 OR #5
#7	neutralizing:ti,ab
#8	#6 NOT #7
#9	'casirivimab plus imdevimab'/exp OR casirivimab/exp OR imdevimab/exp
	('casirivimab-imdevimab' OR 'casirivimab/imdevimab' OR 'casirivimab and imdevimab' OR 'imdevimab
#10	and casirivimab' OR regn10933 OR regn10987 OR 'regn-10933' OR 'regn-10987' OR regen10933 OR
#10	regen10987 OR 'regen-10933' OR 'regen-10987' OR 'regen-COV*' OR 'regn-COV*' OR 'regn COV2' OR
	ronapreve):ti,ab OR (casirivimab NEAR/3 imdevimab):ti,ab
#11	#9 OR #10
#12	sotrovimab/exp
#13	('vir-7831' OR 'vir 7831' OR xevudy):ti,ab
#14	#12 OR #13
#15	molnupiravir/exp
#16	('mk-4482' OR 'mk 4482' OR 'eidd-2801' OR 'eidd 2801' OR lagevrio):ti,ab
#17	#15 OR #16
	(paxlovid OR 'pf-07321332' OR 'pf 07321332' OR nirmatrelvir OR (('pf-07321332' OR nirmatrelvir) NEAR/3
#18	(Ritonavir OR 'abt 538' OR abt538 OR 'abt-538' OR 'a-84538' OR 'abt 84538' OR 'abt-84538' OR norvir OR
	RTV))):ti,ab
#19	fluvoxamine/exp
#20	(luvox OR fluoxamine OR 'fluvoxamine maleate' OR 'du 23000' OR 'fluroxamine'):ti,ab
#21	#19 OR #20
#22	#8 OR #11 OR #14 OR #17 OR #18 OR #21
#23	#3 AND #22
#24	('case report'/de OR 'practice guideline'/de OR 'questionnaire'/de OR 'chapter'/it OR 'conference
π <b>2</b> -	review'/it OR 'editorial'/it OR 'letter'/it OR 'note'/it OR 'review'/it OR 'short survey'/it)
#25	#23 NOT #24
#26	('animal'/exp OR 'nonhuman'/exp OR 'animal experiment'/exp) NOT 'human'/exp
#27	#25 NOT #26
#28	#27 AND [english]/lim
*502rc	h last undated on February 11 2022

<sup>\*</sup>Search last updated on February 11, 2022.

<sup>†</sup>Search strategy updated to incorporate new search terms on February 11, 2022.

2,697 references 30 references identified identified through through other sources literature search 2,394 references after duplicate removal 2,394 references screened 2,269 citations excluded 80 citations excluded 125 references assessed 31 population for eligibility in full text 20 intervention 25 study design 4 duplicate data 45 total references 12 RCTs, 1 non-RCT, 16 **RWEs and 3 SLRs** 

Figure D1. PRISMA Flowchart Showing Results of Literature Search for COVID-19 Treatments

# **Study Selection**

We performed screening at both the abstract and full-text level. A single investigator screened all abstracts identified through electronic searches according to the inclusion and exclusion criteria described earlier. We did not exclude any study at abstract-level screening due to insufficient information. For example, an abstract that did not report an outcome of interest would be accepted for further review in full text. We retrieved the citations that were accepted during abstract-level screening for full text appraisal. One investigator reviewed full papers and provided justification for exclusion of each excluded study.

We also included FDA documents related to products approved under EUA. These included the manufacturer's submission to the agency, internal FDA review documents, and the transcript of Advisory Committee deliberations and discussions, if relevant. All literature that did not undergo a formal peer review process is described separately.

# **Data Extraction and Quality Assessment**

We used criteria published by the US Preventive Services Task Force (USPSTF) to assess the quality of RCTs and comparative cohort studies, using the categories "good," "fair," or "poor." Guidance for quality ratings using these criteria is presented below, as is a description of any modifications we made to these ratings specific to the purposes of this review.

**Good:** Meets all criteria: Comparable groups are assembled initially and maintained throughout the study; reliable and valid measurement instruments are used and applied equally to the groups; interventions are spelled out clearly; all important outcomes are considered; and appropriate attention is paid to confounders in analysis. In addition, intention-to-treat analysis is used for RCTs.

**Fair:** Studies were graded "fair" if any or all of the following problems occur, without the fatal flaws noted in the "poor" category below: Generally comparable groups are assembled initially but some question remains whether some (although not major) differences occurred with follow-up; measurement instruments are acceptable (although not the best) and generally applied equally; some but not all important outcomes are considered; and some but not all potential confounders are addressed. Intention-to-treat analysis is done for RCTs.

**Poor:** Studies were graded "poor" if any of the following fatal flaws exists: Groups assembled initially are not close to being comparable or maintained throughout the study; unreliable or invalid measurement instruments are used or not applied equally among groups (including not masking outcome assessment); and key confounders are given little or no attention. For RCTs, intention-to-treat analysis is lacking.

Note that case series are not considered under this rating system – because of the lack of comparator, these are generally considered to be of poor quality.

# **Assessment of Level of Certainty in Evidence**

We used the <u>ICER Evidence Rating Matrix</u> to evaluate the level of certainty in the available evidence of a net health benefit among each of the interventions of focus. The main report summarizes the ratings and rationale for molnupiravir, Paxlovid, and fluvoxamine.

# **Assessment of Bias**

As part of our quality assessment, we evaluated the evidence base for the presence of potential publication bias. Given the emerging nature of the evidence base for these newer treatments, we performed an assessment of publication bias for REGEN-COV, sotrovimab, molnupiravir, Paxlovid, and fluvoxamine using the ClinicalTrials.gov website. We scanned the site to identify studies completed more than two years ago that would have met our inclusion criteria and for which no findings have been published and did not find any evidence of publication bias. We provided qualitative analysis of the objectives and methods of these studies to ascertain whether there may be a biased representation of study results in the published literature. The primary concern is the lack of peer-reviewed, published data for the molnupiravir and Paxlovid trials.

# **Data Synthesis and Statistical Analyses**

The studies and their results were summarized in evidence tables and synthesized qualitatively in the body of the review. Analyses were descriptive only as differences in entry criteria, patient populations, outcome assessments, and other factors precluded formal quantitative direct or indirect assessments of sotrovimab, molnupiravir, Paxlovid, and fluvoxamine versus usual care.

# D2. Additional Clinical Evidence

# **Evidence Base**

#### REGEN-COV

The discussion of the evidence of REGEN-COV in this section summarizes studies conducted early in the pandemic, prior to the Delta and Omicron variants and should be interpreted with caution. Evidence informing our review of REGEN-COV in outpatients with mild-to-moderate COVID-19 was derived from one multi-center RCT with three phases. Our systematic literature review also identified several real-world studies of REGEN-COV, which are summarized below.

Weinreich 2021 was a multi-center Phase III trial that randomized 2,519 patients to 1200 or 2400 mg IV REGEN-COV or placebo.<sup>45</sup> Non-hospitalized adults were eligible to participate if they had tested positive no more than 72 hours prior with symptom onset no more than seven days prior to randomization. On November 12, 2020, the trial was amended to include only patients with at least

one risk factor for severe COVID-19. Patients were excluded if they had been admitted to a hospital prior to randomization due to COVID-19, had received any other treatments for COVID-19, or were pregnant, breastfeeding, or could become pregnant. Participants received REGEN-COV or placebo intravenously and completed a symptom questionnaire daily and regular virologic testing for 29 days. The primary outcome was COVID-19-related hospitalization or death for any cause through day 29. Secondary outcomes included COVID-19-related hospitalization or death from day four through 29, time to COVID-19 symptom resolution, and adverse events. The mean age of the trial participants at baseline was 48 years, and 52% were female. The majority (84%) of participants were White and a minority (5%) were Black. The most common risk factor for severe COVID-19 was obesity (57%) (Evidence Table D6).

# **Benefits and Harms**

In the Phase III trial of REGEN-COV, COVID-19-related hospitalization or death from any cause by day 29 occurred in 7/736 (1.0%) of participants in the REGEN-COV 1200 mg arm and in 24/748 (3.2%) of participants in the concurrent placebo group, a 70.4% risk reduction (95% CI: 31.6 to 87.1; p=0.002). There was one death (from any cause) in both groups. Among those hospitalized, median length of stay was 4.0 days (IQR: 3 to 6 days) in the REGEN-COV 1200 mg group and 5.5 days (IQR: 4 to 10.5 days) in the placebo group. Three (0.4%) patients in the REGEN-COV 1200 mg arm were admitted to the ICU and one (0.1%) required mechanical ventilation, while seven (0.9%) in the placebo group were admitted to the ICU and two (0.3%) required mechanical ventilation. Median time to symptom resolution was 10 days in the REGEN-COV 1200 mg group and 14 days in the placebo group (p<0.001) (Evidence Table D11).

Adverse events were more common in the placebo group (safety population, N=1,843) and the majority were COVID-19-related. In the placebo group, 74 (4.0%) participants experienced serious adverse events compared to nine (1.1%) in the REGEN-COV 1200 mg group. No patients in the REGEN-COV 1200 mg group withdrew or discontinued treatment, however, one (0.1%) participant had an infusion-related reaction (Evidence Table D18).

#### Real-World Studies of REGEN-COV

We identified 10 real-world evidence studies of REGEN-COV in our population of interest (non-hospitalized patients with mild-moderate COVID-19 symptoms); nine of these studies were based in the US. 48-59 Eight out of 10 studies were retrospective clinical data extraction studies. All studies included a group of patients who either received REGEN-COV or who were not treated acting as the control group (Evidence Table D23). Of note, the Delta variant was first reported in March 2021 and became the most prominent variant in the US in June 2021. 118,119 Six studies completed data collection by April 2021, thus patients in these studies likely contracted earlier variants COVID-19, but four studies included patients with COVID-19 from June to October 2021, all of whom had contracted the Delta variant. 54,56,57,59 In the review of the real-world evidence, we focused on three

commonly reported outcomes: hospitalization, emergency department visits, and death, at day 14-16 or day 28-30.

#### 14-16 Day Outcomes

Three studies examined clinical outcomes at day 14-16 in individuals who received REGEN-COV compared to a control group of patients who did not receive this agent. 48,49

Razonable et al. (2021) was a retrospective study of 1,392 adults (696 who received REGEN-COV and 696 matched controls) from Mayo Clinic sites in five states in the US.<sup>49</sup> All patients had confirmed COVID-19 using PCR tests with symptomatic disease and symptom onset within no more than 10 days, and had at least one medical risk factor; around 50% of patients were >65 years of age, had obesity, or had hypertension (Evidence Table D24). The primary endpoint was hospitalizations at 14, 21, and 28 days, and ICU admission and death at 14, 21, and 28 days were secondary endpoints. By day 14, 9/679 (1.3%) of the patients who received REGEN-COV had been hospitalized for any cause, compared to 22/679 (3.3%) of the control group, representing an absolute 2.0% risk difference (95% CI: 0.5%, 3.7%) in favor of REGEN-COV. There was one death (0.15%) in the group of patients who received REGEN-COV, as a result of issues secondary to COVID-19, and three deaths (0.44%) in the control group, representing a non-significant absolute risk difference of 0.29% (95% CI: -0.3%, 0.9%). By day 28, a total of 11/668 (1.6%) of the patients who received REGEN-COV had been hospitalized for any cause, compared to 32/671 (4.8%) of the control group, representing an absolute 3.2% risk difference (95% CI: 1.4%, 5.1%) in favor of REGEN-COV. At day 28, mortality remained at 1/668 (0.15%) in those who received REGEN-COV, and there was a total of four deaths (0.59%) in the control group, representing a non-significant absolute risk difference of 0.33% (95% CI: -0.2%, 1.1%) (Evidence Table D30). Safety data were only reported for treated patients, with seven patients (1%) reporting adverse events that were all Grade 1 (Evidence Table D38).

Webb et al. (2021) was a retrospective study of 6,130 patients (115 received REGEN-COV, 479 received bamlanivimab [not reviewed here], and 5,536 were untreated contemporaneous controls) in the Intermountain Healthcare system in Utah and Southeastern Idaho in the US.<sup>48</sup> Similar to Razonable et al. (2021), all patients were over 18 years of age and had confirmed COVID-19 with symptomatic disease and symptom onset within no more than seven days before infusion.<sup>49</sup> However, patients in this trial were required to meet specific criteria for high risk constituting a risk score of ≥7.5. For example, a score of two points was assigned to individuals who identified as either non-White race or Hispanic/Latinx ethnicity, had diabetes mellitus, were severely immunocompromised, or had obesity (BMI >30), and a score of one point was given if patients had hypertension, coronary artery disease, chronic liver disease, amongst others. As a result, the patients in this study had more comorbidities compared to other real-world studies, such as reported in Razonable et al. (2021). The median number of total comorbidities was four (IQR: 3 to 5); the most common comorbidities were hypertension (79-89%), obesity (54-62%), and diabetes

(48-64%) (Evidence Table D24). The primary outcome was a composite of emergency department visits or hospitalizations at day 14. Secondary endpoints were mortality and adverse events at day 14. In this review, only data from patients treated with REGEN-COV or untreated were included. At day 14, 1/115 (0.9%) patient who received REGEN-COV had been hospitalized, compared to 538/5,536 (9.7%) of the control group. In the REGEN-COV group, 9/115 (7.8%) patients visited the emergency room, compared to 944/5,536 (17.1%) in the control group. Thus, 10/115 (8.7%) patients receiving REGEN-COV met the composite endpoint of hospitalization/emergency department visit in this study, compared to 1,482/5,536 (26.8) in the control group. The statistical significance of these differences was not reported. There were no deaths in those patients who received REGEN-COV, compared to 57/5,536 deaths (1.0%) in the control group (Evidence Table D30). Safety data were only reported for those who received REGEN-COV, and one patient reported an infusion-related reaction (Evidence Table D38).

Kakinoki et al. (2022)<sup>58</sup> was a retrospective clinical data extraction study that obtained data from patients aged 20 years or older with COVID-19, and with at least one risk factor for progression to severe disease in Asahikawa City Hospital and non-medical facilities in Japan between June and September 2021. Patients received REGEN-COV (N=55) or were placed under watchful observation (N=53), acting as the control group. The primary outcome was the need for additional treatment (such as oxygen support, steroid administration, or antiviral medication) and the secondary outcome was the duration of fever and adverse events in the REGEN-COV group only. Patients had a median age of 51 years (REGEN-COV group) and 52 years (watchful observation group). All other demographics were reported for the full sample, instead of by group, and reported the most common comorbidities were hypertension/cardiovascular disease (20.5%) and diabetes (21.3%) (Evidence Table D27). The study reported that 13/55 (23.6%) in the REGEN-COV group needed further medical interventions but no further deterioration was reported beyond day five. For those in the watchful observation group, 22/53 (41.5%) were transferred to the hospital by day 16. They did not conduct statistical analyses on the comparison of the rate of hospitalization between the groups (Evidence Table D33). For those who received REGEN-COV, three patients reported adverse events related to infusion reaction or skin eruption (Evidence Table D40).

# 28-30 Day Outcomes

Eight real-world evidence studies examined clinical outcomes at days 28, 29, or 30.<sup>49-57,59</sup> Day 28 outcomes from Razonable et al. (2021) are described above.

Polk et al. (2021) was a retrospective study of 324 patients (125 received REGEN-COV, 199 were untreated controls) in a single health system in the US.<sup>55</sup> All patients had confirmed COVID-19 and were assessed and infused within 10 days of symptom onset. Nearly half (43% in the REGEN-COV group vs. 53% in the control group) of the patients had more than one comorbidity; hypertension was the most common comorbidity (45% in REGEN-COV group and 58% of the control group) (Evidence Table D25). The study focused on several outcomes at day 30: COVID-19-related

hospitalizations, COVID-19-related emergency department visits, ICU admission, mechanical ventilation, death, and adverse events. At day 30, 1/125 (2%) patient who received REGEN-COV had a COVID-19 related hospitalization, compared to 25/199 (12%) of the untreated control group, and 1/125 (1%) patient who received REGEN-COV had a COVID-19-related emergency department visit, compared to 18/199 (9%) of the untreated control group. At day 30, there were no deaths in the group of patients who received REGEN-COV and 4/199 (2%) deaths in the group of untreated controls. All four deaths were deemed to be related to COVID-19 (Evidence Table D31). No safety data were reported specifically for patients receiving REGEN-COV. Note that this was a poster presented at IDWeek Conference 2021 and has not been peer-reviewed.

Piccicacco et al. (2021) was a retrospective single-center study of 48 patients who received REGEN-COV and 200 control patients who were randomly selected from the high-risk COVID-19 patients but did not receive REGEN-COV and either declined or were not offered REGEN-COV during the candidacy window.<sup>51-53</sup> Patients were 12 years of age and older (only one patient in the control group was under the age of 18), had mild-to-moderate COVID-19 symptoms for 10 days or fewer before infusion, and were considered high risk for progression to severe COVID-19 (Evidence Table D25). The primary outcome was a composite of COVID-19-related hospitalization and emergency department visits at day 29 and secondary outcomes were incidence of hospitalization, emergency department visits, death, and serious adverse events at day 29. At day 29, 5/48 (10.4%) patients were reported to have had a COVID-19-related emergency department visit or hospitalization, compared to 81/200 (40.5%) in the control group. When examining the individual components of the composite score, all five of the cases in the patients who received REGEN-COV were related to emergency department visits and 26/200 (13%) patients in the control group visited the emergency department for COVID-19-related issues. Thus, no patients who received REGEN-COV were hospitalized for COVID-19 compared to 60/200 (30%) patients in the control group. There were also no deaths in the group of patients who received REGEN-COV, compared to 7/200 deaths (3.5%) in the control group (Evidence Table D31). One serious adverse event was reported for the patients who received REGEN-COV (Evidence Table D39).

Chilimuri et al. (2021) was a single-center retrospective study aimed to provide an inner-city experience of the implementation of infusion therapy in the BronxCare Health System in the South Bronx, New York.<sup>50</sup> The study included patients who received monoclonal antibody therapy, including REGEN-COV (N=22), or who were untreated as they declined therapy (N=11). The sample was more racially diverse than the earlier studies, with 50% of patients who received REGEN-COV identified as Hispanic/Latinx and 27.2% identified as Black/African American (Evidence Table D25). Demographics for the untreated control group were not reported. The primary outcome was hospitalization or death by day 30. At day 30, 1/22 (4.5%) patients who received REGEN-COV had been hospitalized due to COVID-19, compared to 6/11 (54.5%) in the control group. There were no deaths among the patients who received REGEN-COV and there were 2/11 (18.1%) deaths in the control group (Evidence Table D31). No safety data were reported.

A pre-print published by McCreary et al. (2021) describes a prospective quality improvement project that utilized electronic health record data from a 40-hospital health system in Pennsylvania in the US. The study aimed to evaluate the real-world effectiveness of REGEN-COV, administered subcutaneously, in preventing all-cause hospitalization and death at 28 days in patients with the Delta variant of COVID-19, as compared to an untreated control group.<sup>54</sup> The study also aimed to evaluate the effectiveness of REGEN-COV as administered by IV injection compared to subcutaneous injection. All patients were 12 years of age or older, had a positive COVID-19 test, had not been hospitalized due to COVID-19, and were at risk for progression to severe disease. Patients were younger than earlier real-world studies (mean age of 54 years) and the most common comorbidities were hypertension (46%) and asthma (31%), percentages sufficiently lower than the other real-world studies reviewed (Evidence Table D26). The primary outcome of the study was hospitalization or death at day 28, and secondary outcomes were the rate of hospitalization, death, emergency department admission and hospitalization, and adverse events at day 28. To examine the real-world effectiveness of REGEN-COV given subcutaneously, the study obtained data from 652 patients who were treated with REGEN-COV via subcutaneous injection and 1,304 propensity-score matched nontreated control patients. The symptom status of the nontreated patients was unknown, such that patients in this group may have been asymptomatic. At day 28, 22/652 (3.4%) patients who received REGEN-COV had been hospitalized, compared to 85/1,304 (6.5%) in the control group. This difference was statistically significant (p=0.005) providing support for the use of subcutaneous infusion of REGEN-COV. There was one death (0.2%) in the group of patients who received REGEN-COV as compared to 29 deaths (2.2%) in the untreated control group (p=0.009). No initial safety data were available. To examine whether the subcutaneous injection was clinically similar to IV, data was obtained from 969 patients treated with REGEN-COV via subcutaneous injection and 1,216 treated via IV. Around half of the patients in this analysis reported having been given a COVID-19 vaccine, with a higher rate of vaccination in those treated subcutaneously (55.5%) compared to those treated intravenously (44.1%), and such vaccination status was adjusted for within the analysis. At day 28, 27/969 (2.8%) patients who received REGEN-COV subcutaneously had been hospitalized, compared to 20/1,216 (1.6%) of those treated intravenously (p=0.05). There was one reported death (0.1%) in the group of patients treated subcutaneously as compared to three deaths (0.2%) in the intravenously-treated group, which was not statistically significant (Evidence Tables D32 and D36). Initial safety data reported two serious adverse events in those who were treated intravenously, and none reported in those treated subcutaneously (Evidence Table D39).

A pre-print published by Huang et al. (2021) used the same electronic medical record data as McCreary et al. (2021) to evaluate the real-world effectiveness of REGEN-COV on patients with the Delta variant of COVID-19, compared to a matched control group. The study also examined the effectiveness of sotrovimab compared to a matched control group, which is described below. The study only reported combined demographic information for patients who received REGEN-COV and sotrovimab. Patients had a mean age of 54 years and a lower proportion of patients had medical

comorbidities than the earlier reviewed studies, with obesity (59%) and hypertension (30%) as the most common comorbidities (Evidence Table D26). The study obtained data from 712 patients who received REGEN-COV and 2,046 propensity-matched nontreated control patients. The primary outcome was hospitalization or death at 28 days and secondary outcomes were the rate of hospitalization, ICU admission, mechanical ventilation, and mortality at day 28. At day 28, 19/712 (2.7%) patients who received REGEN-COV had been hospitalized, compared to 134/2,046 (6.6%) in the control group, representing a risk ratio of 0.41 (95% CI: 0.25 to 0.65) (p<0.001), in favor of REGEN-COV. There was one death (0.1%) in the group of patients who received REGEN-COV as compared to 60 deaths (2.9%) in the untreated control group, representing a risk ratio of 0.05 (95% CI: 0.01 to 0.34) group (p=0.003), in favor of REGEN-COV (Evidence Table D32 and D36). No safety data were available.

Bierle et al. (2021)<sup>57</sup> was a retrospective clinical data extraction study that obtained data from patients with COVID-19 during the Delta surge (July 2021) within Mayo Clinic sites in the Midwestern US. Patients were either treated with REGEN-COV (N=112) or were eligible for treatment but did not receive it (N=291). The primary outcome was the rate of hospitalization at day 28. Demographics were reported for the total sample only. Patients had a mean age of 46.5 years, 47% were male, and common comorbidities included obesity (39.8%), hypertension (24.3%), and cardiovascular disease (11.6%) (Evidence Table D27). The study reported significantly lower hospitalization rates for those who had received REGEN-COV (2.6%) compared to those who did not receive it (16.6%), OR: 0.14, 95% CI: 0.04 to 0.45, p=0.001 (Evidence Table 33). The study also reported the lowest rate of hospitalization for those who were vaccinated and had received REGEN-COV (1.8%) and the highest rate of hospitalization for those who were both vaccinated (15.1%) and unvaccinated (13.7%) but did not receive REGEN-COV, suggesting that during the Delta surge prior vaccination may not be as protective for high-risk patients in preventing hospitalization (Evidence Table D37). However, these particular results were only reported descriptively and included individuals who had COVID-19 but were ineligible to receive REGEN-COV. Safety data reported that 2/112 (1.8%) of patients who received REGEN-COV reported hypoxia, compared to 47/518 (9.1%) in the control group (Evidence Table D40).

Wei et al. (2022)<sup>59</sup> was a large retrospective cohort study that analyzed data from patients with a confirmed COVID-19 diagnosis in the past 10 days in two claims databases in the US: Optum<sup>®</sup> Clinformatics<sup>®</sup> Data Mart (CDM) and IQVIA Pharmetrics Plus (PMTX+) from December 2020 to March 2021. Patients received REGEN-COV (CDM N=1,116, PMTX+ N=3,280) or did not receive this agent and were matched by demographics to those who did (CDM N=5,291, PMTX+ N=16,284). Across the two databases, the median age across the groups of 56.5 years, with 0.5% of patients in CDM and 0.55% in PMTX+ under the age of 18. The most common comorbidities were hypertension or cardiovascular disease (CDM: 54% and PMTX+: 57.8%) and diabetes (CDM: 30.2% and PMTX+: 32.4%). The groups and databases were matched, with only vaccination status reported as higher in the CDM database (7.2%) compared to the PMTX+ database (2.6%) (Evidence

Table D27). The primary outcome for data in CDM database was a composite endpoint of 30-day all-cause mortality or COVID-19-related hospitalization, and the primary outcome for PMTX+ was 30-day COVID-19-related hospitalization. In the CDM database, those who received REGEN-COV were less likely to be hospitalized due to COVID-19 (23/1,116, 2.1%) and there were no reports of mortality in this group, compared to 276/5,291 (5.3%) in the untreated group were hospitalized due to COVID-19 or had died during this time. There were 27/5,291 deaths (0.5%) reported in the control group in the CDM database, which was significantly higher than in the REGEN-COV group (survival probability analysis, p=0.015, 95% CI: 0.26, 0.60). In the PMTX+ database, those who received REGEN-COV were less likely to be hospitalized due to COVID-19 (59/3,280, 1.9%), compared to a matched untreated group (752/16,284, 4.8%), 95% CI: 0.30, 0.51 (Evidence Table D33). Furthermore, earlier treatment of REGEN-COV (one day) was associated with fewer reports of all-cause death or COVID-19-related hospitalizations in the CDM database (1.2%) compared to later treatment (≥5 days) (4.6%), p=0.027, and a similar pattern was reported of fewer reports of COVID-19-related hospitalizations in the PMTX+ database (one day: 1.3% vs. ≥5 days: 3.28%), p=0.025 (Evidence Table D37).

Finally, Osugi et al. (2022)<sup>120</sup> was a retrospective cohort study of patients with COVID-19 diagnosed in a medical center in Toyota, Japan. Patients either received REGEN-COV (N=30) or did not receive REGEN-COV (N=74). The primary outcome was hospitalization due to COVID-19, and the secondary outcome was mortality due to COVID-19. Patients had a mean age of 47.8 years with those who received REGEN-COV as significantly older (mean age: 54.4 years) than those in the control group (mean age: 45.1 years), 56% were male, and the most common comorbidities were cardiovascular disease (18.1%), chronic lung disease (18.8%), and diabetes (13.1%); lower than other real-world evidence studies (Evidence Table D29). Those who received REGEN-COV had a significantly higher BMI than those who did not receive REGEN-COV. There was a median follow-up of 12 days (IQR: 10-16). There were 19 hospital admissions for COVID-19 across both groups and admissions tended to be lower for those who received REGEN-COV than those who did not (HR: 0.76), but this was not significant (p=0.65). This lack of difference may be the result of the demographic differences across the two groups, but the interpretation is limited as the study did not report the number of patients admitted to the hospital in each group (Evidence Table D35). There were no reports of mortality in either group. No safety data were reported.

The real-world evidence studies provide support for the association between the use of REGEN-COV and lower rates of both all-cause and COVID-19-related hospitalization, emergency visits, and death for patients with mild-to-moderate COVID-19 symptoms. IV infusion of REGEN-COV appeared to be more effective than subcutaneous injection in preventing hospitalizations, but not deaths, although more research is needed. In general, patients in the real-world studies were older than those in the RCTs. The higher overall mortality and hospitalization rates in the real-world evidence studies, as compared to the RCTs, may be explained by this age difference. Additionally, due to the nature of real-world studies that utilize retrospective clinical data, there were several uncontrolled factors

that may have led to this increased rate of hospitalization/death, such as non-random group assignment, lack of blinding, and potential loss of longitudinal data (e.g., if a patient sought care outside of the particular health system) that should be considered when interpreting the studies. Finally, adverse events may be underreported in real-world studies and safety data should be reviewed with caution.

#### Sotrovimab

The discussion of the evidence of sotrovimab in this section summarizes studies conducted at different timepoints in the pandemic and should be interpreted with caution. We identified two RCTs that met our inclusion criteria for sotrovimab. COMET-ICE is a Phase III trial that randomized 1,057 patients to 500 mg IV single infusion administration of sotrovimab or placebo. Evidence for COMET-ICE was acquired from a conference poster and the most recent peer-reviewed publication of the trial. We also examined a non-peer-reviewed pre-print of a real-world study that assessed the effectiveness of sotrovimab in non-hospitalized patients diagnosed with mild-to-moderate severity of COVID-19 (Delta variant) compared to a propensity-matched cohort. This observational real-world study included patients from an integrated health system of 40 hospitals located in Pennsylvania. We included this study in our review as it may be more generalizable than the pivotal trials.

COMET-TAIL is a non-inferiority trial that randomized 983 patients to 500 mg intramuscular or 500 mg IV single infusion of sotrovimab. At the time of this review, data for COMET-TAIL only exists in the form of a press release and data submission; as such, this section will mainly focus on the data for the IV administration of sotrovimab from the COMET-ICE trial.

# **COMET-ICE**

COMET-ICE was a Phase III randomized, placebo-controlled multi-center trial with 57 clinical sites: 45 in the US, six in Brazil, three in Spain, two in Canada, and one in Peru.<sup>8</sup> Patients included in the study were unvaccinated adults with a high risk of progression to severe COVID-19 that had COVID-19 symptom onset as well as a PCR or antigen test within five days of randomization.<sup>8</sup> Obesity was the most common qualifying risk factor in the COMET-ICE trial population (63%),<sup>121</sup> which is consistent with some of the other trials in our review.

A total of 1,057 adult participants were randomly assigned to either of the two treatment arms with 528 participants receiving sotrovimab and 527 participants receiving placebo. The median age of participants in COMET-ICE at baseline was 53 years, and 54% were female. Most participants were White (87%) and 8% were Black; 65% of participants identified as Hispanic or Latino (Evidence Table D6).<sup>8</sup> The primary efficacy outcome of COMET-ICE was the proportion of patients with COVID-19 progression that resulted in hospitalization for more than 24 hours or death through day 29.<sup>8</sup> The main secondary outcome of the trial was a composite of emergency department visit,

hospitalization of any duration, or death due to any cause by day 29 (Evidence Table D5). The trial was stopped early due to positive results.

#### COMET-TAIL

COMET-TAIL is a Phase III randomized, open-label, multi-center, non-inferiority trial designed to evaluate the efficacy, safety, and tolerability of the intramuscular administration of sotrovimab. The trial included adults and adolescents (12 years and up) with (n=376) participants receiving the 500 mg dose of intramuscular sotrovimab and (n=378) participants receiving the 500 mg dose of IV sotrovimab. For the primary endpoint, a 3.5% non-inferiority margin for the upper-bound of the 95% confidence interval was established for the trial in conjunction with input from the FDA (Evidence Table D5). 122,123

# **Benefits and Harms**

In COMET-ICE, 6/528 (1%) of participants who received sotrovimab and 30/529 (6%) of participants who received placebo progressed to hospitalization or death by day 29, a 79% (95% CI: 50% to 91%) relative risk reduction in favor of sotrovimab (Evidence Table D11).<sup>8</sup>

Mortality by day 29 did not differ significantly between the two groups. No deaths occurred in the treatment arm while two deaths were reported in the placebo arm; of the two deaths that occurred in the placebo arm, one patient died without being hospitalized. Sotrovimab was associated with a 66% reduction in the composite outcome of emergency department visit, hospitalization, or death. Among patients hospitalized, none of the participants in the sotrovimab group required high-flow oxygen or mechanical ventilation while 10 patients in the placebo group required high-flow oxygen and four patients were placed on mechanical ventilation (Evidence Table D11).

The secondary endpoint in COMET-ICE, change in total symptom score, was evaluated using the FLU-PRO assessment tool. When compared to the placebo arm, participants that received IV administration of sotrovimab reported a higher mean reduction of -1.07 (95% CI: -1.38 to -0.75, p<0.001) in their FLU-PRO score, which is consistent with the primary outcome (Evidence Table D17). The clinical importance of this tool in patients with COVID-19 is unknown.<sup>8</sup>

Overall, in the safety population, the incidence of any adverse or infusion-related reaction was similar in the treatment and placebo group. Adverse events occurred in 11/523 (2%) of participants in the sotrovimab arm and in 32/526 (6%) of participants in the placebo arm (Evidence Table D18). The most notable disease-specific adverse event was COVID-19 pneumonia, which occurred in 5/523 (<1%) of patients in the sotrovimab arm and in 22/526 (4%) of patients in the placebo arm.<sup>8</sup>

In COMET-TAIL, 2.7% of patients in the intramuscular administration arm of sotrovimab progressed to hospitalization (greater than 24 hours) or death compared to 1.3% of patients in the IV administration arm. <sup>122,123</sup> The 500 mg intramuscular administration of sotrovimab was determined

to be equivalent (non-inferior) to the 500 mg IV administration based on an adjusted difference of 1.07% (95% CI: -1.25% to 3.39%), which is below the pre-specified 3.5% non-inferiority margin. The risk of hospitalization or death in the IV arm was consistent with the risk in the IV arm in COMET-ICE (Evidence Table D11). Of note, the evidence from COMET-TAIL only exists in the form of a press release and data submission.

# **Real-World Studies of Sotrovimab**

Huang 2021 was a real world study that corroborates the evidence in COMET-ICE and supports the effectiveness of sotrovimab against the Delta variant.<sup>56</sup> This study compares outcomes of a cohort of 311 patients who received 500 mg IV single infusion of sotrovimab to 2,046 propensity-matched patients who did not receive active treatment (Evidence Table D23). Participants enrolled in this study had mild-to-moderate COVID-19 (Delta variant) and were enrolled between July 14, 2021 and September 29, 2021. A comparative analysis of sotrovimab with another monoclonal antibody was also performed in this real-world study but is not the focus of our review (Evidence Table D26).

The primary outcome for the real-world study was hospitalization or death by day 28. Sixteen out of 311 (5.1%) patients who received sotrovimab experienced the primary outcome compared to 174/2,046 (8.5%) patients in the nontreated arm by day 28 (RR: 0.60, 95% CI: 0.37 to 1.00, p=0.05). This difference in the primary outcome was mostly driven by higher mortality in the nontreated arm (60/2,046 [2.9%]) compared to 0 deaths in the treatment arm).<sup>56</sup> In the sotrovimab arm, 16 out of 311 (5.1%) patients were hospitalized and 134/2,046 (6.6%) of patients were hospitalized in the nontreated group (RR: 0.79, 95% CI: 0.47 to 1.30, p=0.35) (Evidence Table D32).<sup>56</sup>

Aggarwal et al. (2022) was an observational cohort study of outpatient adults with COVID-19. Health record data from the largest health system in Colorado was used for propensity matching of patients who did not receive monoclonal antibody treatment (n=1,563), to patients who received outpatient treatment with sotrovimab (n=522), in a 3:1 ratio. Health data used in this trial included participants infected with COVID-19 from October 1, 2021 to December 11, 2021, which coincides with when the Delta variant was the dominant strain (Evidence Table D23). Most patients in the study were female: 56.7% of patients treated with sotrovimab and 56.1% of patients not treated with a monoclonal antibody. Approximately 81% of participants identified as non-Hispanic White, 7.5% as Hispanic and 8% as non-Hispanic Black. The most common comorbidities in patients treated with sotrovimab include hypertension (30.7%), obesity (25.5%), pulmonary disease (25.1%), cardiovascular disease (16.5%), and diabetes (11.9%) (Evidence Table D29). The primary outcome in the study was all-cause hospitalization within 28 days of a positive COVID-19 test. The secondary outcome included all-cause mortality by day 28 and emergency department visit by day 28. Assessment of disease severity based on ICU admission and invasive mechanical ventilation, or death were calculated as percentages. A total of 11 patients (2.1%) and 89 patients (5.7%) reached the primary outcome of all-cause hospitalization in the treated and un-treated arms, respectively (OR: 0.37, 95% CI: 0.19 to 0.66) (Evidence Table D35). By day 28, none of the patients who received

sotrovimab had died, compared to 15 patients (1%) in untreated arm. However, there was a higher percentage of patients (8.4%) who received sotrovimab and had a visit to the emergency department, compared to 7.6% of patients not treated with a monoclonal antibody. Furthermore, hospital length of stay and disease severity was assessed by the maximum level of respiratory support in-patient as part of the secondary outcome. The average length of stay for hospitalized patients who received sotrovimab was 5.3 days compared to 9.4 days in patients not treated with a monoclonal antibody. Out of the hospitalized population, two patients (18.2%) treated with sotrovimab were admitted to the ICU compared to 19 patients (21.3%) who were not treated with a monoclonal antibody. None of the patients who received sotrovimab died or required invasive mechanical ventilation while in contrast, 19 patients (21.3%) reached this outcome. No safety data were reported.<sup>125</sup>

Zaqout et al. (2022) is a matched case-control study that includes patients from a national database in Qatar who were diagnosed with COVID-19 between October 20, 2021 and February 28, 2022. Cases of COVID-19 occurring after December 19, 2021 were classified as occurring when Omicron was the dominant variant, during which 70% of cases were due to the BA.2 Omicron subvariant. All other cases were classified as occurring during the Delta variant dominant phase. Cases and controls were matched in a 1:2 ratio; resulting in 345 participants in the treatment arm who received sotrovimab and 583 in the untreated arm (Evidence Table D23). Participants were matched and adjusted for COVID-19 vaccination status, prior infection status, sex, age group, nationality, comorbidity count, and the phase of the pandemic that infection occurred. Overall, participants were eligible to be in the study if they had a confirmatory diagnosis of COVID-19 via PCR or antigen test and fit the eligibility criteria to receive sotrovimab. Patients were excluded if they showed signs or symptoms of severe COVID-19 within seven days of diagnosis. The baseline characteristic across the matched cases and controls were similar. Patients who received sotrovimab had a median age of 39 years, majority were female (64.1%), 94.8% had no prior history of infection, 33.6% were unvaccinated, while a majority 191 (55.4%) participants had received two doses of a vaccine and 38 (11%) had received three doses (Evidence Table D29). The primary outcome of the study was progression to severe, critical, or fatal COVID-19, which was assessed by adjusted odd ratios of progressing to more severe stages of COVID-19. Taking sotrovimab was not shown to reduce the risk of advancing to a more severe form of COVID-19 (OR: 2.67, 95% CI: 0.17 to 11.91) (Evidence Table D35). This result was consistent in a subgroup of patients that included participants who were immunocompromised, pregnant, unvaccinated, and 75 years of age or older (OR: 0.65, 95% CI: 0.17 to 2.48). No specific mortality or safety data were reported. 126

# Molnupiravir

In the Evidence Report, evidence for molnupiravir focused on the primary outcomes from the full population analysis and interim analysis of the Phase III portion of the MOVe-OUT trial. We also identified one open-label trial of molnupiravir conducted in India, which is described below.<sup>36</sup> One of

the secondary endpoint outcome measures in MOVe-OUT is the change in the WHO 11-point scale. The WHO 11-point scale measures the progression of COVID-19 through the mild, moderate, and severe stages with a higher numerical value being assigned to more severe patients. As measured by this outcome, patients in the molnupiravir group were less likely to have clinical progression of the disease by days three, five, 10, and 15. This secondary outcome of clinical progression was only statistically significant at day 10 and day 15, with the maximum difference occurring at day 10 (OR 1.58, 95% CI: 1.14 to 2.20).<sup>12</sup>

The Phase IIa portion of the MOVe-OUT trial functioned primarily as a dose-finding trial and evaluated three doses of molnupiravir (200 mg, 400 mg, and 800 mg) compared to placebo. Outcomes were reported primarily in participants in the 800 mg dose that was carried forward into the Phase III portion of the MOVe-OUT trial (Evidence Table D5).<sup>33</sup>

The primary endpoint of this study was time to clearance of viral RNA in nasopharyngeal swabs confirmed by PCR detection. Median time to viral clearance was 14 days in the 800 mg molnupiravir group compared to 15 days in the placebo group (p=0.013) (Evidence Table D15). This primary outcome was not statistically significant when compared to placebo in the 200 mg and 400 mg molnupiravir treatment arms.<sup>33</sup>

The secondary endpoint of the study was the percentage of participants in each treatment arm that had infectious virus isolations via nasopharyngeal swabs from baseline through days three and five. By the third day of treatment, infectious virus was isolated from 1/53 (1.9%) participants in the 800 mg molnupiravir group and in 9/54 participants in the placebo group (p=0.016). This outcome was consistent with the results on day five, in which 0/53 (0%) participants in the 800 mg molnupiravir group had infectious virus isolated compared to 6/54 (16.7%) participants in the placebo group (p=0.027) (Evidence Table D15). The median time to symptom resolution was not statistically significant across all treatment arms and placebo.<sup>33</sup>

# Kumarasemyet 2022

Conference material by Kumarasemyet et al. (2022) presented results of a Phase III, open-label RCT that studied the safety and efficacy of a generic formulation of molnupiravir in outpatients with mild COVID-19 symptoms in India (Evidence Table D5). Sixty-four percent of trial participants were male and average age was approximately 35 years. Obesity was the most common risk factor for severe disease (Evidence Table D7). Nineteen out of 608 (3.1%) of patients in the molnupiravir arm had obesity, compared to 17/610 (2.8%) of patients in the standard-of-care arm. To be included in the trial, patients had to have mild COVID-19 infection confirmed by PCR, no breathlessness, and an uncomplicated upper respiratory tract infection diagnosis. Patients in the intervention arm (n=608) received 800 mg of molnupiravir twice a day for five days (plus standard of care), while patients in the comparison arm (n=610) received standard of care alone. The primary outcome of the trial was the rate of hospitalization up to day 14. Secondary outcomes were the proportion of patients with

a 2-point improvement on the WHO-11-point scale and rate of negativity from PCR nasopharyngeal swabs. Results of these secondary endpoints were documented on days five, 10, and 14.<sup>36</sup>

Nine patients (1.5%) who received molnupiravir were hospitalized by day 14, compared to 26 patients (4.3%) who received standard of care alone (p<0.01) (Evidence Table D12). Patients who received molnupiravir had clinical improvement rates of 80.8%, 95.6%, and 97.4%, while patients on standard of care alone had clinical improvement rates of 32.1%, 74.3%, and 94.1% by days five, 10 and 14, respectively (p<0.0001). Patients who received molnupiravir had SARS-CoV-2 negativity rates of 77.1%, 91.3%, and 93.9%, while patients on standard of care alone had negativity rates of 29.3%, 70.2%, and 89.0% by days five, 10, and 14 (p<0.001). No serious adverse events were reported in either group. Mild or self-limiting adverse events occurred in 4.8% of the patients in the molnupiravir arm compared to 2.6% of patients in the standard-of-care alone arm (Evidence Table D19). The median time to clinical improvement was six days in the group that received molnupiravir and 10 days in the group that received standard of care alone.<sup>36</sup>

#### **Paxlovid**

The Evidence Report discusses the primary source of data to inform our comparison of Paxlovid to usual care: the EPIC-HR trial, a Phase II/III randomized trial in non-hospitalized patients with mild-to-moderate COVID-19 at high risk of disease progression. In December 2021, the manufacturer released top-line, interim data from the EPIC-SR trial, a Phase II/III randomized trial of Paxlovid in non-hospitalized patients with mild-to-moderate COVID-19 at standard risk for disease progression (including those who were vaccinated with at least one risk factor for progression).<sup>127</sup>

#### EPIC-SR

The primary outcome of the EPIC-SR trial was a self-reported sustained alleviation of all COVID-19 symptoms for four consecutive days. Secondary outcomes included a composite outcome of hospitalization and no death, viral load, and adverse events. In the interim analysis including 45% of the trial's planned enrollment, the primary endpoint for Paxlovid compared to placebo was not met and not reported. However, in a follow-on analysis including 80% of enrolled patients the secondary outcome of hospitalization and no death was 70% lower in the Paxlovid group compared to the placebo group, with 3/428 hospitalized (0.7%) in the Paxlovid group and 10/329 (2.4%) in the placebo group (p=0.051) (Evidence Table D12). Treatment-emergent adverse events were similar across treatment groups (22% in the Paxlovid group and 21% in placebo), as were serious adverse events (1.4% in the Paxlovid group and 1.9% in placebo). Discontinuation rates due to adverse events were 2.1% in the Paxlovid group and 1.2% in placebo (Evidence Table D19). Based on the totality of the data available at the time of the interim results, the Data Monitoring Committee recommended that the trial continue. 127

#### *Fluvoxamine*

The report discusses the primary source of data to inform our comparison of fluvoxamine to usual care, the TOGETHER trial. In addition to the TOGETHER trial, our systematic review identified two additional trials of fluvoxamine, STOP-COVID 1 and STOP-COVID 2 and one real-world study.

### STOP-COVID 1

STOP-COVID 1 was a double-blind, single-site US-based trial that randomized 181 non-hospitalized adults with mild-to-moderate COVID-19 and symptom onset within seven days to 100 mg of fluvoxamine or placebo three times daily for 15 days. The trial was conducted early in the pandemic (April 2020 to August 2020). The primary outcome was clinical deterioration within 15 days of randomization (defined as shortness of breath or hospitalization for shortness of breath or pneumonia or oxygen saturation <92% or need for supplemental oxygen). Secondary outcomes included symptom severity, hospitalization, or emergency department visit (self-reported), and adverse events (Evidence Table D5). Of the 181 patients who were randomized, 152 were included in the study analysis. Mean age of the participants was 46 years at baseline, 25% were Black, and the majority were female (70-74%). The most frequent risk factors for severe disease were obesity (54-58%), hypertension (19-21%), asthma (13-21%), and diabetes (11%) (Evidence Table D8).

In the STOP-COVID 1 trial, 0/80 participants in the fluvoxamine arm and 6/72 (8.3%) in the placebo arm met both criteria for clinical deterioration, the primary outcome (absolute difference 8.7, 95% CI: 1.8 to 16.4, p=0.009). Symptom severity, as measured on a 7-point scale (lower is better) was 0.22 points lower in the fluvoxamine group (95% CI: -0.41 to -0.04, p=0.02). There was no difference in hospitalization or emergency department visits (self-reported) between the two groups (Evidence Table D13). Serious adverse events were reported by one (1.3%) patient in the fluvoxamine group and five (6.9%) in the placebo group (Evidence Table D20).

#### STOP-COVID 2

STOP-COVID 2 was a double-blind, multi-center US and Canada-based trial that randomized 547 non-hospitalized adults with mild-to-moderate COVID-19 and at least one risk factor for severe disease and symptom onset within seven days to 100 mg of fluvoxamine or placebo twice daily for 15 days. Enrollment occurred between December 2020 and May 2021. Like STOP-COVID 1, the primary outcome was clinical deterioration within 15 days of randomization. Secondary outcomes included hospitalization and adverse events (Evidence Table D5). Mean age of the participants was 48 years at baseline and 62% were female; approximately 8% were Black and 13% were Hispanic/Latino. Like STOP-COVID 1, the most frequent risk factors for severe disease were obesity (42-45%), hypertension (20-23%), asthma (12-15%), and diabetes (9-10%) (Evidence Table D8).

The STOP-COVID 2 trial was stopped early due to low power for the primary outcome. In the interim analysis, 13/272 (4.8%) participants in the fluvoxamine arm and 15/275 (5.5%) in the

placebo arm met both criteria for clinical deterioration, the primary outcome (absolute difference 0.0058, 95% CI: -0.034 to 0.045, p=0.758).<sup>68</sup> In the fluvoxamine arm, nine (3.3%) participants had a COVID-19-related hospitalization compared to 10 (3.6%) in the placebo arm (Evidence Table D13). Adverse events were not reported.

# Real-World Study of Fluvoxamine

Seftel and Boulware (2021)<sup>129</sup> was an open-label cohort study in an occupational setting in California that enrolled 152 outpatients with positive rapid test for COVID-19 and allowed individuals to choose fluvoxamine or no treatment. Approximately half of the patients were asymptomatic. Patients were evaluated at days seven and 14. Outcomes included hospitalization, ICU stay with mechanical ventilation, and symptoms. Mean age of the participants was 43-44 years at baseline and 41-59% were female; approximately 1% were Black and the majority were Latino (71-94%). A minority (25-38%) had one chronic comorbidity such as diabetes (8-17%) and hypertension (17-35%) (Evidence Table D23). Demographics were generally similar between the fluvoxamine and no therapy groups, except for race/ethnicity. Latino participants were more likely to opt for fluvoxamine (Evidence Table D28).

No patients in the fluvoxamine group (0/65) and 6/48 (12.5%) in the no treatment group were hospitalized. Of the six patients who were hospitalized, two required an ICU stay with mechanical ventilation and one died. At day 14, all patients in the fluvoxamine group had COVID-19 symptom resolution, compared to 40% in the no treatment group (p<0.001) (Evidence Table D34). No serious adverse events were reported in the fluvoxamine group and no participants discontinued treatment due to adverse events (Evidence Table D40).

# **D3. Evidence Tables**

**Table D4. Study Quality Table** 

		USPSTF Rating									
Trial	Comparable Groups	Non- Differential Follow-Up	Patient/ Investigator Blinding	Clear Definition of Intervention	Clear Definitions of Outcomes	Selective Outcome Reporting	Measurements Valid	ITT Analysis	Approach to Missing Data	USPSTF Overall Rating	
				REGE	N-COV						
Phase III COV-2067	Yes	Yes	Yes	Yes	Yes	No	Yes	mITT	NRI, LW	Good	
Phase I/II COV-2067	Yes	Yes	Yes	Yes	Yes	No	Yes	mITT	NRI	Good	
				Sotro	vimab						
COMET-ICE	Yes	Yes	Yes	Yes	Yes	No	Yes	ITT	MAR	Good	
				Molnu	ıpiravir						
Phase III MOVe- OUT	Yes	Yes	Yes	Yes	Yes	No	Yes	mITT	NRI	Good	
Phase IIa Study 2003 (Fischer 2021)	Yes	Yes	Yes	Yes	Yes	No	Yes	mITT	LOCF	Good	
				Pax	lovid			•			
EPIC-HR	Yes	Yes	Yes	Yes	Yes	No	Yes	mITT	LOCF, BOCF	Good	
				Fluvo	kamine						
STOP-COVID	Yes	Yes	Yes	Yes	Yes	No	Yes	mITT	LOCF	Good	
STOP-COVID 2*	Yes	Yes	Yes	Yes	Yes	Yes	Yes	mITT	LOCF	Fair	
TOGETHER	Yes	No	Yes	Yes	Yes	No	Yes NA LIMA listania	PP, ITT, mITT	ММ	Fair	

BOCF: baseline observation carried forward, ITT: intention-to-treat analysis, LOCF: last observation carried forward, LW: listwise deletion, MAR: missing at random, mITT: modified intention-to-treat analysis, MM: mixed-methods model, NRI: non-responder imputation, PP: per-protocol analysis, USPSTF: United States Preventive Service Task Force

<sup>\*</sup>Pre-print.

**Table D5. Key Features: RCTs** 

Trial & NCT	Study Design & Location	N	Treatment	Inclusion & Exclusion Criteria	Key Outcomes
			REGEN-COV2 (Casir	ivimab/Imdevimab)	
Phase III	MC, DB, PC, RCT	Cohort 1:	(BASED ON PROTOCOL	(BASED ON PROTOCOL AMENDMENT 8)	Primary Endpoint:
COV-2067 (non-		Outpatients ages	AMENDMENT 5)	Inclusion Criteria:	-Proportion of patients with at least
hospitalized) <sup>45,130</sup>	Location: Chile,	≥18 years old with		-Cohort 1: ≥18 years of age and not	one COVID-19-related hospitalization
	US, Mexico,	COVID-19 and at	At day 1 for 1 hour:	pregnant; Cohort 2: <18 years of age and not	or death (through day 29)
NCT04425629	Romania	least one risk	REGEN-COV 1200 mg	pregnant; Cohort 3: pregnant	
		factor for severe	(IV infusion) (n=736)	-SARS-CoV-2-positive diagnostic test from	Secondary Endpoints (through day 29
	Date(s) of	COVID-19		sample collected ≤72 hours prior to	unless otherwise stated):
	Enrollment:		REGEN-COV 2400 mg	randomization, using validated SARS-CoV-2	-Time to resolution of COVID-19
	September	N=4,057	(IV infusion) (n=1,355)	test	symptoms
	2020-January	(modified full		-Symptoms consistent with COVID-19 with	-Change from baseline in viral
	2021	analysis set)	Placebo (n=1,341)	onset ≤7 days before randomization	shedding (log10 copies/mL) from day
				-Maintains O2 saturation ≥93% on room air	1 to day 22
				-Cohort 1 and Cohort 2 only: has ≥1 risk	-Proportion of patients with ≥1/≥2
				factor for severe COVID-19 (age ≥50 years,	COVID-19 related medically-attended
				obesity, BMI ≥30 kg/m2, BMI (kg/m2) ≥95th	visit
				percentile for age and sex based on CDC	-Days of hospitalization due to COVID-
				growth charts (cohort 2 only), CVD, chronic	19
				lung disease, type 1 or 2 diabetes, CKD,	-Hospital/outpatient or telemedicine
				chronic liver disease, immunosuppressed, or	visit/ICU/requiring mechanical
				underlying genetic condition, neurologic condition, metabolic condition, or congenital	ventilation due to COVID-19
				, , ,	-Proportion of patients with all-cause
				heart disease deemed to be risk factor for	mortality
				severe COVID-19 (cohort 2 only)	-Treatment-emergent SAEs, infusion- related reactions, or hypersensitivity
				Exclusion Criteria:	reactions
				-Hospitalized prior to or during	Teactions
				randomization for COVID-19	
				-Use of or participation in a clinical research	
				study evaluating COVID-19 convalescent	
				plasma, mAbs against SARS-CoV-2, IVIG,	
				systemic steroids, or COVID-19 treatments	
				within 3 months or within 5 half-lives of	
				investigational product	

Trial & NCT	Study Design & Location	N	Treatment	Inclusion & Exclusion Criteria	Key Outcomes
Phase I/II COV-2067 (non-hospitalized) <sup>131</sup> NCT04425629		Symptomatic Cohort: Outpatients ages ≥18 years old with COVID-19 N=275	(BASED ON PROTOCOL AMENDMENT 5)  At day 1 for 1 hour: REGEN-COV 2400 mg (IV infusion) (n=92)  REGEN-COV 8000 mg (IV infusion) (n=90)  Placebo (n=93)	-Discharged to quarantine center -Has known positive SARS-CoV-2 serologic test or positive SARS-CoV-2 antigen or molecular diagnostic test from sample collected >72 hours prior to randomization -Has active infection with influenza or other non-SARS-CoV-2 respiratory pathogen -Participation in clinical research study evaluating a COVID-19 vaccine  (BASED ON PROTOCOL AMENDMENT 5) Inclusion Criteria -Male or female & ≥18 years of age -Has SARS-CoV-2-positive antigen or molecular diagnostic test -a) Symptomatic cohort (all phases): COVID- 19 symptoms onset ≤7 days before randomization or b) asymptomatic cohort (Phase 2): no COVID-19 symptoms at any time <2 months prior to randomization, no positive SARS-CoV-2 test results >7 days prior to randomization, and no contact with individual with COVID-19 or positive SARS- COV-2 test result >14 days prior to randomizationMaintains O2 saturation ≥93% on room air  Exclusion Criteria -Hospitalized prior to or at randomization, due to COVID-19 -Use of or participation in study evaluating COVID-19 convalescent plasma, mAbs	Primary Endpoints (through Day 29 unless otherwise indicated): -Change from baseline in viral load (log10 copies/mL) (day 7) -Treatment-emergent SAEs, infusion-related or hypersensitivity reactions  Secondary Endpoints (through day 29 unless otherwise stated): -Concentration of REGN10933 and REGN10987 in serum over time -≥1 COVID-19 related medically attended visit or all-cause death -Time to negative RT-qPCR -COVID-19-related medically-attended visits -Hospital/outpatient or telemedicine visit/ICU/requiring mechanical ventilation due to COVID-19 -Days of hospitalization due to COVID-19 -All-cause mortality
				against SARS-CoV-2, IVIG, systemic corticosteroids, or COVID-19 EUA-approved treatments -Discharged to quarantine center	

Trial & NCT	Study Design & Location	N	Treatment	Inclusion & Exclusion Criteria	Key Outcomes
				-Pregnant or breastfeeding women	
				-Continued sexual activity in women of	
				childbearing potential or sexually	
				active men unwilling to practice highly	
				effective contraception	
			Sotro	vimab	
Phase II/III	MC, QB, PC, RCT	Non-hospitalized	At day 1 for 1 hour:	(BASED ON PROTOCOL AMENDMENT 1)	Primary Endpoint:
COMET-		adults with	Sotrovimab 500 mg (IV	Inclusion Criteria	-Proportion of participants who have
ICE <sup>8,121,124,132,133</sup>	Location:	COVID-19	infusion)	-Participants aged ≥18 years AND at high risk	progression of COVID-19 (up to day
	Austria, Brazil,	N=1,057	(n=528)	of progression of COVID-19 from ≥1 risk	29)
NCT04545060	Canada, Peru,			factor: diabetes, obesity (BMI>35), CKD, CHF	
	Spain, UK, US		Placebo (n=529)	(NYHA class II or more), COPD, chronic	Secondary Endpoints (Up to 24
				obstructive lung disease, emphysema with	weeks unless otherwise indicated):
	Date(s) of			dyspnea on physical exertion, and moderate	-Occurrence of adverse events and
	Enrollment:			to severe asthma, OR participant ≥55 years	SAEs
	August 2020-			-Have positive SARS-CoV-2 test result (by	-Severity and duration of symptoms
	March 2021			any validated diagnostic test)	of COVID-19 related illness using the
				-Oxygen saturation ≥94% on room air	FLU-PRO patient-reported outcome
				-Has COVID-19 symptoms and enrolled ≤5	instrument (Up to 12 weeks)
				days from onset of symptoms	-%AUCextrap
				-Female participants not pregnant or	-all-cause mortality
				breastfeeding, or using effective	-A-UCinf, AUClast, CL, Clast, Cmax
				contraception	-Detection of SARS-CoV-2 in nasal
					secretions by PCR
				Exclusion Criteria	-Incidence and titers of serum ADA to
				-Currently hospitalized or likely to require	VIR-7831
				hospitalization in next 24 hours	-Proportion of participants who
				-Symptoms consistent with severe COVID-19	progress to develop severe and/or
				-Participants likely to die in next 7 days	critical respiratory COVID-19
				-Severely immunocompromised participants	(supplemental oxygen) at day 8, day
				-Previous anaphylaxis or hypersensitivity to	15, day 22, or day 29
				mAb	
				-Enrollment in any investigational study	
				within 180 days	
				-Receipt of any vaccine within 48 hours prior	

Trial & NCT	Study Design & Location	N	Treatment	Inclusion & Exclusion Criteria	Key Outcomes
				to enrollment or convalescent plasma or	
				SARS-CoV-2 mAb within last 3 months	
Phase III	MC, OL,	Adolescent and	Sotrovimab 500 mg (IM	Inclusion Criteria	Primary Endpoint:
COMET-	randomized	adult outpatients	injection)	-Participant aged 12 years or older at time of	-Proportion of participants who have
TAIL <sup>122,123,134</sup>		with mild-to-	(n=376)	consent AND at high risk of progression of	progression of COVID-19 (up to day
NOTO 4040675	Location:	moderate COVID-		COVID-19 or ≥55 years old	29)
NCT04913675	France, Ukraine,	19 at a risk of	Sotrovimab	-Participants must have positive SARS-CoV-2	
	US	progression to	500 mg (IV infusion)	test result and oxygen saturation ≥94% on	Secondary Endpoints (up to 24 weeks
	Date(s) of	severe disease N=983	(n=378)	room air and have COVID-19 symptoms and be less than or equal to 7 days from onset of	unless otherwise stated): -AEs, AESIs, and SAEs
	Enrollment:	N-905			-Incidence and titers of serum ADA to
	June 2021-NR			symptoms	sotrovimab
				Exclusion Criteria	-%AUCextrap, AUCinf, AUClast, CL/F,
				-Currently hospitalized or judged by	Clast, Cmax, t1/2, Tlast, Tmax, Vz/F
				investigator as likely to require	(IV, IM)
				hospitalization in next 24 hours	-Mean AUC of SARS-CoV-2 viral load
				-Symptoms consistent with severe COVID-19	(up to day 8)
				-Participants who, in judgment of	-Proportion of participants with a
				investigator are likely to die in next 7 days	persistently high SARS-CoV-2 viral
				-Known hypersensitivity to any constituent	load at day 8 by qRT-PCR (up to day 8)
				present in the investigational product	-Change from baseline in viral load by
					qRT-PCR (up to day 8)
-1	T	I., , , , , ,		ıpiravir	
Phase III - MOVe- OUT <sup>10-12,35</sup>	MC, DB, PC, RCT	Non-hospitalized	Day 1-5 (twice daily):	Inclusion Criteria	Primary Endpoints:
00110-12,33	1 4:	adults with	Molnupiravir 800 mg	-SARS-CoV-2 infection with sample collection	-Percentage of participants who are
NCTO4F7FF07	Location:	COVID-19	(oral) (n=716)	≤5 days prior to day of randomization	hospitalized and/or die (up to 29
NCT04575597	Argentina,	N=1,550	Dlacaba (n=717)	-Had initial onset of COVID-19	days) -Rates of AEs and discontinuation due
	Brazil, Canada, Chile,		Placebo (n=717)	signs/symptoms ≤5 days prior to day of randomization and ≥1 COVID-19	
	Colombia,			sign/symptom day of randomization	to AEs (Up to ~7 months)
	Egypt, France,			-Has mild or moderate COVID-19	Secondary Endpoints:
	Germany,			-Has at least 1 characteristic or underlying	-Time to sustained resolution or
	Guatemala,			medical condition associated with increased	improvement of each targeted
	Italy, Japan,			risk of severe illness from COVID-19	COVID-19 sign/symptom (up to 29
	Mexico,			-Participants are not pregnant or	days)

Trial & NCT	Study Design & Location	N	Treatment	Inclusion & Exclusion Criteria	Key Outcomes
	Philippines,			breastfeeding, using contraception or	-Time to progression of each targeted
	Russia, South			abstinent	COVID-19 sign/symptom (up to 29
	Africa, Spain,			-For Phase III: unvaccinated	days)
	Taiwan, Ukraine,				-WHO 11-point outcomes score on a
	US			Exclusion Criteria	scale (up to 29 days)
				-Hospitalized for COVID-19 within 48 hours	
	Date(s) of			-On dialysis or has reduced eGFR <30	
	Enrollment: NR			mL/min/1.73m^2 by modification of diet in	
				renal disease equation	
				-Has any of following: HIV with recent viral	
				load >50 copies/mL or AIDS-defining illness	
				in past 6 months, participants with HIV may	
				only be enrolled if on stable antiretroviral	
				regimen; a neutrophilic granulocyte absolute	
				count <500/mm^3	
				-History of HBV or HCV with cirrhosis, ESRD,	
				hepatocellular carcinoma, AST, and/or ALT	
				>3X ULN	
				-Platelet count <100,000/μL or received	
				platelet transfusion in 5 days prior to	
				randomization	
				-Participation with another clinical study	
				with an investigational compound including	
				COVID-19 therapies	
				-Any condition making participation not in	
				best interest of participant: those who are	
				not expected to survive longer than 48 hours	
				after randomization, or those with recent	
				history of mechanical ventilation, or	
				participants with conditions that could limit	
				GI absorption of capsule contents	
Phase III	MC, OL,	Patients with mild	Day 1-5 (twice daily)	NR	Primary Endpoint (Day 14):
Molnupiravir	randomized,	COVID-19	Molnupiravir 800 mg		-Rate of hospitalization
Study in India <sup>36</sup>	parallel study		(n=608)		
		N=1,218			Secondary Endpoints (Day 14):

Trial & NCT	Study Design & Location	N	Treatment	Inclusion & Exclusion Criteria	Key Outcomes
(No NCT provided)	Location: India		Standard of care		-Proportion of patients with clinical
			(n=610)		improvement (Day 10 and Day 14)
	Date(s) of				-Mortality
	Enrollment: NR				-Rate of SARS-CoV2 RT-PCR negativity
					(Day 5, Day 10, Day 14)
					-Change in SARS-CoV2 viral load (Day
					5, Day 10, Day 14)
					-Incidence/severity of TEAEs
					-Proportion of patients who
					discontinued drug due to adverse
					events
Phase IIa	MC, DB, PC, RCT	Symptomatic	Day 1-5 (twice daily):	Inclusion Criteria	Primary Endpoint:
Study 2003		adult outpatients	Molnupiravir 200 mg	-≥18 years of age at screening	-Number of participants with any AEs
Fischer 2021 <sup>33</sup>	Location: US	with COVID-19	(oral)	-Study treatment is expected to begin within	as assessed by Kaplan Meier approach
			(n=23)	≤168 hours from first symptom onset	(28 days)
NCT04405570	Date(s) of	N=204	Molnupiravir 400 mg	-Documentation of confirmed active SARS-	-Virologic efficacy: days until first non-
	Enrollment:		(oral)	CoV-2 infection, as determined by molecular	detectable SARS-CoV-2 in NP swabs
	June 2020- January 2021		(n=62)	test conducted at any US clinic or laboratory or equivalent from an NP swab collected ≤96	(28 days)
	January 2021		Molnupiravir 800 mg	hours prior to study entry	Secondary Endpoint:
			(oral)	-≥1 SARS-CoV-2 infection symptoms: fever	-AEs, Grade 2 or higher (28 days)
			(n=55)	OR signs/symptoms of respiratory illness	ries, Grade 2 of Higher (20 days)
			(11-33)	(including upper respiratory congestion, loss	
			Placebo	of sense of smell or taste, sore throat,	
				cough, shortness of breath)	
				-No participation in another interventional	
				clinical trial for SARS-CoV-2 treatment or	
				other investigational medicine unless	
				hospitalized	
				-Participants must not be of childbearing	
				potential, have surgical sterilization, not be	
				pregnant, use contraception, or have an	
				azoospermic partner	
				-Males must refrain from donating sperm	

Trial & NCT	Study Design & Location	N	Treatment	Inclusion & Exclusion Criteria	Key Outcomes
				Exclusion Criteria  -Need for hospitalization or immediate medical attention in general or due to COVID-19  -Hb <10 g/dL in men and <9 g/dL in women, platelet count <125,000/L, eGFR <60 mL/min/1.73m2, AST/ALT≥3x ULN  -History of kidney disease, liver disease, active HBV, HCV, HIV, or blood dyscrasia  -Use of therapeutic interventions with possible anti-SARS-CoV-2 activity within 30 days prior to study entry  -Receipt of SARS-CoV-2 vaccination  -History of hemorrhagic cerebrovascular	
				accident or major bleed	
	T			trelvir/Ritonavir)	
Phase II/III - EPIC- HR (Nonhospitalized Symptomatic) <sup>6,13</sup> NCT04960202	MC, QB, PC, RCT  Location: Argentina, Brazil, Bulgaria, Colombia, Czechia, Hungary, India, Japan, Korea, Malaysia, Mexico, Poland, Puerto Rico, Russia, South Africa, Spain, Taiwan, Thailand, Turkey, Ukraine, US	Non-hospitalized symptomatic COVID-19 adults with high risk of progression to severe disease N=2,246	Day 1-5: Nirmatrelvir 300 mg + ritonavir 100 mg (oral) twice daily (n=1,120)  Placebo (n=1,126)	Inclusion Criteria -Confirmed SARS-CoV-2 infection and onset of symptoms within 5 days prior to randomization -≥1 COVID-19 signs/symptoms present on day of randomization -Fertile participants on contraception -≥1 risk of developing severe COVID-19  Exclusion Criteria -Hospitalization for COVID-19 -Known history of active liver disease, receiving dialysis or have known renal impairment, or HIV infection with a viral load >400 copies/mL or taking prohibited medications for treatment -Concurrent active systemic non-COVID infection -Use of any medications dependent on or	Primary Endpoint: -COVID-19 related hospitalization or death (all cause) (up to day 28)  Secondary Endpoints: -AEs, TEAEs and SAEs (day 1 through day 34) -Duration and severity of each COVID-19 sign/symptom (day 1 through day 28) -Death (all cause) (day 1 through week 24) -Pharmacokinetics in plasma and whole blood of PF-07321332 (day 1 through day 5) -Viral titers measured by RT-PCR in nasal swabs (day 1 through day 14) -Number of COVID-19 related medical visits other than hospitalization (day 1

Trial & NCT	Study Design & Location	N	Treatment	Inclusion & Exclusion Criteria	Key Outcomes
	Date(s) of			are strong inducers of CYP3A4	through day 34)
	Enrollment: July			-Receive dose of a SARS-CoV-2 vaccine	-Number of days in hospital and ICU
	2021-November			before day 34 or convalescent COVID-19	for the treatment of COVID-19 (day 1
	2021			plasma	through day 34)
				-Participating in other clinical study with	
				investigational product, including PF- 07321332	
				-Oxygen saturation of <92% on room air, or	
				on standard home oxygen supplementation	
				for those who receive supplementary	
				oxygen for an underlying lung condition	
				-Females who are pregnant or breastfeeding	
Phase II/III - EPIC-	MC, QB, PC, RCT	Non-hospitalized	Day 1-5:	Inclusion Criteria	Primary Outcome:
SR <sup>127</sup>		symptomatic	Nirmatrelvir 300 mg +	-SARS-CoV-2 infection and onset COVID-19	-Time to alleviation of COVID-19
	Location:	COVID-19 adults	ritonavir 100 mg (oral)	symptoms within 5 days prior to	symptoms (day 28)
NCT05011513	Argentina,	with low/	twice daily (n=338)	randomization	Secondary Outcomes (up to day 28
	Brazil, Bulgaria,	standard risk of		-Fertile participants on contraception	unless otherwise stated):
	Colombia,	progression to	Placebo (n=355)		-AEs, SAEs, AEs leading to
	Czechia,	severe disease		Exclusion Criteria	discontinuation (day 34)
	Hungary,			-Received any COVID-19 vaccine, except for	-Participants with severe COVID-19
	Japan, Korea,	N~>1,140		patients with increased risk of developing	symptoms
	Malaysia,			severe COVID-19, therefore making patients	-Duration of COVID-19 symptoms
	Mexico, Poland,			low risk	-Progression to a worsening status in
	Puerto Rico,			-History of or need for hospitalization for	COVID-19 symptoms
	Russia, South			COVID-19	-Participants with resting peripheral
	Africa, Spain,			-Previous SARS-CoV-2 infection or active	oxygen saturation ≥95% (days 1, 5)
	Taiwan,			systemic infection other than COVID-19	-Number of COVID-19 related medical
	Thailand,			-Liver disease, has HIV infection with viral	visits
	Turkey,			load >400 copies/ml, taking prohibited	-Number of days in hospital and ICU
	Ukraine, US			medications for HIV, receiving dialysis or has renal impairment	-Participants with COVID-19 related hospitalization or all-cause death
	Date(s) of			-Use of medications dependent on CYP3A4	
	Enrollment:			for clearance	
	August 2021-NR			-Receive mAb treatment, convalescent	
				COVID-19 plasma, SARS-COV-2 vaccine	

Trial & NCT	Study Design & Location	N	Treatment	Inclusion & Exclusion Criteria	Key Outcomes
				-Participation in clinical study with other	
				investigational compound or PF-07321332	
				-Oxygen saturation of <92% on room air	
				-Pregnant or breastfeeding	
			Fluvo	xamine	
Phase III	MC, QB, PC,	Non-hospitalized	Day 1-10:	Inclusion Criteria	Primary Endpoints (through day 28):
TOGETHER <sup>9</sup>	Randomized	adults with mild	Fluvoxamine 100 mg	-Patients over 18 years old with acute flu-	-Need for and evaluation of ED visits
	Adaptive Trial	COVID-19 and	(oral) twice daily	like symptoms <7 days	and observation unit stay >6 hours
NCT04727424		high risk of	(n=739)	-≤1 enhancement criteria: age >50 years,	-Hospitalization due to COVID-19
	Location: Brazil	complications		diabetes, hypertension, CVD, lung disease,	progression and related complications
			Doxazosin (1 or 2 mg	asthma, fever >38C, obesity, transplant	
	Date(s) of	N~3,645	once daily (days 0-3),	patients, stage IV CKD, immunosuppressive	Secondary Endpoints (through day 28
	Enrollment:		titration up to 8	or corticosteroid therapy, cancer, chronic	unless otherwise stated):
	January 2021-		mg/day (days 3-13)	renal disease KDIGO IV or ESRD on therapy	-Change in viral load on day 3 and 7
	August 2021 (for		(oral)	-Patient with positive rapid test for SARS-	after randomization (day 3 and 7)
	fluvoxamine		Ivermectin 6 mg (oral)	CoV2 antigen at screening or diagnostic test	-Time to clinical changes (>50%)
	arm)		once daily	within 7 days of symptom onset	-Time to hospitalization
					-Number of days with respiratory
			Placebo (n=733)	Exclusion Criteria	symptoms
				-Negative SARS-CoV2 test, flu-like symptom	-All-cause hospitalizations
				onset 8+ days, or >14 days of SARS-CoV-2	-COVID-19 hospitalizations
				vaccination	-Number of days on mechanical
				-Hospitalization due to COVID-19	ventilator
				-Non-COVID-19 acute respiratory conditions	-Number of days on ICU
				-Patients with moderate disease or	-Number of days on hospitalizations
				hospitalized	-Health and functioning after COVID-
				-Use of medications in last 14 days: SSRIs,	19 disease using PROMIS Global
				MAOIs, alpha-1 antagonists, sotalol,	Health Score (day 14 and 28)
				clonidine, methyldopa, phosphodiesterase 5	-WHO ordinal scale for clinical
				inhibitors, prazosin, terazosin, doxazosin,	improvement
				antiretroviral agents	-Number of days on respiratory
				-Patients with severe psychiatric disorders or	Symptoms
				major uncontrolled depression	-Adherence
				-Pregnant or breastfeeding patients	
				-History of cardiac arrythmia, long QT	

Trial & NCT	Study Design & Location	N	Treatment	Inclusion & Exclusion Criteria	Key Outcomes
				syndrome, hypotension, syncope, POTS,	
				cerebrovascular accident, MI, CV	
				intervention, mitral or aortic stenosis,	
				seizures, liver cirrhosis or Child-Pugh C	
				classification	
				-Surgical procedure during treatment	
				-Patients with known severe degenerative	
				neurological/serious mental diseases	
Phase II	MC, TB, PC, RCT	Non-hospitalized	Day 0: Fluvoxamine 50	Inclusion Criteria	Primary Endpoint:
STOP COVID <sup>128</sup>		adults with	mg (oral)	-Men and woman ages 18 and older	-Number of participants who met
	Location: US	known SARS-COV-		-Not hospitalized	clinical worsening, defined as
NCT04342663		2	Day 1-2:	-Has recently tested SARS-CoV-2 (COVID-19	presence of dyspnea and/or
	Date(s) of		Fluvoxamine 100 mg	virus) positive	hospitalization for shortness of breath
	Enrollment:	N=152	(oral) twice daily	-Currently symptomatic with one or more of	or pneumonia, AND decrease in O2
	April 2020-			one or more of the following symptoms:	saturation (<92%) on room air and/or
	August 2020		Placebo	fever, cough, myalgia, mild dyspnea,	supplemental oxygen requirement in
				diarrhea, vomiting, anosmia, ageusia, sore	order to keep O2 saturation >92%
			Day 3-15:	throat	(~15 days)
			Fluvoxamine 100 mg		
			(oral) 3 times daily	Exclusion Criteria	Secondary Endpoint:
			(n=80)	-Illness severe enough to require	-Clinical deterioration on a Likert-type
				hospitalization or already meeting study's	scale (0-6) (~15 days)
			Placebo (n=72)	primary endpoint for clinical worsening	-Symptomatic severity using a
				-Unstable medical comorbidities including,	continuous scale of each patient's
				but not limited to: severe underlying lung	most severe baseline symptom on an
				disease (COPD on home oxygen, interstitial	11-point scale (~15 days)
				lung disease, pulmonary hypertension),	
				decompensated cirrhosis, CHF (stage 3 or 4	
				per patient report and/or medical records)	
				-Already enrolled in another COVID-19 trial,	
				or currently taking chloroquine,	
				hydroxychloroquine, azithromycin or	
				colchicine	
				-Immunocompromised (solid organ	
				transplant, BMT, AIDS, on biologics and/or	

Trial & NCT	Study Design & Location	N	Treatment	Inclusion & Exclusion Criteria	Key Outcomes
				high-dose steroids (>20 mg prednisone per day)	
Phase III STOP-COVID 2 <sup>68,135</sup> NCT04668950	MC, TB, PC, RCT Location: Canada and US  Date(s) of Enrollment: December 2020- May 2021	Non-hospitalized symptomatic adults ages 30+ with SARS-COV-2 and high risk of clinical deterioration  N~880	Day 0: Fluvoxamine 50 mg (oral)  Day 1-15: Fluvoxamine 100 mg (oral) twice daily (n=276)  Placebo (n=275)	Inclusion Criteria  -Men and woman age 30 and older and not currently hospitalized -Proven SARS-CoV-2 positive (per lab or physician report)  - Able to provide informed consent -Currently symptomatic with one or more of following symptoms: fever, cough, myalgia, mild dyspnea, chest pain, diarrhea, nausea, vomiting, anosmia, ageusia, sore throat, nasal congestion -Reports one of the following risk factors for clinical deterioration: age ≥40, racial/ethnic group African American, Hispanic, or Native American, or 1+ medical condition increasing risk for moderate-severe COVID-19 illness: obesity, hypertension, diabetes, heart disease, lung disease, immune disorder  Exclusion Criteria: -Illness severe enough to require hospitalization or already meeting study's primary endpoint for clinical worsening -Unstable medical comorbidities -Immunocompromised from following: solid organ transplant, BMT, high-dose steroids (>20 mg prednisone per day), or tocilizumab	Primary Endpoint: -Clinical deterioration, defined as both presence of dyspnea and/or hospitalization for shortness of breath or pneumonia AND decrease in O2 saturation (<92% on room air) and/or supplemental oxygen requirement to keep O2 saturation ≥92%) (~15 days)  Secondary Endpoint: -Post covid functioning via PROMIS Global Health Scale (day 15 and day 90)
				-Already enrolled in another COVID-19 treatment trial or received COVID-19 vaccine -Taking donepezil, sertraline, warfarin, phenytoin, clopidogrel, and St John's wort -Taking SSRIs, SNRIs, tricyclic	

Trial & NCT	Study Design & Location	N	Treatment	Inclusion & Exclusion Criteria	Key Outcomes
				antidepressants, bipolar medication,	
				theophylline, tizanidine, clozapine, or	
				olanzapine	
				-Individuals unwilling to cut alprazolam or	
				diazepam medication by 25%	

ADA: anti-drug antibody, AE: adverse event, AIDS: acquired immunodeficiency syndrome, ALT: alanine aminotransferase, AST: aspartate aminotransferase, AUC<sub>extrap</sub>: area under the curve extrapolated as a percentage of the total, AUC<sub>inf</sub>: area under the curve to infinity, AUC<sub>inst</sub>: area under the curve to the last measurable concentration, BMI: body mass index, BMT: blood or marrow transplant, CKD: chronic kidney disease, CL: drug clearance, CL/F: apparent oral clearance, C<sub>last</sub>: last measurable concentration (above the quantification limit), C<sub>max</sub>: maximum plasma concentration, CVD: cardiovascular disease, CYP3A4: Cytochrome P450 3A4, DB: double-blind, dL: deciliter, eGFR: estimated glomerular filtration rate EUA: Emergency Use Authorization, g: gram, HBV: hepatitis B, HCV: hepatitis C, HIV: human immunodeficiency virus, ICU: intensive care unit, IM: intramuscular, IV: intravenous, IVIG: intravenous immune globin, kg: kilogram, L: liter, m: meter, mAb: monoclonal antibody, MC: multi-center, mg: milligram, mL: milliliter, n: number, N: total number, NCT: National Clinical Trial Identifier, NR: not reported, NYHA: New York Heart Association, OL: open-label, O2: oxygen, PC: placebo-controlled, POTS: postural orthostatic tachycardia syndrome, QB: quadruple-blind, QT: interval representing the time it takes for the heart muscle to contract and then recover, RCT: randomized controlled trial, RT-qPCR: quantitative reverse transcription polymerase chain reaction, SAE: serious adverse event, SNRI: serotonin and norepinephrine reuptake inhibitor, SSRI: selective serotonin reuptake inhibitor, TB: triple-blind, TEAE: treatment-emergent adverse event, T<sub>last</sub>: time of last measurable concentration, T<sub>max</sub>: time to maximum plasma concentration (C<sub>max</sub>), t½: half-life, uL: microliter, U.K.: United Kingdom, ULN: upper limit normal, U.S.: United Status, V<sub>2</sub>/F: apparent volume of distribution during terminal phase, WHO: World Health Organization

Table D6. Baseline Characteristics: Phase III Trials (Monoclonal Antibodies)<sup>8,45,121-123,130,134</sup>

Drug	g Name	REGEN-	COV2 (Casirivi	mab/Imdevima	b)		Sotro	vimab	
Ţ	rial	Phase I	II COV-2067 (N	lon-Hospitalize	d)	COME	T-ICE	COME	T-TAIL
А	ırms	REGEN-COV 2400 mg	PBO 2400 mg	REGEN-COV 1200 mg	PBO 1200 mg	Sotrovimab 500 mg	РВО	Sotrovimab 500 mg (IM) 382 ) 51 (15-90) NR 285/382 (75) 97/382 (25) NR NR NR 362/382 (95) ) 16/382 (4) ) NR	Sotrovimab 500 mg (IV)
	N	1355	1341*	736	748	528	529	382	379
Age, Median Year	s (IQR)	50 (39-60)	50 (37-58)	48.5 (37- 57.5)	48 (35- 57)	53 (41.5-62)	53 (43-63)	51 (15-90)	52 (18-92)
	≥50 Years	715/1355 (52.8)	678/1341 (50.6)	357/736 (48.5)	356/748 (47.6)	NR	NR	NR	NR
Age Group, n/N (%)	<65 Years	1141/1355 (84.2)	1197/1341 (89.3)	632/736 (87.4)	660/748 (88.2)	423/528 (80)	421/529 (80)		284/379 (75)
	≥65 Years	214/1355 (15.8)	144/1341 (10.7)	93/736 (12.6)	88/748 (11.8)	105/528 (20)	108/529 (20)	97/382 (25)	95/379 (25)
Canadan in (N. (04)	Male	656/1355 (48.4)	633/1341 (47.2)	364/736 (49.5)	352/748 (47.1)	229/528 (43)	256/529 (48)	NR	NR
Gender, n/N (%)	Female	699/1355 (51.6)	707/1341 (52.8)	372/736 (50.5)	396/748 (52.9)	299/528 (57)	273/529 (52)	NR	NR
	White	1161/1355 (85.7)	1136/1341 (84.7)	595/736 (80.8)	611/748 (81.7)	458/528 (87)	463/529 (88)		355/379 (94)
	Black or African American	67/1355 (4.9)	66/1341 (4.9)	38/736 (5.2)	38/748 (5.1)	40/528 (8)	42/529 (8)	16/382 (4)	17/379 (4)
	Asian	52/1355 (3.8)	56/1341 (4.2)	38/736 (5.2)	36/748 (4.8)	24/528 (5)	21/529 (4)	NR	NR
Race, n/N (%)	American Indian or Alaska Native	19/1355 (1.4)	13/1341 (1.0)	17/736 (2.3)	10/748 (1.3)	1/528 (<1)	2/529 (<1)	NR	NR
	Hispanic or Latino	NR	NR	NR	NR	NR	NR	NR	NR
	Mixed Race	NR	NR	NR	NR	4/528 (<1)	0	NR	NR
	Other	NR	NR	NR	NR	NR	NR	NR	NR
	Unknown	28/1355 (2.1)	43/1341 (3.2)	36/736 (4.9)	37/748 (4.9)	NR	NR	NR	NR
	Not Reported	24/1355 (1.8)	26/1341 (1.9)	10/736 (1.4)	15/748 (2.0)	NR	NR	NR	NR
Ethnicity, n/N (%)	Hispanic or Latino	464/1355 (34.2)	471/1341 (35.1)	312/736 (42.4)	295/748 (39.4)	345/528 (65)	346/529 (65)	314/382 (82)	321/379 (85)

Drug	, Name	REGEN-	COV2 (Casirivi	mab/Imdevima	b)		Sotro	vimab	
1	rial	Phase I	II COV-2067 (N	Ion-Hospitalize	d)	COME	T-ICE	COME	T-TAIL
А	rms	REGEN-COV 2400 mg	PBO 2400 mg	REGEN-COV 1200 mg	PBO 1200 mg	Sotrovimab 500 mg	РВО	Sotrovimab 500 mg (IM)	Sotrovimab 500 mg (IV)
	N	1355	1341*	736	748	528	529	382	379
	Not Hispanic or Latino	891/1355 (65.8)	870/1341 (64.9)	424/736 (57.6)	453/748 (60.6)	183/528 (35)	183/529 (35)	68/382 (18)	58/379 (15)
Weight, Median k	g (IQR)	87.5 (75.2- 102.1)	87.9 (74.3- 103)	86.2 (74.4- 102.1)	86.2 (72.8- 102.4)	NR	NR	NR	NR
BMI Mean kg/m²	(SD)	31.1 (6.3)	31.2 (6.6)	31.5 (7.3)	31.1 (6.5)	32.3 (6.7)	32.2 (6.6)	NR	NR
DB41 /B1 /0/\	<30 kg/m²	568/1355 (41.9)	569/1341 (42.4)	326/736 (44.3)	321/748 (42.9)	198/528 (37)	188/529 (36)	NR	NR
BMI, n/N (%)	≥30 kg/m²	787/1355 (58.1)	772/1341 (57.6)	410/736 (55.7)	427/748 (57.1)	330/528 (63)	341/529 (64)	NR	NR
Overweight, n/N	(%)	567/2091 (27.1)†	339/1341 (25.3)	567/2091 (27.1)†	NR	NR	NR	NR	NR
Positive Baseline n/N (%)	Qualitative RT-PCR,	1353/1355 (99.9)	1333/1341 (99.4)	734/736 (99.7)	744/748 (99.5)	NR	NR	NR	NR
	Alpha	NR	NR	NR	NR	NR	NR	NR	NR
SARS-COV-2	Gamma	NR	NR	NR	NR	NR	NR	NR	NR
Variant, n/N (%)	Delta	NR	NR	NR	NR	NR	NR	NR	NR
variant, n/ N (%)	Mu	NR	NR	NR	NR	NR	NR	NR	NR
	Lambda	NR	NR	NR	NR	NR	NR	NR	NR
Time from Sympton Randomization, N	om Onset to Median Days (Range)	3.0 (2-5)	3.0 (2-5)	3.0 (2-5)	3.0 (2-4)	NR	NR	NR	NR
	0-3 Days	NR	NR	NR	NR	314/528 (59)	310/529 (59)	365/7	51 (48)
Duration of symptoms, n/N	4-5 Days	NR	NR	NR	NR	213/528 (40)	219/529 (41)	282/7	61 (37)
(%)	4-7 Days	NR	NR	NR	NR	1/528 (<1) +++	0/529 (0) +++	54/382 (14)†††	44/379 (12)†††
	Unspecified	NR	NR	NR	NR	NR	NR	NR	NR
Duration of Follow (SD)	v-Up, Median Days		45‡			103 (79- 128)§	102 (77- 128)§	NR	NR

Drug	Name	REGEN-	COV2 (Casirivi	mab/Imdevima	b)		Sotro	vimab	
Т	rial	Phase I	II COV-2067 (N	lon-Hospitalize	d)	COME	T-ICE	COME	T-TAIL
А	rms	REGEN-COV 2400 mg	PBO 2400 mg	REGEN-COV 1200 mg	PBO 1200 mg	Sotrovimab 500 mg	РВО	Sotrovimab 500 mg (IM)	Sotrovimab 500 mg (IV)
	N	1355	1341*	736	748	528	529	382	379
≥1 Risk Factor for	Progression to	1355/1355	1341/1341	736/736	748/748	525/528	526/529	382/382	379/379
Severe Disease, n	/N (%)	(100)	(100)	(100)	(100)	(>99)	(>99)	(100)	(100)
	Age ≥55 Years	715/1355 (52.8)#	678/1341 (50.6)#	357/736 (48.5)#	356/748 (47.6)#	243/528 (46)	256/529 (48)	239/382 (63)	235/379 (62)
	Obesity (BMI>30)	787/1355 (58.1)	772/1341 (57.6)	410/736 (55.7)	427/748 (57.1)	330/528 (63)	341/529 (64)	239/382 (63)	235/379 (62)
	CVD or Hypertension	520/1355 (38.4)	473/1341 (35.3)	282/736 (38.3)	NR	4/528 (<1)¤	3/529 (<1)¤	NR	NR
	COPD	NR	NR	NR	NR	34/528 (6)	27/529 (5)	60/382 (16)###	69/379 (18)###
	Asthma	216/1355 (15.9)**	219/1341 (16.3)**	139/736 (18.9)**	NR	90/528 (17)††	88/529 (17)††	NR	NR
Any Risk Factor for Progression	CKD	19/1355 (1.4)	9/1341 (0.7)	8/736 (1.1)	NR	5/528 (<1)	8/529 (2)	NR	NR
to Severe Disease, n/N (%)	Diabetes (Type 1/2)	202/1355 (14.9)	210/1341 (15.7)	94/736 (12.8)	NR	119/528 (23)	109/529 (21)	49/382 (13)	46/379 (12)
	Immunosup. Disease	46/1355 (3.4)‡‡	34/1341 (2.5)‡‡	24/736 (3.3)	NR	NR	NR	11/382 (3)	12/379 (3)
	Neurological Disorder	NR	NR	NR	NR	NR	NR	NR	NR
	Liver Disease	14/1355 (1.0)	8/1341 (0.6)	3/736 (0.4)	NR	NR	NR	NR	NR
	High Cholesterol	NR	NR	NR	NR	NR	NR	NR	NR
	Any Other Risk Factors or Comorbidities	NR	NR	NR	NR	NR	NR	NR	NR
Baseline Serum	Negative	940/1355 (69.4)	930/1341 (69.4)	500/736 (67.9)	519/748 (69.4)	NR	NR	NR	NR
Antibody Status, n/N (%)	Positive	323/1355 (23.8)	297/1341 (22.1)	177/736 (24.0)	164/748 (21.9)	NR	NR	NR	NR
	Unknown	NR	NR	NR	NR	NR	NR	NR	NR

Drug	Name	REGEN-0	Sotrovimab						
Т	rial	Phase II	I COV-2067 (N	lon-Hospitalize	d)	COME	COMET-ICE COMET-TAIL		T-TAIL
А	rms	REGEN-COV 2400 mg	PBO 2400 mg	REGEN-COV 1200 mg	PBO 1200 mg	Sotrovimab 500 mg	РВО	Sotrovimab 500 mg (IM)	Sotrovimab 500 mg (IV)
	N	1355	1341*	736	748	528	529	382	379
Baseline Viral Load Nasopharyngeal S Copies/ml (Range	wab, Median Log <sub>10</sub>	7.01 (2.6-10)§§	6.95 (2.6- 10.2)##	6.92 (2.6- 10.5)¤¤	6.85 (2.6- 10.2)***	NR	NR	NR	NR
Geography of	US	2004/2091 (95.8)†	1285/1341 (95.8)	2004/2091 (95.8)†	NR	503/528 (95)‡‡‡	502/529 (95)‡‡‡	NR	NR
Enrollment, n/N (%)	Non-US	87/2091 (4.2)†	56/1341 (4.2)	87/2091 (4.2)†	NR	25 (5)§§§	27 (5)§§§	NR	NR

BMI: body mass index, CKD: chronic kidney disease, COPD: chronic obstructive pulmonary disease, IM: intramuscular, IV: intravenous, IQR: interquartile range, kg: kilogram, m: meter, mg: milligram, mL: milliliter, n: number, N: total number, NR: not reported, PBO: placebo, RT-PCR: reverse transcription polymerase chain reaction, SD: standard deviation, US: United States

‡No SD available.

§Median (IQR).

#Age ≥50 years.

¤Congestive heart failure (NYHA class II or more).

††Moderate-to-severe asthma

‡‡Immunocompromised.

§§N=1,353.

##N=1,333.

¤¤N=734.

\*\*\*N=744.

†††Time from symptom onset to randomization >5 days.

‡‡‡Regions located in North America.

§§§Regions not located in North America.

###Chronic lung disease.

<sup>\*</sup>Number includes patients in the placebo 1200 mg arm.

<sup>†</sup>Pooled data from the two intervention arms.

<sup>\*\*</sup>Chronic lung disease including asthma.

Table D7. Baseline Characteristics: Phase III Trials (Oral Antivirals)  $^{6,10,12,13,36}$ 

Dru	ıg Name		Molnu	piravir		Paxlo	vid (Nirmatre	elvir/Ritonavir)	
	Trial	Phase III MO	Ve-OUT	Phase III Mol Study in	•	Phase II/III E	PIC-HR	Phase II/III EPIC (Interim)	-SR
	Arms	Molnupiravir 800 mg	РВО	Molnupiravir 800 mg	РВО	Nirmatrelvir 300 mg + Ritonavir 100 mg	РВО	Nirmatrelvir 300 mg + Ritonavir 100 mg	РВО
	N	716	717	608	610	1,120	1,126	NR	NR
Age, Median Yea	rs (IQR)	42 (18-90)*	44 (18- 88)*	35.2 (10.8)‡‡	34.8 (10.8)‡‡	45 (18-86)*	46.5 (18- 88)*	NR	NR
	≥50 Years	232/716 (32)	252/717 (35)	NR	NR	NR	NR	NR	NR
Age Group, n/N (%)	<65 Years	643/716 (90)	635/717 (89)	NR	NR	NR	NR	NR	NR
	≥65 Years	73/716 (10)	82/717 (11)	NR	NR	NR	NR	NR	NR
Gender, n/N	Male	332/716 (46.4)	366/717 (51)	408/608 (67.1)	425/610 (69.7)	566/1120 (50.5)	582/1126 (51.7)	NR	NR
(%)	Female	384/716 (53.6)	351/717 (49)	200/608 (32.3)	185/610 (30.3)	554/1120 (49.5)	544/1126 (48.3)	NR	NR
	White	400/716 (55.9)	413/717 (57.6)	NR	NR	800/1120 (71.4)	807/1126 (71.7)	NR	NR
	Black or African American	40/716 (5.6)	35/717 (4.9)	NR	NR	60/1120 (5.4)	50/1126 (4.4)	NR	NR
	Asian	26/716 (3.6)	23/717 (3.2)	NR	NR	154/1120 (13.8)	161/1126 (14.3)	NR	NR
Race, n/N (%)	Indian	NR	NR	608/608 (100)	610/610 (100)	NR	NR	NR	
- •	American Indian or Alaska Native	60/716 (8.4)	44/717 (6.1)	NR	NR	96/1120 (8.6)	95/1126 (8.4)	NR	NR
	Hispanic or Latino	NR	NR	NR	NR	NR	NR	NR	NR
	Mixed Race	190/716 (26.5)	202/717 (28.2)	NR	NR	1/1120 (0.1)	2/1126 (0.2)	NR	NR
	Other	NR	NR	NR	NR	1/1120 (0.1)	2/1126	NR	NR
	Unknown	NR	NR	NR	NR	1/1120 (0.1)	(0.2)	NR	NR

Dr	ug Name		Molnu	piravir		Paxlo	elvir/Ritonavir)		
	Trial	Phase III MC	Ve-OUT	Phase III Mol Study in	•	Phase II/III E	PIC-HR	Phase II/III EPIC (Interim)	-SR
	Arms	Molnupiravir 800 mg	РВО	Molnupiravir 800 mg	РВО	Nirmatrelvir 300 mg + Ritonavir 100 mg	РВО	Nirmatrelvir 300 mg + Ritonavir 100 mg	РВО
	N	716	717	608	610	1,120	1,126	NR	NR
	Not Reported	NR	NR	NR	NR	8/1120 (0.7)	9/1126 (0.8)	NR	NR
Ethnicity, n/N	Hispanic or Latino	355/716 (49.6)	356/717 (49.7)	NR	NR	45%		NR	NR
(%)	Not Hispanic or Latino	355/716 (49.6)	358/717 (49.9)	NR	NR	55%		NR	NR
Weight, Median	kg (IQR)	NR	NR	65 (9.1)‡‡	64.2 (7.9)‡‡	NR	NR	NR	NR
BMI Mean kg/m	<sup>2</sup> (SD)	NR	NR	23.5 (2.6)	23.4 (2.6)	NR	NR	NR	NR
DB41 /B1 (0/)	<30 kg/m²	178/716 (24.9)	199/717 (27.8)	589/608 (96.9)	593/610 (97.2)	749/1120 (66.9)	753/1126 (66.9)	NR	NR
BMI, n/N (%)	≥30 kg/m²	538/716 (75.1)	518/717 (72.2)	19/608 (3.1)	17/610 (2.8)	371/1120 (33.1)	373/1126 (33.1)	NR	NR
Overweight, n/N	N (%)	NR	NR	NR	NR	NR	NR	NR	NR
Positive Baseline n/N (%)	e Qualitative RT-PCR,	NR	NR	608/608 (100)	610/610 (100)	NR	NR	NR	NR
	Alpha	12/716 (1.7)	9/717 (1.3)	NR	NR	NR	NR	NR	NR
SARS SOV 2	Gamma	37/716 (5.2)	48/717 (6.7)	NR	NR	NR	NR	NR	NR
SARS-COV-2 Variant, n/N	Delta	237/716 (33.1)	223/717 (31.1)	NR	NR	NR	NR	NR	NR
(%)	Mu	76/716 (10.6)	86/717 (12)	NR	NR	NR	NR	NR	NR
	Lambda	14/716 (2)	7/717 (1)	NR	NR	NR	NR	NR	NR
Time from Symp Randomization,	otom Onset to Median Days (Range)	4†	4†	NR	NR	3 (0-7)	3 (0-9)	NR	NR

Dru	ıg Name		Molnu	piravir		Paxlo	vid (Nirmatre	lvir/Ritonavir)	
	Trial	Phase III MO	Ve-OUT	Phase III Mol Study in	-	Phase II/III El	PIC-HR	Phase II/III EPIC (Interim)	:-SR
,	Arms	Molnupiravir 800 mg	РВО	Molnupiravir 800 mg	РВО	Nirmatrelvir 300 mg + Ritonavir 100 mg	РВО	Nirmatrelvir 300 mg + Ritonavir 100 mg	РВО
	N	716	717	608	610	1,120	1,126	NR	NR
Time from Symptom	0-3 Days	342/716 (47.8)	342/717 (47.7)	327/608 (53.7)##	335/610 (54.9)##	754/1120 (67.3)	735/1126 (65.3)	NR	NR
Onset to Randomization,	4-5 Days	374/716 (52.2)	375/717 (52.3)	281/608 (46.3)¤¤	275/610 (25.1)¤¤	366/1120 (32.7)	391/1126 (34.7)	NR	NR
n/N (%)	4-7 Days	NR	NR	NR	NR	NR	NR	NR	NR
	Unspecified	NR	NR	NR	NR	NR	NR	NR	NR
Duration of Follo (SD)	w-Up, Median Days	NR	NR	NR	NR	27.2†	26†	NR	NR
≥1 Risk Factor for Severe Disease, r	•	712/716 (99.4)	712/717 (99.3)	NR	NR	1120/1120 (100)	1126/1126 (100)	NR	NR
	Age ≥55 Years	119/716 (16.6)‡	127/717 (17.7)‡	NR	NR	131/1120 (11.7)¤	137/1126 (12.2)¤	NR	NA
	Obesity (BMI>30)	538/716 (75.1)	518/717 (72.2)	19/608 (3.1)	17/610 (2.8)	371/1120 (33.1)	373/1126 (33.1)	NA	NA
	CVD or Hypertension	86/716 (12)§	81/717 (11.3)§	3/608 (0.5)	7/610 (1.1)	338/1120 (30.2)	351/1126 (31.2)	NA	NA
Any Risk Factor	COPD	22/716 (3.1)	35/717 (4.9)	NR	NR	58/1120 (5.2)**	34/1126 (3.0)**	NA	NA
for Progression	Asthma	NR	NR	NR	NR	NR	NR	NA	NA
to Severe Disease, n/N	CKD	38/716 (5.3)	46/717 (6.4)	NR	NR	6/1120 (0.5)	7/1126 (0.6)	NA	NA
(%)	Diabetes (Type 1 and 2)	107/716 (14.9)	121/717 (16.9)	2/608 (0.3)	2/610 (0.3)	125/1120 (11.2)	127/1126 (11.3)	NA	NA
	Immunosuppressive Disease	NR	NR	NR	NR	6/1120 (0.5)	6/1126 (0.5)	NA	NA
	Neurological Disorder	NR	NR	NR	NR	1/1120 (0.1)	1/1126 (0.1)	NA	NA
	Liver Disease	NR	NR	NR	NR	NR	NR	NA	NA
	High Cholesterol	NR	NR	NR	NR	NR	NR	NA	NA

Dru	ıg Name		Molnu	piravir		Paxlo	vid (Nirmatre	lvir/Ritonavir)	
	Trial	Phase III MO	Ve-OUT	Phase III Mol Study in	=	Phase II/III E	PIC-HR	Phase II/III EPIC (Interim)	-SR
	Arms	Molnupiravir 800 mg	РВО	Molnupiravir 800 mg	РВО	Nirmatrelvir 300 mg + Ritonavir 100 mg	РВО	Nirmatrelvir 300 mg + Ritonavir 100 mg	РВО
	N	716	717	608	610	1,120	1,126	NR	NR
	Any Other Risk Factors or Comorbidities	NR	NR	NR	NR	NR	NR	NA	NA
D II C	Negative	541/716 (75.6)	521/717 (72.7)	NR	NR	518/1120 (46.2)	537/1126 (47.7)	NA	NR
Baseline Serum Antibody Status, n/N (%)	Positive	137/716 (19.1)#	147/717 (20.5)#	NR	NR	581/1120 (51.9)	568/1126 (50.4)	NR	NR
Status, II/ N (%)	Unknown	38/716 (5.3)	49/717 (6.8)	NR	NR	NR	NR	NR	NR
Baseline Viral Log Swab, Median log (Range)	ad in Nasopharyngeal g <sub>10</sub> Copies/mL	NR	NR	NR	NR	5.41 (0-9.16)††	5.3 (0- 9.15)††	NR	NR
Geography of Enrollment,	US	45/716 (6.3)	46/717 (6.4)	NR	NR	41%		NR	NR
n/N (%)	Non-US	671/716 (93.7)	671/717 (93.6)	NR	NR	59%		NR	NR

BMI: body mass index, CKD: chronic kidney disease, COPD: chronic obstructive pulmonary disease, IQR: interquartile range, kg: kilogram, m: meter, mg: milligram, mL: milliliter, n: number, N: total number, NA: not applicable, NR: not reported, PBO: placebo, RT-PCR: reverse transcription polymerase chain reaction, SD: standard deviation, US: United States

\*Median (range). †No SD, IQR, or range available. ‡Age ≥60 years. §Serious heart condition. #These data do not reflect prior vaccination status. ¤Age ≥65 years. \*\*Chronic lung disease. ††Mean (range). ‡‡Mean (SD). ##Time from symptom onset to randomization <3 days. ¤¤Time from symptom onset to randomization between 3 to 5 days.

Table D8. Baseline Characteristics: Phase III Trials (Fluvoxamine)  $^{9,68,128,135}$ 

[	Orug Name			Fluvoxan	nine		
	Trial	TOGE	THER	STOP-0	COVID 1	STOP-	COVID 2
	Arms	Fluvoxamine 100 mg	РВО	Fluvoxamine 100 mg	РВО	Fluvoxamine 100 mg	РВО
	N	741	756	80	72	272	275
Age, Median Year	s (IQR)	50 (39-56)	49 (38-56)	46 (35-58)	45 (36-54)	47 (40-55)	48 (41-56)
A = 0 Cue un un /Al	≥50 Years	327/741 (44)	328/756 (43)	NR	NR	NR	NR
Age Group, n/N	<65 Years	NR	NR	NR	NR	NR	NR
(%)	≥65 Years	NR	NR	NR	NR	NR	NR
Candan n /N /0/)	Male	332/741 (45)	303/756 (40)	24/80 (30)	19/72 (26)	103/272 (38)	105/275 (38.2)
Gender, n/N (%)	Female	409/741 (55)	453/756 (60)	56/80 (70)	53/72 (74)	169/272 (62)	170/275 (61.8)
	White	6/741 (1)	6/756 (1)	56/80 (70)	50/72 (69)	197/272 (72.4)	201/275 (73.1)
	Black or African American	5/741 (1)	5/756 (1)	18/80 (23)	20/72 (28)	22/272 (8.1)	23/275 (8.4)
	Asian	NR	NR	3/80 (4)	1/72 (1)	8/272 (2.9)	5/275 (1.8)
Race, n/N (%)	American Indian or Alaska Native	NR	NR	0/80 (0)	1/72 (1)	6/272 (2.2)	8/275 (2.9)
	Hispanic or Latino	NR	NR	NR	NR	NR	NR
	Mixed Race	709/741 (96)	719/756 (95)	NR	NR	NR	NR
	Other	NR	NR	2/80 (3)	1/72 (1)	29/272 (10.7)	21/275 (7.6)
	Unknown	21/741 (3)	26/756 (3)	1/80 (1)	0/72 (0)	17/272 (6.2)	22/275 (0)
	Not Reported	NR	NR	NR	NR	17/272 (6.3)	22/275 (8)
Ethnicity, n/N	Hispanic or Latino	NR	NR	3/80 (4)	2/72 (3)	35/272 (12.7)	37/275 (13.5)
(%)	Not Hispanic or Latino	NR	NR	75/80 (94)	66/72 (92)	234/272 (86)	236/275 (85.8)
Weight, Median k	g (IQR)	NR	NR	NR	NR	NR	NR
BMI Mean kg/m <sup>2</sup>	(SD)	NR	NR	NR	NR	NR	NR
	<30 kg/m <sup>2</sup>	355/741 (48)	373/756 (49)	38/80 (46)	30/72 (42)	NR	NR
BMI, n/N (%)	≥30 kg/m²	376/741 (51)	375/756 (50)	43/80 (54)	42/72 (58)	115/272 (42.3)	123/275 (44.7)
Overweight, n/N	%)	NR	NR	22/80 (28)	22/72 (31)	86/272 (31.6)	90/275 (32.7)
Positive Baseline	Qualitative RT-PCR, n/N (%)	NR	NR	NR	NR	NR	NR
CARC COV 2	Alpha	NR	NR	NR	NR	NR	NR
SARS-COV-2	Gamma	NR	NR	NR	NR	NR	NR
Variant, n/N (%)	Delta	NR	NR	NR	NR	NR	NR

1	Orug Name			Fluvoxar	nine		
	Trial	TOGE	THER	STOP-0	COVID 1	STOP-	COVID 2
	Arms	Fluvoxamine 100 mg	РВО	Fluvoxamine 100 mg	РВО	Fluvoxamine 100 mg	РВО
Arms         Fluvoxamine 100 mg           N         741           Mu         NR		756	80	72	272	275	
	Mu	NR	NR	NR	NR	NR	NR
	Lambda	NR	NR	NR	NR	NR	NR
		3.8 (1	1.87)*	4 (3-5)	4 (3-5)	5 (4-6)	5 (4-6)
Time from	0-3 Days	328/741 (44)	310/756 (41)	NR	NR	NR	NR
Symptom Onset	4-5 Days	NR	NR	NR	NR	NR	NR
to	4-7 Days	239/741 (32)	267/756 (35)	NR	NR	NR	NR
Randomization, n/N (%)	Unspecified	174/741 (23)	179/756 (24)	NR	NR	NR	NR
<b>Duration of Folloy</b>	v-Up, Median Days (SD)	NR	NR	NR	NR	NR	NR
≥1 Risk Factor for Disease, n/N (%)	Progression to Severe	741/741 (100)	733/733 (100)	NR	NR	NR	NR
	Age ≥55 years	327/741 (44)†	328/756 (43)†	NR	NR	NR	NR
	Obesity (BMI>30)	376/741 (51)	375/756 (50)	NR	NR	115/272 (42.3)	123/275 (44.7)
	CVD or Hypertension	115/741 (15)‡	95/756 (13)‡	15/80 (19)	15/72 (21)	59/272 (21.7)‡	66/275 (24)‡
	COPD	6/741 (1)§	3/756 (<1)§	NR	NR	2/272 (0.7)#	2/275 (0.7)#
Any Risk Factor	Asthma	12/741 (2)	16/756 (2)	17/80 (21)	9/72 (13)	40/272 (15.4)	33/275 (12)
for Progression	CKD	2/741 (<1)	2/756 (<1)	NR	NR	1/272 (0.4)¤	2/275 (0.7)¤
to Severe	Diabetes (Type 1 and 2)	129/741 (17)	114/756 (12)	9/80 (11)	8/72 (11)	23/272 (8.5)	28/275 (10.2)
Disease, n/N (%)	Immunosuppressive Disease	0/741 (0)**	2/756 (<1)**	NR	NR	14/272 (5.2)	4/275 (1.5)
	Neurological Disorder	NR	NR	NR	NR	NR	NR
	Liver Disease	NR	NR	NR	NR	1/272 (0.4)	1/275 (0.4)
	High Cholesterol	NR	NR	7/80 (9)	7/72 (10)	NR	NR
	Any Other Risk Factors or Comorbidities	25/741 (3)	24/756 (3)	NR	NR	42/272 (15.2)††	54/275 (19.6)††
Baseline Serum	Negative	NR	NR	NR	NR	NR	NR
Antibody Status,	Positive	NR	NR	NR	NR	NR	NR
n/N (%)	Unknown	NR	NR	NR	NR	NR	NR

С	Orug Name			Fluvoxan	nine		
	Trial	TOGETHER		STOP-0	COVID 1	STOP-0	COVID 2
Arms		Fluvoxamine 100 mg	РВО	Fluvoxamine 100 mg	РВО	Fluvoxamine 100 mg	РВО
	N		756	80	72	272	275
Baseline Viral Load Median log <sub>10</sub> Copi	d in Nasopharyngeal Swab, es/mL (Range)	NR	NR	NR	NR	NR	NR
Geography of Enrollment, n/N		NA	NA	80/80 (100)	72/72 (100)	272/272 (100)‡‡	275/275 (100)‡‡
(%)	Non-US	741/741 (100)	756/756 (100)	NA	NA	NA	NA

BMI: body mass index, CKD: chronic kidney disease, COPD: chronic obstructive pulmonary disease, IQR: interquartile range, kg: kilogram, m: meter, mg: milligram, mL: milliliter, n: number, N: total number, NA: not applicable, NR: not reported, PBO: placebo, RT-PCR: reverse transcription polymerase chain reaction, SD: standard deviation, US: United States

‡Cardiac disease and hypertension summed.

§Chronic pulmonary disease

#Lung disease.

¤Kidney disease.

‡‡North America (US and Canada).

<sup>\*</sup>Mean (SD).

<sup>†</sup>Age ≥50 years.

<sup>\*\*</sup>Autoimmune disease.

<sup>††</sup>Other medical condition.

Table D9. Baseline Characteristics: Phase I/II Trials (REGEN-COV)<sup>131</sup>

Dru	g Name		REGEN-COV2 (Cas	sirivimab/Imdevimab)	
-	Trial		Phase I/II COV-20	67 (Non-Hospitalized)	
ļ	Arms	REGEN-COV2 2.4 g	REGEN-COV2 8.0 g	REGEN-COV2 Combined	РВО
	N	92	90	182	93
Age, Median Years (IQR)		43 (33.5-51)	44 (36-53)	43 (35-52)	45 (34-54)
	≥50 Years	NR	NR	NR	NR
Age Group, n/N (%)	<65 Years	NR	NR	NR	NR
	≥65 Years	NR	NR	NR	NR
Candar (2/01/07)	Male	46/92 (50)	38/90 (42)	84/182 (46)	50/93 (54)
Gender, n/N (%)	Female	46/92 (50)	52/90 (58)	98/182 (54)	43/90 (46)
	White	74/92 (80)	78/90 (87)	152/182 (84)	72/93 (77)
	Black or African American	15/92 (16)	6/90 (7)	21/182 (12)	14/93 (15)
	Asian	0/92 (0)	1/90 (1)	1/182 (1)	2/93 (2)
	American Indian or Alaska Native	0/92 (0)	0/90 (0)	0/182 (0)	2/93 (2)
Race, n/N (%)	Hispanic or Latino	NR	NR	NR	NR
	Mixed Race	NR	NR	NR	NR
	Other	NR	NR	NR	NR
	Unknown	0/92 (0)	1/90 (1)	1/182 (1)	2/93 (2)
	Not Reported	3/92 (3)	4/90 (4)	7/182 (4)	1/93 (1)
F41	Hispanic or Latino	52/92 (57)	55/90 (61)	107/182 (59)	46/93 (49)
Ethnicity, n/N (%)	Not Hispanic or Latino	40/92 (43)	35/90 (39)	75/182 (41)	47/93 (51)
Weight, Median kg (IQR)		85.7 (72.2-97.1)	86.3 (72.6-98.3)	86.1 (72.6-97.3)	83.9 (72.9-97.7)
BMI Mean kg/m² (SD)		30.4 (6.6)	30.6 (7.2)	30.5 (6.9)	29.7 (7.1)
DB41 ~ /B1 (0/)	<30 kg/m²	53/92 (58)	48/90 (53)	101/182 (55)	59/93 (63)
BMI, n/N (%)	≥30 kg/m²	39/92 (42)	42/90 (47)	81/182 (45)	34/93 (37)
Overweight, n/N (%)		NR	NR	NR	NR
Positive Baseline Qualitative R	T-PCR, n/N (%)	73/92 (79)	74/90 (82)	147/182 (81)	81/93 (87)
	Alpha	NR	NR	NR	NR
	Gamma	NR	NR	NR	NR
SARS-COV-2 Variant, n/N (%)	Delta	NR	NR	NR	NR
	Mu	NR	NR	REGEN-COV2 Combined         PBO           182         93           43 (35-52)         45 (34-54)           NR         NR           NR         NR           NR         NR           NR         NR           NR         NR           84/182 (46)         50/93 (54)           98/182 (54)         43/90 (46)           152/182 (84)         72/93 (77)           21/182 (12)         14/93 (15)           1/182 (1)         2/93 (2)           NR         NR           NR         NR           NR         NR           NR         NR           1/182 (1)         2/93 (2)           7/182 (4)         1/93 (1)           107/182 (59)         46/93 (49)           75/182 (41)         47/93 (51)           10 86.1 (72.6-97.3)         83.9 (72.9-97.           30.5 (6.9)         29.7 (7.1)           101/182 (55)         59/93 (63)           81/182 (45)         34/93 (37)           NR         NR           147/182 (81)         81/93 (87)           NR         NR           NR         NR	NR
	Lambda	NR	NR	NR	NR
Time from Symptom Onset to Randomization, Median Days (range)		3.5 (0-7)	3.0 (0-8)	3.0 (0-8)	3.0 (0-8)

Druį	g Name		REGEN-COV2 (Cas	irivimab/Imdevimab)			
7	<sup>[</sup> rial		Phase I/II COV-20	REGEN-COV2 8.0 g  90  182  93  NR  NR  NR  NR  NR  NR  NR  NR  NR  N			
Д	ırms	REGEN-COV2 2.4 g	REGEN-COV2 8.0 g	Phase I/II COV-2067 (Non-Hospitalized)           REGEN-COV2         REGEN-COV2           8.0 g         Combined           90         182           NR         NR           NR         NR			
	N	92	90	182	93		
	0-3 Days	NR	NR	NR	NR		
Time from Symptom Onset to	4-5 Days	NR	NR	NR	NR		
Randomization, n/N (%)	4-7 Days	NR	NR	NR	NR		
	Unspecified	NR	NR	NR	NR		
<b>Duration of Follow-Up, Median</b>	days (SD)	NR	NR	NR	NR		
≥1 Risk Factor for Progression t	o Severe Disease, n/N (%)	57/92 (62)	61/90 (68)	118/182 (65)	58/93 (62)		
	Age ≥55 Years	NR	NR	NR	NR		
	Obesity (BMI>30)	39/92 (42)	42/90 (47)	81/182 (45)	34/93 (37)		
	CVD or Hypertension	NR	NR	NR	NR		
	COPD	NR	NR	NR	NR		
	Asthma	NR	NR	NR	NR		
Any Risk Factor for	CKD	NR	NR	NR	NR		
Progression to Severe	Diabetes (Type 1 and 2)	NR	NR	NR	NR		
Disease, n/N (%)	Immunosuppressive Disease	NR	NR	NR	NR		
	Neurological Disorder	NR	NR	NR	NR		
	Liver Disease	NR	NR	NR	NR		
	High Cholesterol	NR	NR	NR	NR		
	Any Other Risk Factors or Comorbidities	NR	NR	NR	NR		
Deceline Comme Antibodi	Negative	41/92 (45)	39/90 (43)	80/182 (44)	33/93 (35)		
Baseline Serum Antibody	Asthma         NR         NR         NR         NR           CKD         NR         NR         NR         NR         NR           Diabetes (Type 1 and 2)         NR         NR         NR         NR         NR           Immunosuppressive Disease         NR         NR         NR         NR         NR           Neurological Disorder         NR         NR         NR         NR         NR           Liver Disease         NR         NR         NR         NR         NR           High Cholesterol         NR         NR         NR         NR         NR           Any Other Risk Factors or Comorbidities         NR         NR         NR         NR         NR           Negative         41/92 (45)         39/90 (43)         80/182 (44)         33/93 (3)	47/93 (51)					
Status, n/N (%)	Unknown	14/92 (15)	12/90 (13)	26/182 (14)	13/93 (14)		
Baseline Viral Load in Nasopha Copies/mL (Range)	ryngeal Swab, Median log <sub>10</sub>	5.41 (0.0-7.9)*	5.29 (0.0-7.9)†	5.30 (0.0-7.9)‡	4.70 (0.0-7.9)§		
Geography of Enrollment,	US	92/92 (100)	90/90 (100)	182/182 (100)	93/93 (100)		
n/N (%)	Non-US	NA	NA	NA	NA		

BMI: body mass index, CKD: chronic kidney disease, COPD: chronic obstructive pulmonary disease, g: gram, IQR: interquartile range, kg: kilogram, m: meter, mL: milliliter, n: number, N: total number, NA: not applicable, NR: not reported, PBO: placebo, RT-PCR: reverse transcription polymerase chain reaction, SD: standard deviation, US: United States

<sup>\*</sup>N=84. †N=83. ‡N=167. §N=91.

Table D10. Baseline Characteristics: Phase I/II Trials (Molnupiravir)<sup>33</sup>

Dru	ıg Name				М	olnupiravir			
	Trial		Phase II MO	Ve-OUT			Phase IIa Study	2003 (Fischer 20	21)
	Arms	Molnupiravir 200 mg	Molnupiravir 400 mg	Molnupiravir 800 mg	Placebo	Molnupiravir 200 mg	Molnupiravir 400 mg	Molnupiravir 800 mg	Placebo
	N	75	77	76	74	23	62	55	62
Age, Median Yea	rs (IQR)	NR	NR	NR	NR	32.0 (19-65)	42.5 (19-82)	42.0 (18-68)	39.0 (19-71)
A = 0 Cross = 1/N	≥50 Years	NR	NR	NR	NR	NR	NR	NR	NR
Age Group, n/N	<65 Years	NR	NR	NR	NR	22/23 (95.7)	59/62 (95.2)	51/55 (92.7)	59/62 (95.2)
(%)	≥65 Years	NR	NR	NR	NR	1/23 (4.3)	3/62 (4.8)	4/55 (7.3)	3/62 (4.8)
Gender, n/N	Male	NR	NR	NR	NR	12/23 (52.2)	30/62 (48.4)	28/55 (50.9)	28/62 (45.2)
(%)	Female	NR	NR	NR	NR	11/23 (47.8)	32/62 (51.6)	27/55 (49.1)	34/62 (54.8)
	White	NR	NR	NR	NR	17/23 (73.9)	56/62 (90.3)	49/55 (89.1)	54/62 (87.1)
	Black or African American	NR	NR	NR	NR	3/23 (13.0)	3/62 (4.8)	3/55 (5.5)	2/62 (3.2)
	Asian	NR	NR	NR	NR	1/23 (4.3)	2/62 (3.2)	1/55 (1.8)	2/62 (3.2)
Race, n/N (%)	American Indian or Alaska Native	NR	NR	NR	NR	NR	NR	NR	NR
	Hispanic or Latino	NR	NR	NR	NR	NR	NR	NR	NR
	Mixed Race	NR	NR	NR	NR	0/23 (0)	1/62 (1.6)	0/55 (0)	3/62 (4.8)
	Other	NR	NR	NR	NR	2/23 (8.7)	0/62 (0)	2/55 (3.6)	1/62 (1.6)
	Unknown	NR	NR	NR	NR	NA	NA	NA	NA
	Not Reported	NR	NR	NR	NR	NA	NA	NA	NA
Ethnicity, n/N	Hispanic or Latino	NR	NR	NR	NR	7/23 (30.4)	23/62 (37.1)	33/55 (60)	23/62 (37.1)
(%)	Not Hispanic or Latino	NR	NR	NR	NR	16/23 (69.6)	39/62 (62.9)	22/55 (40)	39/62 (62.9)
Weight, Median	kg (IQR)	NR	NR	NR	NR	NR	NR	NR	NR
BMI Mean kg/m <sup>2</sup>	<sup>2</sup> (SD)	NR	NR	NR	NR	25.5*	26.7*	27*	27.1*
BMI, n/N (%)	<30 kg/m <sup>2</sup>	NR	NR	NR	NR	16/23 (69.6)	44/62 (71)	40/55 (72.7)	46/62 (74.2)
DIVII, 11/ IV (%)	≥30 kg/m²	NR	NR	NR	NR	7/23 (30.4)	18/62 (29)	15/55 (27.3)	16/62 (25.8)
Overweight, n/N	(%)	NR	NR	NR	NR	NR	NR	NR	NR
Positive Baseline n/N (%)	ositive Baseline Qualitative RT-PCR,		NR	NR	NR	11/22 (50.0)	18/43 (41.9)	20/52 (38.5)	25/53 (47.2)
	Alpha	NR	NR	NR	NR	NR	NR	NR	NR
	Gamma	NR	NR	NR	NR	NR	NR	NR	NR

Dru	ıg Name				М	olnupiravir			
	Trial		Phase II MO	Ve-OUT			Phase IIa Study	2003 (Fischer 202	21)
	Arms	Molnupiravir 200 mg	Molnupiravir 400 mg	Molnupiravir 800 mg	Placebo	Molnupiravir 200 mg	Molnupiravir 400 mg	Molnupiravir 800 mg	Placebo
	N	75	77	76	74	23	62	55	62
SARS-COV-2	Delta	NR	NR	NR	NR	NR	NR	NR	NR
Variant, n/N	Mu	NR	NR	NR	NR	NR	NR	NR	NR
(%)	Lambda	NR	NR	NR	NR	NR	NR	NR	NR
	Time from Symptom Onset to Randomization, Median Days (Range)		NR	NR	NR	4.0 (1.8-7.0)	4.9 (2.5-7.1)	4.6 (1.4-7.1)	4.6 (1.8-7.5)
Time from	0-3 Days	NR	NR	NR	NR	NR	NR	NR	NR
Symptom	4-5 Days	NR	NR	NR	NR	NR	NR	NR	NR
Onset to	4-7 Days	NR	NR	NR	NR	NR	NR	NR	NR
Randomization, n/N (%)	Unspecified	NR	NR	NR	NR	NR	NR	NR	NR
Duration of Follo	w-Up, Median Days	NR	NR	NR	NR	NR	NR	NR	NR
≥1 Risk Factor for Severe Disease, r	_	NR	NR	NR	NR	15/23 (65.2)	37/62 (59.7)	33/55 (60.0)	37/62 (59.7)
	Age ≥55 Years	NR	NR	NR	NR	NR	NR	NR	NR
	Obesity (BMI>30)	NR	NR	NR	NR	NR	NR	NR	NR
	CVD or Hypertension	NR	NR	NR	NR	NR	NR	NR	NR
	COPD	NR	NR	NR	NR	NR	NR	NR	NR
	Asthma	NR	NR	NR	NR	NR	NR	NR	NR
<b>Any Risk Factor</b>	CKD	NR	NR	NR	NR	NR	NR	NR	NR
for Progression	Diabetes (Type 1/2)	NR	NR	NR	NR	NR	NR	NR	NR
to Severe Disease, n/N	Immunosuppressive Disease	NR	NR	NR	NR	NR	NR	NR	NR
(%)	Neurological Disorder	NR	NR	NR	NR	NR	NR	NR	NR
	Liver disease	NR	NR	NR	NR	NR	NR	NR	NR
	High Cholesterol	NR	NR	NR	NR	NR	NR	NR	NR
	Any Other Risk Factors or Comorbidities	NR	NR	NR	NR	NR	NR	NR	NR
	Negative	NR	NR	NR	NR	NR	NR	NR	NR

Dru	ug Name				М	olnupiravir			
	Trial		Phase II MO	Ve-OUT			400 mg         800 mg         Placebo           62         55         62           15/50 (30.0)         18/51 (35.3)         10/55 (18.2)		
Arms N		Molnupiravir 200 mg	Molnupiravir 400 mg	Molnupiravir 800 mg	Placebo	Molnupiravir 200 mg	Molnupiravir 400 mg		Placebo
		75	77	76	74	23	62	55	62
Baseline Serum	Positive	NR	NR	NR	NR	3/20 (15.0)	15/50 (30.0)	18/51 (35.3)	10/55 (18.2)
Antibody Status, n/N (%)	Unknown	NR	NR	NR	NR	NR	NR	NR	NR
Baseline Viral Load in Nasopharyngeal Swab, Median log <sub>10</sub> Copies/mL (Range)		NR	NR	NR	NR	7.25 (3.0- 9.5)	6.72 (3.0-9.9)	6.12 (3.0-9.4)	6.40 (3.0-9.3)
Geography of	US	NR	NR	NR	NR	23/23 (100)	62/62 (100)	55/55 (100)	62/62 (100)
Enrollment, n/N (%)	Non-US	NR	NR	NR	NR	NR	NR	NR	NR

BMI: body mass index, COPD: chronic obstructive pulmonary disease, IQR: interquartile range, kg: kilogram, m: meter, mg: milligram, mL: milliliter, n: number, N: total number, NA: not applicable, NR: not reported, RT-PCR: reverse transcription polymerase chain reaction, SD: standard deviation, US: United States \*No SD available.

Table D11. Efficacy Outcomes: Phase III Trials<sup>8,45,121-124,130,132,134</sup>

Drug	Name	R	EGEN-COV2 (Casi	rivimab/Imdevima	ab)		Sotro	ovimab	
T	rial	Р	hase III COV-206	7 (Non-Hospitalize	ed)	СОМЕ	T-ICE	COME	T-TAIL
A	rms	REGEN-COV 2400 mg	Placebo 2400 mg	REGEN-COV 1200 mg	Placebo 1200 mg	Sotrovimab 500 mg	Placebo	Sotrovimab 500 mg (IM)	Sotrovimab 500 mg (IV)
	N	1355	1341*	736	748	528	529	378	376
	epoint	1333		Days	, , ,	29 D			Days
	edically-Attended	43/1355 (3.2)	109/1341 (8.1)	20/736 (2.7)	51/748 (6.8)	NR	NR	NR	NR
Type of Any- Cause	ED	NR	NR	NR	NR	6/528 (1)	10/529 (2)	NR	NR
Medically- Attended Visit,	Hospitalization	NR	NR	NR	NR	7/528 (1)	29/529 (5)	5/378 (1.5)***	10/376 (2.7)***
n/N (%)	ICU Admission	6/1355 (0.4)	18/1341 (1.3)	3/736 (0.4)	7/738 (0.9)	0/528 (0)	10/529 (1.9)	NR	NR
≥1 COVID-Relate Attended Visit, n	•	NR	NR	NR	NR	NR	NR	NR	NR
Type of COVID-	Outpatient Visit	13/1355 (1)†	24/1341 (1.8)†	10/736 (1.4)†	12/748 (1.6)†	NR	NR	NR	NR
19 Related	Urgent Care	3/1355 (0.2)	7/1341 (0.5)	1/736 (0.1)	5/748 (0.7)	NR	NR	NR	NR
Medically- Attended Visit,	ED	9/1355 (0.7)	16/1341 (1.2)	2/736 (0.3)	10/748 (1.3)	NR	NR	NR	NR
n/N (%)	Hospitalization	17/1355 (1.3)	59/1341 (4.4)	6/736 (0.8)	23/748 (3.1)	3/528 (0.6)	NR	NR	NR
11/14 (70)	ICU Admission	NR	NR	NR	NR	NR	NR	NR	NR
COVID-Related H Any-Cause Death	•	18/1855 (1.3)	62/1341 (4.6)	7/736 (1)	24/748 (3.2)	NR	NR	NR	NR
Relative Risk Red Placebo of Prima (Hospitalization of Death), % (95% C	ry Outcome or All-Cause	71.3 (51.	7 - 82.9)‡	70.4 (31.0	6 - 87.1)‡	79 (50	)-91)§	NR	NR
Hospitalized or D Cause, n/N (%)	eath from Any	20/1355 (1.5)	66/1341 (4.9)	7/736 (1)	26/748 (3.5)	7/528 (1)	30/529 (6)	10/376 (2.7)§	5/378 (1.3)§
Time to Hospital Days (IQR)	ŕ	NR	NR	NR	NR	NR	NR	NR	NR
Hospital Length ( Days (IQR)	of Stay, Median	6 (3-11)	7 (5-13)	4 (3-6)	5.5 (4-10.5)	NR	NR	NR	NR
ED Observation f Hospitalization f n/N (%)		NR	NR	NR	NR	NR	NR	NR	NR
Time to ED Visit Median Days (IQ		NR	NR	NR	NR	NR	NR	NR	NR
Mortality, n/N (9	6)	1 (<0.1)	3 (0.2)	1 (0.1)	1 (0.1)	0/528 (0)	2/529 (<1)	0/378 (0)	2/376 (0.5)

Drug	Name	RI	GEN-COV2 (Casi	rivimab/Imdevima	ab)		Sotro	ovimab	
Т	rial	P	hase III COV-2067	7 (Non-Hospitalize	ed)	COME	T-ICE	COME	T-TAIL
А	rms	REGEN-COV 2400 mg	Placebo 2400 mg	REGEN-COV 1200 mg	Placebo 1200 mg	Sotrovimab 500 mg	Placebo	Sotrovimab 500 mg (IM)	Sotrovimab 500 mg (IV)
	N	1355	1341*	736	748	528	529	378	376
Time	epoint		29	Days		29 🖸	ays	29 [	Days
Time to Death, N	Mean Days (SD)	NR	NR	NR	NR	NR	NR	NR	NR
Time to Symptor Mean Days (SD)	m Resolution,	10#	14#	10#	14#	NR	NR	NR	NR
Ventilation	Non-Invasive Ventilation	NR	NR	NR	NR	0/528 (0)	10/529 (2)	NR	NR
Requirement, n/N (%)	Mechanical Ventilation	1/1355 (<0.1)	6/1341 (0.4)	1/736 (0.1)	2/748 (0.3)	0/528 (0)	4/529 (<1)	NR	NR
Time to SARS-Co Mean Days (SD)	•	NR	NR	NR	NR	NR	NR	NR	NR
Viral Clearance,	n/N (%)	NR	NR	NR	NR	NR	NR	NR	NR
Change from	Day 5	NR	NR	NR	NR	NR	NR	NR	NR
Baseline in SARS-CoV-2 Viral Load, LSM log <sub>10</sub> Copies/mL (SE)	Day 7	-3.52 (0.08)++	-2.67 (0.08)‡‡	-3.35 (0.08)§§	NR	-2.59¤ (-2.71, -2.47)**##¤¤	-2.36¤ (-2.48, -2.24)**##	NR	NR
	Placebo in Change SARS-CoV-2 Viral es/mL (95% CI)	NR	NR	NR	NR	NR	NR NR		NR
Adherence, n/N	(%)	NR	NR	NR	NR	NR	NR	NR	NR

CI: confidence interval, ER: emergency room, ICU: intensive care unit, IQR: interquartile range, IM: intramuscular, IV: intravenous, LSM: least squares mean, mg: milligram, mL: milliliter, n: number, N: total number, NR: not reported, SD: standard deviation, SE: standard error, vs.: versus

<sup>\*</sup>Number includes patients in the placebo 1200 mg arm. †Physician office/telemedicine visit. ‡Primary outcome is COVID-19-related hospitalization or death. §Primary outcome is hospitalization >24 hours or death. #Median (no SD available). ¤Day 8 timepoint. \*\*LSM (95% CI). ††N=736. ‡‡N=744. §§N=734. ##N=294. ¤¤N=305. \*\*\*Hospitalization >24 hours.

Table D12. Efficacy Outcomes: Phase III Trials (Oral Antivirals)<sup>6,10-13,36,127</sup>

Drug	Name		Moli	nupiravir		Pax	lovid (Nirma	trelvir/Ritonavir)	
Т	rial	Phase III M	OVe-OUT	Phase III M Study i	=	Phase II/III EI	PIC-HR	Phase II/III EPIC-SR (Interim)	
A	rms	Molnupiravir 800 mg	РВО	Molnupiravir 800 mg	РВО	Nirmatrelvir 300 mg + Ritonavir 100 mg	РВО	Nirmatrelvir 300 mg + Ritonavir 100 mg	РВО
	N	709	699	608	610	1,039	1,046	333	329
Time	epoint	29 D	ays	14 🗅	ays	28 Days	S	28 Days	
≥1 Any-Cause I Attended Visit,	· <del>-</del>	NR	NR	NR	NR	NR	NR	NR	NR
Type of Any- Cause	ED	NR	NR	NR	NR	NR	NR	NR	NR
Medically- Attended	Hospitalization	48/709 (6.8)	67/699 (9.6)	9/608 (1.5)	26/610 (4.3)	NR	NR	NR	NR
Visit, n/N (%)	ICU Admission	NR	NR	NR	NR	NR	NR	NR	NR
≥1 COVID-Rela Attended Visit,	•	NR	NR		NR	NR	NR	NR	NR
Type of	Outpatient Visit	NR	NR	NR	NR	NR	NR	NR	NR
COVID-19 Related	Urgent Care	NR	NR	NR	NR	NR	NR	NR	NR
Medically-	ED	NR	NR	NR	NR	NR	NR	NR	NR
Attended	Hospitalization	NR	NR	NR	NR	8/1039 (0.8)	65/1046 (6.2)	2/333 (0.6)	8/329 (2.4)
Visit, n/N (%)	ICU Admission	NR	NR	NR	NR	NR	NR	NR	NR
COVID-Related or Any-Cause D	Hospitalization Death, n/N (%)	45/709 (6.3)	64/699 (9.2)	NR	NR	8/1039 (0.8)	66/1046 (6.3)	2/333 (0.6)	8/329 (2.4)
Relative Risk R Placebo of Prin (Hospitalizatio Death), % (95%	nary Outcome n or All-Cause	30%*		NR	NR	88%*†		70%*†	
Hospitalized or Any Cause, n/N	Death from	48/709 (6.8)	68/699 (9.7)	NR	NR	NR	NR	NR	NR
-	Time to Hospitalization, Median Days (IQR)		NR	NR	NR	NR	NR	NR	NR

Drug	Name		Moln	upiravir		Pax	lovid (Nirma	trelvir/Ritonavir)	
Т	rial	Phase III M	OVe-OUT	Phase III Mo Study in	•	Phase II/III E	PIC-HR	Phase II/III EPIC-SI	R (Interim)
A	rms	Molnupiravir 800 mg	РВО	Molnupiravir 800 mg	РВО	Nirmatrelvir 300 mg + Ritonavir 100 mg	РВО	Nirmatrelvir 300 mg + Ritonavir 100 mg	РВО
	N	709	699	608	610	1,039	1,046	333	329
	epoint	29 D	ays	14 D	ays	28 Day	S	28 Days	
Hospital Lengtl Median Days (I	• •	NR	NR	NR	NR	NR	NR	NR	NR
ED Observation Hospitalization 19, n/N (%)	n for ≥6 Hours or n from COVID-	NR	NR	NR	NR	NR	NR	NR	NR
Time to ED Visi Median Days (I	•	NR	NR	NR	NR	NR	NR	NR	NR
Mortality, n/N	(%)	1/709 (0.1)	9/699 (1.3)	NR	NR	0/1039 (0)	12/1046 (1.2)	0/333 (0)	0/329 (0)
Time to Death, (SD)	Mean Days	NR	NR	NR	NR	NR	NR	NR	NR
Time to Symptomer Mean Days (SD	om Resolution, ))	NR	NR	NR	NR	NR	NR	NR	NR
Ventilation	Non-Invasive Ventilation	NR	NR	NR	NR	NR	NR	NR	NR
Requirement, n/N (%)	Mechanical Ventilation	NR	NR	NR	NR	NR	NR	NR	NR
Time to SARS-O Mean Days (SD	Cov-2 Clearance,	NR	NR	NR	NR	NR	NR	NR	NR
Viral Clearance	e, n/N (%)	NR	NR	NR	NR	NR	NR	NR	NR
Change from	Day 5	NR	NR	-9.5#	-5.3#	-2.98§	-2.37§	NR	NR
Baseline in SARS-CoV-2 Viral Load, LSM log <sub>10</sub> Copies/mL (SE)	Day 7	NR	NR	NR	NR	-3.53§	-2.92§	NR	NR
Difference from	n Placebo in aseline in SARS-	-0.33 (-0.5, - 0.16)‡	REF	NR	NR	-0.70 (-0.86, - 0.53)‡	REF	-1†‡	REF

Drug Name		Moln	upiravir		Paxl	ovid (Nirma	trelvir/Ritonavir)	
Trial	Phase III MOVe-OUT		Phase III Molnupiravir Study in India		Phase II/III EPIC-HR		Phase II/III EPIC-SR (Interim)	
Arms	Molnupiravir 800 mg	РВО	Molnupiravir 800 mg	РВО	Nirmatrelvir 300 mg + Ritonavir 100 mg	РВО	Nirmatrelvir 300 mg + Ritonavir 100 mg	РВО
N	709	699	608	610	1,039	1,046	333	329
Timepoint	29 Da	ays	14 Days		28 Days		28 Days	
CoV-2 Viral Load, log10 Copies/mL (95% CI)								
Adherence, n/N (%)	NR	NR	NR	NR	NR	NR	NR	NR

CI: confidence interval, ER: emergency room, ICU: intensive care unit, IQR: interquartile range, IM: intramuscular, IV: intravenous, LSM: least squares mean, mg: milligram, mL: milliliter, n: number, N: total number, NR: not reported, PBO: placebo, REF: reference, SD: standard deviation, SE: standard error, vs: versus \*Primary outcome is COVID-19-related hospitalization or death.

#Unclear whether this is mean or least squares mean.

<sup>†</sup>No 95% CI available.

<sup>‡</sup>Day 5 timepoint.

<sup>§</sup>No SE available.

Table D13. Efficacy Outcomes: Phase III Trials (Fluvoxamine)<sup>9,68,128</sup>

Drug	Name			Fluv	oxamine		
T	rial	TOGE	THER	STO	P-COVID 1	STOP-	COVID 2
Ai	rms	Fluvoxamine 100 mg	Placebo	Fluvoxamine 100 mg	Placebo	Fluvoxamine 100 mg	Placebo
	N	741	756	80	72	272	275
	epoint	28 🗅	ays	1	L5 Days	15	Days
≥1 Any-Cause Me Visit, n/N (%)	≥1 Any-Cause Medically-Attended Visit, n/N (%)		NR	NR	NR	NR	NR
Type of Any- Cause	ED	7/741 (1)*	36/756 (5)*	NR	NR	NR	NR
Medically-	Hospitalization	76/741 (10)	99/756 (13)	NR	NR	11/272 (4.0)	12/275 (4.4)
Attended Visit, n/N (%)	ICU Admission	NR	NR	NR	NR	NR	NR
≥1 COVID-Related Attended Visit, n	•	NR	NR	NR	NR	NR	NR
Type of COVID-	<b>Outpatient Visit</b>	NR	NR	NR	NR	NR	NR
19 Related	<b>Urgent Care</b>	NR	NR	NR	NR	NR	NR
Medically-	ED	NR	NR	NR	NR	NR	NR
Attended Visit,	Hospitalization	75/741 (10)	97/756 (13)	NR	NR	9/272 (3.3)	10/275 (3.6)
n/N (%)	ICU Admission	NR	NR	NR	NR	NR	NR
COVID-Related H Any-Cause Death		NR	NR	NR	NR	NR	NR
of Primary Outco (Hospitalization of Death), % (95% C	or All-Cause I)	32 (12-48)†		NR	NR	NR	NR
Hospitalized or D Cause, n/N (%)	eath from Any	NR	NR	NR	NR	NR	NR
Time to Hospitali Days (IQR)	zation, Median	5 (3-7)	5 (3-7.5)	NR	NR	NR	NR
Hospital Length of days (IQR)	-	8 (5-13)	6 (3-10.75)	NR	NR	NR	NR
ED Observation for Hospitalization from (%)		79/741 (11)	119/756 (16)	NR	NR	NR	NR

Drug	Name			Fluv	oxamine		
Tı	rial	TOGE	THER	STO	P-COVID 1	STOP-	COVID 2
Aı	rms	Fluvoxamine 100 mg	Placebo	Fluvoxamine 100 mg	Placebo	Fluvoxamine 100 mg	Placebo
	N	741	756	80	72	272	275
Timepoint		28 [	Days		15 Days	15	Days
Time to ED Visit f Median Days (IQI	•	4 (3-7)	5 (3-8.25)	NR	NR	NR	NR
Mortality, n/N (%	Mortality, n/N (%)		25/756 (3)	NR	NR	NR	NR
Time to Death, N	lean Days (SD)	17 (9-21)‡	14 (8-20)‡	NR	NR	NR	NR
Time to Sympton Mean Days (SD)	n Resolution,	NR	NR	NR	NR	NR	NR
Ventilation	Non-Invasive Ventilation	NR	NR	0/80 (0)	0/72 (0)	NR	NR
Requirement, n/N (%)	Mechanical Ventilation	26§	34§	0/80 (0)	1/72 (1.4)	NR	NR
Time to SARS-Cov Mean Days (SD)	/-2 Clearance,	NR	NR	NR	NR	NR	NR
Viral Clearance, r	/N (%)	40/207 (19)#	58/221 (26)#	NR	NR	NR	NR
Change from	Day 5	NR	NR	NR	NR	NR	NR
Baseline in SARS-CoV-2 Viral Load, LSM log <sub>10</sub> copies/mL (SE)	Day 7	NR	NR	NR	NR	NR	NR
Difference from Placebo in Change from Baseline in SARS-CoV-2 Viral Load, log10 Copies/mL (95% CI)		NR	NR	NR	NR	NR	NR
Adherence, n/N (	%)	548/741 (74)	618/738 (82)	NR	NR	NR	NR

CI: confidence interval, ER: emergency room, ICU: intensive care unit, IQR: interquartile range, IM: intramuscular, IV: intravenous, LSM: least squares mean, mg: milligram, mL: milliliter, n: number, N: total number, NR: not reported, SD: standard deviation, SE: standard error, vs.: versus

<sup>\*</sup>ED visits ≥6 hours. †Primary outcome is ED visits ≥6 hours or COVID-related hospitalization, ‡Median (IQR). §Unclear in publication whether these values were reported as percentages or numbers of patients. #Day 7 timepoint.

Table D14. Efficacy Outcomes: Phase I/II Trials (REGEN-COV)<sup>131</sup>

Drug N	ame		REGEN-COV2 (Cas	sirivimab/Imdevimab)				
Tria	nl .		Phase I/II COV-20	67 (Non-Hospitalized)				
Arm	ns	REGEN-COV2 2.4 g	REGEN-COV2 8.0 g	REGEN-COV2 Combined	Placebo			
N		92	90	182	93			
Timep	oint	29 Days						
≥1 Any-Cause Medically-Attended Vi	sit, n/N (%)	NR	NR	NR	NR			
Type of Any-Cause Medically-	ED	NR	NR	NR	NR			
Attended Visit, n/N (%)	Hospitalization	NR	NR	NR	NR			
Attended visit, II/N (%)	ICU Admission	NR	NR	NR	NR			
≥1 COVID-Related Medically-Attended	ed Visit, n/N (%)	3/92 (3)	3/90 (3)	6/182 (3)	6/93 (6)			
	NR	NR	NR	NR				
Type of COVID 10 Poleted	Urgent Care	NR	NR	NR	NR			
Type of COVID-19 Related Medically-Attended Visit, n/N (%)	ED	NR	NR	NR	NR			
Medically-Attended Visit, 11/14 (%)	Hospitalization	NR	NR	NR	NR			
	ICU Admission	NR	NR	NR	NR			
COVID-Related Hospitalization or Any-Cause Death, n/N (%)		NR	NR	NR	NR			
Relative Risk Reduction vs. Placebo		NR	NR	NR	NR			
(Hospitalization or All-Cause Death),	·	ND	ALD.	NB	NB			
Hospitalized or Death from Any Caus		NR	NR	NR	NR			
Time to Hospitalization, Median Day		NR	NR	NR	NR			
Hospital Length of Stay, Median Day		NR	NR	NR	NR			
ED Observation for ≥6 Hours or Hosp (%)	italization from COVID-19, n/N	NR	NR	NR	NR			
Time to ED Visit for ≥6 Hours, Media	n Days (IQR)	NR	NR	NR	NR			
Mortality, n/N (%)		NR	NR	NR	NR			
Time to Death, Mean Days (SD)		NR	NR	NR	NR			
Time to Symptom Resolution, Mean	Days (SD)	NR	NR	NR	NR			
Ventilation Requirement, n/N (%)	Non-Invasive Ventilation	NR	NR	NR	NR			
ventuation Requirement, n/N (%)	Mechanical Ventilation	NR	NR	NR	NR			
Time to SARS-Cov-2 Clearance, Mear	Days (SD)	NR	NR	NR	NR			
Viral Clearance, n/N (%)		NR	NR	NR	NR			
Change from Baseline in SARS-CoV-2	Day 5	NR	NR	NR	NR			
Viral Load, LSM log <sub>10</sub> Copies/mL (SE)	Day 7	-1.60 (0.14)	-1.90 (0.14)	-1.74 (0.11)	-1.34 (0.13)			

Drug Name		REGEN-COV2 (Casi	rivimab/Imdevimab)			
Trial	Phase I/II COV-2067 (Non-Hospitalized)					
Arms	REGEN-COV2 2.4 g	REGEN-COV2 8.0 g	REGEN-COV2 Combined	Placebo		
N	92	90	182	93		
Timepoint		29	Days			
Difference from Placebo in Change from Baseline in SARS-CoV-2 Viral Load, log10 Copies/mL (95% CI)	NR	NR	NR	NR		
Adherence, n/N (%)	NR	NR	NR	NR		

CI: confidence interval, ER: emergency room, g: gram, ICU: intensive care unit, IQR: interquartile range, IM: intramuscular, IV: intravenous, LSM: least squares mean, mL: milliliter, n: number, N: total number, NR: not reported, SD: standard deviation, SE: standard error, vs.: versus

Table D15. Efficacy Outcomes: Phase I/II Trials (Molnupiravir)<sup>10,33</sup>

Drug	Name				Мо	Inupiravir			
Tr	ial		Phase II MO	Ve-OUT		ı	Phase IIa Study 2	003 (Fischer 202	1)
Ar	ms	Molnupiravir 200 mg	Molnupiravir 400 mg	Molnupiravir 800 mg	Placebo	Molnupiravir 200 mg	Molnupiravir 400 mg	Molnupiravir 800 mg	Placebo
١	N	75	77	76	74	23	62	55	62
Timepoint		29 Days					28	Days	
≥1 Any-Cause Me Visit, n/N (%)	dically-Attended	NR	NR	NR	NR	NR	NR	NR	NR
Type of Any- Cause	ER	NR	NR	NR	NR	NR	NR	NR	NR
Attended Visit, n/N (%)	Hospitalization	NR	NR	NR	NR	NR	NR	NR	NR
	ICU Admission	NR	NR	NR	NR	NR	NR	NR	NR
≥1 COVID-Related Attended Visit, n/	•	NR	NR	NR	NR	3/23 (13)	4/62 (6.5)	5/55 (9.1)	5/62 (8.1)
Type of COVID-	Outpatient visit	NR	NR	NR	NR	NR	NR	NR	NR
19 Related	<b>Urgent Care</b>	NR	NR	NR	NR	NR	NR	NR	NR
Medically-	ER	NR	NR	NR	NR	NR	NR	NR	NR
Attended Visit,	Hospitalization	NR	NR	NR	NR	NR	NR	NR	NR
n/N (%)	ICU Admission	NR	NR	NR	NR	NR	NR	NR	NR
COVID-Related Ho	-	NR	NR	NR	NR	NR	NR	NR	NR
Relative Risk Redu of Primary Outcom (Hospitalization of Death), % (95% Cl	r All-Cause	NR	NR	NR	NR	NR	NR	NR	NR
Hospitalized or Do	eath from Any	1/74 (1.4)	3/77 (3.9)	3/74 (4.1)	4/74 (5.4)	NR	NR	NR	NR
Time to Hospitaliz	zation, Median	NR	NR	NR	NR	NR	NR	NR	NR
Hospital Length o Days (IQR)	f Stay, Median	NR	NR	NR	NR	NR	NR	NR	NR
ER Observation for Hospitalization fron (%)		NR	NR	NR	NR	NR	NR	NR	NR

Drug I	Name				Мо	Inupiravir			
Tri	ial		Phase II MO	Ve-OUT		ı	Phase IIa Study 2	003 (Fischer 202	1)
Arı	ms	Molnupiravir 200 mg	Molnupiravir 400 mg	Molnupiravir 800 mg	Placebo	Molnupiravir 200 mg	Molnupiravir 400 mg	Molnupiravir 800 mg	Placebo
N	I	75	77	76	74	23	62	55	62
Time	point		29 Day	rs			28	Days	
Time to ED Visit for Median Days (IQR	•	NR	NR	NR	NR	NR	NR	NR	NR
Mortality, n/N (%)	)	NR	NR	NR	NR	NR	NR	NR	NR
Time to Death, Mo	ean Days (SD)	NR	NR	NR	NR	NR	NR	NR	NR
Time to Symptom Mean Days (SD)	Resolution,	NR	NR	NR	NR	NR	NR	NR	NR
Ventilation	Non-Invasive Ventilation	NR	NR	NR	NR	NR	NR	NR	NR
Requirement, n/N (%)	Mechanical Ventilation	NR	NR	NR	NR	NR	NR	NR	NR
Time to SARS-Cov Mean Days (SD)	-2 Clearance,	NR	NR	NR	NR	22.0 (15.0, 28.0)*	27.0 (15.0, 28.0)*	14.0 (13.0, 14.0)*	15.0 (15.0, 27.0)*
Viral Clearance, n	/N (%)	NR	NR	NR	NR	21/23 (91.3)	49/62 (78.7)	51/55 (92.5)	50 (80.3)
Change from	Day 5	NR	NR	NR	NR	-1.47 (0.21)	-1.75 (0.13)†	-1.87 (0.13)‡	-1.32 (0.15)§
Baseline in SARS-CoV-2 Viral Load, LSM log <sub>10</sub> Copies/mL (SE)	Day 7	NR	NR	NR	NR	-2.03 (0.20)	-2.26 (0.12)#	-2.49 (0.11)¤	-1.95 (0.16)†
Difference from Placebo in Change from Baseline in SARS-CoV-2 Viral Load, log10 Copies/mL (95% CI)		NR	NR	NR	NR	-0.08 (-0.59, 0.44)	-0.31 (-0.7, 0.08)	-0.53 (-0.91, - 0.16)	REF
Adherence, n/N (9	%)	NR	NR	NR	NR	NR	NR	NR	NR

CI: confidence interval, ER: emergency room, ICU: intensive care unit, IQR: interquartile range, IM: intramuscular, IV: intravenous, LSM: least squares mean, mg: milligram, mL: milliliter, n: number, N: total number, NR: not reported, REF: reference, SD: standard deviation, SE: standard error, vs.: versus \*Median (95% CI). †N=56. ‡N=52. §N=57. #N=52. gN=49.

Table D16. Subgroup Efficacy: Primary Outcome  $^{6,11,13,127,133}$ 

Study Name	Subgroup Category	Arms	N	Timepoint	Hospitalization or Any-Cause Death, n/N (%)†
		Sotrovii	mab		
	Positivo Antihody Status	Sotrovimab 500mg	97	20 days	4/97 (4)‡
COMET-ICE	Positive Antibody Status	Placebo	105	29 days	2/105 (2)‡
COIVIET-ICE	Negative Antibody Status	Sotrovimab 500mg	375	30 days	25/375 (7)‡
	Negative Antibody Status	Placebo	365	29 days	4/365 (1)‡
		Molnupi	ravir		
	Time from Symptom	Molnupiravir 800 mg	339	29 days	25/339 (7.4)
	Onset ≤3 Days	Placebo	335	29 uays	28/335 (8.4)
	Time from Symptom	Molnupiravir 800 mg	370	29 days	23/370 (6.2)
	Onset >3 days	Placebo	364	29 uays	40/364 (11)
	Ago CGO Voors	Molnupiravir 800 mg	591	29 days	36/591 (6.1)
	Age ≤60 Years	Placebo	572	29 uays	52/572 (9.1)
	A = a > CO Y = a = a	Molnupiravir 800 mg	118	20 days	12/118 (10.2)
	Age >60 Years	Placebo	127	29 days	16/127 (12.6)
	Obesity (BMI ≥30)	Molnupiravir 800 mg	535	20 days	29/535 (5.4)
		Placebo	507	29 days	46/507 (9.1)
	No Obseits (BMI 420)	Molnupiravir 800 mg	174	20 days	19/174 (10.9)
	No Obesity (BMI <30)	Placebo	192	29 days	22/192 (11.5)
	Diabetes	Molnupiravir 800 mg	107	20 days	17/107 (15.9)
Dhara III MOVA OUT	Diabetes	Placebo	117	29 days	17/117 (14.5)
Phase III MOVe-OUT	No Dishatas	Molnupiravir 800 mg	602	20 days	31/602 (5.1)
	No Diabetes	Placebo	582	29 days	51/582 (8.8)
	AATH COMP Commit	Molnupiravir 800 mg	395	20 1	19/395 (4.8)
	Mild COVID Severity	Placebo	376	29 days	27/376 (7.2)
	Madanata COVID Cavanita	Molnupiravir 800 mg	311	20 days	29/311 (9.3)
	Moderate COVID Severity	Placebo	321	29 days	40/321 (12.5)
	Comment Western	Molnupiravir 800 mg	37	20 4	0/37 (0)
	Gamma Variant	Placebo	47	29 days	9/47 (19.1)
	Dalta Variant	Molnupiravir 800 mg	237	20 days	18/237 (7.6)
	Delta Variant	Placebo	221	29 days	22/221 (10)
	Man Maniant	Molnupiravir 800 mg	75	20 days	6/75 (8)
	Mu Variant	Placebo	82	29 days	13/82 (15.9)
	Danish of Austin and Control	Molnupiravir 800 mg	136	20 days	5/136 (3.7)
	Positive Antibody Status	Placebo	146	29 days	2/146 (1.4)

Study Name	Subgroup Category	Arms	N	Timepoint	Hospitalization or Any-Cause Death, n/N (%)†
	Nagative Autibady Status	Molnupiravir 800 mg	541	20 days	39/541 (7.2)
	Negative Antibody Status	Placebo	520	29 days	64/520 (12.3)
	North America Basis	Molnupiravir 800 mg	42	20 days	4/42 (9.5)
	North America Region	Placebo	45	29 days	5/45 (11.1)
	Latin America Basism	Molnupiravir 800 mg	329	20 days	22/329 (6.7)
	Latin America Region	Placebo	321	29 days	34/321 (10.6)
	European Region	Molnupiravir 800 mg	229	29 days	13/229 (5.7)
	European Region	Placebo	233	29 uays	18/233 (7.7)
	Africa Region	Molnupiravir 800 mg	90	29 days	4/90 (4.4)
	Africa Region	Placebo	84	29 days	7/84 (8.3)
		Molnupiravir 200 mg	38		1/38 (2.6)
	Symptom Onset ≤5 Days	Molnupiravir 400 mg	38	29 days	2/38 (5.3)
	and 1 Risk Factor	Molnupiravir 800 mg	31	29 uays	1/31 (3.2)
Phase II MOVe-OUT		Placebo	34		4/34 (11.8)
riiase ii iviove-ooi	MOVE-OUT	Molnupiravir 200 mg	18		0/18 (0)
	Age >60 Years	Molnupiravir 400 mg	17	29 days	1/17 (5.9)
	Age 200 Tears	Molnupiravir 800 mg	20	29 uays	1/20 (5)
		Placebo	14		3/14 (21.4)
		Paxlovi	d		
	Time from Symptom	Nirmatrelvir 300 mg + Ritonavir 100 mg	697	28 days	5/697 (0.7)
	Onset ≤3 Days	Placebo	682		44/682 (6.5)
	Time from Symptom	Nirmatrelvir 300 mg + Ritonavir 100 mg	342	28 days	3/342 (0.9)
	Onset >3 Days	Placebo	364		22/364 (6)
	Age ≥65 Years	Nirmatrelvir 300 mg + Ritonavir 100 mg	131	28 days	1/131 (0.8)
Phase II/III EPIC-HR*		Placebo	137		20/137 (14.6)
	Age ≤65 Years	Nirmatrelvir 300 mg + Ritonavir 100 mg	908	28 days	7/908 (0.8)
		Placebo	909		46/909 (5.1)
	Age >60 Years	Nirmatrelvir 300 mg + Ritonavir 100 mg	194	28 days	1/194 (0.5)
		Placebo	225		29/225 (12.9)
	No Obesity (BMI <30)	Nirmatrelvir 300 mg + Ritonavir 100 mg	667	28 days	4/667 (0.6)

Study Name	Subgroup Category	Arms	N	Timepoint	Hospitalization or Any-Cause Death, n/N (%)†
		Placebo	673		37/673 (5.5)
	Obesity (BMI ≥30)	Nirmatrelvir 300 mg + Ritonavir 100 mg	371	28 days	4/371 (1.1)
		Placebo	373		29/373 (7.8)
	Diabetes	Nirmatrelvir 300 mg + Ritonavir 100 mg	125	28 days	2/125 (1.6)
		Placebo	127		9/127 (7.2)
	No Diabetes	Nirmatrelvir 300 mg + Ritonavir 100 mg	913	28 days	6/913 (0.7)
		Placebo	919		57/919 (6.2)
	Hypertension	Nirmatrelvir 300 mg + Ritonavir 100 mg	338	28 days	5/338 (1.5)
	, ,	Placebo	351	7	42/351 (12)
	No Hypertension	Nirmatrelvir 300 mg + Ritonavir 100 mg	700	28 days	3/700 (0.4)
	7,	Placebo	695		24/695 (3.5)
	Negative Antibody Status	Nirmatrelvir 300 mg + Ritonavir 100 mg	487	28 days	7/487 (1.4)
		Placebo	505	, , , , , , , , , , , , , , , , , , ,	58/505 (11.5)
	Positive Antibody Status	Nirmatrelvir 300 mg + Ritonavir 100 mg	540	28 days	1/540 (0.2)
		Placebo	528		8/528 (1.5)
	Viral load <10 <sup>7</sup> copies/mL	Nirmatrelvir 300 mg + Ritonavir 100 mg	734	28 days	6/734 (0.8)
	than load (10 copies, ini	Placebo	762		36/762 (0.7)
	Viral load ≥10 <sup>7</sup> copies/mL	Nirmatrelvir 300 mg + Ritonavir 100 mg	276	28 days	2/276 (0.7)
	. ,	Placebo	257		27/257 (10.5)

BMI: body mass index, mg: milligram, n: number, N: total number

<sup>\*</sup>Primary outcome in Paxlovid trial is COVID-19-related hospitalization or death.

<sup>†</sup>Primary outcome was not available in subgroups of fluvoxamine trials.

<sup>‡</sup>Hospitalization >24 hours or death.

Table D17. Patient-Reported Outcomes<sup>8,9,121,135</sup>

Drug Name	Sotrovin	nab	Fluvoxamine				
Trial*	COMET-ICE		STOP-COVID	2	TOGETHER		
Arms	Sotrovimab 500 mg	Placebo	Fluvoxamine 100 mg	Placebo	Fluvoxamine 100 mg	Placebo	
N	528	529	272	275	739	733	
Timepoint	7 Day	S	15 Days		28 Days		
PROMIS Global Health Scale, Mean (SD)	NR	NR	No difference	<u> </u>	No differen	ce	
Change in FLU-PRO Plus Total Score, Mean (95% CI)	3.1 (-3.3, -2.8)†	-2.0 (-2.2, -1.8)	NR	NR	NR	NR	

Cl: confidence interval, IM: intramuscular, IV: intravenous, mg: milligram, N: total number, NR: not reported, SD: standard deviation

†N=412.

‡N=399.

<sup>\*</sup>There were no PRO data available for REGEN-COV, molnupiravir, or Paxlovid trials.

Table D18. Adverse Events: Phase III Trials (Monoclonal Antibodies)<sup>8,45,121-123,134</sup>

D	rug Name	REG	EN-COV2 (Casiriv	vimab/Imdevim	ab)		Sotro	vimab	
Trial		Pha	se III COV-2067	(Non-Hospitalize	ed)	COME	T-ICE	COME	T-TAIL
	Arms	REGEN-COV 1200 mg	REGEN-COV 2400 mg	REGEN-COV 8000 mg	Placebo 1200 mg	Sotrovimab 500 mg	Placebo	Sotrovimab 500 mg (IM)	Sotrovimab 500 mg (IV)
	N	827	1849	1012	1843	523	526	376	378
T	Timepoint		29 D	ays		24 W	eeks	24 W	/eeks
≥1 AE, n/N	(%)	59/827 (7.1)	142/1849 (7.7)	85/1012 (8.4)	189/1843 (10.3)	114/523 (22)	123/526 (23)	30/393 (8)	28 (7)
≥1 TEAE, n	/N (%)	NR	NR	NR	NR	NR	NR	NR	NR
Drug-Relat	ed AE, n/N (%)	NR	NR	NR	NR	8/523 (2)	9/526 (2)	2 (<1)	1 (<1)
AE Leading Discontinu	g to lation, n/N (%)	0/827 (0)	1/1849 (<0.1)	2/1012 (0.2)	1/1843 (<0.1)	0/523 (0)	0/526 (0)	NR	NR
AE Leading Interruption	g to Dose on, n/N (%)	1/827 (0.1)	0/1849 (0)	1/1012 (0.1)	0/1843 (0)	2/523 (<1)	0/526 (0)	NR	NR
≥1 Serious	AE, n/N (%)	9/827 (1.1)	24/1849 (1.3)	17/1012 (1.7)	74/1843 (4)	11/523 (2)	32/526 (6)	3 (<1)	4 (1)
Serious AE Treatment	Related to , n/N (%)	NR	NR	NR	NR	0/523 (0)	2/526 (<1)	0 (0)	0 (0)
Fatal AE, n	/N (%)	1/827 (0.1)	1/1849 (<0.1)	0/1012 (0)	5/1843 (0.3)	0/523 (0)	4/526 (<1)	0 (0)	0 (0)
All-Cause N	Mortality, n/N (%)	NR	NR	NR	NR	0/523 (0)	4/526 (<1)	NR	NR
Grade 3 or	4 AE, n/N (%)	11/827 (1.3)	18/1849 (1)	15/1012 (1.5)	62/1843 (3.4)	15/523 (3)	36/526 (7)	5 (1)	4 (1)
	Grade 1	NR	NR	NR	NR	NR	NR	NR	NR
TEAE	Grade 2	NR	NR	NR	NR	NR	NR	NR	NR
Severity,	Grade 3	NR	NR	NR	NR	NR	NR	NR	NR
n/N (%)	Grade 4	NR	NR	NR	NR	NR	NR	NR	NR
	Grade 5	NR	NR	NR	NR	NR	NR	NR	NR
	Any	NR	NR	NR	NR	6/523 (1)	6/526 (1)	NR	NR
Infusion- Related	Grade ≥2	2/827 (0.2)*	1/1849 (<0.1)*	3/1012 (0.3)*	0/1843 (0)*	NR	NR	NR	NR
AE, n/N	Grade 3 or 4	NR	NR	NR	NR	NR	NR	NR	NR
(%)	Related to Treatment	NR	NR	NR	NR	0/523 (0)	3/526 (<1)	NR	NR

Drug Name Trial		REG	EN-COV2 (Casiri	vimab/Imdevim	ab)		Sotro	vimab	
		Pha	se III COV-2067	(Non-Hospitalize	ed)	COME	T-ICE	COME	T-TAIL
	Arms N		REGEN-COV 2400 mg	REGEN-COV 8000 mg	Placebo 1200 mg	Sotrovimab 500 mg	Placebo	Sotrovimab 500 mg (IM)	Sotrovimab 500 mg (IV)
			1849	1012	1843	523	526	376	378
Ti	mepoint		29 D	ays		24 W	eeks eeks	24 W	/eeks
	Leading to Discontinuation	NR	NR	NR	NR	0/523 (0)	0/526 (0)	NR	NR
	Leading to Dose Interruption	NR	NR	NR	NR	0/523 (0)	0/526 (0)	NR	NR
≥1 Hyperse n/N (%)	nsitivity Reaction,	0/827 (0)†	1/1849 (<0.1)†	0/1012 (0)†	1/1843 (<0.1)†	10/523 (2)	5/526 (1)	<1%	NR
Dyspnea, n	/N (%)	0/827 (0)	1/1512 (<0.1)	0/1012 (0)	1/1476 (<0.1)	NR	NR	NR	NR
Diarrhea, n	/N (%)	NR	NR	NR	NR	8/523 (2)	4/526 (<1)	NR	NR
Nausea n/N	I (%)	2/827 (0.2)	0/1849 (0)	1/1012 (<0.1)	0/1843 (0)	5/523 (<1)	9/526 (2)	NR	NR
Vomiting, n	/N (%)	NR	NR	NR	NR	NR	NR	NR	NR
Dizziness, n	/N (%)	2/827 (0.2)	1/1849 (<0.1)	0/1012 (0)	1/1843 (<0.1)	NR	NR	NR	NR
Headache,	n/N (%)	2/827 (0.2)	1/1849 (<0.1)	1/1012 (<0.1)	2/1843 (0.1)	4/523 (<1)	11/526 (2)	NR	NR
Hypoxia, n/	'N (%)	1/827 (0.1)	1/1849 (<0.1)	1/1012 (<0.1)	6/1843 (0.3)	NR	NR	NR	NR
COVID-19 P (%)	neumonia, n/N	2/827 (0.2)	4/1849 (0.2)	5/1012 (0.5)	14/1843 (0.8)	5/523 (<1)	22/526 (4)	NR	NR
Rash, n/N (	%)	NR	NR	NR	NR	1%	NR	NR	NR

AE: adverse event, IM: intramuscular, IV: intravenous, mg: milligram, n: number, N: total number, NR: not reported, TEAE: treatment emergent adverse event \*Experienced within 4 days.

<sup>†</sup>Severity ≥2.

Table D19. Adverse Events: Phase III Trials (Oral Antivirals)<sup>6,10,12,13,36,127</sup>

D	Drug Name Molnupiravir				Pa	axlovid (Nirmat	relvir/Ritonavir)		
	Trial	Phase III MO	OVe-OUT	Phase III Moln in Ir		Phase II/III EPIC-HR		Phase II/III EPIC-SR (Interim)	
	Arms	Molnupiravir 800 mg	Placebo	Molnupiravir 800 mg	Placebo	Nirmatrelvir 300 mg + Ritonavir 100 mg	Placebo	Nirmatrelvir 300 mg + Ritonavir 100 mg	Placebo
	N	710	701	608	610	1,109	1,115	NR	NR
Т	imepoint	19 Da	ys	14 0	ays	34 D	ays	34 Days	3
≥1 AE, n/N	N (%)	216/710 (30.4)	231/701 (33)	NR	NR	251/1109 (22.6)	266/1115 (23.9)	NR	NR
≥1 TEAE, r	n/N (%)	NR	NR	30/608 (4.9)	17/610 (2.8)	NR	NR	22%	21%
Drug-Rela	ted AE, n/N (%)	57/710 (8)	59/701 (8.4)	NR	NR	86/1109 (7.8)	42/1115 (3.8)	NR	NR
AE Leading Discontinu	g to uation, n/N (%)	10/710 (1.4)	20/701 (2.9)	NR	NR	23/1109 (2.1)	47/1115 (4.2)	2.1%	1.2%
AE Leading	g to Dose on, n/N (%)	NR	NR	NR	NR	4/1109 (0.4)	4/1115 (0.4)	NR	NR
≥1 Serious	s AE, n/N (%)	49/710 (6.9)	67/701 (9.6)	0/608 (0)	0/610 (0)	18/1109 (1.6)	74/1115 (6.6)	1.4%	1.9%
Serious Al	E Related to t, n/N (%)	0/710 (0)	1/701 (0.1)	NR	NR	1/1109 (<0.1)	0/1115 (0)	NR	NR
Fatal AE, r	n/N (%)	NR	NR	NR	NR	NR	NR	NR	NR
All-Cause (%)	Mortality, n/N	2/710 (0.3)	12/701 (1.7)	NR	NR	0/1109 (0)	13/1115 (1.2)	NR	NR
Grade 3 o	r 4 AE, n/N (%)	NR	NR	NR	NR	45/1109 (4.1)*	93/1115 (8.3)*	NR	NR
<u> </u>	Grade 1	NR	NR	NR	NR	NR	NR	NR	NR
	Grade 2	NR	NR	NR	NR	NR	NR	NR	NR
TEAE Severity, n/N (%)	Grade 3	NR	NR	NR	NR	NR	NR	NR	NR
	Grade 4	NR	NR	NR	NR	2/1109 (0.2)	10/1115 (0.9)	NR	NR
	Grade 5	NR	NR	NR	NR	0/1109 (0)†	13/1115 (1.2)†	NR	NR
	Any	NA	NA	NA	NA	NA	NA	NA	NA

Drug Name			Molni	upiravir		P	axlovid (Nirmat	relvir/Ritonavir)	
	Trial	Phase III MO	OVe-OUT	Phase III Moln in Ir		Phase II/III	EPIC-HR	Phase II/III EPIC-SR (Interim)	
	Arms	Molnupiravir 800 mg	Placebo	Molnupiravir 800 mg	Placebo	Nirmatrelvir 300 mg + Ritonavir 100 mg	Placebo	Nirmatrelvir 300 mg + Ritonavir 100 mg	Placebo
	N	710	701	608	610	1,109	1,115	NR	NR
Т	imepoint	19 Da	ys	14 D	ays	34 D	ays	34 Days	
	Grade ≥2	NA	NA	NA	NA	NA	NA	NA	NA
	Grade 3 or 4	NA	NA	NA	NA	NA	NA	NA	NA
Infusion- Related	Related to Treatment	NA	NA	NA	NA	NA	NA	NA	NA
AE, n/N (%)	Leading to Discontinuation	NA	NA	NA	NA	NA	NA	NA	NA
	Leading to Dose Interruption	NA	NA	NA	NA	NA	NA	NA	NA
≥1 Hypers Reaction,	•	NR	NR	NR	NR	NR	NR	NR	NR
Dyspnea,	n/N (%)	NR	NR	NR	NR	7/1109 (0.6)	9/1115 (0.8)	NR	NR
Diarrhea,	n/N (%)	16/710 (2.3)	21/701 (3)	1/608 (0.2)	4/610 (0.7)	34/1109 (3.1)	18/1115 (1.6)	NR	NR
Nausea n/	/N (%)	13/710 (1.8)	6/701 (0.9)	0/608 (0)	6/610 (1.0)	16/1109 (1.4)	19/1115 (1.7)	NR	NR
Vomiting,	n/N (%)	NR	NR	1/608 (0.2)	1/610 (0.2)	12/1109 (1.1)	9/1115 (0.8)	NR	NR
Dizziness,	n/N (%)	NR	NR			3/1109 (0.3)	6/1115 (0.5)	NR	NR
Headache, n/N (%)		NR	NR	7/608 (1.2)	7/610 (1.1)	15/1109 (1.4)	14/1115 (1.3)	NR	NR
Hypoxia, r	n/N (%)	NR	NR	NR	NR	0/1109 (0)	4/1115 (0.4)	NR	NR
COVID-19 (%)	Pneumonia, n/N	45/710 (6.3)	67/701 (9.6)	NR	NR	6/1109 (0.5)	37/1115 (3.3)	NR	NR
Rash, n/N	(%)	NR	NR	0/608 (0)	2/610 (0.3)	2/1109 (0.2)	3/1115 (0.3)	NR	NR

AE: adverse event, mg: milligram, n: number, N: total number, NA: not applicable, NR: not reported, TEAE: treatment emergent adverse event

<sup>\*</sup>Maximum Grade 3 or 4 adverse event. †Maximum Grade 5 adverse event.

Table D20. Adverse Events: Phase III Trials (Fluvoxamine)<sup>9,135</sup>

	Drug Name			Fluvoxam	nine		
	Trial	TOGET	THER	STOP-C	OVID 1	STOP-C	OVID 2
	Arms	Fluvoxamine 100 mg	Placebo	Fluvoxamine 100 mg	Placebo	Fluvoxamine 100 mg	Placebo
	N	741	756	80	72	272	275
	Timepoint	28 Days		45 D	ays*	N	R
≥1 AE, n/N (%)		NR	NR	11/80 (13.8)	6/72 (8.3)	NR	NR
≥1 TEAE, n/N (	≥1 TEAE, n/N (%)		NR	NR	NR	NR	NR
Drug-Related A	AE, n/N (%)	NR	NR	NR	NR	NR	NR
AE Leading to	Discontinuation, n/N (%)	NR	NR	NR	NR	NR	NR
AE Leading to	Dose Interruption, n/N (%)	NR	NR	NR	NR	NR	NR
≥1 Serious AE,	n/N (%)	NR	NR	1/80 (1.3)	5/72 (6.9)	NR	NR
Serious AE Rela	ated to Treatment, n/N (%)	NR	NR	NR	NR	NR	NR
Fatal AE, n/N (	%)	NR	NR	NR	NR	NR	NR
All-Cause Mort	tality, n/N (%)	17/741 (2)	25/756 (3)	NR	NR	NR	NR
Grade 3 or 4 A	E, n/N (%)	59/741 (8)	70/756 (9)	NR	NR	NR	NR
	Grade 1	20/741 (3)	11/756 (1)	NR	NR	NR	NR
TEAE	Grade 2	72/741 (10)	81/756 (11)	NR	NR	NR	NR
Severity, n/N	Grade 3	38/741 (5)	50/756 (7)	NR	NR	NR	NR
(%)	Grade 4	21/741 (3)	20/756 (3)	NR	NR	NR	NR
	Grade 5	18/741 (2)	26/756 (3)	NR	NR	NR	NR
	Any	NA	NA	NA	NA	NA	NA
Infusion-	Grade ≥2	NA	NA	NA	NA	NA	NA
Related AE.	Grade 3 or 4	NA	NA	NA	NA	NA	NA
n/N (%)	Related to Treatment	NA	NA	NA	NA	NA	NA
11/14 (70)	Leading to Discontinuation	NA	NA	NA	NA	NA	NA
	Leading to Dose Interruption	NA	NA	NA	NA	NA	NA
≥1 Hypersensit	tivity Reaction, n/N (%)	NR	NR	NR	NR	NR	NR
Dyspnea, n/N (%)		NR	NR	NR	NR	NR	NR
Diarrhea, n/N (%)		NR	NR	NR	NR	NR	NR
Nausea n/N (%	6)	NR	NR	1/80 (1.3)†‡	5/72 (6.9)†‡	NR	NR
Vomiting, n/N	(%)	NR	NR	1/80 (1.3)+	5/72 (0.9) +	NR	NR
Dizziness, n/N	(%)	NR	NR	NR	NR	NR	NR
Headache, n/N	I (%)	NR	NR	2/80 (2.5)+‡	1/72 (1.4)‡	NR	NR

Drug Name			Fluvoxam	nine		
Trial	TOGET	TOGETHER		OVID 1	STOP-C	OVID 2
Arms	Fluvoxamine 100 mg	Placebo	Fluvoxamine 100 mg	Placebo	Fluvoxamine 100 mg	Placebo
N	741	756	80	72	272	275
Timepoint	28 Da	ays	45 D	ays*	NR	
Hypoxia, n/N (%)	NR	NR	0/80 (0)‡	6/72 (8.3)‡	NR	NR
Covid-19 Pneumonia, n/N (%)	NR	NR	3/80 (3.8)‡§	6/72 (8.3)‡§	NR	NR
Rash, n/N (%)	NR	NR	NR	NR	NR	NR

AE: adverse event, mg: milligram, n: number, N: total number, NA: not applicable, NR: not reported, TEAE: treatment emergent adverse event

§General pneumonia.

<sup>\*</sup>During treatment period (15 days) and 30 days after end of treatment period.

<sup>†</sup>Gastroenteritis, nauseas, or vomiting

<sup>‡</sup>Reported as number of instances of each individual AE, not the number of patients who experienced them.

Table D21. Adverse Events: Phase I/II Trials (REGEN-COV)<sup>131</sup>

	Drug Name		REGEN-COV2 (Cas	irivimab/Imdevimab)	
	Trial		Phase I/II COV-20	67 (Non-Hospitalized)	
	Arms	REGEN-COV2 2.4 g	REGEN-COV2 8.0 g	REGEN-COV2 Combined	Placebo
	N	88	88	176	93
	Timepoint		29	Days	
≥1 AE, n/N (%)		NR	NR	NR	NR
≥1 TEAE, n/N (%)		NR	NR	NR	NR
Drug-Related AE, r	n/N (%)	NR	NR	NR	NR
AE Leading to Disc	ontinuation, n/N (%)	0/88 (0)	0/88 (0)	0/176 (0)	0/93 (0)
AE Leading to Dose	e Interruption, n/N (%)	0/88 (0)	1/88 (1)	1/176 (1)	1/93 (1)
≥1 Serious AE, n/N	l (%)	1/88 (1)	0/88 (0)	1/176 (1)	2/93 (2)
	I to Treatment, n/N (%)	NR	NR	NR	NR
Fatal AE, n/N (%)		0/88 (0)	0/88 (0)	0/176 (0)	0/93 (0)
All-Cause Mortalit	y, n/N (%)	NR	NR	NR	NR
Grade 3 or 4 AE, n	/N (%)	1/88 (1)	0/88 (0)	1/176 (1)	1/93 (1)
Grade 5 or 4 AL, II,	Grade 1	NR	NR	NR	NR
	Grade 2	NR	NR	NR	NR
TEAE Severity,	Grade 3	NR	NR	NR	NR
n/N (%)	Grade 4	NR	NR	NR	NR
	Grade 5	NR	NR	NR	NR
	Any	NR	NR	NR	NR
	Grade ≥2	0/88 (0)*	2/88 (2)*	2/176 (1)*	1/93 (1)*
Infusion-Related	Grade 3 or 4	NR	NR	NR	NR
AE, n/N (%)	Related to Treatment	NR	NR	NR	NR
	Leading to Discontinuation	NR	NR	NR	NR
	Leading to Dose Interruption	NR	NR	NR	NR
≥1 Hypersensitivit	y Reaction, n/N (%)	0/88 (0)	1/88 (1)	1/176 (1)	2/93 (2)
Dyspnea, n/N (%)		NR	NR	NR	NR
Diarrhea, n/N (%)		NR	NR	NR	NR
Nausea n/N (%)		1/88 (1.1)	0/88 (0)	1/176 (0.6)	0/176 (0)
Vomiting, n/N (%)		1/88 (1.1)	0/88 (0)	1/176 (0.6)	0/176 (0)
Dizziness, n/N (%)		0/88 (0)	0/88 (0)	0/176 (0)	1/93 (1.1)
Headache, n/N (%	)	0/88 (0)	0/88 (0)	0/176 (0)	1/93 (1.1)

Drug Name		REGEN-COV2 (Casirivimab/Imdevimab)						
Trial		Phase I/II COV-206	7 (Non-Hospitalized)					
Arms	REGEN-COV2 2.4 g	REGEN-COV2 8.0 g	REGEN-COV2 Combined	Placebo				
N	88	88	176	93				
Timepoint		29	Days					
Hypoxia, n/N (%)	0/88 (0)	0/88 (0)	0/176 (0)	1/93 (1.1)				
Covid-19 Pneumonia, n/N (%)	NR	NR	NR	NR				
Rash, n/N (%)	0/88 (0)	0/88 (0)	0/176 (0)	1/93 (1)				

AE: adverse event, g: gram, n: number, N: total number, NR: not reported, TEAE: treatment emergent adverse event

<sup>\*</sup>Experienced within 4 days.

Table D22. Adverse Events: Phase I/II Trials (Molnupiravir)<sup>33-35</sup>

D	rug Name				Moln	nupiravir			
	Trial		Phase II MC	Ve-OUT		P	hase IIa Study 200	3 (Fischer 2021)	
	Arms	Molnupiravir 200 mg	Molnupiravir 400 mg	Molnupiravir 800 mg	Placebo	Molnupiravir 200 mg	Molnupiravir 400 mg	Molnupiravir 800 mg	Placebo
	N	75	77	76	74	23	62	55	62
T	imepoint		19 Da	ys*			28 Da	iys	
≥1 AE, n/N	N (%)	NR	NR	NR	NR	11/23 (47.8)	20/62 (32.3)	11/55 (20.0)	18/62 (29.0)
≥1 TEAE, n	n/N (%)	NR	NR	NR	NR	NR	NR	NR	NR
Drug-Rela	ted AE, n/N (%)		14/225 (6.2)		5/74 (6.8)	4/23 (17.4)	13/62 (21)	1/55 (1.8)	8/62 (12.9)
AE Leading Discontinu	g to uation, n/N (%)		3/228 (1.3)		1/74 (1.4)	0/23 (0)	1/62 (1.6)	1/55 (1.8)	1/62 (1.6)
AE Leading	g to Dose on, n/N (%)	NR	NR	NR	NR	NR	NR	NR	NR
≥1 Serious	S AE, n/N (%)		8/228 (3.6)		4/74 (5.4)	0/23 (0)	2/62 (3.2)	1/55 (1.8)	1/62 (1.6)
Serious AE	Related to t, n/N (%)	NR	NR	NR	NR	NR	NR	NR	NR
Fatal AE, n		NR	NR	NR	NR	0/23 (0)	0/62 (0)	0/55 (0)	1/62 (1.6)
All-Cause	Mortality, n/N (%)	NR	NR	NR	1/74 (1.4)	NR	NR	NR	NR
Grade 3 or	r 4 AE, n/N (%)	NR	NR	NR	NR	1/23 (4.3)†	2/62 (3.2)†	4/55 (7.3)†	5/62 (8.1)†
	Grade 1	NR	NR	NR	NR	NR	NR	NR	NR
TEAE	Grade 2	NR	NR	NR	NR	NR	NR	NR	NR
Severity,	Grade 3	NR	NR	NR	NR	NR	NR	NR	NR
n/N (%)	Grade 4	NR	NR	NR	NR	NR	NR	NR	NR
	Grade 5	NR	NR	NR	NR	NR	NR	NR	NR
	Any	NA	NA	NA	NA	NA	NA	NA	NA
	Grade ≥2	NA	NA	NA	NA	NA	NA	NA	NA
Infusion-	Grade 3 or 4	NA	NA	NA	NA	NA	NA	NA	NA
Related AE, n/N (%)	Related to Treatment	NA	NA	NA	NA	NA	NA	NA	NA
	Leading to Discontinuation	NA	NA	NA	NA	NA	NA	NA	NA
	Leading to Dose Interruption	NA	NA	NA	NA	NA	NA	NA	NA

Drug Name				Moln	upiravir				
Trial		Phase II MC	Ve-OUT		Phase IIa Study 2003 (Fischer 2021)				
Arms	Molnupiravir 200 mg	Molnupiravir 400 mg	Molnupiravir 800 mg	Placebo	Molnupiravir 200 mg	Molnupiravir 400 mg	Molnupiravir 800 mg	Placebo	
N	75	77	76	74	23	62	55	62	
Timepoint		19 Day	/s*			28 Da	ays		
≥1 Hypersensitivity Reaction, n/N (%)	NR	NR	NR	NR	NR	NR	NR	NR	
Dyspnea, n/N (%)	NR	NR	NR	NR	0/23 (0)	1/62 (1.6)	0/55 (0)	0/62 (0)	
Diarrhea, n/N (%)	NR	NR	NR	4/74 (5.4)	0/23 (0)	1/62 (1.6)	0/55 (0)	1/62 (1.6)	
Nausea n/N (%)	NR	NR	NR	NR	1/23 (4.3)	2/62 (3.2)	0/55 (0)	1/62 (1.6)	
Vomiting, n/N (%)	NR	NR	NR	NR	NR	NR	NR	NR	
Dizziness, n/N (%)	NR	NR	NR	NR	2/23 (8.7)	1/62 (1.6)	0/55 (0)	0/62 (0)	
Headache, n/N (%)	NR	NR	NR	NR	1/23 (4.3)	3/62 (4.8)	2/55 (3.6)	3/62 (4.8)	
Hypoxia, n/N (%)	NR	NR	NR	NR	0/23 (0)	0/62 (0)	0/55 (0)	1/62 (1.6)	
Covid-19 Pneumonia, n/N (%)	NR	NR	4/76 (5.4)	NR	0/23 (0)†	1/62 (1.6)‡	1/55 (1.8)‡	0/62 (0)†	
Rash, n/N (%)	NR	NR	NR	NR	0/23 (0)	1/62 (1.6)	1/55 (1.8)	0/62 (0)	

AE: adverse event, mg: milligram, n: number, N: total number, NA: not applicable, NR: not reported, TEAE: treatment emergent adverse event

<sup>\*</sup>During treatment period (5 days) and 14 days after end of treatment period.

<sup>†</sup>Grade 3 or higher severity.

<sup>‡</sup>General pneumonia.

**Table D23. Key Features: Real-World Studies** 

Study Name & Author	Study Design & Location	N	Treatment	Inclusion & Exclusion Criteria	Key Outcomes
RW Study	Retrospective	Ambulatory patients	Casirivimab/	Key Inclusion Criteria	Primary Endpoint
Webb et al. 2021 <sup>48</sup>	clinical data extraction  Location: Intermountain Healthcare in UT	ages ≥18 years with COVID-19  N=115 (combined both bamlanivimab and casirivimab/	imdevimab  Control cohort	-At or above the risk score threshold (set at ≥7.5 points, which identified approximately top decile of estimated risk among COVID-19-positive patients) -Confirmed COVID-19	(through day 14): - Number of hospitalizations/ED visits (composite)  Secondary Endpoints (at
	and Southeastern ID, US  Dates: 11/20-	imdevimab)		-Symptomatic disease with symptom onset within no more than 7 days -Over 18 years of age	day 14): - Adverse events - Mortality
	1/21			Key Exclusion Criteria -Hospitalized due to COVID-19 -New COVID-related hypoxemia (defined as peripheral oxygen saturation <90% at rest or new supplemental oxygen requirement, or for those with chronic hypoxia, a new change in baseline saturation or oxygen demand) -Pregnant -Hypersensitivity to other mAbs	
RW Study Razonable et al. 2021 <sup>49</sup>	Retrospective clinical data extraction  Location: Patients from several geographic Mayo Clinic sites, e.g., AZ, FL, MN, and WI; US  Dates: 12/20-4/21	Ambulatory patients ages ≥18 years with COVID-19  N=696 patients w/ casirivimab/ imdevimab	Casirivimab/ imdevimab  Control cohort	Key Inclusion Criteria -Patients 18 years and older -Had symptoms of mild-to-moderate COVID-19 -Within 10 days of symptom onset -Had at least one of following criteria: age 65 years, BMI 35, diabetes mellitus, CKD, immunosuppressive medication use, or an immunocompromising condition; patients 55 years and older qualified if they had hypertension, CVD, or chronic lung disease	Primary Endpoint (through day 14, 21, and 28): - Rates of hospitalizations  Secondary Endpoints (day 14, 21, and 28): - ICU admissions - Mortality

Study Name & Author	Study Design & Location	N	Treatment	Inclusion & Exclusion Criteria	Key Outcomes
				Key Exclusion Criteria -Patients with clinical manifestations of severe COVID-19 (e.g., new or worsening hypoxemia) and those requiring hospitalization for COVID-19 were excluded -Received bamlanivimab with or without etesevimab -Have canceled casirivimab/imdevimab order -Were in hospice or comfort care -Have a DNI, DNR, or DNH status -Had SpO2 of <93%; were currently hospitalized at the time of positive PCR test or casirivimab/imdevimab infusion	
RW Study Polk et al. 2021 <sup>55</sup>	Retrospective clinical data extraction	Patients with COVID-19  N=125 patients w/ casirivimab/	Casirivimab/ imdevimab Untreated cohort	Key Inclusion Criteria: -Patients who had COVID-19 -Assessed and infused within 10 days of symptom onset	Primary Endpoints (through day 30): -Completion of treatment and reasons not treated
	Location: NR	imdevimab		-Screened between 12/16/20 and 3/5/21	-Rates of hospitalizations -ED visits
	Dates: 12/16/20- 3/5/21	n=199 untreated patients			-ICU stays -Mechanical ventilation required -Death
RW Study Chilimuri et al. 2021 <sup>50</sup>	Retrospective observational study	Patients with COVID-19  N=22 patients w/ casirivimab/	Casirivimab/ imdevimab Control group	Key Inclusion Criteria -Patients >18 years of age -Diagnosed with mild-moderate COVID-19	Primary Endpoints: -Symptom improvement at day 1 and day 14 -30-day all-cause
	Location: South- Bronx, NY, US	imdevimab n=11 control patients		-Symptoms <10 days duration -≥1 high-risk conditions for progression to severe disease,	hospitalization -30-day hospitalization related to COVID-19
	Dates: 11/27/20- 3/17/21	(declined therapy)		including BMI ≥35 kg/m², CKD, diabetes, immunosuppressive disease, or treatment, ≥65 years of age	-30-day mortality

Study Name & Author	Study Design & Location	N	Treatment	Inclusion & Exclusion Criteria	Key Outcomes
				Exclusion -Patients who required admission for COVID-19, patients with severe disease, patients requiring oxygen, or increasing oxygen requirements in patients on long-term oxygen therapy for non-COVID-19 causes	
RW Study Piccaccio et al. 2021 <sup>51-53</sup>	Retrospective cohort study  Location: Single-center in FL, US  Dates: 11/18/20-1/5/21	Patients with COVID-19  N=48 patients w/ casirivimab/ imdevimab  n=200 control patients	Casirivimab/ imdevimab Control group	Key Inclusion Criteria -Confirmed COVID-19 infection ->12 years of age -Weighed at least 40 kg -Mild-to-moderate symptoms for 10 days of less -Considered high-risk based on EUA document  Exclusion -No documentation from clinic after initial diagnoses or mAb administration	Primary Endpoints (through day 29): -Composite of COVID-19 related hospitalization (>24-hour acute stay) and ED visits  Secondary Endpoints (day 29): -COVID-19 hospitalizations -COVID-19 ED visit -All-cause mortality -SAEs in the mAb cohort
RW Study McCreary et al. 2021 <sup>54,136</sup> NCT04790786	Prospective quality improvement project using electronic health record data  Location: UPMC Health System  Dates: Project was from 3/21-9/21; but data in analysis was from 7/14/21 - 10/26/21	Patients with COVID-19 in the OPTIMISE-C19 QI project  First analysis: -N=969 SC casirivimab/ imdevimab (N=652 matched) N=4,353 non-treated eligible controls (N=1,304 matched)  Second analysis: N=969 SC w/ casirivimab/ imdevimab (N=652	Casirivimab/ imdevimab (SC and IV)  Untreated cohort	Key Inclusion Criteria: -Confirmed COVID-19 infection ->12 years of age -Considered high risk based on EUA document  Exclusion: -Admission to ED or hospital on date of positive COVID-19 test results	Primary Endpoints: -28-day adjusted RR or adjusted risk difference for hospitalization or death  Secondary Endpoints: -28-day adjusted RR/differences of hospitalizations, death, composite endpoint of ED admissions and hospitalizations, and rates of AEs

Study Name & Author	Study Design & Location	N	Treatment	Inclusion & Exclusion Criteria	Key Outcomes
RW Study	Prospective	matched) N=1,216 IV w/ casirivimab/ imdevimab Patients with COVID-19	Casirivimab/	Key Inclusion Criteria	Primary Endpoints:
Huang et al. 2021 <sup>56</sup> NCT04790786	quality improvement project using electronic health record data  Location: UPMC Health System  Dates: 7/14/21 - 9/10/21	in the OPTIMISE-C19 QI project  First analysis: N=717 casirivimab/imdevimab (N=712 when matched) N=5,171 non-treated matched controls (N=2,046 when matched)  Second analysis: N=311 sotrovimab (N=311 matched) N=5,171 non-treated matched controls (N=2,046 matched)	imdevimab IV  Sotrovimab IV  Untreated cohort	-Confirmed COVID-19 infection -Considered high-risk based on EUA document  Exclusion -Admission to hospital	-28-day hospitalization or death  Secondary Endpoints: -28-day rate of hospitalizations, ICU admission, mechanical ventilation, and death
RW Study Bierle et al. 2021 <sup>57</sup>	Retrospective clinical data extraction  Location: Patients from Mayo clinic sites in the Midwest.  Dates: 07/2021	N=112 patients w/ casirivimab/imdevimab  N=518 untreated (291 eligible but did not receive treatment, 227 ineligible)	Casirivimab/imdevimab Untreated cohort	Key Inclusion Criteria: (criteria used for FDA EUA) - Confirmed COVID-19 infection - Considered high-risk based on FDA EUA document	Primary Endpoint (by Day 28): - Rates of hospitalizations
RW Study Kakinoki et al. 2021 <sup>58</sup>	Retrospective clinical data extraction	Patients with COVID-19  N=55 patients w/ casirivimab/imdevimab	Casirivimab/imdevimab Untreated cohort (watchful observation)	Key Inclusion Criteria: - Confirmed mild-moderate COVID-19 infection - >=20 years of age	Primary Endpoints: - Need for additional further treatment (oxygen, steroid

Study Name & Author	Study Design & Location	N	Treatment	Inclusion & Exclusion Criteria	Key Outcomes
	Location: Patients from Asahikawa City Hospital and non-medical facilities in Japan.  Dates: 06/2021-09/2021	N=53 control group (watchful observation)		- Considered high-risk based on FDA EUA document	administration, or antiviral drugs)  Secondary Endpoints: - In REGEN-COV group only, duration of fever and AEs
RW Study Wei et al. 2022 <sup>59</sup>	Retrospective cohort study using data from two databases.  Location: CDM database: administrative health claims for 68 million members in commercial and Medicare advantage health plans. PMTX+ database: national claims database of commerical health plans with 190 million patients in all 50 states.  Dates: 12/2020 - 03/2021	Patients with COVID-19  CDM N=1116 patients w/ casirivimab/imdevimab N=5291 control group  pmtx+ N=3280 patients w/ casirivimab/imdevimab N=16284 control group	Casirivimab/imdevimab  Matched no mAb treatment	Key Inclusion Criteria:  - Confirmed COVID-19 infection with COVID-19 diagnosis or positive COVID-19 virus test within the last 10 days  - EUA eligible patients  - Continuous healthcare plan enrollment for at least 6 months preindex  - >= 12 years of age  - No diagnosis in the previous 30 days  - CDM only, have a valid date of death  Exclusion Criteria:  - Patients who were hospitalized as a result of the encounter  - Received mAbs during baseline or multiple mAbs on index date  - Died or were hospitalized between COVID-19 diagnosis and index date	Primary Endpoints: - Composite endpoint 30-day all-cause mortality or COVID-19-related hospitalization for CDM, and 30-day COVID-19-related hospitalization for PMTX+
RW Study Seftel & Boulware 2021 <sup>129</sup>	Prospective, open-label cohort study in the	N=65 patients treated with fluvoxamine (patient choice)	Fluvoxamine	Key Inclusion Criteria:	Primary Endpoints: -Hospitalization at Day 14

Study Name & Author	Study Design & Location	N	Treatment	Inclusion & Exclusion Criteria	Key Outcomes
	setting of a mass		Untreated cohort (under	-Attended Golden Gate Field horse	-Persisted symptoms at
	outbreak at a	N=48 patients under	observation)	racetrack in November-December	Day 14
	horse racing track	observation with no		2020 -Confirmed positive SARS-CoV-2	Sacandan, Endnaints
	Location: Bay	treatment (patient choice)		antigen test and PCR-tests by the	Secondary Endpoints: -ICU at Day 14
	Area, CA, US	choice)		California Department of Public	-Death at Day 14
	Alea, CA, OS			Health Viral and Rickettsial Disease	-Respiratory rates at Day
	Dates: 11/2020-			Laboratory in Richmond, California	1 and Day 7
	12/2020			(asymptomatic, mild, and moderate	-AEs and SAEs
	, , , ,			severity)	
				-Have to isolate after positive SARS-	
				CoV-2 test	
RW Study	Retrospective	N=30 patients treated	Casirivimab/imdevimab	Key Inclusion Criteria	Primary Endpoint:
Osugi et al.	cohort study of	with REGEN-COV		-Diagnosed with COVID-19	-Hospitalization due to
2022120	patients with		Untreated cohort	-Had at least one risk factor for	COVID-19 at Day 10-16
	COVID-19	N=74 patients who did		mortality due to COVID-19, such as	
	diagnosed at the	not receive REGEN-COV		cardiovascular disease, chronic lung	Secondary Endpoints:
	family medicine			disease, diabetes, chronic kidney	-Mortality due to COVID-
	department			disease, chronic liver disease,	19 at Day 10-16
	Location: Toyota			immunocompromised status, smoking, or obesity.	
	Regional Medical			Silloking, of obesity.	
	Center, Toyota,				
	Japan				
	- Capan				
	Dates: 08/2021-				
	09/2021				
RW Study	Observational	N=522 patients treated	Sotrovimab	Key Inclusion Criteria	Primary Endpoint:
Aggarwal et al.	cohort study of	with Sotrovimab		-Diagnosed with COVID-19	- Hospitalization at Day 28
2022125	patients with		Untreated cohort		
	COVID-19	N=1563 patients who		Exclusion Criteria:	Secondary Endpoints:
	obtaining data	did not receive		-Tested positive on same day of or	- All-cause mortality at
	from EHR	Sotrovimab (propensity		during hospitalization	Day 29
		matched)		-Patients missing a positive test date	- ED visit at Day 28
	Location:			and administration date, or if it had	- Severity of
	UCHealth in			been more than 10 days between	hospitalization based on
	Colorado, US			positive test and administration	maximum level of

Study Name & Author	Study Design & Location	N	Treatment	Inclusion & Exclusion Criteria	Key Outcomes
	Dates: 10/2021 - 12/2021			-(NOTE: did not exclude based on EUA eligibility as not all eligibility criteria were available in EHR)	respiratory support - ICU length of stay - Rates of ICU admission - In-hospital mortality
RW Study Zaqout et al. 2022 <sup>126</sup>	Matched case- control study among resident population Location: Qatar Dates: 10/2021-	N=345 patients treated with sotrovimab (exact matched)  N=583 patients who did not receive treatment (untreated control)	Sotrovimab  Untreated cohort	Inclusion Criteria: -tested positive for SARS-CoV-2 using RT-qPCR testing or rapid antigen testing and had at least one risk factor that increases their risk of severe COVID-19 progression -12 years of age and older, weighing at least 40 kg	Primary Endpoint: -Progression to severe, critical, or fatal COVID-19

AE: adverse event, AZ: Arizona, BMI: body mass index, CA: California, CDM: Clinformatics Data Mart, ED: emergency department, e.g.: exempli gratia (for example), EHR: electronic health record, ER: emergency room, EUA: Emergency Use Authorization, FDA: Food and Drug Administration, FL: Florida, ICU: intensive care unit, ID: Idaho, IV: intravenous, kg: kilogram, mAb: monoclonal antibody, MN: Minnesota, n: number, N: total number, NCT: National Clinical Trial Identifier, PMTX: IQVIA Pharmetrics Plus, QI: Quality Improvement, RW: real-world, SAE: serious adverse event, SC: subcutaneous, UCHeath: University of Colorado Health, UPMC: University of Pittsburgh Medical Center, US: United States, UT: Utah, WI: Wisconsin

Table D24. Baseline Characteristics: RWE Studies I<sup>48,49</sup>

Dr	ug Name		REGEN-	COV		
Stu	ıdy Name	Webb et a	. 2021	Razonable et al	. 2021	
	Arms	Casirivimab/Imdevimab	Contemporaneous Controls	Casirivimab/Imdevimab	Controls	
	N	115	5,536	696	696	
Age, Median Years (I	QR)	66 (15)	62 (15)	63 (52-71)	63 (52-71)	
	≥50 Years	NR	NR	NR	NR	
Age Group, n/N (%)	<65 Years	NR	NR	378/696 (54.3)	386/696 (55.5)	
	≥65 Years	NR	NR	NR	NR	
Gender, n/N (%)	Male	61/115 (53)	3005/5536 (54.3)	340/696 (48.9)	321/696 (46.1)	
Gender, n/N (%)	Female	54/115 (47)	2531/5536 (45.7)	356/696 (51.1)	375/696 (53.9)	
	White	108/115 (93.9)	4787/5536 (86.5)	645/696 (92.7)	646/696 (92.8)	
	Black or African American	1/115 (0.9)	170/5536 (3.1)	26/696 (3.7)	28/696 (4.0)	
	Asian	1/115 (0.9)	89/5536 (1.6)	8/696 (1.1)	5/696 (0.7)	
	American Indian or Alaska Native	0/115 (0)	77/5536 (1.4)	3/696 (0.4)	2/696 (0.3)	
Race, n/N (%)	Native Hawaiian or Pacific Islander	1/115 (0.9)	170/5536 (3.1)	NR	NR	
, , ,	South Asian	NR	NR	NR	NR	
	Hispanic or Latino	NR	NR	NR	NR	
	Mixed Race	NR	NR	NR	NR	
	Communities of Color	19/115 (16.5)	1494 (27.0)	NR	NR	
	Other	NR	NR	8/696 (1.1)	10/696 (1.4)	
	Unknown	NR	NR	6/696 (0.9)	5/696 (0.7)	
	Not Reported	NR	NR	NA	NA	
Ethnicity, n/N (%)	Hispanic or Latino	15/115 (13.0)	933/5536 (16.9)	29/696 (4.2)	32/696 (4.6)	
Ethnicity, n/N (%)	Not Hispanic or Latino	100/115 (87)	4603/5536 (83.1)	655/696 (94.1)	653/696 (93.8)	
Weight, Median kg (I	QR)	NR	NR	NR	NR	
BMI, Mean kg/m² (SI	0)	NR	NR	NR	NR	
BMI n/N/9/\	<30 kg/m²	53/115 (46.1)	2120/5536 (39.3)	214/696 (31)	216/696 (31)	
BMI, n/N (%)	≥30 kg/m²	62/115 (53.9)	3416/5536 (61.7)	340/696 (49)	347/696 (50)	
Overweight, n/N (%)		NR	NR	145/696 (20.8)	147/696 (21.1)	
Positive Baseline Qua	alitative RT-PCR, n/N (%)	NR	NR	696/696 (100)	696/696 (100)	

Dr	ug Name	REGEN-COV					
Stu	dy Name	Webb et a	l. 2021	Razonable et al	. 2021		
	Arms	Casirivimab/Imdevimab	Contemporaneous Controls	Casirivimab/Imdevimab	Controls		
	N	115	5,536	696	696		
Previous Anti-SARS-C	OV-2 Vaccination, n/N (%)	NR*	NR*	NR	NR		
Time from Symptom Days (Range)	Onset to Infusion, Median	2.2 (1.8-3.1)	NR	2.61 (1.25)†	NR		
	0-3 Days	NR	NR	NR	NR		
Time from	4-5 Days	NR	NR	NR	NR		
Symptom Onset to	>5 Days	NR	NR	NR	NR		
Infusion, n/N (%)	>7 Days	NR	NR	NR	NR		
	Unspecified	NR	NR	NR	NR		
Duration of Follow-Up, Median Days (SD)		NR	NR	NR	NR		
	Age ≥55 Years	NR	NR	318/696 (45.7)‡	310/696 (44.5)‡		
	Obesity (BMI >30)	62/115 (53.9)	3416/5536 (61.7)	340/696 (48.9)	347/696 (50.0)		
	Hypertension	102/115 (88.7)	4392/5536 (79.3)	363/696 (52.5)	365/696 (52.4)		
	CVD	16/115 (13.9)§	529/5536 (9.6)§	NR	NR		
	Heart failure	19/115 (16.5)	827/5536 (14.9)	53/696 (7.6)	37/696 (5.3)		
	COPD	65/115 (56.5)	2928/5536 (52.9)	151/696 (21.7)	135/696 (19.4)		
Any Risk Factor for	Asthma	NR	NR	NR	NR		
Progression to	СКО	35/115 (30.4)	1077/5536 (19.5)	NR	NR		
Severe Disease, n/N	Diabetes (Type 1 and 2)	73/115 (63.5)	2656/5536 (48.0)	164/696 (23.6)	130/696 (18.7)		
(%)	Immunosuppressive Disease	6/115 (5.2)	236/5536 (4.3)	6.7%#			
	Neurological Disorder	0/115 (0)	903/5536 (16.3)	NR	NR		
	Liver Disease	34/115 (29.6)	1476/5536 (26.7)	65/696 (9.3)	48/696 (6.9)		
	High Cholesterol	NR	NR	NR	NR		
	Any Other Risk Factors or Comorbidities	NR	NR	NR	NR		
Total Comorbidities,	Median (IQR)	4 (3-5)	4 (3-5)	NR	NR		
	≥1 Risk Factor for Progression to Severe Disease,		NR	696/696 (100)	NR		
Baseline Serum	Negative	NR	NR	NR	NR		
Antibody Status,	Positive	NR	NR	NR	NR		
n/N (%)	Other	NR	NR	NR	NR		

Drug N	Name	REGEN-COV					
Study I	Name	Webb et al. 2021 Razonable et al. 20					
Arms		Casirivimab/Imdevimab	Contemporaneous Controls	Casirivimab/Imdevimab	Controls		
N		115	5,536	696	696		
Uı	nknown	NR	NR	NR	NR		
	Baseline Viral Load in Nasopharyngeal Swab, Median log <sub>10</sub> Copies/mL (Range)		NR	NR	NR		
Geography of US (%)		100%	100%	100%	100%		
Enrollment No	· · ·		NA	NA	NA		

BMI: body mass index, CKD: chronic kidney disease, COPD: chronic obstructive pulmonary disease, IQR: interquartile range, kg: kilogram, m: meter, mL: milliliter, n: number, N: total number, NA: not applicable, NR: not reported, RT-PCR: reverse transcription polymerase chain reaction, SD: standard deviation, US: United States

§Coronary artery disease.

#Compromised immune function.

<sup>\*</sup>All patients had a positive PCR or antigen COVID-19 test.

<sup>†</sup>Mean (SD).

<sup>‡</sup>Age ≥65 years.

Table D25. Baseline Characteristics: RWE Studies II<sup>50-53,55</sup>

1	Orug Name	REGEN-COV							
S	tudy Name	Polk et a	l. 2021	Chilimuri et al. 2021		Piccicacco et al. 2021			
	Arms	Casirivimab/ Imdevimab	Untreated	Casirivimab/ Imdevimab	Control Group	Casirivimab/ Imdevimab	Controls		
	N	125	199	22	11	48	200		
Age, Median	Years (IQR)	59 (19-98)	62 (20-92)	65 (55-65)	NR	65 (52.8-74.3)	65 (56-73.3)		
Ago Croup	≥50 Years	NR	NR	NR	NR	41/48 (85.4)	174/200 (87)		
Age Group, n/N (%)	<65 Years	NR	NR	NR	NR	23/48 (47.9)	96/200 (48)		
N/N (%)	≥65 Years	38/125 (30)	85/199 (44)	NR	NR	25/48 (52.1)	104/200 (52)		
Gender,	Male	62/125 (50)	87/199 (44)	9/22 (40.9)	NR	23/48 (48)	91/200 (45.5)		
n/N (%)	Female	63/125 (50)	112/199 (56)	13/22 (59)	NR	25/48 (52)	109/200 (54.5)		
	White	97/125 (78)	119/199 (60)	3/22 (13.6)	NR	30/48 (62.5)	110/200 (55)		
	Black or African American	17/125 (14)	56/199 (28)	6/22 (27.2)	NR	8/48 (16.7)	42/200 (21)		
	Asian	2/125 (1)	7/199 (3)	2/22 (0.9)	NR	1/48 (2.1)	3/200 (1.5)		
	American Indian or Alaska Native	NR	NR	NR	NR	NR	NR		
Race, n/N	Native Hawaiian or Pacific Islander	NR	NR	NR	NR	NR	NR		
(%)	South Asian	NR	NR	NR	NR	NR	NR		
	Hispanic or Latino	7/125 (6)	12/199 (6)	11/22 (50)	NR	4/48 (8.3)	23/200 (11.5)		
	Mixed Race	NR	NR	NR	NR	NR	NR		
	Communities of Color	NR	NR	NR	NR	NR	NR		
	Other	2/425/4)	5 /4 00 /0)	NR	NR	5/40/40 4)	22 (222 (44)		
	Unknown	2/125 (1)	5/199 (2)	NR	NR	5/48 (10.4)	22/200 (11)		
	Not Reported	NA	NA	NA	NR	NA	NA		
Falson Later .	Hispanic or Latino	NR	NR	NR	NR	NR	NR		
Ethnicity, n/N (%)	Not Hispanic or Latino	NR	NR	NR	NR	NR	NR		
Weight, Med	lian kg (IQR)	NR	NR	NR	NR	NR	NR		
BMI, Mean k		NR	NR	30.1 (26.1-35.0)	NR	30.7 (6.9)	31.3 (7.3)		
BMI, n/N	<30 kg/m²	83/125 (66)*	133/199 (67)*	NR	NR	23/48 (47.9)	99/200 (49.5)		
(%)	≥30 kg/m²	42/125 (34)†	66/199 (33)†	NR	NR	23/48 (47.9)	96/200 (48)		

1	Drug Name			REGEN	N-COV		
S	tudy Name	Polk et al	. 2021	Chilimuri et al. 2021		Piccicacco et al. 2021	
	Arms	Casirivimab/ Imdevimab	Untreated	Casirivimab/ Imdevimab	Control Group	Casirivimab/ Imdevimab	Controls
	N	125	199	22	11	48	200
Overweight,	n/N (%)	NR	NR	NR	NR	NR	NR
Positive Base PCR, n/N (%)	line Qualitative RT-	NR	NR	22/22 (100)	NR	NR	NR
Previous Ant Vaccination,	i-SARS-COV-2 n/N (%)	NR	NR	NR	NR	NR	NR
	mptom Onset to dian Days (Range)	5 (1-10)‡	NR	6 (4-7)	NR	4.9 (2.1)§	NR
Time From	0-3 Days	NR	NR	NR	NR	NR	NR
Symptom	4-5 Days	NR	NR	NR	NR	NR	NR
Onset to	>5 Days	48/125 (38)	NR	NR	NR	NR	NR
Infusion,	>7 Days	NR	NR	NR	NR	NR	NR
n/N (%)	Unspecified	NR	NR	NR	NR	NR	NR
Duration of F Days (SD)	ollow-Up, Median	NR	NR	NR	NR	NR	NR
	Age ≥55 years	38/125 (30)#	85/199 (44)#	NR	NR	35/48 (72.9)	161/200 (80.5)
	Obesity (BMI >30)	42/125 (34)†	66/199 (33)†	NR	NR	23/48 (47.9)	96/200 (48)
	Hypertension	56/125 (45)	116/199 (58)	18/22 (81.8)	NR	25/48 (52.1)¤	120/200 (60)¤
	CVD	12/125 (10)	19/199 (9)	8/22 (36.4)	NR	5/48 (10.4)**	29/200 (14.5)**
. 5: 1	Heart Failure	NR	NR	NR	NR	NR	NR
Any Risk Factor for	COPD	19/125 (15)	28/199 (14)	NR	NR	2/48 (4.2)++	32/200 (16) ††
Progression	Asthma	NR	NR	9/22 (40.9)‡‡	NR	NR	NR
to Severe	CKD	13/125 (10)	19/199 (9)	3/22 (13.6)	NR	3/48 (6.3)§§	17/200 (8.5)§§
Disease, n/N (%)	Diabetes (Type 1 and 2)	36/125 (29)	57/199 (29)	10/22 (45.4)	NR	16/48 (33.3)	85/200 (42.5)
11/14 (70)	Immunosuppressive Disease	19/125 (15)	20/199 (10)	4/22 (18.2)	NR	9/48 (18.8)	15/200 (7.5)
	Neurological Disorder	NR	NR	NR	NR	NR	NR
	Liver Disease	NR	NR	NR	NR	NR	NR
	High cholesterol	NR	NR	NR	NR	NR	NR

[	Orug Name	REGEN-COV							
S	tudy Name	Polk et al. 2021		Chilimuri et al. 2021		Piccicacco et al. 2021			
	Arms	Casirivimab/ Imdevimab	Untreated	Casirivimab/ Imdevimab	Control Group	Casirivimab/ Imdevimab	Controls		
	N	125	199	22	11	48	200		
	Any Other Risk								
	Factors or	NR	NR	NR	NR	NR	NR		
	Comorbidities								
Total Comorl	oidities, Median (IQR)	NR	NR	NR	NR	2 (1.2)§ ¤¤	2.3 (1.2)§ ¤¤		
≥1 Risk Facto Severe Disea	r for Progression to se, n/N (%)	54/125 (43)	105/199 (53)	22/22 (100)	NR	48/48 (100)	200/200 (100)		
Baseline	Negative	NR	NR	NR	NR	NR	NR		
Serum	Positive	NR	NR	NR	NR	NR	NR		
Antibody	Other	NR	NR	NR	NR	NR	NR		
Status, n/N (%)	Unknown	NR	NR	NR	NR	NR	NR		
Baseline Vira	l Load in								
Nasopharyng	eal Swab, Median	NR	NR	NR	NR	NR	NR		
log <sub>10</sub> Copies/	mL (Range)								
Geography	US (%)	100%	100%	100%	NR	100%	100%		
of Enrollment	Non-US (%)	NA	NA	NA	NA	NA	NA		

BMI: body mass index, CKD: chronic kidney disease, COPD: chronic obstructive pulmonary disease, CVD: cardiovascular disease, ESRD: end-stage renal disease, IQR: interquartile range, kg: kilogram, m: meter, mL: milliliter, n: number, N: total number, NA: not applicable, NR: not reported, RT-PCR: reverse transcription polymerase chain reaction, SD: standard deviation, US: United States

<sup>\*</sup>BMI ≤35 kg/m². †BMI >35 kg/m². ‡Mean (range). §Mean (SD). #Age >65 years. ¤55 years of age with hypertension. \*\*55 years of age with CVD. †+55 years of age with chronic lung disease. ‡‡Chronic respiratory disease. §§CKD and ESRD. ¤¤Number of risk factors.

Table D26. Baseline Characteristics: RWE Studies III<sup>54,56</sup>

Dr	ug Name		REGEN-0	COV		REGE	N-COV & Sotrov	vimab
Stı	ıdy Name		McCreary et	al. 2021		Huang et al. 2021		
	Arms	SC: Casirivimab/ Imdevimab	IV: Casirivimab/ Imdevimab	SC Matched: Casirivimab/ Imdevimab	Controls	Casirivimab/ Imdevimab	Sotrovimab	Control Group
	N	969	1,216	652	1,304*	712	311	2,046
Age, Median Y	ears (IQR)	53.8 (16.7)†	54.3 (16.6)†	53.7 (16.9)†	53.0 (19.3)†	53.2 (1	16.4)†	52.8 (19.5)†
Ago Croup	≥50 Years	NR	NR	NR	NR	NR	NR	NR
Age Group, n/N (%)	<65 Years	NR	NR	NR	NR	NR	NR	NR
11/14 (70)	≥65 Years	NR	NR	NR	NR	NR	NR	NR
Gender, n/N	Male	422/969 (43.6)	544/1216 (45.6)	264/652 (50.5)	519/1304 (39.8)	454/102	3 (44.4)	889/2046 (43.7)
(%)	Female	547/969 (56.4)	672/1216 (54.4)	388/652 (59.5)	785/1304 (60.2)	569/102	3 (55.6)	1157/2046 (56.6)
	White	852/969 (89.8)	1071/1216 (89.4)	NR	NR	NR	NR	NR
	Black or African American	49/969 (5.2)	83/1216 (6.9)	35/652 (5.4)	50/1304 (3.8)	61/1023 (6.0)		112/2046 (5.5)
	Asian	NR	NR	NR	NR	NR	NR	NR
	American Indian or Alaska Native	NR	NR	NR	NR	NR	NR	NR
Race, n/N	Native Hawaiian or Pacific Islander	NR	NR	NR	NR	NR	NR	NR
(%)	South Asian	NR	NR	NR	NR	NR	NR	NR
•	Hispanic or Latino	NR	NR	NR	NR	NR	NR	NR
	Mixed Race	NR	NR	NR	NR	NR	NR	NR
	Communities of Color	NR	NR	NR	NR	NR	NR	NR
	Other	48/969 (5.1)	44/1216 (3.7)	NR	NR	NR	NR	NR
	Unknown	NR	NR	NR	NR	NR	NR	NR
	Not Reported	NR	NR	NR	NR	NR	NR	NR
Ethnicity	Hispanic or Latino	NR	NR	NR	NR	NR	NR	NR
Ethnicity, n/N (%)	Not Hispanic or Latino	NR	NR	NR	NR	NR	NR	NR
Weight, Media	an kg (IQR)	NR	NR	NR	NR	NR	NR	NR
BMI, Mean kg	/m² (SD)	31.8 (7.5)	32.8 (8.4)	32.0 (7.6)	32.1 (7.7)	32.5	(7.4)	32.6 (7.8)
BMI, n/N (%)	<30 kg/m²	NR	NR	NR	NR	NR	NR	NR

Dr	ug Name		REGEN-C	COV		REGE	N-COV & Sotro	vimab
Stu	ıdy Name		McCreary et	al. 2021		ı	Huang et al. 202	1
	Arms	SC: Casirivimab/ Imdevimab	IV: Casirivimab/ Imdevimab	SC Matched: Casirivimab/ Imdevimab	Controls	Casirivimab/ Imdevimab	Sotrovimab	Control Group
	N	969	1,216	652	1,304*	712	311	2,046
	≥30 kg/m²	NR	NR	NR	NR	NR	NR	NR
Overweight, n	/N (%)	NR	NR	NR	NR	NR	NR	NR
Positive Baseli PCR, n/N (%)	ine Qualitative RT-	NR	NR	NR	NR	NR	NR	NR
Previous Anti- Vaccination, n		447/969 (55.5)‡	485/1216 (44.1)‡	NR	NR	NR	NR	NR
•	nptom Onset to ian Days (Range)	6.1 (1.9)†	6.1 (2.0)†	NR	NA	NR	NR	NR
Time from	0-3 Days	170/969 (21.2)‡	257/1216 (23.4)‡	NR	NA	NR	NR	NR
Symptom	4-5 Days	170/909 (21.2)+	237/1210 (23.4)+	NR	NA	NR	NR	NR
Onset to	>5 Days	293/969 (36.5)§	352/1216 (32.0)§	NR	NA	NR	NR	NR
Infusion,	>7 Days	339/969 (42.3)	491/1216 (44.6)	NR	NA	NR	NR	NR
n/N (%)	Unspecified	NR	NR	NR	NR	NR	NR	NR
Duration of Fo Days (SD)	llow-Up, Median	NR	NR	NR	NR	NR	NR	NR
	Age ≥55 Years	NR	NR	NR	NR	NR	NR	NR
	Obesity (BMI >30)	NR	NR	NR	NR	NR	NR	NR
	Hypertension	314/969 (47.0)**	408/1216 (43.3)**	303/652 (46.5)**	591/1304 (45.3)**	423/1023	(41.4)**	861/2046 (42.1)**
Any Risk	CVD	73/969 (10.9)#**	105/1216 (11.1)#**	71/652 (10.9)#**	142/1304 (10.9)#**	103/1023	(10.1)#**	188/2046 (9.2)#**
Factor for Progression	Heart Failure	36/969 (5.4)**	50/1216 (5.3)**	32/653 (4.9)**	85/1304 (6.4)**	46/1023	(4.5)**	93/2046 (4.6)**
to Severe Disease, n/N	COPD	115/969 (17.2)**	151/1216 (16.0)**	108/653 (16.6)**	202/1304 (15.5)**	146/1023	(14.3)**	272/2046 (13.3)**
(%)	Asthma	220/969 (32.9)**	283/1216 (30.0)**	213/652 (32.7)**	387/1304 (29.7)**	311/1023	(30.4)**	593/2046 (29.0)**
	CKD	34/969 (5.1)**	63/1216 (6.7)**	27/652 (4.1)**	80/1304 (6.1)**	53/1023	(5.2)**	117/2046 (5.7)**
	Diabetes (Type 1 and 2)	112/969 (16.8)**	161/1216 (17.1)**	107/652 (16.4)**	203/1304 (15.6)**	166/1023	(16.2)**	331/2046 (16.2)**

Dr	ug Name		REGEN-C	cov		REGE	N-COV & Sotrov	vimab	
Stu	ıdy Name		McCreary et	al. 2021		Huang et al. 2021			
	Arms	SC: Casirivimab/ Imdevimab	IV: Casirivimab/ Imdevimab	SC Matched: Casirivimab/ Imdevimab	Controls	Casirivimab/ Imdevimab	Sotrovimab	Control Group	
	N	969	1,216	652	1,304*	712	311	2,046	
	Immunosup. Disease	NR	NR	NR	NR	NR	NR	NR	
	Neurological Disorder	NR	NR	NR	NR	NR	NR	NR	
	Liver Disease	28/969 (4.2)¤**	23/1216 (2.4)¤**	28/652 (4.3)¤**	42/1304 (3.2)¤**	34/1023	(3.3)¤**	59/2046 (2.9)¤**	
	High Cholesterol	NR	NR	NR	NR	NR	NR	NR	
	Any Other Risk Factors or Comorbidities	NR	NR	NR	NR	NR	NR	NR	
Total Comorbi	dities, Median (IQR)	NR	NR	NR	NR	NR	NR	NR	
≥1 Risk Factor Severe Disease	for Progression to e, n/N (%)	NR	NR	NR	NR	NR	NR	NR	
Baseline	Negative	NR	NR	NR	NR	NR	NR	NR	
Serum	Positive	NR	NR	NR	NR	NR	NR	NR	
Antibody	Other	NR	NR	NR	NR	NR	NR	NR	
Status, n/N (%)	Unknown	NR	NR	NR	NR	NR	NR	NR	
Nasopharynge	Baseline Viral Load in Nasopharyngeal Swab, Median log <sub>10</sub> Copies/mL (Range)		NR	NR	NR	NR	NR	NR	
Geography	US (%)	100%	100%	100%	100%	100%	100%	100%	
of Enrollment	Non-US (%)	NA	NA	NA	NA	NA	NA	NA	

BMI: body mass index, CKD: chronic kidney disease, COPD: chronic obstructive pulmonary disease, CVD: cardiovascular disease, IQR: interquartile range, IV: intravenous, kg: kilogram, m: meter, mL: milliliter, n: number, N: total number, NA: not applicable, NR: not reported, RT-PCR: reverse transcription polymerase chain reaction, SC: subcutaneous, SD: standard deviation, US: United States

<sup>\*</sup>Matched controls. †Mean (SD). ‡Fully vaccinated patients. ‡1-4 days. §5-6 days. #Coronary artery disease. ¤Fatty liver disease. \*\*Having a history of the condition/risk factor.

Table D27. Baseline Characteristics: RWE Studies IV<sup>57-59</sup>

D	rug Name					REGEN-COV			
St	udy Name	Bierle et a	al. 2021	Kakinoki	et al. 2021		Wei et al	. 2022	
	Arms	Casirivimab /Imdevimab	Control Group	Casirivimab/ Imdevimab	Watchful Observation Group	CDM: Casirivimab/ Imdevimab	CDM: Matched Control Group	PMTX+: Casirivimab/ Imdevimab	PMTX+: Matched Control Group
	N	112	518	55	53	1,116	5,291	3,280	16,284
Age, Med	ian Years (IQR)	46.5*		51.0 (20.0- 94.0)	52.0 (20.0- 68.0)	55 (45-61)	56 (47-62)	57 (49-62)	58 (50-63)
	<18 Years	NR	NR	NR	NR	3/1116 (0.3)	36/5291 (0.7)	15/3280 (0.5)	89/16284 (0.6)
0	≥18 Years	NR	NR	NR	NR	1113/1116 (99.7)	5255/5291 (99.3)	3265/3280 (99.5)	16195/16284 (99.4)
Age Group,	≥50 Years	NR	NR	28/55 (50.9)	NR	NR	NR	NR	NR
n/N (%)	<65 Years	NR	NR	NR	NR	972/1116 (87.1)	4473/5291 (84.5)	2819/3280 (85.9)	14015/16284 (86.1)
	≥65 Years	NR	NR	NR	NR	144/1116 (12.9)	818/5291 (15.5)	461/3280 (14.1)	2269/16284 (13.9)
Gender,	Male	296/630 (47)		38/55 (69.1)	30/53 (56.6)	583/1116 (52.2)	2768/5291 (52.3)	1627/3280 (50.5)	8658/16284 (53.2)
n/N (%)	Female	334/630 (53)		17/55 (30.9)	23/53 (43.4)	533/1116 (47.8)	2523/5291 (47.7)	1623/3280 (49.5)	7626/16284 (46.8)
	White	NR	NR	NR	NR	778/1116 (69.7)	3712/5291 (70.2)	NR	NR
	Black or African American	NR	NR	NR	NR	113/1116 (10.1)	553/5291 (10.5)	NR	NR
	Asian	NR	NR	NR	NR	24/1116 (2.2)	96/5291 (1.6)	NR	NR
Race.	American Indian or Alaska Native	NR	NR	NR	NR	NR	NR	NR	NR
n/N (%)	Native Hawaiian or Pacific Islander	NR	NR	NR	NR	NR	NR	NR	NR
	South Asian	NR	NR	NR	NR	NR	NR	NR	NR
	Hispanic or Latino	NR	NR	NR	NR	140/1116 (12.5)	632/5291 (11.9)	NR	NR
	Mixed Race	NR	NR	NR	NR	NR	NR	NR	NR
	Communities of Color	NR	NR	NR	NR	NR	NR	NR	NR

Dı	rug Name					REGEN-COV			
St	udy Name	Bierle et a	al. 2021	Kakinoki	et al. 2021		Wei et a	l. 2022	
	Arms	Casirivimab /Imdevimab	Control Group	Casirivimab/ Imdevimab	Watchful Observation Group	CDM: Casirivimab/ Imdevimab	CDM: Matched Control Group	PMTX+: Casirivimab/ Imdevimab	PMTX+: Matched Control Group
	N	112	518	55	55 53	1,116	5,291	3,280	16,284
	Other	NR	NR	NR	NR	NR	NR	NR	NR
	Unknown	NR	NR	NR	NR	C1 /111C (F F)	200/5201/5.6\	NR	NR
	NR	NR	NR	NR	NR	61/1116 (5.5)	298/5291 (5.6)	NR	NR
Hispanic or Latino	NR	NR	NR	NR	NR	NR	NA	NA	
n/N (%)	Not Hispanic or Latino	NR	NR	NR	NR	NR	NR	NR	NR
Weight, N	ledian kg (IQR)	NR	NR	NR	NR	NR	NR	NR	NR
BMI, Mea	n kg/m² (SD)	NR	NR	27.5 (17.2- 47.5)‡	23.5 (14.7- 38.6)‡	NR	NR	NR	NR
BMI, n/N	<30 kg/m²	379/630 (60.1)		36/55 (65.5)	0/53 (0)	856/1116 (76.7)	4065/5291 (76.8)	2681/3280 (81.7)	13362/16284 (82.1)
(%)	≥30 kg/m²	251/630 (39.8)		19/55 (34.5)	0/53 (0)	260/1116 (23.3)	1226/5291 (23.2)	599/3280 (18.3)	2965/16284 (18.2)
Overweigh	ht, n/N (%)	NR	NR	NR	NR	49/1116 (4.4)	226/5291 (4.3)	94/3280 (2.9)	464/16284 (2.8)
Positive Back Qualitative (%)	aseline e RT-PCR, n/N	NR	NR	NR	NR	NR	NR	NR	NR
-	Alpha	NR	NR	NR	NR	NR	NR	NR	NR
	Beta	NR	NR	NR	NR	NR	NR	NR	NR
	Gamma	NR	NR	NR	NR	NR	NR	NR	NR
SARS-	Delta	NR	NR	NR	NR	NR	NR	NR	NR
Cov-2	Epsilon	NR	NR	NR	NR	NR	NR	NR	NR
Variant,	Eta	NR	NR	NR	NR	NR	NR	NR	NR
n/N (%)	lota	NR	NR	NR	NR	NR	NR	NR	NR
	Карра	NR	NR	NR	NR	NR	NR	NR	NR
	Mu	NR	NR	NR	NR	NR	NR	NR	NR
	Zeta	NR	NR	NR	NR	NR	NR	NR	NR
	Anti-SARS-COV-2 on, n/N (%)	NR	NR	NR	NR	87/1116 (7.8)	346/5291 (6.5)	94/3280 (2.9)	359/16284 (2.2)

Dr	rug Name	REGEN-COV  Weight at al. 2021							
Stu	udy Name	Bierle et a	al. 2021	Kakinoki	et al. 2021		Wei et al	. 2022	
	Arms	Casirivimab /Imdevimab			Watchful Observation Group	CDM: Casirivimab/ Imdevimab	CDM: Matched Control Group	PMTX+: Casirivimab/ Imdevimab	PMTX+: Matched Control Group
	N	112	518	55	53	1,116	5,291	3,280	16,284
	Symptom Onset n, Median Days	5.7†	NA	3 (0-7)	NA	2 (1-4)#	3 (1-4)#	2 (1-4)#	2 (1-4)#
Time	0-3 Days	NR	NR	NR	NR	NR	NR	NR	NR
from	4-5 Days	NR	NR	NR	NR	NR	NR	NR	NR
Sympto	>5 Days	NR	NR	NR	NR	NR	NR	NR	NR
m Onset	>7 Days	NR	NR	NR	NR	NR	NR	NR	NR
To Infusion, n/N (%)	Unspecified	NR	NR	NR	NR	NR	NR	NR	NR
Duration of Median Da	of Follow-Up, ays (SD)	NR	NR	NR	NR	NR	NR	NR	NR
	Age ≥55 Years	NR	NR	NR	NR	144/1116 (12.9)¤	818/5291 (15.6)¤	461/3280 (14.1)¤	2269/16284 (13.9)¤
	Obesity (BMI >30)	251/630 (39.8)		NR	NR	260/1116 (23.3)	1126/5291 (23.2)	599/3280 (18.3)	2951/16284 (18.1)
	Hypertension	153/630	(24.3)	22/108 (20.4)		591/1116 (53.0)	2908/5291	1857/3280	9608/16284
	CVD	73/630	(11.6)	22/10	18 (20.4)	591/1116 (53.0)	(55.0)	(56.6)	(59.0)
	Heart Failure	NR	NR	NR	NR	NR	NR	NR	NR
Any Risk Factor for	COPD	65/630 (10.3)		NR	NR	186/1116 (16.7)	930/5291 (17.6)	516/3280 (15.7)	2934/16284 (18.0)
Progressi	Asthma	NR	NR	12/108	3 (11.1)§	NR	NR	NR	NR
on to Severe	СКД	37/630	(5.9)	2/10	8 (1.9)	57/1116 (5.1)	312/5291 (5.9)	181/3280 (5.5)	1263/16284 (7.8)
Disease, n/N (%)	Diabetes (Type 1 and 2)	NR	NR	23/10	8 (21.3)	318/1116 (28.5)	1685/5291 (31.9)	1028/3280 (31.3)	5441/16284 (33.4)
11/19 (70)	Immunosuppre ssive Disease	NR	NR	0/10	08 (0)	177/1116 (15.9)	1048/5291 (19.8)	441/3280 (13.5)	2542/16284 (15.6)
	Neurological Disorder	NR	NR	NR	NR	254/1116 (22.8)	1207/5291 (22.8)	733/3280 (22.4)	3430/16284 (21.1)
	Liver Disease	NR	NR	8/10	8 (7.4)	NR	NR	NR	NR
	High Cholesterol	NR	NR	NR	NR	NR	NR	NR	NR

Dr	ug Name					REGEN-COV			
Stu	ıdy Name	Bierle et a	al. 2021	Kakinoki	et al. 2021		Wei et al	. 2022	
	Arms	Casirivimab /Imdevimab	Control Group	Casirivimab/ Imdevimab	Watchful Observation Group	CDM: Casirivimab/ Imdevimab	CDM: Matched Control Group	PMTX+: Casirivimab/ Imdevimab	PMTX+: Matched Control Group
	N	112	518	55	53	1,116	5,291	3,280	16,284
	Any Other Risk Factors or Comorbidities	NR	NR	NR	NR	NR	NR	NR	NR
Total Com Median (IC	•	NR	NR	NR	NR	NR	NR	NR	NR
≥1 Risk Fac Progressio Disease, n	n to Severe	NR	NR	55/55 (100)	53/53 (100)	NR	NR	NR	NR
Baseline	Negative	NR	NR	NR	NR	NR	NR	NR	NR
Serum	Positive	NR	NR	NR	NR	NR	NR	NR	NR
Antibod	Other	NR	NR	NR	NR	NR	NR	NR	NR
y Status, n/N (%)	Unknown	NR	NR	NR	NR	NR	NR	NR	NR
Nasophary	iral Load in Ingeal Swab, Ig <sub>10</sub> Copies/mL	NR	NR	NR	NR	NR	NR	NR	NR
Geograp	US (%)	100%	100%	NR	NR	100%	100%	100%	100%
hy of Enrollme nt	Non-US (%)	NR	NR	100%	100%	0%	0%	0%	0%
Pregnant I	ndividuals, n (%)	NR	NR	NR	NR	8/1116 (0.7)	40/5291 (0.8)	10/3280 (0.3)	72/16284 (0.4)

BMI: body mass index, CDM: Clinformatics Data Mart, CKD: chronic kidney disease, COPD: chronic obstructive pulmonary disease, CVD: cardiovascular disease, IQR: interquartile range, kg: kilogram, m: meter, mL: milliliter, n: number, N: total number, NR: not reported, PMTX: IQVIA Pharmetrics Plus, RT-PCR: reverse transcription polymerase chain reaction, SD: standard deviation, US: United States

<sup>\*</sup>Mean. †No range available. ‡Median (IQR). §Chronic lung disease and asthma. #Time from diagnosis to index date. ¤Age ≥65 years.

Table D28. Baseline Characteristics: RWE Studies V<sup>129</sup>

	Drug Name		Fluvoxamine
	Study Name	Seft	tel and Boulware 2021
	Arms	Fluvoxamine	Untreated Cohort
	N	65	48
Age, Median Years (IQR)		44 (15)*	43 (13)*
	<18 Years	NR	NR
	≥18 Years	NR	NR
Age Group, n/N (%)	≥50 Years	22/65 (33)	17/48 (35)
	<65 Years	60/65 (93)	46/48 (96)
	≥65 Years	5/65 (7)	2/48 (4)
Condor n/N/9/	Male	50/65 (76.9)	35/48 (72.9)
Gender, n/N (%)	Female	15/65 (23.1)	13/48 (27.1)
	White	3/65 (5)	13/48 (27)
	Black or African American	1/65 (1.5)	0/48 (0)
	Asian	0/65 (0)	1/48 (2)
	American Indian or Alaska Native	NR	NR
	Native Hawaiian or Pacific Islander	NR	NR
Daga = /N /9/)	South Asian	NR	NR
Race, n/N (%)	Hispanic or Latino	NR	NR
	Mixed Race	NR	NR
	Communities of Color	NR	NR
	Other	NR	NR
	Unknown	NR	NR
	Not Reported	NR	NR
Ethnicitus n (NI (O/)	Hispanic or Latino	61/65 (94)	34/48 (71)
Ethnicity, n/N (%)	Not Hispanic or Latino	NR	NR
Weight, Median kg (IQR)		NR	NR
BMI, Mean kg/m² (SD)		NR	NR
PMI = /N (9/)	<30 kg/m²	NR	NR
BMI, n/N (%)	≥30 kg/m²	NR	NR
Overweight, n/N (%)		NR	NR
Positive Baseline Qualitative RT-PC	R, n/N (%)	NR	NR
SARS Cov. 2 Variant in (N. 194)	Alpha	NR	NR
SARS-Cov-2 Variant, n/N (%)	Beta	NR	NR

Dru	g Name		Fluvoxamine
Stud	dy Name	Seftel	and Boulware 2021
	Arms	Fluvoxamine	Untreated Cohort
	N	65	48
	Gamma	NR	NR
	Delta	NR	NR
	Epsilon	NR	NR
	Eta	NR	NR
	lota	NR	NR
	Карра	NR	NR
	Mu	NR	NR
	Zeta	NR	NR
Previous Anti-SARS-COV-2 Vaccination, r	n/N (%)	NR	NR
Time from Symptom Onset to Infusion, I	Median Days (Range)	3.7 (1.3)	3.4 (1.4)
	0-3 Days	NR	NR
Time from Symptom Opent to Infusion	4-5 Days	NR	NR
Time from Symptom Onset to Infusion, n/N (%)	>5 Days	NR	NR
11/14 (/6)	>7 Days	NR	NR
	Unspecified	NR	NR
<b>Duration of Follow-Up, Median Days (SD</b>	1	NR	NR
	Age ≥55 Years	NR	NR
	Obesity (BMI>30)	NR	NR
	Hypertension	11/65 (17)	17/48 (35)
	CVD	NR	NR
	Heart Failure	NR	NR
	COPD	2/65 (3)	1/48 (2)
Any Risk Factor for Progression to	Asthma	NR	NR
Severe Disease, n/N (%)	CKD	NR	NR
	Diabetes (Type 1 and 2)	11/65 (17)	4/48 (8)
	Immunosuppressive Disease	NR	NR
	Neurological Disorder	NR	NR
	Liver Disease	NR	NR
	High Cholesterol	NR	NR
	Any Other Risk Factors or Comorbidities	NR	NR
Total Comorbidities, Median (IQR)		NR	NR
≥1 Risk Factor for Progression to Severe	Disease, n/N (%)	16/65 (25)	18/48 (38)

Dru	ıg Name		Fluvoxamine
Stu	dy Name	Sefte	l and Boulware 2021
	Arms	Fluvoxamine	Untreated Cohort
	N	65	48
	Negative	NR	NR
Baseline Serum Antibody Status, n/N	Positive	NR	NR
(%)	Other	NR	NR
	Unknown	NR	NR
Baseline Viral Load in Nasopharyngeal S	wab, Median log <sub>10</sub> Copies/mL (Range)	NR	NR
Goography of Enrollment	US (%)	NR	NR
Geography of Enrollment	Non-US (%)	NR	NR
Pregnant Individuals, n (%)		NR	NR

BMI: body mass index, CKD: chronic kidney disease, COPD: chronic obstructive pulmonary disease, CVD: cardiovascular disease, IQR: interquartile range, kg: kilogram, m: meter, mL: milliliter, n: number, N: total number, NR: not reported, , RT-PCR: reverse transcription polymerase chain reaction, SD: standard deviation, US: United States

<sup>\*</sup>Mean (SD).

Table D29. Baseline Characteristics: RWE Studies VI<sup>120,125,126</sup>

[	Drug Name	REGE	N-COV	Sotr	ovimab	Sotr	ovimab
	Trial	Osugi et	t al. 2022	Aggarwa	al et al. 2022	Zaqout	et al. 2022
	Arms	Casirivimab/ Imdevimab	Untreated Cohort	Sotrovimab	Untreated Cohort	Sotrovimab (Matched Treatment)	Matched Control
	N	30	74	522	1563	345	583
Age, Median Ye	ars (IQR)	54.5 (14.6)*	45.1 (15.3)*	NR	NR	40 (32-50)	39 (33-46)
	<18 Years	NR	NR	NA	NA	NR	NR
A C	≥18 Years	NR	NR	522/522 (100)	1563/1563 (100)	NR	NR
Age Group,	≥50 Years	NR	NR	NR	NR	NR	NR
n/N (%)	<65 Years	NR	NR	346/522 (66.3)	1023/1563 (65.5)	NR	NR
	≥65 Years	NR	NR	176/522 (33.7)	540/1563 (34.5)	29/345 (8.4)¤	40/583 (6.9)¤
Gender, n/N	Male	18/30 (60)	39/74 (52.7)	226/522 (43.3)	686/1563 (43.9)	124/345 (35.9)	195/583 (33.5)
(%)	Female	12/30 (40)	35/74 (47.3)	296/522 (56.7)	877/1563 (56.1)	221/345 (64.1)	388/583 (66.6)
	White	NR	NR	421/522 (80.7)	1271/1563 (81.3)	NR	NR
	Black or African American	NR	NR	21/522 (4)	57/1563 (3.6)	NR	NR
	Asian	NR	NR	NR	NR	NR	NR
	American Indian or Alaska Native	NR	NR	NR	NR	NR	NR
Race, n/N (%)	Native Hawaiian or Pacific Islander	NR	NR	NR	NR	NR	NR
	South Asian	NR	NR	NR	NR	NR	NR
	Hispanic or Latino	NR	NR	39/522 (7.5)	118/1563 (7.5)	NR	NR
	Mixed Race	NR	NR	NR	NR	NR	NR
	Communities of Color	NR	NR	NR	NR	NR	NR
	Other	NR	NR	41/522 (7.9)	117/1563 (7.5)	NR	NR
	Unknown	NR	NR	NR	NR	NR	NR
	Not Reported	NR	NR	NR	NR	NR	NR
Ethnicity, n/N	Hispanic or Latino	NR	NR	NR	NR	NR	NR
(%)	Not Hispanic or Latino	NR	NR	NR	NR	NR	NR
Weight, Median	n kg (IQR)	NR	NR	NR	NR NR		NR
BMI, Mean kg/ı	m² (SD)	29.6 (6.1)	25.3 (5.6)	NR	NR	NR	NR
DMI = /NI /0/\	<30 kg/m <sup>2</sup>	NR	NR	NR	NR	NR	NR
BMI, n/N (%)	≥30 kg/m²	NR	NR	NR	NR	NR	NR
Overweight, n/	N (%)	NR	NR	NR	NR	NR	NR

	Drug Name	REGEI	N-COV	Sotr	ovimab	Sotro	vimab
	Trial	Osugi et	al. 2022	Aggarwa	l et al. 2022	Zaqout e	t al. 2022
	Arms	Casirivimab/ Imdevimab	Untreated Cohort	Sotrovimab	Untreated Cohort	Sotrovimab (Matched Treatment)	Matched Control
	N		74	522	1563	345	583
Positive Baselinn/N (%)	ne Qualitative RT-PCR,	NR	NR	NR	NR	NR	NR
	Alpha	NR	NR	NR	NR	NR	NR
	Beta	NR	NR	NR	NR	NR	NR
	Gamma	NR	NR	NR	NR	NR	NR
	Delta	NR	NR	NR	NR	112/345 (32.5)	152/583 (26.1)
SARS-Cov-2	Epsilon	NR	NR	NR	NR	NR	NR
Variant, n/N	Eta	NR	NR	NR	NR	NR	NR
(%)	lota	NR	NR	NR	NR	NR	NR
	Карра	NR	NR	NR	NR	NR	NR
	Mu	NR	NR	NR	NR	NR	NR
	Omicron	NR	NR	NR	NR	233/345 (67.5)	431/583 (73.9)
	Zeta	NR	NR	NR	NR	NR	NR
Previous Anti-S n/N (%)	ARS-COV-2 Vaccination,	NR	NR	322/522 (61.7)	959/1563 (61.4)	229/345 (66.4)**	384/583 (65.9)**
Time from Sym Median Days (I	ptom Onset to Infusion, Range)	NR	NR	3.7 (1.8)*	NA	NR	NR
Time from	0-3 Days	NR	NR	NR	NR	NR	NR
Symptom	4-5 Days	NR	NR	NR	NR	NR	NR
Onset to	>5 Days	NR	NR	NR	NR	NR	NR
Infusion, n/N	> 7 Days	NR	NR	NR	NR	NR	NR
(%)	Unspecified	NR	NR	NR	NR	NR	NR
Duration of Fol	low-Up, Median Days	12 (10	D-16†)	NR	NR	NR	NR
-	Age ≥55 Years	NR	NR	NR	NR	NR	NR
Any Risk	Obesity (BMI >30)	NR	NR	133/522 (25.5)	394/1563 (25.2)	NR	NR
Factor for	Hypertension	NR	NR	160/522 (30.7)	497/1563 (31.8)	NR	NR
Progression	CVD	6/30 (20)	12/74 (16.2)	86/522 (16.5)	242/1563 (15.5)	NR	NR
to Severe	Heart failure	NR	NR	NR	NR	NR	NR
Disease, n/N	COPD	NR	NR	131/522 (25.1)	390/1563 (25.0)	NR	NR
(%)	Asthma	6/30 (20)‡	13/74 (17.6)‡	NR	NR	NR	NR
	CKD	0/30 (0)	2/74 (2.7)	32/522 (6.1)#	112/1563 (7.2)#	NR	NR

l	Drug Name	REGE	N-COV	Sotr	ovimab	Sotro	ovimab
	Trial	Osugi et	t al. 2022	Aggarwa	al et al. 2022	Zaqout	et al. 2022
	Arms	Casirivimab/ Imdevimab	Untreated Cohort	Sotrovimab	Untreated Cohort	Sotrovimab (Matched Treatment)	Matched Control
	N	30	74	522	1563	345	583
	Diabetes (Type 1 and 2)	3/30 (10)	12/74 (16.2)	62/522 (11.9)	209/1563 (13.4)	NR	NR
	Immunosuppressive Disease	1/30 (3.3)§	1/74 (1.4)§	130/522 (24.9) §	347/1563 (22.2) §	NR	NR
	Neurological Disorder	NR	NR	NR	NR	NR	NR
	Liver Disease	1/30 (3.3)	1/74 (1.4)	39/522 (7.5)	114/1563 (7.3)	NR	NR
	High Cholesterol	NR	NR	NR	NR	NR	NR
	Any Other Risk Factors or Comorbidities	NR	NR	NR	NR	NR	NR
Total Comorbio	lities, Median (IQR)	NR	NR	NR	NR	NR	NR
≥1 Risk Factor f Disease, n/N (9	for Progression to Severe %)	30/30 (100)	74/74 (100)	271/522 (51.9)	796/1563 (50.9)	303/345 (87.8)	505/583 (86.6)
Baseline	Negative	NR	NR	NR	NR	NR	NR
Serum	Positive	NR	NR	NR	NR	NR	NR
Antibody	Other	NR	NR	NR	NR	NR	NR
Status, n/N (%)	Unknown	NR	NR	NR	NR	NR	NR
Baseline Viral Load in Nasopharyngeal Swab, Median Log <sub>10</sub> Copies/mL (Range)		NR	NR	NR	NR	NR	NR
Geography of	US (%)	0%	0%	NR	NR	0/345 (0)	0/583 (0)
Enrollment	Non-US (%)	100%	100%	NR	NR	345/345 (100)	583/583 (100)

BMI: body mass index, CKD: chronic kidney disease, COPD: chronic obstructive pulmonary disease, CVD: cardiovascular disease, IQR: interquartile range, kg: kilogram, m: meter, mL: milliliter, n: number, N: total number, NR: not reported, , RT-PCR: reverse transcription polymerase chain reaction, SD: standard deviation, US: United States

\*Mean (SD).

†IQR.

‡Chronic lung disease.

§Immunocompromised.

#Renal disease.

¤Age ≥60 years.

<sup>\*\*</sup>Received two or three vaccination doses.

Table D30. Efficacy Outcomes: RWE Studies I<sup>48,49</sup>

Drug	, Name				REGEN-CO	ov			
Study	y Name	Webb	et al. 2021			Razonable e	et al. 2021		
А	rms	Casirivimab/ Imdevimab	Contemporaneous Controls	Casirivimab/ Imdevimab	Controls	Casirivimab/ Imdevimab	Controls	Casirivimab/ Imdevimab	Controls
	N	115	5,536	679	679	673	674	668	671
Time	epoint		Day 14	Day 1	L4	Day 2	1	Day 28	3
≥1 Any-Cause Medically- Attended Visit, n/N (%)		NR	NR	NR	NR	NR	NR	NR	NR
Type of	Outpatient Visit	NR	NR	NR	NR	NR	NR	NR	NR
Any-Cause	Urgent Care	NR	NR	NR	NR	NR	NR	NR	NR
Medically-	ED	9/115 (7.8)	944/5536 (17.1)	NR	NR	NR	NR	NR	NR
Attended Visit, n/N	Hosp.	1/115 (0.9)	538/5536 (9.7)	9/679 (1.3)	22/679 (3.3)	9/673 (1.3)	28/674 (4.2)	11/668 (1.6)	32/671 (4.8)
(%)	ICU Admission	NR	NR	5/679 (0.7)	6/679 (0.9)	5/673 (0.7)	6/674 (0.9)	5/668 (0.7)	7/671 (1.0)
≥1 COVID-Rel Medically-Att n/N (%)		NR	NR	NR	NR	NR	NR	NR	NR
Type of COVID-19	Outpatient Visit	NR	NR	NR	NR	NR	NR	NR	NR
Related	<b>Urgent Care</b>	NR	NR	NR	NR	NR	NR	NR	NR
Medically-	ED	NR	NR	NR	NR	NR	NR	NR	NR
Attended	Hosp.	NR	NR	NR	NR	NR	NR	NR	NR
Visit, n/N (%)	ICU Admission	NR	NR	NR	NR	NR	NR	NR	NR
COVID-19-Related Hospitalization or Any- Cause Death, n/N (%)		NR	NR	NR	NR	NR	NR	NR	NR
-	Hospitalized or Death from Any Cause, n/N (%)		NR	NR	NR	NR	NR	NR	NR
Time to First ED Visit or Hospitalization, Median Days (IQR)		NR	6.7 (5.8)	NR	NR	NR	NR	NR	NR

Drug	Name			REGEN-COV					
Study	y Name	Webb	et al. 2021			Razonable e	et al. 2021		
Aı	rms	Casirivimab/ Imdevimab	Contemporaneous Controls	Casirivimab/ Imdevimab	Controls	Casirivimab/ Imdevimab	Controls	Casirivimab/ Imdevimab	Controls
	N	115	5,536	679	679	673	674	668	671
Time	epoint		Day 14	Day 1	L4	Day 2	<b>1</b>	Day 2	3
Hospital Leng Median Days	• • •	NR	NR	0.06 (0.64)*	0.14 (0.92)*	0.07 (0.80)*	0.18 (1.20)*	0.07 (0.81)*	0.23 (1.45)*
(≥1 COVID-19	imary Outcome -Related on or All-Cause	NR	NR	NR	NR	NR	NR	NR	NR
ED Observation Hospitalization 19, n/N (%)	on or on from COVID-	10/115 (8.7)	1482/5536 (26.8)	NR	NR	NR	NR	NR	NR
ICU Length of Days (SD)	Stay, Mean	NR	NR	0.03 (0.46)	0.03 (0.44)	0.03 (0.46)	0.03 (0.49)	0.03 (0.47)	0.03 (0.49)
COVID-19-Rel n/N (%)	lated Death,	NR	NR	NR	NR	NR	NR	NR	NR
Overall Morta	ality, n/N (%)	0/115 (0)	57/5536 (1.0)	1/679 (0.15)	3/679 (0.44)	1/673 (0.15)	3/674 (0.44)	1/668 (0.15)	4/671 (0.59)
Time to Death (SD)	h, Mean Days	NR	NR	NR	NR	NR	NR	NR	NR
Time to Symp Resolution, M	otom Mean Days (SD)	NR	NR	NR	NR	NR	NR	NR	NR
Reduction in 1 19 Symptom I Mean Days (S		NR	NR	NR	NR	NR	NR	NR	NR
	Alleviation of lean Days (SD)	NR	NR	NR	NR	NR	NR	NR	NR
Ventilation Requirement,	Non-Invasive Ventilation	NR	NR	NR	NR	NR	NR	NR	NR
n/N (%)	Mechanical Ventilation	NR	NR	NR	NR	NR	NR	NR	NR

Drug	Name				REGEN-CO	ov			
Stud	y Name	Webb	et al. 2021			Razonable e	et al. 2021		
Arms		Casirivimab/ Imdevimab	Contemporaneous Controls	Casirivimab/ Imdevimab	Controls	Casirivimab/ Imdevimab	Controls	Casirivimab/ Imdevimab	Controls
	N	115	5,536	679	679	673	674	668	671
Tim	epoint	!	Day 14	Day 1	L4	Day 2	21	Day 2	8
Days on Mechanical Ventilator, Median Days (IQR)		NR	NR	NR	NR	NR	NR	NR	NR
	Time to SARS-Cov-2 Clearance, Mean Days (SD)		NR	NR	NR	NR	NR	NR	NR
Viral Clearan	ce, n/N (%)	NR	NR	NR	NR	NR	NR	NR	NR
Change	Day 5	NR	NR	NR	NR	NR	NR	NR	NR
from Baseline in SARS-Cov-2 Viral Load (log <sub>10</sub> Copies/mL) LSM (SE)	Day 7	NR	NR	NR	NR	NR	NR	NR	NR
Adherence, n	/N (%)	NR	NR	NR	NR	NR	NR	NR	NR

CI: confidence interval, ED: emergency department, ED: emergency department, ICU: intensive care unit, IQR: interquartile range, LSM: least squares mean, mL: milliliter, n: number, N: total number, NR: not reported, SD: standard deviation, SE: standard error, vs.: versus \*Median (SD).

Table D31. Efficacy Outcomes: RWE Studies II<sup>50,52,53,55</sup>

Dr	ug Name			REGEI	N-COV		
Stu	ıdy Name	Polk et	al. 2021	Chilimuri	et al. 2021	Piccicacco e	et al. 2021
	Arms	Casirivimab/ Imdevimab	Controls	Casirivimab/ Imdevimab	Control Group	Casirivimab/ Imdevimab	Controls
	N	125	199	22	11	48	200
Ti	Timepoint		<i>,</i> 30	Da	y 30	Day	29
≥1 Any-Cause Med (%)	≥1 Any-Cause Medically-Attended Visit, n/N (%)		NR	NR	NR	NR	NR
Tune of Ann.	Outpatient Visit	NR	NR	NR	NR	NR	NR
Type of Any-	Urgent Care	NR	NR	1. NR	NR	NR	NR
Cause Medically- Attended Visit.	ED	3/125 (2)	21/199 (10)	NR	NR	NR	NR
n/N (%)	Hospitalization	3/125 (2)	25/199 (12)	2/22 (9.1)	6/11 (54.5)	NR	NR
11/14 (70)	ICU Admission	0/125 (0)	8/199 (4)	NR	NR	NR	NR
≥1 COVID-19-Relate Visit, n/N (%)	ed Medically-Attended	NR	NR	NR	NR	NR	NR
Type of COVID-19	Outpatient Visit	NR	NR	NR	NR	NR	NR
Related	Urgent Care	NR	NR	NR	NR	NR	NR
Medically-	ED	1/125 (1)	18/199 (9)	NR	NR	5/48 (10.4)	26/200 (13)
Attended Visit,	Hospitalization	3/125 (2)	24/199 (12)	1/22 (4.5)	6/11 (54.5)	0/48 (0)	60/200 (30)
n/N (%)	ICU Admission	0/125 (0)	8/199 (4)	NR	NR	NR	NR
COVID-19-Related Cause Death, n/N (	Hospitalization or Any- %)	NR	NR	NR	NR	NR	NR
Hospitalized or Dea	th from Any Cause, n/N	NR	NR	NR	NR	NR	NR
Time to First ED Vis Median Days (IQR)	it or Hospitalization,	NR	NR	NR	NR	NR	NR
Hospital Length of	Stay, Median Days (IQR)	NR	NR	NR	NR	NR	NR
Primary Outcome (	Relative Risk Reduction vs. Placebo of Primary Outcome (≥1 COVID-19-Related Hospitalization or All-Cause Death), % (95% CI)		NR	NR	NR	NR	NR
COVID-19, n/N (%)	ED Observation or Hospitalization from COVID-19, n/N (%)		NR	NR	NR	5/48 (10.4)	81/200 (40.5)
ICU Length of Stay,		NR	NR	NR	NR	NR	NR
COVID-Related Dea	ith, n/N (%)	0/125 (0)	4/199 (2)	NR	NR	NR	NR

Dr	rug Name			REGEN	N-COV		
Stu	udy Name	Polk et a	al. 2021	Chilimuri	et al. 2021	Piccicacco e	et al. 2021
	Arms	Casirivimab/ Imdevimab	Controls	Casirivimab/ Imdevimab	Control Group	Casirivimab/ Imdevimab	Controls
	N	125	199	22	11	48	200
Ti	Timepoint		30	Da	y 30	Day	29
Overall Mortality, r	n/N (%)	0/125 (0)	4/199 (2)	0/22 (0)	2/11 (18.1)	0/48 (0)	7/200 (3.5)
Time to Death, Me	an Days (SD)	NR	NR	NR	NR	NR	NR
Time to Symptom F (SD)	Resolution, Mean Days	NR	NR	NR	NR	NR	NR
Reduction in Time to Resolution, Mean I	to COVID-19 Symptom Days (SD)	NR	NR	NR	NR	NR	NR
Time to First Allevia Days (SD)	ation of Symptoms, Mean	NR	NR	NR	NR	NR	NR
Ventilation Requirement,	Non-Invasive Ventilation	NR	NR	NR	NR	NR	NR
n/N (%)	Mechanical Ventilation	0/125 (0)	3/199 (1)	NR	NR	NR	NR
Days on Mechanica (IQR)	l Ventilator, Median Days	NR	NR	NR	NR	NR	NR
Time to SARS-Cov-2 (SD)	2 Clearance, Mean Days	NR	NR	NR	NR	NR	NR
Viral Clearance, n/I	Viral Clearance, n/N (%)		NR	NR	NR	NR	NR
Change from Day 5		NR	NR	NR	NR	NR	NR
Baseline in SARS- Cov-2 Viral Load (log <sub>10</sub> Copies/mL) LSM (SE)	Day 7	NR	NR	NR	NR	NR	NR
Adherence, n/N (%	)	NR	NR	NR	NR	NR	NR

CI: confidence interval, ED: emergency department, ER: emergency room, ICU: intensive care unit, IQR: interquartile range, LSM: least squares mean, mL: milliliter, n: number, N: total number, NR: not reported, SD: standard deviation, SE: standard error, vs.: versus

Table D32. Efficacy Outcomes: RWE Studies III<sup>54,56,136</sup>

Drug	Name		REGEN	I-COV		REGEI	N-COV & Sotrov	imab
Study	Name		McCreary 6	et al. 2021		н	uang et al. 2023	l
Ar	ms	SC: Casirivimab/ Imdevimab	IV: Casirivimab/ Imdevimab	SC Matched: Casirivimab/ Imdevimab	Controls	Casirivimab/ Imdevimab	Sotrovimab	Control Group
	N		1,216	653	1,306*	712	311	2,046
Time	point		Day		Day 28			
≥1 Any-Cause Me Visit, n/N (%)	dically-Attended	NR	NR	NR	NR	NR	NR	NR
Type of Any-	Outpatient Visit	NR	NR	NR	NR	NR	NR	NR
Cause	<b>Urgent Care</b>	NR	NR	NR	NR	NR	NR	NR
Medically- Attended Visit, n/N (%)	ED	NR	NR	NR	NR	NR	NR	NR
	Hospitalization	27/969 (2.8)	20/1216 (1.6)	22/653 (3.4)	72/1306 (5.5)	19/712 (2.7)	16/311 (5.1)	134/2046 (6.6)
	ICU Admission	3/969 (0.3)	3/1216 (0.2)	NR	NR	NR	NR	NR
≥1 COVID-19-Rela Attended Visit, n		NR	NR	NR	NR	NR	NR	NR
Type of COVID- 19 Related	Outpatient Visit	NR	NR	NR	NR	NR	NR	NR
	<b>Urgent Care</b>	NR	NR	NR	NR	NR	NR	NR
Medically- Attended Visit,	ED	NR	NR	NR	NR	NR	NR	NR
n/N (%)	Hospitalization	NR	NR	NR	NR	NR	NR	NR
11/14 (70)	ICU Admission	NR	NR	NR	NR	NR	NR	NR
COVID-19-Related or Any-Cause Dea		NR	NR	NR	NR	NR	NR	NR
Hospitalized or Death from Any Cause, n/N (%)		27/969 (2.8)	21/1216 (1.7)	22/653 (3.4)	92/1306 (7)	19/712 (2.7)	16/311 (5.1)	174/2046 (8.5)
	Time to First ED Visit or Hospitalization, Median Days (IQR)		NR	NR	NR	NR	NR	NR
Days (IQR)	Hospital Length of Stay, Median Days (IQR)		3 (4-6.5)	NR	NR	NR	NR	NR
Relative Risk Reduction vs. Placebo of Primary Outcome (≥1 COVID-19-		NR	NR	NR	NR	NR	NR	NR

Drug l	Name		REGEN	I-COV		REGEI	REGEN-COV & Sotrovimab		
Study	Name		McCreary (	et al. 2021		Н	uang et al. 202	L	
Arı	ms	SC: Casirivimab/ Imdevimab	IV: Casirivimab/ Imdevimab	SC Matched: Casirivimab/ Imdevimab	Controls	Casirivimab/ Imdevimab	Sotrovimab	Control Group	
N	I	969	1,216	653	1,306*	712	311	2,046	
Time	point		Day	28			Day 28		
Related Hospitaliz Cause Death), % (									
ED Observation of from COVID-19, n		47/969 (4.8)†	71/1216 (5.8)†	40/653 (6.1)†	129/1306 (9.9)†	NR	NR	NR	
ICU Length of Stay (SD)	, Mean Days	NR	NR	NR	NR	NR	NR	NR	
COVID-19-Related	Death, n/N (%)	NR	NR	NR	NR	NR	NR	NR	
Overall Mortality,	n/N (%)	1/969 (0.1)	3/1216 (0.2)	1/653 (0.2)	31/1306 (2.4)	1/712 (0.1)	0/311 (0)	60/2046 (2.9)	
Time to Death, M	ean Days (SD)	NR	NR	NR	NR	NR	NR	NR	
Time to Symptom Mean Days (SD)	Resolution,	NR	NR	NR	NR	NR	NR	NR	
Reduction in Time Symptom Resolut (SD)		NR	NR	NR	NR	NR	NR	NR	
Time to First Alley Symptoms, Mean		NR	NR	NR	NR	NR	NR	NR	
Ventilation	Non-Invasive Ventilation	NR	NR	NR	NR	NR	NR	NR	
Requirement, n/N (%)	Mechanical Ventilation	3/969 (0.3)	2/1216 (0.2)	NR	NR	NR	NR	NR	
Days on Mechanic Median Days (IQR	-	NR	NR	NR	NR	NR	NR	NR	
Time to SARS-Cov-2 Clearance, Mean Days (SD)		NR	NR	NR	NR	NR	NR	NR	
Viral Clearance, n/N (%)		NR	NR	NR	NR	NR	NR	NR	
Change from	Change from Day 5		NR	NR	NR	NR	NR	NR	
Baseline in SARS-Cov-2 Viral Load (log <sub>10</sub>	Day 7	NR	NR	NR	NR	NR	NR	NR	

Drug N	lame		REGEN	-COV		REGE	N-COV & Sotrov	imab
Study I	Name		McCreary e	et al. 2021	Н	uang et al. 2021	L	
Arms		SC: Casirivimab/ Imdevimab	IV: Casirivimab/ Imdevimab	SC Matched: Casirivimab/ Imdevimab	Controls	Casirivimab/ Imdevimab	Sotrovimab	Control Group
N		969	1,216	653	1,306*	712	311	2,046
Timep	oint		Day		Day 28			
Copies/mL) LSM (SE)								
Adherence, n/N (%	6)	NR	NR	NR	NR	NR	NR	NR

CI: confidence interval, ED: emergency department, ER: emergency room, ICU: intensive care unit, IQR: interquartile range, IV: intravenous, LSM: least squares mean, mL: milliliter, n: number, N: total number, NR: not reported, SC: subcutaneous, SD: standard deviation, SE: standard error, vs.: versus \*Matched controls.

<sup>†</sup>ED observation or any-cause hospitalization.

Table D33. Efficacy Outcomes: RWE Studies IV<sup>57-59</sup>

Drug	g Name				REGI	EN-COV			
Stud	y Name	Bierle e	t al. 2021	Kakinoki e	t al. 2021		Wei et	al. 2022	
А	rms	Casirivimab/ Imdevimab	Control Group	Casirivimab/ Imdevimab	Watchful Observation Group	CDM: Casirivimab/ Imdevimab	CDM: Matched Control Group	PMTX+: Casirivimab/ Imdevimab	PMTX+: Matched Control Group
	N		291	55	53	1,116	5,291	3,280	16,284
Time	epoint	Da	y 28	Day 14	Day 16		Day	<sub>/</sub> 30	
≥1 Any-Cause I Attended Visit	•	NR	NR	NR	NR	NR	NR	NR	NR
Type of Any-	Outpatient Visit	NR	NR	NR	NR	NR	NR	NR	NR
Cause	Urgent Care	NR	NR	NR	NR	NR	NR	NR	NR
Medically- Attended	Emergency Department	NR	NR	NR	NR	NR	NR	NR	NR
Visit, n/N	Hospitalization	3/112 (2.6)	48/291 (16.6)	NR	22/53 (41.5)	NR	NR	NR	NR
(%)	ICU Admission	NR	NR	NR	NR	NR	NR	NR	NR
≥1 COVID-19-R Medically-Atte (%)	ended Visit, n/N	NR	NR	NR	NR	NR	NR	NR	NR
Type of COVID-19	Outpatient Visit	NR	NR	NR	NR	NR	NR	NR	NR
Related	Urgent Care	NR	NR	NR	NR	NR	NR	NR	NR
Medically-	ED	NR	NR	NR	NR	NR	NR	NR	NR
Attended Visit, n/N	Hospitalization	NR	NR	NR	NR	NR	NR	59/3280 (1.9)	752/16284 (4.8)
(%)	ICU Admission	NR	NR	NR	NR	NR	NR	NR	NR
	COVID-19-Related Hospitalization or Any-Cause Death, n/N (%)		NR	NR	NR	23/1116 (2.1)	276/5291 (5.2)	NR	NR
Hospitalized or Death from Any Cause, n/N (%)		NR	NR	NR	NR	NR	NR	NR	NR
	Time to First ED Visit or Hospitalization, Median Days (IQR)		NR	NR	NR	NR	NR	NR	NR
	Hospital Length of Stay, Median Days (IQR)		NR	NR	NR	NR	NR	NR	NR

Drug	g Name				REGI	EN-COV			
Stud	y Name	Bierle e	t al. 2021	Kakinoki e	t al. 2021		Wei et	al. 2022	
А	ırms	Casirivimab/ Imdevimab	Control Group	Casirivimab/ Imdevimab	Watchful Observation Group	CDM: Casirivimab/ Imdevimab	CDM: Matched Control Group	PMTX+: Casirivimab/ Imdevimab	PMTX+: Matched Control Group
	N	112	291	55	53	1,116	5,291	3,280	16,284
Tim	epoint	Da	y 28	Day 14	Day 16		Day	y 30	
Relative Risk R Placebo of Prir (≥1 COVID-19-I Hospitalization Death), % (95%	mary Outcome Related n or All-Cause	NR	NR	NR	NR	NR	NR	NR	NR
ER Observation Hospitalization n/N (%)	n or n from COVID-19,	NR	NR	NR	NR	NR	NR	NR	NR
ICU Length of S (SD)	Stay, Mean Days	NR	NR	NR	NR	NR	NR	NR	NR
COVID-19-Rela (%)	ited Death, n/N	NR	NR	NR	NR	NR	NR	NR	NR
Overall Mortal	lity, n/N (%)	NR	NR	NR	NR	0/1116 (0)	27/5291 (0.5)	NR	NR
Time to Death	, Mean Days (SD)	NR	NR	NR	NR	NR	NR	NR	NR
Showing Symp	toms, n/N (%)	NR	NR	NR	NR	NR	NR	NR	NR
Time to Sympt Mean Days (SI	com Resolution, D)	NR	NR	42/55 (76.4)*	NR	NR	NR	NR	NR
Reduction in T Symptom Reso Days (SD)	ime to COVID-19 plution, Mean	NR	NR	NR	NR	NR	NR	NR	NR
Time to First A Symptoms, Me		NR	NR	NR	NR	NR	NR	NR	NR
Ventilation Requirement	Non-Invasive Ventilation	NR	NR	13/55	NR	NR	NR	NR	NR
, n/N (%)	Mechanical Ventilation	NR	NR	(23.6)†	NR	NR	NR	NR	NR
Days on Mecha Median Days (	anical Ventilator, IQR)	NR	NR	NR	NR	NR	NR	NR	NR
Time to SARS- Mean Days (SI	Cov-2 Clearance, D)	NR	NR	NR	NR	NR	NR	NR	NR
Viral Clearance	e, n/N (%)	NR	NR	NR	NR	NR	NR	NR	NR
	Day 5	NR	NR	NR	NR	NR	NR	NR	NR

Drug	Name				REGI	N-COV				
Stud	y Name	Bierle e	t al. 2021	Kakinoki e	t al. 2021		Wei et al. 2022			
Arms		Casirivimab/ Imdevimab	Control Group	Casirivimab/ Imdevimab	Watchful Observation Group	CDM: Casirivimab/ Imdevimab	CDM: Matched Control Group	PMTX+: Casirivimab/ Imdevimab	PMTX+: Matched Control Group	
	N	112	291	55	53	1,116	5,291	3,280	16,284	
Tim	epoint	Da	y 28	Day 14	Day 16	Day 30				
Change from Baseline in SARS-Cov-2 Viral Load (log <sub>10</sub> Copies/mL) LSM (SE)	Day 7	NR	NR	NR	NR	NR	NR	NR	NR	
Adherence, n/	N (%)	NR	NR	NR	NR	NR	NR	NR	NR	

CDM: Clinformatics Data Mart, CI: confidence interval, ED: emergency department, ER: emergency room, ICU: intensive care unit, IQR: interquartile range, LSM: least squares mean, mL: milliliter, n: number, N: total number, NR: not reported, PMTX: IQVIA Pharmetrics Plus, SD: standard deviation, SE: standard error, vs.: versus \*Percentage of patients who recovered within 5 days.

<sup>†</sup>Further medical interventions (oxygen, steroids, or antiviral drugs).

Table D34. Efficacy Outcomes: RWE Studies V129

	Drug Name		Fluvoxamine		
	Study Name	Seft	el & Boulware 2021		
	Arms	Fluvoxamine	Untreated Cohort		
	N	65	48		
	Timepoint	Day 14			
≥1 Any-Cause Medically-Attended V	isit, n/N (%)	NR	NR		
	Outpatient Visit	NR	NR		
Type of Any-Cause Medically-	Urgent Care	NR	NR		
Attended Visit, n/N (%)	ED	NR	NR		
Attended visit, II/N (78)	Hospitalization	0/65 (0)	6/48 (12.5)		
	ICU Admission	0/65 (0)	2/48 (4.2)		
≥1 COVID-19-Related Medically-Atte	ended Visit, n/N (%)	NR	NR		
	Outpatient Visit	NR	NR		
Type of COVID-19 Related	Urgent Care	NR	NR		
Medically-Attended Visit, n/N (%)	ED	NR	NR		
iviedically-Attended visit, II/N (%)	Hospitalization	NR	NR		
	ICU Admission	NR	NR		
COVID-19-Related Hospitalization of	r Any-Cause Death, n/N (%)	NR	NR		
Hospitalized or Death from Any Cau	se, n/N (%)	NR	NR		
Time to First ED Visit or Hospitalizat	ion, Median Days (IQR)	NR	NR		
Hospital Length of Stay, Median Day	ys (IQR)	NR	NR		
Relative Risk Reduction vs. Placebo Hospitalization or All-Cause Death),	of Primary Outcome (≥1 COVID-19-Related % (95% CI)	NR	NR		
ER Observation or Hospitalization fr	om COVID-19, n/N (%)	NR	NR		
ICU Length of Stay, Mean Days (SD)		NR	NR		
COVID-19-Related Death, n/N (%)		NR	NR		
Overall Mortality, n/N (%)		0/65 (0)	1/48 (2.1)		
Time to Death, Mean Days (SD)		NR	NR		
Showing Symptoms, n/N (%)		0/65 (0)	29/48 (60.4)		
Time to Symptom Resolution, Mean	Days (SD)	NR	NR		
Reduction in Time to COVID-19 Sym	ptom Resolution, Mean Days (SD)	NR	NR		
Time to First Alleviation of Sympton	ns, Mean Days (SD)	NR	NR		
Ventilation Requirement, n/N (%)	Non-Invasive Ventilation	NR	NR		
ventuation kequirement, n/N (%)	Mechanical Ventilation	NR	2/48 (4.2)		

	Drug Name	Fluvoxamine	
	Study Name	Seftel	& Boulware 2021
	Arms	Fluvoxamine	Untreated Cohort
	N	65	48
	Timepoint	Day 14           NR         NR	
Days on Mechanical Ventilator, Med	ian Days (IQR)	NR	NR
Time to SARS-Cov-2 Clearance, Mean	n Days (SD)	NR	NR
Viral Clearance, n/N (%)		NR	NR
Change from Baseline in SARS-Cov-	Day 5	NR	NR
2 Viral Load (log <sub>10</sub> Copies/mL) LSM (SE)	Day 7	NR	NR
Adherence, n/N (%)		NR	NR

CI: confidence interval, ED: emergency department, ER: emergency room, ICU: intensive care unit, IQR: interquartile range, LSM: least squares mean, mL: milliliter, n: number, N: total number, NR: not reported, SD: standard deviation, SE: standard error, vs.: versus

Table D35. Efficacy Outcomes: RWE Studies VI<sup>120,125,126</sup>

	Drug Name		N-COV	Sotro	vimab	Sotrov	rimab
	Trial	Osugi et	al. 2022	Aggarwal	et al. 2022	Zaqout et	al. 2022
	Arms	Casirivimab/ Imdevimab	Untreated Cohort	Sotrovimab	Untreated Cohort	Sotrovimab (Matched Treatment)	Matched Control
	N	30	74	522 1563		345	583
	Timepoint	Day	12*	Da	y 28	Follow	∕-up¤
≥1 Any-Cause Me (%)	dically-Attended Visit, n/N	NR	NR	NR	NR	NR	NR
Type of Any-	Outpatient Visit	NR	NR	NR	NR	NR	NR
Cause	Urgent Care	NR	NR	NR	NR	NR	NR
Medically-	ED	NR	NR	44/522 (8.4)	119/1563 (7.6)	NR	NR
Attended Visit,	Hospitalization	NR	NR	11/522 (2.1)	89/1563 (5.7)	NR	NR
n/N (%)	ICU Admission	NR	NR	2/11 (18.2)†	19/89 (21.3)†	NR	NR
≥1 COVID-Related n/N (%)	d Medically-Attended Visit,	NR	NR	NR	NR	NR	NR
Type of COVID-	Outpatient Visit	NR	NR	NR	NR	NR	NR
19 Related	Urgent Care	NR	NR	NR	NR	NR	NR
Medically-	ED	NR	NR	NR	NR	NR	NR
Attended Visit,	Hospitalization	19/104 (18.3)		NR	NR	NR	NR
n/N (%)	ICU Admission	NR	NR	NR	NR	NR	NR
COVID-Related Ho Death, n/N (%)	ospitalization or Any-Cause	NR	NR	NR	NR	NR	NR
Hospitalized or D (%)	eath from Any Cause, n/N	NR	NR	NR	NR	NR	NR
Time to First ED V	/isit or Hospitalization, R)	NR	NR	NR	NR	NR	NR
Hospital Length o	f Stay, Median Days (IQR)	NR	NR	5.3 (5.9)+‡	9.4 (10.6)†§	NR	NR
Relative Risk Reduction vs. Placebo of Primary Outcome (≥1 COVID-19-Related Hospitalization or All-Cause Death), % (95% CI)		NR	NR	NR	NR	NR	NR
COVID-19, n/N (%	ED Observation or Hospitalization from COVID-19, n/N (%)		NR	NR	NR	NR	NR
	y, Mean Days (SD)	NR	NR	5.5 (6.4)++	8.6 (10.1)†§	NR	NR
COVID-19-Related	d Death, n/N (%)	0/30 (0)	0/74 (0)	NR	NR	NR	NR

0	Drug Name	REGE	N-COV	Sotro	vimab	Sotrov	imab
	Trial	Osugi et	al. 2022	Aggarwal	et al. 2022	Zaqout et	al. 2022
	Arms		Untreated Cohort	Sotrovimab	Untreated Cohort	Sotrovimab (Matched Treatment)	Matched Control
	N	30	74	522	1563	345	583
•	Timepoint	Day	12*		y 28	Follow	∕-up¤
Overall Mortality,	n/N (%)	NR	NR	0/522 (0)	15/1563 (1.0)	NR	NR
Time to Death, M	ean Days (SD)	NR	NR	NR	NR	NR	NR
Progression to Sev COVID-19, n/N (%	vere, Critical, or Fatal )	NR	NR	NR	NR	4/345 (1.2)	3/583 (0.5)
Showing Sympton	ns, n/N (%)	NR	NR	NR	NR	NR	NR
Time to Symptom (SD)	Resolution, Mean Days	NR	NR	NR	NR	NR	NR
Reduction in Time Resolution, Mean	to COVID-19 Symptom Days (SD)	NR	NR	NR	NR	NR	NR
Time to First Alley Days (SD)	riation of Symptoms, Mean	NR	NR	NR	NR	NR	NR
Ventilation	Non-Invasive Ventilation	NR	NR	NR (72.7)#	NR (48.3)#	NR	NR
Requirement, n/N (%)	Mechanical Ventilation	NR	NR	0/11 (0)†	19/89 (21.3)†	NR	NR
Days on Mechanic	cal Ventilator, Median Days	NR	NR	NR	NR	NR	NR
Time to SARS-Cov (SD)	-2 Clearance, Mean Days	NR	NR	NR	NR	NR	NR
Viral Clearance, n	/N (%)	NR	NR	NR	NR	NR	NR
Change from	Day 5	NR	NR	NR	NR	NR	NR
Baseline in SARS-Cov-2 Viral Load (log <sub>10</sub> Copies/mL) LSM	Day 7	NR	NR	NR	NR	NR	NR
(SE)							

CI: confidence interval, ED: emergency department, ER: emergency room, ICU: intensive care unit, IQR: interquartile range, LSM: least squares mean, mL: milliliter, n: number, N: total number, NR: not reported, SD: standard deviation, SE: standard error

<sup>\*</sup>Median timepoint; follow-up periods varied. †Among patients who were hospitalized. ‡N=11. §N=89. #No supplemental or low flow standard oxygen. ¤Timepoint unclear.

Table D36. Subgroup Outcomes: RWE Studies I<sup>54,56</sup>

Drug	Name		REGEN-C	OV		REGE	N-COV & Sotrovi	mab	
Study	Name		McCreary et	al. 2021		Huang et al. 2021			
Subgroup	Category	Same Site Inf	nfused Patients Unmatched Cohort			U	Inmatched Cohor	t	
Aı	rms	SC: Casirivimab/ Imdevimab	IV: Casirivimab/ Imdevimab	SC Matched: Casirivimab/ Imdevimab	Controls	Casirivimab/ Imdevimab	Sotrovimab	Control Group	
	N	721	441	665	3,821	717	311	5,171	
Time	epoint	Da	y <b>2</b> 9	Day 29	9		Day 29		
Hospitalized or Any Cause, n/N		17/721 (2.4)	4/441 (0.9)	23/665 (3.5)	251/3821 (6.6)	19/717 (2.6)	16/311 (5.1)	479/5171 (9.3)	
Hospitalization	1	17/721 (2.4)	4/441 (0.9)	23/665 (3.5)	208/3821 (5.4)	19/717 (2.6)	16/311 (5.1)	357/5171 (6.9)	
ICU Admission		3/721 (0.4)	1/441 (0.2)	NR	NR	NR	NR	NR	
Hospital Lengtl Days (SD)	h of Stay, Mean	6 (3,10)	4.5 (2,6)	NR	NR	NR	NR	NR	
ED Observation Hospitalization 19, n/N (%)		38/721 (5.3)*	26/441 (5.9)*	40/665 (6.0)*	376/3821 (9.8)*	NR	NR	NR	
Overall Mortal	ity, n/N (%)	1/721 (0.1)	1/441 (0.2)	1/665 (0.2)	80/3821 (2.1)	1/717 (0.1)	0/311 (0)	184/5171 (3.6)	
Ventilation	Non-Invasive Ventilation	NR	NR	NR	NR	NR	NR	NR	
Requirement, n/N (%)	Mechanical Ventilation	2/721 (0.3)	1/441 (0.2)	NR	NR	NR	NR	NR	

ER: emergency room, ICU: intensive care unit, IV: intravenous, n: number, N: total number, NR: not reported, SC: subcutaneous, SD: standard deviation \*ED observation or any-cause hospitalization.

Table D37. Subgroup Outcomes: RWE Studies II<sup>57,59</sup>

Study Name*	Subgroup Category	Arms	N	Timepoint	Any-Cause Hospitalization, n/N (%)	COVID-19- Related Hospitalization, n/N (%)	COVID-19-Related Hospitalization or Any-Cause Death, n/N (%)
			REGEN-CO	ΟV			
	Vaccinated	Casirivimab/Imdevimab	55	Day 20	1/55 (1.8)	NR	NR
Bierle et	vaccinated	Control Group	146	Day 29	22/146 (15.1)	NR	NR
al. 2021 U	Linuacinatad	Casirivimab/Imdevimab	57	Day 20	2/57 (3.5)	NR	NR
	Unvaccinated	Control Group	372	Day 29	51/372 (13.7)	NR	NR
	Age <65 Years	CDM: Casirivimab/Imdevimab	972		NR	NR	16/972 (1.6)
		CDM: Matched Control Group	4,473	Day 20	NR	NR	221/4473 (4.9)
		PMTX+: Casirivimab/Imdevimab	2,819	Day 30	NR	52/2819 (1.8)	NR
		PMTX+: Matched Control Group	14,015		NR	582/14015 (4.2)	NR
		CDM: Casirivimab/Imdevimab	144		NR	NR	7/144 (4.9)
Wei et	Age SCE Veers	CDM: Matched Control Group	818	Day 20	NR	NR	55/818 (6.7)
al. 2022	Age ≥65 Years	PMTX+: Casirivimab/Imdevimab	461	Day 30	NR	7/461 (1.5)	NR
		PMTX+: Matched Control Group	2,269		NR	170/2269 (7.5)	NR
	Early Treatment (1	CDM: Casirivimab/Imdevimab	NR	Day 20	NR	NR	1.2%
	Day)	PMTX+: Casirivimab/Imdevimab	NR	Day 30	NR	NR	1.3%
	Later Treatment	CDM: Casirivimab/Imdevimab	NR	Day 20	NR	NR	4.6%
	(≥5 Days)	PMTX+: Casirivimab/Imdevimab	NR	Day 30	NR	NR	3.3%

CDM: Clinformatics Data Mart, n: number, N: total number, NR: not reported, PMTX: IQVIA Pharmetrics Plus

<sup>\*</sup>No subgroup data available from Webb et al. 2021, Razonable et al. 2021, Polk et al. 2021, Chilimuri et al. 2021, or Piccicacco et al. 2021.

Table D38. Adverse Events: RWE Studies 148,49

	Drug Name		REGEN-CO	V	
	Study Name	Webb et al.	2021	Razonable et al. 2	021
	Arms	Casirivimab/Imdevimab	Contemporaneous Controls	Casirivimab/Imdevimab	Controls
	N	115	5,536	696	696
	Timepoint	Day 14	1	Day 28	
≥ Any AE, n/N	I (%)	1/115 (0.9)	NR	7/696 (1.0)	NR
≥ Any TEAE, n	/N (%)	NR	NR	NR	NR
Drug-Related	AE, n/N (%)	NR	NR	NR	NR
AE Leading to	Discontinuation, n/N (%)	NR	NR	NR	NR
AE Leading to	Dose Interruption, n/N (%)	NR	NR	NR	NR
AE Leading to	Death, n/N (%)	NR	NR	NR	NR
Serious AE Re	lated to Treatment, n/N (%)	0/115 (0)	NR	0/696 (0)	NR
≥1 Serious AE	, n/N (%)	0/115 (0)	NR	0/696 (0)	NR
Fatal AE, n/N	(%)	NR	NR	0/696 (0)	NR
All-Cause Mo	rtality, n/N (%)	NR	NR	0/696 (0)	NR
Grade 3 or 4	AE, n/N (%)	NR	NR	NR	NR
	Grade 1	NR	NR	7/696 (1.0)	NR
TEAE	Grade 2	NR	NR	0/696 (0)	NR
Severity,	Grade 3	NR	NR	0/696 (0)	NR
n/N (%)	Grade 4	NR	NR	0/696 (0)	NR
	Grade 5	NR	NR	0/696 (0)	NR
	Any	1/115 (0.9)	NR	NR	NR
	Grade ≥2	NR	NR	NR	NR
Infusion-	Grade 3 or 4	NR	NR	NR	NR
Related AE,	Related to Treatment	NR	NR	NR	NR
n/N (%)	Leading to Discontinuation	NR	NR	NR	NR
	Leading to Dose Interruption	NR	NR	NR	NR
(%)	ity Reactions Grade ≥2, n/N	NR	NR	0/696 (0)	NR
Dyspnea, n/N		NR	NR	NR	NR
Diarrhea, n/N	(%)	NR	NR	NR	NR

Drug Name	REGEN-COV							
Study Name	Webb et a	l. 2021	Razonable et al. 2	021				
Arms	Casirivimab/Imdevimab	Contemporaneous Controls	Casirivimab/Imdevimab	Controls				
N	115	5,536	696	696				
Timepoint	Day 1	Day 14 Day 28						
Nausea n/N (%)	NR	NR	2/696 (0.3)	NR				
Vomiting, n/N (%)	NR	NR	NR	NR				
Dizziness, n/N (%)	NR	NR	NR	NR				
Headache, n/N (%)	NR	NR	1/696 (0.1)	NR				
Hypoxia, n/N (%)	NR	NR	NR	NR				
COVID-19 Pneumonia, n/N (%)	NR	NR	NR	NR				
Hives, n/N (%)	1/115 (0.9)	NR	NR	NR				

AE: adverse event, n: number, N: total number, NR: not reported, TEAE: treatment emergent adverse event

Table D39. Adverse Events: RWE Studies II<sup>51,54,136</sup>

D	rug Name	REGEN-COV						
Stı	udy Name*	Piccicacco	et al. 2021		McCrear	y et al. 2021		
	Arms	Casirivimab/ Imdevimab	Controls	SC: Casirivimab/ Imdevimab	IV: Casirivimab/ Imdevimab	SC Matched: Casirivimab/ Imdevimab	Controls	
	N	48	200	969	1,216	653	1,306†	
T	Timepoint	Da	y 29		D	ay 28		
≥ Any AE,	n/N (%)	NR	NR	NR	NR	NR	NR	
≥ Any TEA	.E, n/N (%)	NR	NR	NR	NR	NR	NR	
Drug-Rela	ted AE, n/N (%)	NR	NR	NR	NR	NR	NR	
AE Leading	g to uation, n/N (%)	NR	NR	NR	NR	NR	NR	
AE Leading	g to Dose on, n/N (%)	NR	NR	NR	NR	NR	NR	
AE Leading	g to Death, n/N	NR	NR	NR	NR	NR	NR	
Serious AE	E Related to t, n/N (%)	NR	NR	NR	NR	NR	NR	
≥1 Serious	s AE, n/N (%)	1/48 (2.1)	NR	0/969 (0)	2/1216 (0.2)	NR	NR	
Fatal AE, r	n/N (%)	NR	NR	NR	NR	NR	NR	
All-Cause	Mortality, n/N (%)	NR	NR	1/969 (0.1)	3/1216 (0.2)	1/653 (0.2)	31/1306 (2.4)	
Grade 3 o	r 4 AE, n/N (%)	NR	NR	NR	NR	NR	NR	
	Grade 1	NR	NR	NR	NR	NR	NR	
TEAE	Grade 2	NR	NR	NR	NR	NR	NR	
Severity,	Grade 3	NR	NR	NR	NR	NR	NR	
n/N (%)	Grade 4	NR	NR	NR	NR	NR	NR	
	Grade 5	NR	NR	NR	NR	NR	NR	
	Any	NR	NR	NR	NR	NR	NR	
Infusion-	Grade ≥2	NR	NR	NR	NR	NR	NR	
	Grade 3 or 4	NR	NR	NR	NR	NR	NR	
Related AE, n/N	Related to Treatment	NR	NR	NR	NR	NR	NR	
(%)	Leading to Discontinuation	NR	NR	NR	NR	NR	NR	

Di	rug Name			RI	EGEN-COV					
Stu	ıdy Name*	Piccicacco	et al. 2021		McCreary et al. 2021					
	Arms	Casirivimab/ Imdevimab	Controls	ontrols SC: Casirivimab/ IV: Casirivimab/ Imdevimab		SC Matched: Casirivimab/ Imdevimab	Controls			
	N	48	200	969	1,216	653	1,306†			
Ti	imepoint	Da	y 29		D	ay 28				
	Leading to Dose Interruption	NR	NR	NR	NR	NR	NR			
Hypersens Grade ≥2, i	itivity Reactions n/N (%)	NR	NR	NR	NR	NR	NR			
Dyspnea, n	n/N (%)	NR	NR	NR	NR	NR	NR			
Diarrhea, r	n/N (%)	NR	NR	NR	NR	NR	NR			
Nausea n/l	N (%)	NR	NR	NR	NR	NR	NR			
Vomiting,	n/N (%)	NR	NR	NR	NR	NR	NR			
Dizziness, ı	n/N (%)	NR	NR	NR	NR	NR	NR			
Headache,	n/N (%)	NR	NR	NR	NR	NR	NR			
Hypoxia, n	/N (%)	NR	NR	NR	NR	NR	NR			
COVID-19 I (%)	Pneumonia, n/N	NR	NR	NR	NR	NR	NR			
Hives, n/N	(%)	NR	NR	NR	NR	NR	NR			

AE: adverse event, n: number, N: total number, NR: not reported, TEAE: treatment emergent adverse event

<sup>\*</sup>No safety data available for Polk et al. 2021, Chilimuri et al. 2021, or Huang et al. 2021.

<sup>†</sup>Matched controls.

Table D40. Adverse Events: RWE Studies III<sup>57,58,129</sup>

[	Drug Name REGEN-COV					Fluvo	xamine
S	tudy Name	Bierle e	t al. 2021	Kakinoki	i et al. 2021	Seftel & Bo	ulware 2021
	Arms	Casirivimab/ Imdevimab	Control Group	Casirivimab/ Imdevimab	Watchful Observation Group	Fluvoxamine	Untreated Cohort
	N	112	518*	55	53	65	48
•	Timepoint	Da	y 28	Da	ay 14	Da	y 14
≥ Any AE, ı	n/N (%)	NR	NR	3/55 (5.5)	NR	NR	NR
≥ Any TEAI	E, n/N (%)	NR	NR	NR	NR	NR	NR
Drug-Relat	ted AE, n/N (%)	NR	NR	NR	NR	NR	NR
AE Leading n/N (%)	g to Discontinuation,	NR	NR	NR	NR	0/65 (0)	0/48 (0)
AE Leading	g to Dose on, n/N (%)	NR	NR	NR	NR	NR	NR
AE Leading	g to Death, n/N (%)	NR	NR	NR	NR	NR	NR
	Related to ;, n/n/N (%)	NR	NR	NR	NR	NR	NR
≥1 Serious	AE, n/N (%)	NR	NR	NR	NR	0/65 (0)	NR
Fatal AE, n	/N (%)	NR	NR	NR	NR	NR	NR
All-Cause I	Mortality, n/N (%)	NR	NR	NR	NR	NR	NR
Grade 3 or	4 AE, n/N (%)	NR	NR	NR	NR	NR	NR
	Grade 1	NR	NR	NR	NR	NR	NR
TEAE	Grade 2	NR	NR	NR	NR	NR	NR
Severity,	Grade 3	NR	NR	NR	NR	NR	NR
n/N (%)	Grade 4	NR	NR	NR	NR	NR	NR
	Grade 5	NR	NR	NR	NR	NR	NR
	Any	NR	NR	3/55 (5.5)	NR	NR	NR
	Grade ≥2	NR	NR	NR	NR	NR	NR
Infusion-	Grade 3 or 4	NR	NR	NR	NR	NR	NR
Related AE, n/N	Related to Treatment	NR	NR	NR	NR	NR	NR
(%)	Leading to Discontinuation	NR	NR	NR	NR	NR	NR
	Leading to Dose Interruption	NR	NR	NR	NR	NR	NR

Drug Name		REG	EN-COV		Fluvoxamine	
Study Name	Bierle e	t al. 2021	Kakinoki	et al. 2021	Seftel & Bo	ulware 2021
Arms	Casirivimab/ Imdevimab	Control Group	Casirivimab/ Imdevimab	Watchful Observation Group	Fluvoxamine	Untreated Cohort
N	112	518*	55	53	65	48
Timepoint	Da	y 28	Da	y 14	Da	y 14
Hypersensitivity Reactions Grade ≥2, n/N (%)	NR	NR	NR	NR	NR	NR
Anaphylaxis, n/N (%)	NR	NR	NR	NR	NR	NR
Dyspnea, n/N (%)	NR	NR	NR	NR	NR	NR
Diarrhea, n/N (%)	NR	NR	NR	NR	NR	NR
Nausea n/n/N (%)	NR	NR	NR	NR	NR	NR
Vomiting, n/N (%)	NR	NR	NR	NR	NR	NR
Dizziness, n/N (%)	NR	NR	NR	NR	NR	NR
Headache, n/N (%)	NR	NR	NR	NR	NR	NR
Hypoxia, n/N (%)	2/112 (1.8)	47/518 (9.1)	NR	NR	NR	NR
Covid-19 Pneumonia, n/N (%)	NR	NR	NR	NR	NR	NR
Hives, n/N (%)	NR	NR	NR	NR	NR	NR

AE: adverse event, n: number, N: total number, NR: not reported, TEAE: treatment emergent adverse event

<sup>\*</sup>Included patients ineligible to receive casirivimab/imdevimab treatment.

## **D4.** Ongoing Studies

**Table D41. Ongoing Studies** 

Title/Trial Sponsor	Study Design	Treatment Arms	Patient Population	Primary Outcomes	Estimated Completion Date
		So	trovimab		
Intramuscular VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19 (COMET-TAIL)  Vir Biotechnology, Inc; GlaxoSmithKline  NCT04913675	Phase III MC, OL, RCT N=983	Sotrovimab 500 mg IV     Sotrovimab 500 mg IM     Sotrovimab 250 mg IM	Inclusion Criteria:  Participant aged 12+ years AND at high risk of progression of COVID-19 or ≥55 years old  Participants must have a positive SARS-CoV-2 test result and oxygen saturation ≥94% on room air and have COVID-19 symptoms and be less than or equal to 7 days from onset of symptoms  Exclusion Criteria:  Currently hospitalized or likely hospitalization in next 24 hours  Symptoms consistent with severe COVID-19  Participants who are likely to die in the next 7 days	Primary Outcome:  Progression of COVID- 19 [day 29] Secondary Outcomes (up to 24 weeks unless otherwise stated):  AEs, SAEs, and AESIs Incidence and titers of serum ADA to sotrovimab Cmax, Clast, Tmax, Tlast, AUCinf, AUClast, %AUCextrap, t1/2, Vz/F, CL/F Mean AUC of SARS CoV-2 viral load [day 8] Change from baseline in viral load [day 8]	August 2022
Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participants With Mild to Moderate COVID-19 (COMET-PEAK)  Vir Biotechnology, Inc; GlaxoSmithKline	Phase II MC, DB, parallel group, RCT N=352	Part A:  Sotrovimab 500 mg IV (Gen 1)  Sotrovimab 500 mg IM (Gen 2) Part B:  Sotrovimab 500 mg IV (Gen 2) Part C:  Sotrovimab 500 mg IV (Gen 2)	<ul> <li>Inclusion Criteria:</li> <li>Part A: Patients ages 18+ years</li> <li>Parts B and C: Patients ages 18-69 years</li> <li>Positive SARS-CoV-2 test result ≤7 days prior to enrollment, oxygen saturation ≥94% on room air, has COVID-19 symptoms and ≤7 days from onset of symptoms</li> <li>Exclusion Criteria:</li> <li>Currently or soon hospitalized</li> </ul>	Primary Outcome:  AEs, SAEs and AESIs [day 29, 12 weeks, and 24 weeks]  Occurrence of clinically significant abnormalities on 12-lead ECG [day 29 and 12 weeks]  Disease progression events [day 29 and 24 weeks]	June 2022

Title/Trial Sponsor	Study Design	Treatment Arms	Patient Population	Primary Outcomes	Estimated Completion Date
		Sotrovimab 250 mg IM	<ul> <li>Symptoms consistent with severe COVID-19</li> <li>Likely to die in next 7 days or are severely immunocompromised</li> <li>Parts A and B: Prior receipt of a SARS-CoV-2 vaccination</li> <li>Parts B and C: Conditions that would prohibit receipt of IM injections</li> <li>Any vaccination within 48 hours prior</li> </ul>	Mean AUC of SARS-CoV-2 viral load [day 1-day 8, day 5, and day 11]      Secondary Outcomes:     Cmax, Clast, Tmax, Tlast, AUCD0-28, AUCinf, AUClast, %AUCexp, T1/2, Vz, Vss, CL [24 weeks]     Change from baseline in viral load [day 29]	
		Mol	nupiravir		
Phase II AGILE Merck (No NCT provided)	Phase I: OL Phase II: PC, RCT N~198	<ul><li>Molnupiravir</li><li>Placebo</li></ul>	<ul> <li>Inclusion Criteria:         <ul> <li>Outpatient adults with mild or moderate COVID</li> </ul> </li> </ul>	NR	NR
		Pa	axlovid		
A Study of PF- 07321332/Ritonavir in Non- Hospitalized Low-Risk Adult Participants With COVID-19 (EPIC-SR)  Pfizer NCT05011513	Phase II/III DB, PC, RCT N~1,140	<ul> <li>Nirmatrelvir 300         mg + ritonavir 100         mg</li> <li>Placebo</li> </ul>	<ul> <li>Inclusion Criteria:         <ul> <li>SARS-CoV-2 infection and onset COVID-19 symptoms within 5 days prior to randomization</li> <li>Fertile participants must be on contraception</li> </ul> </li> <li>Exclusion Criteria:         <ul> <li>Received any COVID-19 vaccine</li> <li>History of or need for hospitalization for COVID-19</li> </ul> </li> <li>Previous SARS-CoV-2 or active infection other than COVID-19</li> <li>Has liver disease, HIV infection with viral load &gt;400 copies/ml, taking prohibited medications for HIV, receiving dialysis or has renal impairment</li> <li>Use of medications dependent on CYP3A4 for clearance</li> </ul>	Primary Outcome:  Time to alleviation of COVID-19 symptoms [day 28]  Secondary Outcomes (up to day 28 unless otherwise stated):  AES, SAES, AES leading to discontinuation [day 34]  Severe COVID-19 symptoms  Duration of COVID-19 symptoms  Progression to a worsening status in COVID-19 symptoms	April 2022

Title/Trial Sponsor	Study Design	Treatment Arms	Patient Population	Primary Outcomes	Estimated Completion Date
			<ul> <li>Receive monoclonal antibody, convalescent COVID-19 plasma, SARS-COV-2 vaccine</li> <li>Participation in clinical study with other investigational compound or PF-07321332</li> <li>Oxygen saturation of &lt;92% on room air</li> <li>Pregnant or breastfeeding</li> </ul>	<ul> <li>Resting peripheral oxygen saturation ≥95% [days 1, 5]</li> <li>Number of COVID-19 related medical visits</li> <li>Number of days in hospital and ICU</li> <li>COVID-19 related hospitalization or all-cause death</li> </ul>	
Repurposed Approved and	Phase III	Fluvoxamine 100	roxamine Inclusion Criteria:	Primary Outcomes:	Г
Under Development Therapies for Patients With Early-Onset COVID-19 and Mild Symptoms	QB, PC, RCT  Adaptive platform trial  N~3,645	mg (oral) twice daily (n=739)  Doxazosin (1 or 2 mg once daily (days 0-3), titration up to 8 mg/day (days 3-13) (oral)  Ivermectin 6 mg (oral) once daily  Placebo (n=733)	<ul> <li>Patients 18+ years with acute flulike symptoms &lt;7 days</li> <li>≤1 enhancement criteria: age &gt;50 years, diabetes, asthma, hypertension, CVD, lung disease, fever &gt;38C, obesity, transplant patients, CKD, immunosuppressive or corticosteroid therapy, cancer, chronic renal disease KDIGO IV or ESRD</li> <li>Patient with SARS-CoV2 Exclusion Criteria:</li> <li>Negative SARS-CoV2 test, flu-like symptom onset 8+ days, or &gt;14 days of SARS-CoV-2 vaccination</li> <li>Non-COVID acute respiratory conditions</li> <li>Moderate disease or hospitalized due to COVID-19</li> </ul>	<ul> <li>(through day 28):</li> <li>Need for ED visits and observation unit stay &gt;6 hours</li> <li>Hospitalization due to COVID-19 progression</li> <li>Secondary Outcomes (through day 28 unless otherwise stated):</li> <li>Change in viral load (day 3 and 7)</li> <li>Time to clinical changes (&gt;50%)</li> <li>Time to hospitalization</li> <li>Days with respiratory symptoms</li> <li>All-cause and COVID-19 hospitalizations</li> <li>Number of days on mechanical ventilator</li> </ul>	March 2022
			Moderate disease or hospitalized	Number of days on	

Title/Trial Sponsor	Study Design	Treatment Arms	Patient Population	Primary Outcomes	Estimated Completion Date
			<ul> <li>inhibitors, doxazosin, antiretroviral agents</li> <li>Have severe psychiatric/mental disorders</li> <li>Pregnant or breastfeeding</li> <li>History of cardiac arrythmia, long QT syndrome, syncope, hypotension, POTS, MI, cerebrovascular accident, cardiovascular intervention, mitral or aortic stenosis, seizures, liver cirrhosis</li> <li>Surgery during treatment</li> </ul>	<ul> <li>Health and functioning after COVID-19 disease using PROMIS Global Health Score (day 14 and 28)</li> <li>WHO ordinal scale for clinical improvement</li> <li>Number of days on respiratory Symptoms</li> <li>Adherence</li> </ul>	
COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19) University of Minnesota NCT04510194	Phase III DB, PC, RCT N~1350	Metformin     500/1000 mg     Ivermectin 390- 470 mcg/kg     Fluvoxamine 50     mg     Metformin     500/1000 mg +     Fluvoxamine 50     mg     Metformin     500/1000 mg +     Ivermectin 390- 470 mcg/kg	Inclusion Criteria:  Positive lab test for SARS-CoV-2 infection within 3 days of randomization.  No history of SARS-CoV-2 infection  BMI ≥25kg/m2 by self-report height/weight or ≥23kg/m2 in South Asian or Latinx patients  GFR >45ml/min within 2 weeks for patients >75 years old, or with history of heart, kidney, or liver failure.  Exclusion Criteria: Hospitalized, for COVID-19 or other reasons. Symptom onset >7 days before randomization Hepatic impairment, alcohol use disorder, severe kidney disease, CKD, bipolar disease, immunocompromised	Primary Outcome:  Clinical progression (day 14) Secondary Outcomes  Maximum symptom severity (days 14 and 28)  Clinical progression Scale (days 14 and 28)  Time to meaningful recovery (days 14 and 28)  Laboratory Outcome – Subsidy & Microbiome (days 1, 5, 10)  Participants with postacute sequelae of SARS-CoV-2 infection (PASC) (6 and 12 months)	February 2023

Title/Trial Sponsor	Study Design	Treatment Arms	Patient Population	Primary Outcomes	Estimated Completion Date
			<ul> <li>Enrollment in another RCT for COVID-19 or already received effective COVID-19 therapy</li> <li>Typhoid, BCG, or cholera vaccination within the 14-days</li> </ul>		
ACTIV-6: COVID-19 Study of Repurposed Medications  NCT04885530	Phase III DB, PC, RCT  Adaptive platform trial  N~15,000	<ul> <li>Ivermectin 7 mg</li> <li>Arm A Placebo</li> <li>Fluvoxamine 50 mg</li> <li>Arm B Placebo</li> <li>Fluticasone 200 μg</li> <li>Arm C Placebo</li> </ul>	Inclusion Criteria:  • Age ≥30 years old  • Confirmed SARS-CoV-2 infection by any authorized or approved PCR or antigen test within 10 days of screening  • 2+ current symptoms of acute infection for ≤7 days  Exclusion Criteria:  • Prior diagnosis of COVID-19 infection (>10 days from screening)  • Current or recent hospitalization	Primary Outcomes (Day 14):  Hospitalizations  Death Secondary Outcomes (Day 28 unless otherwise stated):  Change in COVID-19 clinical progression scale  Hospitalizations  Deaths  Number of symptoms  Symptom resolution  PROMIS-29 (days 7, 14, 28, 29)	March 2023
Randomized-controlled Trial of the Effectiveness of COVID-19 Early Treatment in Community NCT05087381	OL, RCT  Adaptive platform trial  N~1,800	Fluvoxamine 50 mg     Fluvoxamine 50 mg + Bromhexine 8 mg     Fluvoxamine 50 mg + Cyproheptadine 4 mg     Niclosamide 1000 mg     Niclosamide 1000 mg + Bromhexine 8 mg     Usual care	Inclusion Criteria:  COVID-19 adult patients with mild symptoms and the results were confirmed by antigen test kit or PCR for SARS-CoV-2  People who have symptoms consistent with COVID-19 and test positive for SARS-CoV-2 infection within 48 hours of being known  Exclusion Criteria: Almost recovered Previous randomization to an arm of the trial Pregnant or breastfeeding	Primary Outcomes:  COVID-19-related hospital admission or mortality related to COVID-19 (day 28)  Time to recovery (through final participation day)  Secondary Outcomes:  Change in Gl viral shedding (days 7, 14)  Change in respiratory viral clearance (days 7, 14)	April 2022

Title/Trial Sponsor	Study Design	Treatment Arms	Patient Population	Primary Outcomes	Estimated Completion Date
			<ul> <li>Severe hepatic or renal impairment.</li> <li>Currently taking fluvoxamine, bromhexine, cyproheptadine, or niclosamide</li> </ul>	<ul> <li>Time to fever resolution (through final participation day)</li> <li>WHO 5 Well Being Index (days 7, 15, 28, 60)</li> </ul>	

AE: adverse event, AIDS: acquired immunodeficiency syndrome, AUC: area under the curve, AUC<sub>extrap</sub>: area under the curve extrapolated as a percentage of the total, AUC<sub>inf</sub>: area under the curve to infinity, AUC<sub>iast</sub>: area under the curve to the last measurable concentration, BCG: Bacille Calmette-Guérin, BMI: body-mass index, CKD: chronic kidney disease, CL: drug clearance, CL/F: apparent oral clearance, C<sub>iast</sub>: last measurable concentration (above the quantification limit), C<sub>max</sub>: maximum plasma concentration, COPD: chronic obstructive pulmonary disease, CVD: cardiovascular disease, CYP3A4: Cytochrome P450 3A4, DB: double-blind, ED: emergency department, eGFR: estimated glomerular filtration rate, ESRD: end-stage renal disease, EUA: Emergency Use Authorization, GI: gastrointestinal, Hb: hemoglobin, HIV: human immunodeficiency virus, HCV: hepatitis C virus, HBV: hepatitis B virus, ICU: intensive care unit, IM: intramuscular, IVIG: intravenous immunoglobulin, IV: intravenous, KDIGO: Kidney Disease Improving Global Outcomes, kg: kilogram, m: meter, mAb: monoclonal antibody, MAOI: monoamine oxidase inhibitors, MC: multicenter, mcg: microgram, mg: milligram, MI: myocardial infarction, mL: milliliter, N: total number, NCT: National Clinical Trial Identifier, NR: not reported, NYHA: New York Heart Association, OL: open-label, PC: placebo-controlled, PCR: polymerase, chain reaction, PDE5: phosphodiesterase type 5, POTS: postural orthostatic tachycardia syndrome, QB: quadruple-blind, QT: interval representing the time it takes for the heart muscle to contract and then recover, RCT: randomized controlled trial, SAE: serious adverse event, TEAE: treatment-emergent adverse event, T<sub>last</sub>: time of last measurable concentration, T<sub>max</sub>: time to maximum plasma concentration (Cmax), t½: half-life, Vss: steady state volume of distribution, VZ/F: apparent volume of distribution during terminal phase, WHO: World Health Organization Source: www.ClinicalTrials.gov (NOTE: studies listed on site include both clinical trials and

### **D5. Previous Systematic Reviews and Technology Assessments**

We identified 17 systematic literature reviews or meta-analyses evaluating therapies for the treatment of COVID-19, three of which evaluated interventions of interest in our population of focus and are summarized below.

## Kreuzberger, N., et al. (2021). "SARS-CoV-2-Neutralising Monoclonal Antibodies for Treatment of COVID-19" 137

This living systematic literature review from the Cochrane database evaluated the effectiveness and safety of SARS-CoV-2 neutralizing monoclonal antibodies for the treatment of patients with COVID-19. The interventions assessed included bamlanivimab, bamlanivimab/etesevimab, casirivimab/imdevimab, sotrovimab, and regdanvimab. Inclusion criteria included studies evaluating SARS-CoV-2 neutralizing monoclonal antibody treatments for patients with COVID-19. By July 2021, investigators identified six RCTs (N=17,495), four studies looking at non-hospitalized patients with no symptoms or mild COVID-19 (N=3,474), and two looking at hospitalized patients with moderate-to-severe COVID-19 (N=10,099). Because of the limited number of studies and events, the level of certainty for all outcomes reported in the non-hospitalized population was low.

For non-hospitalized patients with COVID-19, fewer patients in the bamlanivimab arm were hospitalized compared to those in the placebo arm (RR: 0.17, 95% CI: 0.02 to 1.33; RR: 0.32, 95% CI: 0.07 to 1.47; RR: 0.34, 95% CI: 0.08 to 1.56). The treatment and placebo arms had similar rates of adverse events, and no arms had any deaths. Similarly, patients treated with bamlanivimab/etesevimab had a decreased likelihood of being hospitalized (RR: 0.30, 95% CI: 0.16 to 0.59), but an increased likelihood of experiencing adverse events and serious adverse events; there were also 10 deaths in the placebo arm and none in the treatment arm. Additionally, casirivimab/imdevimab was found to likely reduce the risk of hospitalization or death in non-hospitalized patients (RR: 0.43, 95% CI: 0.08 to 2.19; RR: 0.21, 95% CI: 0.02 to 1.79), but it is uncertain what effect this drug has on adverse events. Sotrovimab may reduce the number of patients requiring oxygen (RR: 0.11, 95% CI: 0.02 to 0.45) and experiencing hospitalization and death (RR: 0.14, 95% CI: 0.04 to 0.48), and serious adverse events, but it is uncertain whether sotrovimab reduces mortality, mechanical ventilation, or death. Regdanvimab may decrease hospitalization or death, but also may increase serious adverse events.

Due to the numerous limitations in the studies, such as lack of blinding, too few events, and serious imprecision, investigators found that the certainty level of evidence for the non-hospitalized COVID patients was low and that this evidence was not sufficient to derive meaningful conclusions about monoclonal antibody treatments for COVID-19.

# Siemieniuk, R.A.C., et al. (2021). "Antibody and Cellular Therapies for Treatment of COVID-19: A Living Systematic Review and Network Meta-Analysis" 138

Investigators conducted a living systematic literature review and network meta-analysis to evaluate the efficacy and safety of antiviral antibody therapies and blood products for the treatment of patients with COVID-19. They included RCTs of non-hospitalized patients and/or outpatients with suspected, probable, or confirmed COVID-19 that assessed blood products and COVID-19 antiviral antibodies. As of July 2021, 47 RCTs meeting inclusion criteria were identified, nine of which focused solely on mild/moderate COVID-19 patients and 24 of which focused only on severe/critical COVID-19 patients. The interventions included convalescent plasma, IV immunoglobulin, umbilical cord mesenchymal stem cells, bamlanivimab, casirivimab/imdevimab, bamlanivimab/etesevimab, control plasma, peripheral blood non-haematopoetic stem cells, sotrovimab, anti-SARS-CoV-2 IV immunoglobulin, therapeutic plasma exchange, XAV-19 polyclonal antibody, CT-P59 monoclonal antibody, and INM005 polyclonal antibody. Outcomes were stratified by disease severity, so only findings in the non-severe COVID-19 population are discussed.

For patients with non-severe COVID-19, it was found that those who received the interventions casirivimab/imdevimab (OR: 0.29, 95% CI: 0.17 to 0.47), bamlanivimab (OR: 0.24, 95% CI: 0.06 to 0.86), bamlanivimab/estevimab (OR: 0.31, 95% CI: 0.11 to 0.81), and sotrovimab (OR: 0.17, 95% CI: 0.04 to 0.57) had a lower risk of hospitalization. This level of evidence had low-to-moderate certainty. Since the risks of both mortality and need for mechanical ventilation are already very low in patients with non-severe disease, no interventions were found to have a significant reduction in either of these outcomes. Casirivimab/imdevimab was found to probably reduce the time to symptom resolution (ratio of means: 0.72, 95% CI: 0.58 to 0.92), while there was no effect for the other three monoclonal antibodies. None of the evaluated interventions seemed to have any effect on viral clearance or time to viral clearance.

In terms of adverse events, investigators did not distinguish findings between non-severe and severe COVID-19. Convalescent plasma and IV immunoglobulin may have an effect on adverse events leading to drug discontinuation, but with low certainty, and bamlanivimab and casirivimab/imdevimab likely do not have an effect on this outcome. Only convalescent plasma was found to cause infusion reactions, transfusion-associated circulatory overload, and transfusion-related acute lung injury, but the risks of these outcomes are very low.

Investigators concluded that monoclonal antibodies seem more effective in patients with non-severe COVID-19 than those with severe disease, given that the monoclonal antibodies appear to lower the risk of hospitalization, but noted that only casirivimab/imdevimab had moderate certainty for this outcome. Convalescent plasma seemed to have no benefit to patients with COVID-19, regardless of severity. Limitations include not enrolling patients with contemporary SARS-CoV-2 variants, such as Delta, using thresholds for imprecision that were determined within

the review team and not based on empirical data, lack of blinding in most of included trials of blood products, and potentially differential administration of cointerventions and supportive care.

## Lee, T., et al. (2021). "Fluvoxamine for Outpatient Management of COVID-19 to Prevent Hospitalization: A Systematic Review and Meta-Analysis" 139

Investigators conducted a systemic literature review and meta-analysis to assess the effectiveness of fluvoxamine in patients with COVID-19. They included completed studies that evaluated fluvoxamine compared to placebo or standard of care in the outpatient COVID-19 population. By November 2021, three RCTs (STOP-COVID 1, STOP-COVID 2, and TOGETHER) were identified and included, with a total of 2,196 patients and a median age of 46 to 50. Investigators conducted a frequentist DerSimonian-Laird random effects meta-analysis and two sensitivity analyses with a Bayesian random effects meta-analysis on the log risk ratio scale. The primary outcome in this meta-analysis was all-cause hospitalization.

Both forms of analyses favored fluvoxamine. In the frequentist-meta-analysis, RR: 0.75 (95% CI: 0.57 to 0.97); additionally, there was nearly a 99% probability that fluvoxamine prevents hospitalization with a moderate or greater effect. In the sensitivity analysis, RR: 0.78, (95% CI: 0.58 to 1.08) (weakly neutral prior) and RR: 0.73 (95% CI: 0.53 to 1.01) (moderately optimistic prior). The probability of a moderate effect ranged from 82% to 91%. The risk of bias in all trials was considered low and the evidence was found to have a moderate level of certainty.

Findings indicated that fluvoxamine likely has at least a moderate effect on preventing hospitalizations due to COVID-19. Investigators identified several potential limitations in their analysis, including the difference in baseline event rates due to variability in resource availability, disease variants, and health care practices, exclusion of fully vaccinated individuals who have a much lower rate of hospitalization, and inclusion of only three trials in this analysis. Investigators plan to use a living systematic review approach in their future research.

# E. Long-Term Cost-Effectiveness: Supplemental Information

### E1. Detailed Methods

**Table E1. Impact Inventory** 

Sector	Type of Impact	Included in Th from [] Per	-	Notes on Sources (if Quantified), Likely			
Sector	(Add Additional Domains, as Relevant)	Health Care Sector	Societal	Magnitude & Impact (if Not)			
	Formal Health Care Sector						
Health	Longevity effects	Х	Х				
Outcomes	Health-related quality of life effects	Х	Х				
Outcomes	Adverse events	Χ	X				
	Paid by third-party payers	X	X				
Medical Costs	Paid by patients out-of-pocket	Х	Х				
iviedical Costs	Future related medical costs	Х	Х				
	Future unrelated medical costs	Х	Х				
	Informal Health Ca	are Sector					
Heelth	Patient time costs	N/A					
Health- Related Costs	Unpaid caregiver-time costs	N/A					
Related Costs	Transportation costs	N/A					
	Non-Health Care	e Sector					
	Labor market earnings lost	N/A	Х				
Productivity	Cost of unpaid lost productivity due to illness	N/A	Х				
	Cost of uncompensated household production	N/A					
Consumption	Future consumption unrelated to health	N/A					
Social services	Cost of social services as part of intervention	N/A					
Legal/Criminal	Number of crimes related to intervention	N/A					
Justice	Cost of crimes related to intervention	N/A					
Education	Impact of intervention on educational achievement of population	N/A					
Housing	Cost of home improvements, remediation	N/A					
Environment	Production of toxic waste pollution by intervention	N/A					
Other	Other impacts (if relevant)	N/A	Х	ICU capacity			

ICU: intensive care unit, N/A: not applicable

Adapted from Sanders et al. 2016.77

#### **Target Population**

The population of focus for the economic evaluation consisted of individuals with mild-to-moderate COVID-19 and a high risk of progression to severe disease or hospitalization. Table E2 presents the baseline population characteristics from each pivotal trial. We calculated a single pooled estimate across these estimates, so the baseline characteristics of the cohort modeled were consistent across all intervention arms and the comparator arm. Pooling was based on a weighted average across the trials, where the weight assigned was based on the US sample size (i.e., trial overall sample size multiplied by the percent of trial participants from the US). The population characteristics used in the model after this pooling equated to a baseline age of 49 years and 52% of the population being female.

**Table E2. Baseline Population Characteristics** 

	REGEN-COV	Sotrovimab	Molnupiravir	Paxlovid	Fluvoxamine
Sample Size	1,484	1,057	1,408	2,246	1,497
Percent US	95.8%	92%	6.2%	41%	0%
Weight for Pooling	42%	29%	3%	27%	0%
Age at Study Enrollment	48 years	53 years	43 years	46 years	50 years
Percent Female	52%	54%	52%	49%	58%
Source	Weinreich et al., 2021 <sup>45</sup>	Gupta et al., 2021 <sup>8,121</sup>	Jayk Bernal et al., 2021 <sup>12</sup>	Pfizer Press Release, <sup>127</sup> FDA EUA Label <sup>6</sup>	TOGETHER <sup>9</sup>

EUA: Emergency Use Authorization, FDA: Food and Drug Administration, NR: not reported, UK: United Kingdom, US: United States

The economic model accounted for the vaccination status of the population modeled in the base-case analysis and included both unvaccinated and vaccinated individuals. The trials were conducted prior to an available vaccine or excluded individuals who were vaccinated, and thus real-world evidence was used to estimate the percent of the real-world COVID-19 cases that likely occurred among vaccinated individuals. As of the posting of this report, approximately 29% of COVID-19 cases are among individuals who were fully vaccinated with at least the primary series.<sup>73</sup> A subpopulation including only unvaccinated individuals with mild-to-moderate COVID-19 and at high risk of progression to severe disease or hospitalization was evaluated in a scenario analysis.

Because current clinical and epidemiological evidence for COVID-19 suggests the average age of those who die from COVID-19 is higher than the average age of those infected with COVID-19,<sup>140</sup> the model allows for the average age of the treated population to differ from the average age of the population who died from COVID-19. When a survival benefit is observed, this results in a different average age for those who recovered between the intervention and comparator arm. Trial evidence was reviewed for the age at death. The trial for REGEN-COV was the only trial that

reported an age at death: 58 years.<sup>45</sup> Because the evidence for the age at death was available for less than 50% of our comparator weighted average, evidence from outside the trials was sourced for the trials that did not report this model input. A publication from the CDC reported the age of those who died from COVID-19 as 78 years.<sup>141</sup> Therefore, 78 years was used as the age at death for the trials that did not report this model input (e.g., sotrovimab, molnupiravir, Paxlovid, and fluvoxamine). After weighting across all five trials using the weights reported in Table E2, the age at death equated to 69.6 years.

### **Treatment Strategies**

The list of interventions was developed with input from clinicians, manufacturers, and payers on which treatments to include. The list of interventions included:

- REGEN-COV
- Sotrovimab
- Molnupiravir
- Paxlovid
- Fluvoxamine

At the posting of this report, REGEN-COV and sotrovimab were determined by US authorities to no longer be effective against the dominant Omicron COVID-19 variant and thus were no longer authorized for use in the US. Therefore, economic estimates for REGEN-COV and sotrovimab are not included in the Evidence Report. Economic estimates for REGEN-COV and sotrovimab that use evidence from when they were thought to be effective against prior COVID-19 variants can be found within this Supplement. We continue to use evidence from the usual care arm of the REGEN-COV and sotrovimab pivotal trials in the comparator arm of our economic model due to their large US population and relevance to the comparator of our model.

## **E2. Model Inputs and Assumptions**

Our model includes several assumptions stated in Table E3.

**Table E3. Key Model Assumptions** 

Assumption	Rationale
The comparator arm was consistent across all interventions studied. The evidence for the comparator was based on a pooling of the usual care arms from each pivotal trial. Pooling was based on a weighted average across the trials, where the weight assigned was based on the US sample size (i.e., trial overall sample size multiplied by the percent of trial participants from the US).	Pooling across the usual care arms from each pivotal trial provided a more generalizable finding to the outcomes experienced by patients receiving usual care by accounting for different time periods within the pandemic, patient populations, and variants.
The relative treatment effects reported in each trial were applied to the outcomes from the pooled usual care evidence. The relative effectiveness seen in the trial population was generalizable to the comparator arm in the model that was constructed based on pooling evidence across the usual care arms in the pivotal trials. If a trial did not report a specific treatment effect, or the reported treatment effect was not statistically significant, a treatment effect of 1.0 was assumed.	The systematic differences in the trial populations should not affect the relative effectiveness of any of the drugs relative to usual care. We did not compare the cost effectiveness between the interventions given the systematic differences in the trial populations and design.
The baseline characteristics of the cohort modeled was consistent across all intervention arms and the comparator arm. The baseline characteristics of the cohort modeled was based on a pooling of the baseline characteristics from each pivotal trial. Pooling was based on a weighted average across the trials, where the weight assigned was based on the US sample size (i.e., trial overall sample size multiplied by the percent of trial participants from the US).	The US population eligible for each treatment is expected to be similar based on clinical expert consultation. Pooling across each pivotal trial was likely to provide a more generalizable finding to the population of individuals with mild-to-moderate COVID-19 and a high risk of progression to severe disease or hospitalization.
Adjustments were made to the risk of hospitalization and death observed in the usual care arms in the pivotal trials to account for the effectiveness of the vaccine in reducing hospitalization and death for the percent of infected patients that were vaccinated.	The trials were either conducted prior to an available vaccine or predominately included unvaccinated individuals. Given a vaccine is now available, more than 70% of US adults have received at least one dose, 73 and the vaccine is effective at reducing hospitalization and death even for breakthrough cases, 74 the evidence from the trials was weighted by the effectiveness of the vaccine for those individuals who were infected but also vaccinated. Clinical experts advised that these treatments, once widely available, are unlikely to be reserved solely for unvaccinated patients, and in fact would likely be widely prescribed for patients who are not at high risk of progression, leading to lower absolute risks of hospitalization and death than those seen in the clinical trials.

Assumption	Rationale
Death due to COVID-19 occurred at the end of the COVID-19 infected period in the model. Patients who died due to COVID-19 entered the Markov model in the dead health state.	Based on real-world data, death due to COVID-19 occurs later on in the infected period, rather than at the beginning.
The model accounted for the long-term sequelae of COVID-19 for those who were discharged alive following a hospitalization that required mechanical ventilation. These long-term sequelae consisted of an additional disutility, cost, and mortality risk.	Recommendations in the US report the occurrence and features characteristic of the long-term sequelae possible after a COVID-19 infection. 72 Ongoing engagement with patients will be important to further inform the long-term sequelae associated with COVID-19.
A patient is 100% adherent to each intervention.	Treatment duration is short; for some interventions, treatment is a single administration.
The economic evaluation for REGEN-COV was based on the IV administration and the 1200 mg dose (600 mg of casirivimab and 600 mg of imdevimab) and its associated evidence from before the Omicron variant when it was expected to be effective.	The 1200 mg dose is the dose under EUA. The fact sheet recommends the IV infusion with the subcutaneous injection as an alternative when IV infusion is not possible. Evidence specific to the current Omicron variant is not available.
The economic evaluation for sotrovimab was based on the IV administration and its associated evidence from before the Omicron variant when it was expected to be effective.	The fact sheet specifies the IV infusion. <sup>142</sup>
The economic evaluation for IV-administered treatments assumed a clinic administration, rather than a home administration as well as a 6% markup.	Home administration infusions have historically been relatively low in frequency. 143
All patients in the intervention arm had an outpatient visit. All patients in the comparator arm with an outpatient visit as their highest setting of care visited their outpatient provider.	All patients in the intervention arm visited their provider in order to get a prescription for these treatments.
Patients were hospitalized prior to dying from COVID-19. Any deaths averted between the intervention and the comparator arm resulted from reductions in the severity of the hospitalization associated with the treatment.	Deaths in patients who only received outpatient management or an emergency department visit are not common. <sup>75</sup> Further, evidence suggested an increased probability of death with higher levels of respiratory support required during the hospitalization. <sup>76</sup> Therefore, we modeled deaths averted indirectly based on hospitalizations averted and higher levels of respiratory support within a hospitalization averted. Trial estimates of the mortality in the intervention arm were not used given the small numbers and clinical rationale that the deaths averted should result from a treatment's effect on averting hospitalizations or reducing the severity of hospitalizations.

EUA: emergency use authorization, IV: intravenous, mg: milligram, US: United States

## **Model Inputs**

Key model inputs included clinical probabilities, utility values, and health care costs. The comparator arm was consistent across all interventions and was based on a pooling of the outcomes observed in the usual care arms from each pivotal trial. Pooling was based on a weighted

average across the trials, where the weight assigned was based on the US sample size (i.e., trial overall sample size multiplied by the percent of trial participants from the US). Adjustments were made to the pooled probability of hospitalization and death from the usual care arms of the pivotal trials to account for the effectiveness of the vaccine in reducing hospitalizations and death for the COVID-19 positive cases who are expected to be vaccinated. Relative treatment effectiveness as well as treatment acquisition and associated costs were different among interventions and sourced from best available evidence. The relative treatment effect(s) reported in each trial was applied to the outcomes in the comparator arm (that was derived by pooling evidence from the usual care arms in the trials and adjusting for the effectiveness of the vaccine).

#### **Clinical Inputs**

Clinical inputs included probabilities of the highest setting of care a patient received during the COVID-19 infected period, the level of respiratory support received during a hospitalization, the probability of death, total symptoms days until recovery, and condition- and treatment-specific adverse events.

#### <u>Highest Setting of Care to Manage COVID-19 Infection</u>

The model tracked the highest setting of care a patient received during their COVID-19 infected period. Table E4 presents the highest setting of care from each pivotal trial. Evidence for the comparator arm was calculated based on a pooled estimate across the usual care arms from all pivotal trials, which was then adjusted for the percent of the population assumed to be vaccinated. Pooling was based on a weighted average across the trials, where the weight assigned was based on the US sample size (i.e., trial overall sample size multiplied by percent of trial participants from the US). Three trials did not report the probability of an emergency department visit and thus they were excluded from the pooled average of the emergency department probability. Evidence on the emergency department probability was available for more than 50% of the weighted average so no external sources were sourced for those three trials missing that model input.

**Table E4. Highest Setting of Care Inputs, Unvaccinated Population** 

REGEN-COV					
Parameter	Comparator	Relative Risk	Source/Notes		
Outpatient Management Only, %	95.6%	N/A			
ED Visit, %	1.3%	0.203	Weinreich et al., 2021 <sup>45</sup>		
Hospitalization, %	3.1%	0.265			
	Sotr	ovimab	•		
Parameter	Comparator	Relative Risk	Source/Notes		
Outpatient Management Only, %	92.2%	N/A			
ED Visit, %	1.9%	1.0	Gupta et al., 2021 <sup>121</sup>		
Hospitalization, %	5.9%	0.21			
	Moln	upiravir	•		
Parameter	Comparator	Relative Risk	Source/Notes		
Outpatient Management Only, %	90.3%	N/A			
ED Visit, %	NR	1.0	Jayk Bernal et al., 2021 <sup>12</sup>		
Hospitalization, %	9.7%	0.70			
	Pa	xlovid			
Parameter	Comparator	Relative Risk	Source/Notes		
Outpatient Management Only, n (%)	93.7%	N/A	Df:		
ED Visit, n (%)	NR	1.0	Pfizer press release <sup>127</sup>		
Hospitalization, n (%)	6.3%	0.12			
	Fluvo	oxamine			
Parameter	Comparator	Relative Risk	Source/Notes		
Outpatient Management Only, n (%)	84%	N/A	TOGETHER <sup>9</sup>		
ED Visit, n (%)	NR	1.0	TOGETHER		
Hospitalization, n (%)	16%	0.68			

ED: emergency department, N/A: not available, n: number, NR: not reported

The pooled probabilities of the highest setting of care calculated using evidence from the unvaccinated population in the trials (values reported in Table E4) equated to 93.6% of the cohort treated with an outpatient visit only, 1.5% of the cohort treated with an emergency department visit, and 4.9% of the cohort treated with an inpatient hospitalization. The pooled probability of hospitalization was then adjusted using real-world COVID-19 case data. For the percent of the total COVID-19 cases that occurred among vaccinated individuals (29%), 73 the probability of hospitalization based on the pooled evidence across the usual care arms was multiplied by the effectiveness of the vaccine in reducing hospitalizations (RR of 0.04). No adjustments were made to the pooled probability of hospitalization for the cases that occurred among unvaccinated individuals. After adjusting for the vaccinated population, the hospitalization probability among the comparator arm equated to 3.6%. In the one-way sensitivity analysis, the probability of hospitalization was varied using the lower bound from the trial that reported the lowest probability of hospitalization (after adjustments for the vaccinated population) to an upper bound from the trial that reported the highest probability of hospitalization (after adjustments for the vaccinated population).

The relative risk reported in Table E4 observed for each intervention was applied to the evidence used in the comparator arm to estimate the outcomes for each intervention.

#### Severity of Hospitalizations

Evidence from the usual care arms of the trials that reported information on the severity of hospitalization was used to estimate the respiratory support received for a COVID-19 hospitalization for this population in the comparator arm. If the evidence suggested a statistically significant reduction in the level of respiratory support received associated with an intervention, then the model accounted for this in the respective intervention arm. If the evidence for an intervention did not provide this information, we modeled the same severity in the intervention arm as what was used in the comparator arm (e.g., RR of 1.0). Table E5 presents the level of respiratory support received if an individual was hospitalized as reported in the pivotal trials. Evidence for the comparator arm was calculated based on pooling across the usual care arms from all pivotal trials. Pooling was based on a weighted average across the trials, where the weight assigned was based on the US sample size (i.e., trial overall sample size multiplied by percent of trial participants from the US).

The respiratory support inputs used in the comparator arm of the model after this pooling equated to 26% requiring no oxygen support, 35% requiring low-flow oxygen, 29% requiring high-flow oxygen or non-invasive ventilation, and 10% requiring mechanical ventilation. Three trials did not report the respiratory support required and thus they were excluded from the pooled average of the emergency department probability. Evidence on the respiratory support required was available for more than 50% of the weighted average so no external sources were sourced for those three trials missing these model inputs.

The relative risks reported in Table E5 were applied to the evidence used in the comparator arm to estimate the respiratory support for each intervention.

**Table E5. Respiratory Support Received Among Those Hospitalized** 

REGEN-COV						
Parameter	Comparator	Relative Risk	Source/Notes			
No Oxygen, %	33.4%	N/A	Split single evidence data point for			
Low-Flow Oxygen, %	31.8%	1.0	low-flow oxygen and high-flow			
High-Flow Oxygen or Non-Invasive Ventilation, %	26.5%	1.0	oxygen combined based on distribution observed; data on file			
Mechanical Ventilation, %	8.3%	1.0	from Regeneron <sup>130</sup> and assumption			
	S	otrovimab				
Parameter	Comparator	Relative Risk	Source/Notes			
No Oxygen, %	16.1%	N/A				
Low-Flow Oxygen, %	38.7%					
High-Flow Oxygen or Non-Invasive Ventilation, %	32.3%	0.26*	Gupta et al., 2021 <sup>121</sup>			
Mechanical Ventilation, %	12.9%					
Molnupiravir						
Parameter	Comparator	Relative Risk	Source/Notes			
No Oxygen, %	NR	N/A				
Low-Flow Oxygen, %	NR	1.0				
High-Flow Oxygen or Non-Invasive Ventilation, %	NR	1.0	Assumption			
Mechanical Ventilation, %	NR	1.0				
		Paxlovid				
Parameter	Comparator	Relative Risk	Source/Notes			
No Oxygen, %	NR	N/A				
Low-Flow Oxygen, %	NR	1.0				
High-Flow Oxygen or Non-Invasive Ventilation, %	NR	1.0	Assumption			
Mechanical Ventilation, %	NR	1.0				
	Fl	uvoxamine				
Parameter	Comparator	Relative Risk	Source/Notes			
No Oxygen, %	NR	N/A				
Low-Flow Oxygen, %	NR	1.0				
High-Flow Oxygen or Non-Invasive Ventilation, %	NR	1.0	TOGETHER <sup>9</sup> and assumption			
Mechanical Ventilation, %	4.5%	1.0				
n: number N/A: not available NP: not						

n: number, N/A: not available, NR: not reported

#### **Mortality**

Mortality in the model included COVID-19-related mortality and all-cause mortality. COVID-19-related mortality occurred from hospitalizations, with the probability of death based on the level of respiratory support received. Therefore, we modeled deaths averted indirectly based on hospitalizations averted and higher levels of respiratory support averted rather than direct estimates of mortality from the intervention arms of the trials. Direct estimates of mortality for the intervention arm are not used from the pivotal trials given the small numbers and clinical rationale

<sup>\*</sup>Relative risk is from a composite endpoint for progression to severe and/or critical respiratory COVID-19.

that the deaths averted should result from a treatment's effect on averting hospitalizations or reducing the severity of the hospitalizations (as measured by respiratory support required). Table E6 presents the probability of mortality conditioned on each level of respiratory support that was applied in the model. Because of the small number of deaths reported across the pivotal trials, these probabilities were sourced from real-world evidence.

Table E6. Probability of Death Following COVID-19 Hospitalization

Respiratory Support Received	Probability of Death	Source
No Oxygen	4.6%	
Low-Flow Oxygen	7.6%	Obstaldt at al. 202176
High-Flow Oxygen or Non-Invasive Ventilation	25.8%	Ohsfeldt et al., 2021 <sup>76</sup>
Mechanical Ventilation	60.6%	

Table E7 presents the mortality observed in the comparator arms of the pivotal trials. The evidence from Table E7 was used to calibrate the model findings using the probabilities reported in Table E6. A multiplier was applied to each of the probabilities from Table E6 in the model to calibrate the model outcomes so the overall mortality in the acute phase of the comparator arm of the model equated to the weighted overall mortality reported in the usual care arms of the pivotal trials from Table E7. The probability of death after pooling the evidence from Table E7 equated to 0.521%. After accounting for the percent of the eligible population assumed to be vaccinated (29%)<sup>73</sup> and the effectiveness of the vaccine at preventing death following breakthrough infections (hazard ratio of 0.49),<sup>144</sup> the adjusted probability of death for the comparator arm equated to 0.44%.

**Table E7. Probability of Death from Pivotal Trials** 

Intervention	Comparator	Source
REGEN-COV	0.13%	Weinreich et al., 2021 <sup>45</sup>
Sotrovimab	0.38%	Gupta et al., 2021 <sup>8</sup>
Molnupiravir	1.29%	Jayk Bernal et al., 2021 <sup>12</sup>
Paxlovid	1.20%	Pfizer press release <sup>127</sup>
Fluvoxamine	3.00%	TOGETHER <sup>9</sup>

All-cause mortality was based on an exponential distribution fit to age- and sex-adjusted mortality from the general population. Differences in life years gained between the intervention and comparator were modeled by way of preventing COVID-19 hospitalizations and by reducing the severity of those hospitalizations if evidence suggests.

#### **Total Symptom Days**

Total symptom days (Table E8) were tracked in the model based on the highest setting of care and level of respiratory support received. If evidence for an intervention suggested reductions in symptom days associated with the treatment, the model accounted for that accordingly. The only treatment with evidence suggestive of a reduction in symptom days was for REGEN-COV, which

reported a statistically significant hazard ratio of resolution of symptoms of 1.18 for outpatient management.<sup>45</sup>

**Table E8. COVID-19 Symptom Days** 

	Symptom Days	Notes	Source	
Outpatient Management Alone	11 days	Median 8 days of	CDC MANAVAD	
ED Visit	11 days	symptoms after positive test plus median 3 days of symptoms prior to test	CDC MMWR, Vol 69, No 30 <sup>146</sup>	
Hospitalization (Without Oxygen)	17 days	Length of stay reported in	Ohsfeldt et	
Hospitalization (With Low-Flow Oxygen)	19 days	source plus 9 days, which	al., 2021 <sup>76</sup> and Beigel et al., 2020 <sup>147</sup>	
Hospitalization (With High-Flow Oxygen or Noninvasive Ventilation)	21 days	was the median time from symptom onset to		
Hospitalization (With Mechanical Ventilation)	28 days	hospitalization	ai., 2020-	

CDC MMWR: Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report, ED: emergency department

#### Adverse Events

No treatment-related adverse events were included in the model. Condition-specific adverse events, outside of hospitalizations and the receipt of respiratory support, were incorporated in the economic model as data suggested. Condition-specific adverse events included the long-term sequelae some patients experience after the COVID-19 infected period. We used recommendations from COVID-19 research to include post-acute costs and consequences for patients who were discharged alive after being mechanically ventilated.<sup>72</sup> For those individuals, the model accounted for an increased probability of death for five years (hazard ratio of 1.33), a decrease in quality of life for five years (-0.13 in the first year and -0.04 in years two to five), and an increase in health care costs for one year (\$7,859 in the first year).<sup>72</sup>

#### Societal Clinical Inputs

Recent research has reported that when ICUs are near capacity, excess deaths occur over the following weeks. Given these outpatient COVID-19 treatments may be associated with a reduction in ICU admissions, we include the potential indirect benefits of these treatments on ICU capacity in our modified societal perspective. In our model, we estimate the excess deaths averted associated with averting an ICU admission. To estimate the excess deaths averted, we estimate the slope of the curve reported in this recent research between the points of the non-COVID-19-related ICU occupancy and the total (COVID-19-related and non-COVID-19-related) occupancy. As of February 2021, total (COVID-19-related and non-COVID-19-related) ICU bed occupancy was at 74% nationally. Non-COVID ICU occupancy was at 64% nationally. The slope between these two points suggested 0.519 excess deaths averted per ICU admission averted. The average length of stay for COVID-19 patients admitted to the ICU has been reported as approximately two weeks. Thus, we assumed that the excess deaths over a two-week period at the national-level occupancy

level could be divided evenly among each ICU admission to estimate a per-treated patient effect. We then calculated the number of ICU admissions averted for each treatment, assuming that hospitalizations that required high-flow oxygen, non-invasive mechanical ventilation, or mechanical ventilation would have been in the ICU. We then multiplied the number of ICU admissions averted for each treatment by 0.519 to calculate the number of excess societal deaths averted. We estimated the lifetime discounted costs, life years, QALYs, and evLYs for an excess societal death averted using the mean age at ICU admission of 78 years<sup>151</sup> and the same general population age-adjusted costs, mortality, and quality-of-life inputs described earlier in the report. These indirect costs, QALYs, life years, and evLYs resulting from fewer excess deaths were included in the societal costs and societal health outcomes.

We did not include any societal benefits associated with the potential lower viral load associated with a treatment. This decision was the result of numerous conversations with clinical experts who suggested that vaccine uptake in the US is now at such a level that the benefit of these treatments in preventing secondary cases is minor. We also did not include any potential societal harms that may result if fewer people get vaccinated with the availability of outpatient treatments.

#### **Utility Inputs**

Health state utilities were derived from publicly available literature. Age-adjusted utilities were applied over the lifetime time horizon. COVID-19-related disutilities were applied during the infected period, with a larger disutility as the setting of care and respiratory support received increases. Table E9 reports the COVID-19-related disutilities. The duration of the disutility was based on the symptom days for each setting of care and respiratory support received.

Table E9. COVID-19-Related Disutilities

	Disutility	Notes	Source
		Calculated disutility from	
Outpatient Management Alone		utility reported in source	Poteet and Craig,
	-0.19	(0.68) from subtracting	2021 <sup>153</sup> and Sullivan
		utility from age-adjusted	et al., 2020 <sup>152</sup>
		utility (0.87) <sup>152</sup>	
ED Visit	-0.30		
Hospitalization (Without Oxygen or With	-0.30	Applied in addition to the	Barbut et al., 2019
Low-Flow Oxygen)	-0.30	Applied in addition to the	·
Hospitalization (With High-Flow Oxygen or	-0.50	outpatient management alone disutility	and Campbell et al., 2020 <sup>69</sup>
Noninvasive Ventilation)	-0.50	alone disutility	2020**
Hospitalization (With Mechanical Ventilation)	-0.60		

ED: emergency department

Patients who were discharged alive after being mechanically ventilated experienced an additional disutility for five years. This long-term sequelae was associated with a disutility of -0.13 for the first year and a disutility of -0.04 for the second through fifth year.<sup>72</sup>

#### **Economic Inputs**

The model included direct medical costs, including but not limited to costs related to treatment acquisition, administration, and monitoring; condition-related care; and general age-adjusted health care costs. In addition, productivity costs were included in a separate analysis. All costs used in the model were inflated to 2021 US dollars.

#### **Drug Acquisition Costs**

The following inputs were used to model drug utilization and associated costs:

- Dose
- Frequency of administration
- Route of administration

Table E10 reports the regimens that were modeled in this economic evaluation.

**Table E10. Recommended Treatment Regimen** 

	REGEN-COV	Sotrovimab	Molnupiravir	Paxlovid	Fluvoxamine
Manufacturer	Regeneron	GlaxoSmithKline and Vir Biotechnology	Merck and Ridgeback Biotherapeutics	Pfizer	Generic
Dose	1200 mg total (600 mg per active ingredient)	500 mg	800 mg	NR	100 mg
Frequency of Administration	One time	One time	Twice daily for 5 days	Twice daily for 5 days	Two times per day for 10 days
Route of Administration	IV	IV	Oral	Oral	Oral
Source	EUA <sup>154</sup>	EUA <sup>142</sup>	Khoo et al., 2021 <sup>155</sup>	Clinicaltrials.gov	TOGETHER <sup>9</sup>

EUA: Emergency Use Authorization, IV: intravenous, mg: milligrams, NR: not reported

Table E11 includes the treatment acquisition costs that were included in the model. The costs reported are per treatment course. The IV-administered treatments included a 6% mark-up in the economic evaluation given these treatments are provider-administered.

**Table E11. Treatment Acquisition Costs** 

Treatment	Treatment Course Acquisition Cost	Notes	Source
REGEN-COV	\$2,100	In addition to the acquisition cost, model included a 6% mark-up due to these treatments being provider-	Regeneron press release <sup>156</sup>
Sotrovimab	\$2,100	administered; including 6% mark-up, a treatment course cost \$2,226	REDBOOK
Molnupiravir	\$707	Based on government-contract price per treatment course	Beasley and O'Donnell, 2021 <sup>157</sup>
Paxlovid	\$529	Based on government-contract price per treatment course	CBS News, 2021 <sup>158</sup>
Fluvoxamine	\$12	Lowest price of 20 100 mg tablets	REDBOOK

mg: milligram

#### Administration and Monitoring Costs

For the IV-administered treatments, an additional cost of \$450 was included in the economic evaluation to account for administration and monitoring costs. This cost was based on the Medicare Part B payment for COVID-19 monoclonal antibodies during the public health emergency and is inclusive of the IV infusion and post-administration monitoring. Orally-administered treatments did not have any additional costs associated with administration or monitoring outside of the initial office visit to receive the prescription (further detail about this office visit available beneath the heading for COVID-19-related health care utilization).

#### Condition-Related Care Costs

#### COVID-19-Related Health Care Utilization

All individuals in the intervention arms had an office visit to receive their prescription for outpatient treatment. In the comparator arm, we assumed everyone with outpatient management as the highest setting of care had an office visit. The model also included health care utilization costs if a patient was in the emergency department or hospitalized. Hospitalization costs did not vary with length of stay. Table E12 reports the average unit cost for health care utilization that was used in this economic evaluation.

**Table E12. Health Care Utilization Costs** 

Health Care Utilization	<b>Unit Price</b>	Notes	Source
Outpatient Visit	\$84	Every individual in intervention arms received this; every individual in comparator arm with outpatient management as highest setting of care received this	CMS Physician Fee Schedule (HCPCS code: 99203 for office visit of moderate complexity) <sup>160</sup>
COVID-19 ED Visit	\$563	Any individual with ED visit as highest setting of care received this	Moore and Liang et al., 2020 <sup>161</sup>
COVID-19 Hospitalization (No Oxygen)	\$16,442	Any individual hospitalized that didn't receive any respiratory support received this; any individual that was re-admitted received an additional COVID-19 hospitalization with no oxygen received	
COVID-19 Hospitalization (Low-Flow Oxygen)	\$19,706	Any individual hospitalized that received low-flow oxygen as highest level of respiratory support received this	Ohsfeldt et al., 2021 <sup>76</sup>
COVID-19 Hospitalization (High-Flow Oxygen or Non-Invasive Ventilation)	\$35,139	Any individual hospitalized that received high-flow oxygen or non-invasive ventilation as highest level of respiratory support received this	
COVID-19 Hospitalization (Mechanical Ventilation)	\$60,958	Any individual hospitalized that received mechanical ventilation as highest level of respiratory support received this	

CMS: Centers for Medicare and Medicaid Services, ED: emergency department, HCPCS: Healthcare Common Procedure Coding System

#### **Hospital Readmissions**

Recent research evaluated COVID-19 US hospitalizations and found that 9% of patients discharged alive are readmitted within two months. The median number of days that elapsed between discharge and readmission was eight (IQR: 3 to 20 days). In alignment with this evidence, the model included an additional hospitalization for 9% of those individuals who were hospitalized and discharged alive. The model accounted for these readmissions in the first cycle of the Markov model by applying a cost and disutility for this readmission. The cost, disutility value, and disutility duration were based on the characteristics for a hospitalization that does not require oxygen. Hospital characteristics from a low severity hospitalization were used given the very favorable outcomes associated with these readmissions. In the cost, disutility alive the very favorable outcomes associated with these readmissions.

#### Long-Term Sequelae

Patients discharged from a hospitalization alive after being mechanically ventilated experienced long-term sequelae that was associated with an additional cost of \$7,859 for the first year after discharge.<sup>72</sup>

#### Other Health Care Costs

Age-adjusted health care costs were applied over the lifetime time horizon.<sup>163</sup> Treatment costs and condition-related care were in addition to these age-adjusted health care costs.

#### Societal Costs

We included productivity gains/losses associated with the COVID-19 infection. To account for lost productivity while an individual was infected with COVID-19, the model assumed that the patient was not working for the duration of their symptom days. The model accounted for this lost productivity by multiplying the average daily wage (eight hours multiplied by \$27.07 per hour) by the number of symptom days experienced for each setting of care and respiratory support received.<sup>164</sup>

#### E3. Results

### **Description of evLY Gained Calculations**

The cost per evLY gained considers any extension of life at the same "weight" no matter what treatment is being evaluated. Below are the stepwise calculations used to derive the evLY gained.

- 1) First, we attribute a utility of 0.851, the age- and gender-adjusted utility of the general population in the US that are considered healthy. 165
- 2) For each cycle (Cycle I) in the model where using the intervention results in additional years of life gained, we multiply this general population utility with the additional life years gained.
- 3) We sum the product of the life years and average utility (cumulative LYs/cumulative QALYs) for Cycle I in the comparator arm with the value derived in Step 2 to derive the evLY for that cycle.
- 4) If no life years were gained using the intervention versus the comparator, we use the conventional utility estimate for that Cycle I.
- 5) The total evLY is then calculated as the cumulative sum of QALYs gained using the above calculations for each arm.
- 6) The evLY for the comparator arm was equivalent to the QALY estimate for that model cycle.

Finally, the evLY gained is the incremental difference in evLY between the intervention and the comparator arms.

#### **Base-Case Results**

Base-case results for molnupiravir, Paxlovid, and fluvoxamine can be found in the main report. In this Supplement, we include economic estimates for REGEN-COV and sotrovimab using efficacy data from before the Omicron variant. It is expected that REGEN-COV and sotrovimab are not effective against the Omicron variant of COVID-19. However, in Tables E13 and E14, we present economic estimates for REGEN-COV and sotrovimab using evidence prior to the Omicron variant.

Table E13. Results for the Base Case, Health Care Sector Perspective

Treatment	Treatment Cost*	<b>Total Cost</b>	Hospitalizations	QALYs	Life Years	evLYs
REGEN-COV	\$2,100	\$300,600	0.94%	15.9583	19.4970	15.9597
Sotrovimab	\$2,100	\$300,700	0.75%	15.9648	19.5059	15.9665
Usual Care		\$297,700	3.56%	15.9247	19.4580	15.9247

evLY: equal-value life year, QALY: quality-adjusted life year

Table E14. Incremental Cost-Effectiveness Ratios for the Base Case, Health Care Sector Perspective

Treatment	Comparator	Cost per QALY Gained	Cost per Life Year Gained	Cost per evLY Gained	Cost per Hospitalization Averted
REGEN-COV	Usual care	\$87,000	\$75,000	\$83,000	\$111,000
Sotrovimab	Usual care	\$76,000	\$63,000	\$73,000	\$108,000

evLY: equal-value life year, QALY: quality-adjusted life year

## **E4. Sensitivity Analyses**

We conducted one-way sensitivity analyses to identify the impact of parameter uncertainty and key drivers of model outcomes. The key inputs and results from the one-way sensitivity analyses can be found in Tables E15-E17. Figures E1-E3 present this information graphically by way of a tornado diagram for each intervention.


<sup>\*</sup>Excludes administration, monitoring, or markup-related costs.

Table E15. Tornado Diagram Inputs and Results for Molnupiravir versus Usual Care

Input Name	Lower Input ICER	Upper Input ICER	Lower Input	Upper Input
Relative Risk of Hospitalization – Molnupiravir*	\$37,000	>\$1,000,000	0.45	1.00
Percent of Usual Care with a Hospitalization as Highest Setting of Care	\$72,000	\$36,000	0.02	0.07
Percent of Hospitalizations Receiving Ventilation – Usual Care	\$62,000	\$60,000	0.08	0.12
Percent of Hospitalizations Receiving Non- Invasive Ventilation – Usual Care	\$62,000	\$60,000	0.23	0.35
P(Death) of Death for Hospitalized Patients Receiving No Respiratory Support	\$61,000	\$60,000	0.02	0.05
Outpatient Management Symptom Days	\$61,000	\$60,000	7.12	15.71
Probability of Hospital Readmission	\$61,000	\$60,000	0.06	0.13
Percent of Hospitalizations Receiving Oxygen – Usual Care	\$61,000	\$60,500	0.28	0.42
Duration of Long-Term Sequelae (Years) Influence on Utility	\$61,000	\$60,500	3.24	7.14

ICER: incremental cost-effectiveness ratio, P: probability

Figure E1. Tornado Diagram for Molnupiravir versus Usual Care



P: probability, QALY: quality-adjusted life year


<sup>\*</sup>Incremental cost-effectiveness ratio extends to a very high incremental cost-effectiveness ratio (>\$1,000,000) given a near zero denominator. The X axis has been truncated at an upper bound of \$500,000 for clarity of the graph.

Table E16. Tornado Diagram Inputs and Results for Paxlovid versus Usual Care

Input Name	Lower Input ICER	Upper Input ICER	Lower Input	Upper Input
Percent of Usual Care with a Hospitalization as Highest Setting of Care	\$30,000	\$60	0.02	0.07
Percent of Hospitalizations Receiving Non- Invasive Ventilation – Usual Care	\$22,000	\$20,000	0.23	0.35
Percent of Hospitalizations Receiving Ventilation – Usual Care	\$22,000	\$20,000	0.08	0.12
Relative Risk of Hospitalization – Paxlovid	\$20,000	\$22,000	0.08	0.17
Probability of Hospital Readmission	\$21,000	\$20,000	0.06	0.13
P(death) of Death for Hospitalized Patients Receiving No Respiratory Support	\$20,700	\$21,300	0.02	0.05
Percent of Hospitalizations Receiving Oxygen – Usual Care	\$21,100	\$20,800	0.28	0.42
Outpatient Management Symptom Days	\$21,100	\$20,800	7.12	15.71
Annual Cost of Long-Term Sequelae – Year 1	\$21,000	\$20,800	\$5,090	\$11,200

ICER: incremental cost-effectiveness ratio, P: probability

Figure E2. Tornado Diagram for Paxlovid versus Usual Care




QALY: quality-adjusted life year

Table E17. Tornado Diagram Inputs and Results for Fluvoxamine versus Usual Care

Input Name	Lower Input ICER	Upper Input ICER	Lower Input	Upper Input
Percent of Usual Care with a Hospitalization as Highest Setting of Care	\$17,000	-\$11,000	0.02	0.07
Relative Risk Of Hospitalization – Fluvoxamine	\$8,000	\$11,000	0.49	0.89
Percent of Hospitalizations Receiving Non- Invasive Ventilation – Usual Care	\$9,000	\$8,000	0.23	0.35
Percent of Hospitalizations Receiving Ventilation – Usual Care	\$9,000	\$8,000	0.08	0.12
P(Death) of Death for Hospitalized Patients Receiving No Respiratory Support	\$8,000	\$9,000	0.02	0.05
Probability of Hospital Readmission	\$9,000	\$8,000	0.06	0.13
Percent of Hospitalizations Receiving Oxygen – Usual Care	\$8,600	\$8,200	0.28	0.42
Annual Cost of Long-Term Sequelae – Year 1	\$8,500	\$8,300	\$5,000	\$11,000
Cost of an Outpatient Visit of Moderate Complexity	\$8,300	\$8,500	\$50	\$120

ICER: incremental cost-effectiveness ratio, P: probability

Figure E3. Tornado Diagram for Fluvoxamine versus Usual Care



P: probability, QALY: quality-adjusted life year

Probabilistic sensitivity analyses were also performed by jointly varying all model parameters over 1,000 simulations, then calculating 95% credible range estimates for each model outcome based on the results. Table E18 reports the mean and credible range for each intervention, usual care, and incremental comparisons.

**Table E18. Results of Probabilistic Sensitivity Analysis** 

	In	tervention	Usua	al Care	Incremental	
	Mean	Credible Range	Mean	Credible Range	Mean	Credible Range
			Molnupiravir			
Total Costs	\$298,483	(\$297,846, \$298,942)	\$297,678	(\$296,751, \$298,331)	\$805	(\$608, \$1,209)
Total QALYs	15.96	(15.93, 15.99)	15.95	(15.90, 15.98)	0.01	(0.00, 0.04)
ICER (\$/QALY)	\$61,400					
	Paxlovid					
Total Costs	\$298,483	(\$298,358, \$298,575)	\$297,678	(\$296,751, \$298,331)	\$806	(\$226, \$1,609)
Total QALYs	15.99	(15.98, 16.00)	15.95	(15.90, 15.98)	0.04	(0.01, 0.08)
ICER (\$/QALY)	\$21,000					
Fluvoxamine						
Total Costs	\$297,793	(\$297,155, \$298,234)	\$297,678	(\$296,751, \$298,331)	\$115	(-\$95, \$443)
Total QALYs	15.96	(15.93, 15.99)	15.95	(15.90, 15.98)	0.01	(0.00, 0.03)
ICER (\$/QALY)	\$8,200					

ICER: incremental cost-effectiveness ratio, QALY: quality-adjusted life year

Table E19 reports the percent of iterations less than commonly used thresholds for each intervention.


**Table E19. Probability of Being Cost Effective at Various Thresholds** 

Outcome: QALYs Gained	\$50,000 per QALY Gained	\$100,000 per QALY Gained	\$150,000 per QALY Gained	\$200,000 per QALY Gained
Molnupiravir	31%	69%	84%	89%
Paxlovid	97%	100%	100%	100%
Fluvoxamine	100%	100%	100%	100%
Outcome: evLYs Gained	\$50,000 per evLY Gained	\$100,000 per evLY Gained	\$150,000 per evLY Gained	\$200,000 per evLY Gained
Molnupiravir	33%	71%	85%	90%
Paxlovid	98%	100%	100%	100%
Fluvoxamine	100%	100%	100%	100%

evLY: equal-value life year, QALY: quality-adjusted life year


Figures E4-E6 report a scatterplot of each intervention to usual care using the outcome of the evLY gained. The figure using the QALY outcome generates similar findings.

Figure E4. Probabilistic Sensitivity Analysis Results: Cost-Effectiveness Clouds, Molnupiravir versus Usual Care



evLY: equal-value life year

Figure E5. Probabilistic Sensitivity Analysis Results: Cost-Effectiveness Clouds, Paxlovid versus Usual Care



evLY: equal-value life year

\$1,000 \$800 \$600 incremental Cost \$400 \$200 0.04 0.05 0.06 -0.01 0.00 0.07 \$(200) \$(400) \$(600) Incremental evLY

Figure E6. Probabilistic Sensitivity Analysis Results: Cost-Effectiveness Clouds, Fluvoxamine versus Usual Care

evLY: equal-value life year

## **E5. Scenario Analyses**

Table E20 reports the incremental cost-effectiveness ratios for Scenario Analysis 1, which expanded the perspective to a modified societal perspective. The incremental cost-effectiveness ratios from the modified societal perspective attenuate to \$30,000 per QALY gained across the treatments given the excess deaths averted are associated with an incremental cost-effectiveness ratio of approximately \$30,000 per health outcome gained. Given that the incremental cost-effectiveness ratios for Paxlovid and fluvoxamine were less than \$30,000 per health outcome gained in the health care sector perspective, their ratio from the modified societal perspective slightly increases. However, as shown in the report, the threshold prices for the modified societal perspective are all higher than the threshold prices for the health care sector perspective because the lowest threshold is \$50,000 per health outcome gained.

Table E20. Incremental Cost-Effectiveness Ratios for the Modified Societal Perspective

Treatment	Comparator	Cost per QALY Gained	Cost per Life Year Gained	Cost per evLY Gained
Molnupiravir	Usual care	\$46,000	\$38,000	\$44,000
Paxlovid	Usual care	\$26,000	\$25,000	\$25,000
Fluvoxamine	Usual care	\$20,000	\$20,000	\$20,000

evLY: equal-value life year, QALY: quality-adjusted life year

#### E6. Model Validation

First, we provided the preliminary model structure, methods, and assumptions to manufacturers. Based on feedback from these groups, we refined data inputs used in the model, as needed. Second, we varied model input parameters to evaluate face validity of changes in results. We performed model verification for model calculations using internal reviewers. As part of ICER's efforts in acknowledging modeling transparency, we also shared the model with the relevant manufacturers for external verification around the time of publishing the draft Evidence Report for this review. Finally, we compared results to other cost-effectiveness models in this therapy area. The outputs from the model were validated against the trial/study data of the interventions and also any relevant observational datasets.

#### **Prior Economic Models**

To our knowledge, there are no other published cost-effectiveness analyses that assess the cost effectiveness of outpatient treatments for COVID-19. Mills et al. 2021 (pre-print)<sup>166</sup> conducted a cost-consequence analysis assessing fluvoxamine versus placebo for adult patients with symptomatic COVID-19 infection at increased risk of progression to severe infection or hospitalization. The study was conducted from the US health care system perspective over a 28-day time horizon and consisted of a decision tree modeled according to the highest level of care received (i.e., emergency department visit only, extended emergency room visit, or hospital admission with ICU stay or not). Our model similarly tracked patients according to the highest setting of care received using an upfront acute phase decision tree. In our model, patients were permitted to be managed in the outpatient setting only and included highest setting of care according to oxygen and ventilation status. Our model also used a lifetime time horizon and included quality of life outcomes. The base-case probability of hospitalization used in Mills et al. was 10%, and their analysis found that fluvoxamine was a cost-saving treatment (\$232 vs. placebo). Our model included a lower base-case hospitalization rate of 3.6%; however, when varied in a sensitivity analysis, we also found that fluvoxamine would be cost-saving versus usual care when hospitalization was greater than 5%.

In the absence of other full cost-effectiveness analyses to compare our results, two published papers offer recommendations for assessing the cost effectiveness of COVID-19 interventions, though not specific to outpatient treatments. Sheinson et al. 2021<sup>72</sup> published a cost-effectiveness framework for evaluating acute treatments for hospitalized patients with COVID-19. Our model structure is closely aligned with the recommendations in this study consisting of an acute decision tree followed by a lifetime Markov model, model outcomes based on the highest level of care received (i.e., hospitalized with or without oxygen and with non-invasive or mechanical ventilation), the inclusion of long-term sequalae based on the level of respiratory support received, and utilities based on the average US population with disutilities applied for each level of care received. There

were differences between our model and Sheinson et al. in terms of how societal costs were measured – authors estimated productivity impacts due to COVID-19 mortality for the full cohort regardless of age whereas our model included lost productivity costs for the duration of COVID-19 symptom days. A white paper published by Elvidge et al. 2021<sup>167</sup> also provided guidance for economic evaluations of COVID-19 interventions. Recommendations included using a whole disease pathway model, an individual level simulation (to allow for assessing impact on transmission and system capacity), the inclusion of the long-term impacts of COVID-19, and analyses conducted from the societal and health care system perspective. Our model focused on treatments at one position in the disease pathway – an example of a decision question where the guidelines suggest that a cohort model may be sufficient.

## F. Public Comments

This section includes summaries of the public comments prepared for the Midwest Public Meeting on April 12, 2022. These summaries were prepared by those who delivered the public comments at the meeting. Please note that only two out of the three speakers submitted a summary of remarks.

A video recording of all comments can be found <u>here</u>. Conflict of interest disclosures are included at the bottom of each statement for each speaker who is not employed by a pharmaceutical manufacturer.

#### Oved Amitay, President, and CEO, Solve ME/CFS Initiative

My name is Oved Amitay, I serve as the President and CEO of Solve ME/CFS Initiative, a non-profit advocacy organization dedicated to improving outcomes for people with post-infection diseases.

Thank you for the opportunity to contribute to your Special Assessment and for acknowledging that in your report. We appreciate the opportunity to provide additional public comments.

The focus of our comments is long COVID, which is the term preferred by patients. Other terms are post-COVID conditions, or post-acute sequalae of COVID-19 PASC used by NIH). As noted in the report, there is a large number of symptoms associated with COVID-19 that may persist for many months after the initial infection. Many patients are not recovered by seven months, and continue to experience significant symptom burden with fatigue (78%), post-exertional malaise (72%), and cognitive dysfunction (55%) are the most frequent symptoms, and as many as two thirds do not return to their level of employment prior to the COVID infection.

The Government Accountability Office estimated that up to 23 million Americans have been impacted by long COVID. The importance of this less visible dimension of COVID-19 was highlighted last week when President Biden issued a Presidential Memorandum directing the Secretary of Health and Human Services (HHS) to coordinate a new effort across the federal government to develop and issue the interagency national action plan on long COVID and associated conditions.

We also recently published a white-paper that estimated the total financial burden on people with long COVID is in the order of \$400 billion in the US. Given the significant health deterioration in this condition and related cost, any future cost-effectiveness analysis of interventions, particularly in non-hospitalized outpatients with mild-to-moderate disease should look at the potential to reduce this burden. The long-term outcomes are potentially an added dimension of benefit, on top of reducing hospitalization and prevention of death.

We are therefore concerned about your interim conclusion that "should these treatments be used in lower-risk populations, including patients with full vaccination, their cost effectiveness would be

significantly reduced." We submit that the potential of these treatments to reduce the burden of long COVID must be studied. The absence of this data could produce a significant underestimation of the cost effectiveness of these treatments, and may prevent people from having access to them.

We ask ICER to include long COVID impact in your models, which is of such high importance to patients and caregivers. As co-founders of the Long COVID Alliance we are available to facilitate a broad patient engagement in this effort, especially with underserved populations that are disproportionally impacted by COVID-19.

We also urge drug developers to include long COVID assessments in their studies, so that it could be included in cost-effective analysis to demonstrate an additional benefit.

#### No conflicts of interest to disclose.

#### Carisa de Anda, PharmD, Executive Director, Clinical Research, Merck

Molnupiravir significantly reduced the risk hospitalization or death with an approximately 30% relative risk reduction demonstrated in the MK4482-002 study. There was a strong survival benefit, with nine of the 10 deaths occurring in the placebo group through day 29.

Molnupiravir demonstrated efficacy of molnupiravir that should also be considered include secondary, exploratory, and post hoc analyses including onset and/or progression of COVID-19 signs and symptoms, WHO 11-point scale, C-reactive protein, supplemental oxygen use, and hospital length of stay to name a few.

Molnupiravir was also associated with a greater decrease in viral RNA and importantly viral infectivity across SARS-COV-2 variants. Among patients who had infectious virus at baseline, no infectious virus was detected in patients receiving molnupiravir at day three, five, or 10. The lack of infectious virus at during and post treatment has which has the potentially important implications for both patient and public health. Rapid cessation of infectivity may impact clinical outcome and also reduce communicability. Recent in vitro and in vivo data has shown that molnupiravir is active against omicron isolates, including BA.2. It is a well-tolerated treatment that can be provided at home.

Molnupiravir has no known drug-drug interactions, and no dose adjustment is needed for renal or hepatic impairment. Several medications are contraindicated for concomitant use with ritonavir-containing antiviral therapies due to the potential life-threatening drug interaction associated with ritonavir's potent inhibition of CYP3A4 isoenzyme. Therefore, it is important to understand the extent of potential drug-drug interactions (pDDIs) that might exist among the US population with COVID-19 and at-risk subgroups.

The abstract accepted for presentation at the MAD-ID 24th Annual conference evaluated the prevalence of potential drug-drug interactions with ritonavir-containing COVID-19 therapies. This is a retrospective study utilizing the U.S. Optum Clinformatics® database evaluating patients diagnosed with COVID-19 between January 1, 2020 and June 30, 2021 who had continuous insurance coverage. The list of potential DDIs and their severity classification was generated from three sources: University of Liverpool, Lexicomp® database, and the US FDA. pDDI severity was classified into four groups: contraindicated, major, moderate, and minor.

The results demonstrated that, of 718,387 adults diagnosed with COVID-19, a majority (432,707, 60.2%) had at least one pDDI. By severity of pDDIs, 29.7% of COVID-19 patients had contraindicated pDDIs, followed by major pDDIs (13.5%), moderate pDDIs (7.8%), and minor pDDIs (9.2%). Among those 60 years or older, the prevalence of contraindicated or major pDDIs was 61.7% (207,607/336,556).

With all of this in consideration, it reinforces the importance of molnupiravir as part of the treatment options to combat the COVID-19 pandemic.

Carisa de Anda is a full-time employee of Merck.

# G. Conflict of Interest Disclosures

Tables G1 through G3 contain conflict of interest disclosures for all participants at the April 12, 2022 Public Meeting of Midwest CEPAC.

**Table G1. Policy Roundtable Participants** 

Policy Roundtable Participant	Conflict of Interest
Adarsh Bhimraj, MD, Chair, Infectious Diseases Society of America COVID-19 Treatment Guidelines	No financial conflicts to disclose.
<b>Linda Goler Blount, MPH</b> , President and CEO, Black Women's Health Imperative	BWHI receives funding from Hologic Inc., and Gilead Sciences.
<b>Sree Chaguturu, MD</b> , Chief Medical Officer, CVS Caremark	Sree Chaguturu is a full-time employee of CVS Caremark.
<b>Jim Curotto, MBA</b> , Vice President, Integrated Account Management, Merck	Jim Curotto is a full-time employee of Merck.
Mohammad Dar (MoDar), MD, Senior Medical Director, MassHealth	Full-time employee of MassHealth.
Mohamed Hussein, MSCS, MSPH, PHD, Senior Director, Health Economics and Outcomes Research General Medicine, Regeneron	Dr. Hussein is a full-time employee of Regeneron.
<b>Edward Mills, PhD</b> , Professor of Health Sciences, McMaster University	Edward Mills has stock ownership and employee status at Cytel. He received funding from Eiger Biosciences for the TOGETHER trial.
Mary Roberts, Vice President, US Market Access Strategy, GlaxoSmithKline	Mary Roberts is a full-time employee of GlaxoSmithKline.

#### **Table G2. ICER Staff and Consultants**

ICER Staff and Consultants			
Molly Beinfeld, MPH,* Senior Research Lead, Evidence Synthesis, ICER	Marina Richardson, MSc, *Health Economist, ICER		
Laura Cianciolo,* Program Manager, ICER	Steven D. Pearson, MD, MSc,* President, ICER		
Noemi Fluetsch, MSc, MPH,* Research Assistant,	Abigail Wright, PhD, MSc,* Senior Research Lead,		
Health Economics and Outcomes Research, ICER	Evidence Synthesis, ICER		
Monica Frederick,* Program Associate, ICER	Melanie Whittington, PhD, MS,* Director of Health Economics, ICER		
Rasheed Mohammed, PharmD, MPh,* HTA Fellow,	Kai Yeung, PharmD, PhD,* Assistant Investigator, Kaiser		
ICER	Permanente Washington Health Research Institute		
Emily Nhan,* Research Assistant, ICER			

<sup>\*</sup>No conflicts of interest to disclose, defined as individual health care stock ownership (including anyone in the member's household) in any company with a product under study, including comparators, at the meeting in excess of \$10,000 during the previous year, or any health care consultancy income from the manufacturer of the product or comparators being evaluated.

**Table G3. Participating Members of Midwest CEPAC** 

Participating Members of Midwest CEPAC			
Eric Armbrecht, PhD,* Associate Professor, Saint Louis University Center for Health Outcomes Research, School of Medicine and College for Public Health and Social Justice	Jill Johnson, PharmD,* Professor, Department of Pharmacy Practice, University of Arkansas for Medical Sciences College of Pharmacy		
Kurt Vanden Bosch, PharmD,* System Formulary Manager, St. Luke's Health System, Idaho	Tim McBride, PhD,* Co-Director, Center for Health Economics and Policy Professor, Brown School, Washington University in St. Louis		
Aaron Carroll, MD,* Professor of Pediatrics, Associate Dean for Research Mentoring; Director, Center for Health Policy and Professionalism Research and the Center for Pediatric and Adolescent Comparative Effectiveness Research at the Indiana University School of Medicine	Reem Mustafa, MD, MPH, PhD* (Chair), Associate Professor of Medicine, Division of Nephrology and Hypertension, and Director, Outcomes and Implementation Research, University of Kansas Medical Center		
<b>Don Casey, MD, MPH, MBA,*</b> President, American College of Medicine	Rachel Sachs, JD, MPH,* Associate Professor of Law, Washington University in St. Louis		
Sneha Dave,* Executive Director, Health Advocacy Summit	Stuart A. Winston, DO,* Cardiologist in the Sub- Specialty of Cardiac Electrophysiology, St. Joseph Mercy Health System, Physician Lead: Patient Experience, Quality Improvement Integrated Health Associates, St. Joseph Mercy Health System		
Stacie B. Dusetzina, PhD,* Vanderbilt University School of Medicine	Yngve Falck-Ytter, MD, AGAF,* VA Northeast Ohio Healthcare System		
<b>Heather Guidone, BCPA,*</b> Program Director, Center for Endometriosis Care			

<sup>\*</sup>No conflicts of interest to disclose, defined as individual health care stock ownership (including anyone in the member's household) in any company with a product under study, including comparators, at the meeting in excess of \$10,000 during the previous year, or any health care consultancy income from the manufacturer of the product or comparators being evaluated.